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About the Health Information and Quality Authority 
The Health Information and Quality Authority (HIQA) is an independent 
authority established to drive high quality and safe care for people using our 
health and social care services in Ireland. HIQA’s role is to develop standards, 
inspect and review health and social care services and support informed 
decisions on how services are delivered. 
HIQA aims to safeguard people and improve the safety and quality of health 
and social care services across its full range of functions. 
HIQA’s mandate to date extends across a specified range of public, private 
and voluntary sector services. Reporting to the Minister for Health and 
engaging with the Minister for Children and Youth Affairs, HIQA has statutory 
responsibility for: 
 Setting Standards for Health and Social Services – Developing 
person-centred standards, based on evidence and best international 
practice, for health and social care services in Ireland. 
 
 Regulation – Registering and inspecting designated centres. 
 
 Monitoring Children’s Services – Monitoring and inspecting children’s 
social services. 
 
 Monitoring Healthcare Safety and Quality – Monitoring the safety 
and quality of health services and investigating as necessary serious 
concerns about the health and welfare of people who use these services. 
 
 Health Technology Assessment – Providing advice that enables the 
best outcome for people who use our health service and the best use of 
resources by evaluating the clinical effectiveness and cost-effectiveness of 
drugs, equipment, diagnostic techniques and health promotion and 
protection activities. 
 
 Health Information – Advising on the efficient and secure collection and 
sharing of health information, setting standards, evaluating information 
resources and publishing information about the delivery and performance 
of Ireland’s health and social care service. 
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Foreword 
Since the 1950s, evidence has shown the link between tobacco smoking and 
morbidity. Early studies provided evidence for an association between 
smoking and lung cancer. Subsequent studies in the 1960s have shown the 
causal link between smoking and a wide range of conditions including heart 
disease, stroke, respiratory conditions and other types of cancer. Smokers 
have a mortality rate two to three times higher than that of people who have 
never smoked. The high morbidity and mortality associated with smoking has 
a negative impact on both the quantity and quality of life of those who 
smoke. 
Given the higher risk of disease and death in smokers, the economic cost of 
smoking in Ireland is substantial. In 2013, the estimated cost to the 
healthcare system was over €460 million, the cost of lost productivity was 
over €1 billion, and the cost of loss of welfare was over €9 billion. Smoking 
cessation substantially reduces the risk of developing most of the smoking-
related diseases and reduces the risk of death. A diverse range of smoking 
cessation interventions and services are currently funded by the public health 
system in Ireland. To consolidate activity in this area and to maximise the 
clinical benefits for the current level of funding, an evidence-based analysis of 
the clinical and cost-effectiveness of the existing smoking cessation 
treatments was deemed necessary 
The National Tobacco Control Advisor to the Department of Health requested 
that the Health Information and Quality Authority (HIQA) undertake a health 
technology assessment (HTA) of the clinical and cost-effectiveness of 
pharmaceutical and non-pharmaceutical smoking cessation products and 
services. This request followed a recommendation in the national strategy 
‘Tobacco Free Ireland’ to examine the national and international evidence on 
the effects of the use of nicotine replacement therapy and other interventions 
that support smokers to quit smoking. This HTA will provide the evidence to 
underpin a planned national clinical guideline on smoking cessation 
interventions and will inform policy decisions about potential improvements to 
the provision of smoking cessation services in the public health service. 
Work on the assessment was undertaken by an Evaluation Team from the 
HTA Directorate in HIQA. A multidisciplinary Expert Advisory Group was 
convened to advise HIQA during the course of the assessment. A public 
consultation is being carried out to get feedback from members of the public 
before finalising the report. 
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HIQA would like to thank its Evaluation Team, the members of the Expert 
Advisory Group and all who contributed to the preparation of this report. 
 
 
Dr Máirín Ryan, 
Deputy Chief Executive and Director of Health Technology Assessment, 
Health Information and Quality Authority
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Executive Summary 
Background and terms of reference 
The Health Information and Quality Authority (HIQA) agreed to undertake a health 
technology assessment (HTA) of smoking cessation interventions in Ireland following 
a formal request from the Department of Health’s National Tobacco Control Advisor. 
An evidence-based analysis of the clinical effectiveness and cost-effectiveness of 
treatments that help people stop smoking was carried out to ensure that the 
benefits achieved from the current level of funding available are maximised. This 
HTA will also provide evidence to support development of a national clinical guideline 
on smoking cessation. National Clinical Guidelines are quality assured by the National 
Clinical Effectiveness Committee (NCEC) and mandated by the Minister for Health to 
provide guidance and standards for improving the quality, safety and cost-
effectiveness of healthcare in Ireland. 
This HTA assesses the clinical and cost-effectiveness of pharmaceutical and non-
pharmaceutical interventions that aid smoking cessation, in order to inform policies 
aimed at helping individual smokers in their attempt to quit smoking. The Terms of 
Reference agreed between HIQA and the Department of Health were to: 
 Describe the range of smoking cessation therapies available. 
 Describe the epidemiology of smoking and smoking-related illness in Ireland. 
 Review the effectiveness and safety of the available smoking cessation 
interventions and their impact on long-term quit rates. 
 Compare the cost-effectiveness of interventions that are associated with 
improved rates of smoking cessation and estimate the costs associated with 
these interventions within the public health system in Ireland. 
 Examine any other relevant issues associated with a decision to change the 
provision of smoking cessation services by the HSE that may affect patients, 
staff or the organisation of existing services. 
 Based on this assessment, advise on the optimal use of smoking cessation 
interventions in Ireland. 
Methods 
This research was carried out in accordance with HIQA’s guidelines for the conduct 
of health technology assessments. In summary, the following took place: 
 The Terms of Reference of the HTA were agreed between HIQA and the 
Department of Health.  
 An Expert Advisory Group was convened, with representation from health 
policy decision-makers, clinicians, patient advocates, professional bodies and 
experts in health services research and economic evaluation. An Evaluation 
Team was appointed comprising HIQA staff. 
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 The Expert Advisory Group reviewed and endorsed a protocol defining the 
approach to be adopted in the evaluation. Long-term smoking cessation was 
the agreed primary outcome of interest, consistent with the broader 
population-based initiatives that aim for a tobacco-free Ireland. The primary 
population of interest was the general population of adult smokers. Specific 
subgroups of smokers were identified on the basis of important differences in 
either the clinical effectiveness or costs associated with their care. 
 The burden of smoking and smoking-related diseases in Ireland was 
assessed. 
 Smoking cessation interventions that are routinely available and used in 
Ireland were identified and described. A comprehensive review of the safety 
of these interventions was undertaken. 
 A systematic review and network meta-analysis was carried out to summarise 
the available evidence on the clinical effectiveness of smoking cessation 
interventions among a general population of adult smokers, users of 
secondary mental health services, and pregnant women.  
 An original economic evaluation was performed to estimate the cost-
effectiveness and budget impact of prospective changes in the mix of 
interventions used among the general population of adult smokers to help 
them quit.  
 Clinical outcomes examined in this HTA included the number of successful 
quit attempts, as well as longer term clinical outcomes in relation to smoking-
related mortality and morbidity.  
 The major costs examined in this HTA included the cost of pharmacological 
and behavioural smoking cessation interventions, and the costs of treating 
smoking-related illnesses in Ireland. 
 The primary analysis compared the cost-effectiveness of current practice in 
Ireland with alternative mixes of smoking cessation interventions. The choice 
of comparator was informed by the results of the clinical effectiveness 
analysis and international data on uptake rates of smoking cessation 
interventions in other countries.  
 The analysis was carried out from a quasi-societal perspective that included 
costs to the publicly funded health and social care system in Ireland, along 
with the costs of smoking cessation interventions that fall on individual 
smokers. The time horizon over which the costs and benefits of screening was 
calculated was 20 years and both costs and benefits were discounted at 5%.  
 A budget impact analysis which reports the incremental costs associated with 
changes to the provision of smoking cessation services over a five-year time 
horizon, was performed from the perspective of the public health system only.  
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 An analysis of the ethical, legal and organisational implications of changes to 
the provision of smoking cessation services was carried out to identify 
broader considerations that may influence decision-making. 
Technology description 
Currently, the Health Service Executive (HSE) policy is that every person who 
engages with front-line staff should be asked about their smoking status and the 
response should be documented. Every smoker should be advised to quit and 
offered support by HSE staff - this is known as ‘brief advice’ and should be provided 
at every opportunity. The HSE currently funds training in brief advice in the form of 
‘Brief Interventions for Smoking Cessation’. Training is aimed at a wide range of 
healthcare professionals in both the acute and community care settings. This 
support differs from intensive cessation support services that are provided by trained 
cessation specialists working in community or hospital settings, or with the national 
telephone-based intervention QUITline. Brief advice also raises awareness of the 
harms of smoking in order to discourage people from starting and to motivate more 
smokers to make a quit attempt. 
A diverse range of smoking cessation interventions is currently provided by the HSE 
to individual smokers in addition to the brief advice targeted at all smokers as 
outlined above. Based on the analysis conducted in this HTA, total annual 
expenditure on smoking cessation activity in Ireland is estimated to be over €40 
million. This figure includes the cost to the HSE of providing smoking cessation 
support though the HSE Tobacco Control Programme, the costs of GP services and 
pharmacological treatment to those with a medical card, as well as out-of-pocket 
expenditure by smokers on various smoking cessation products. Pharmacological 
interventions include nicotine replacement therapy (NRT), electronic cigarettes, 
antidepressants (specifically bupropion) and nicotine receptor partial agonists 
(specifically varenicline). Nicotine replacement therapy (NRT), varenicline and 
bupropion are currently reimbursed when prescribed through the Primary Care 
Reimbursement Scheme (PCRS), although reimbursement of NRT is limited to 
Medical Card holders only. Behavioural interventions funded and provided free-of-
charge by the HSE to all Irish residents include internet-based support 
(www.quit.ie), telephone-based support (QUITline), and HSE smoking cessation 
clinics which offer individual and group behavioural support in some locations. 
Electronic cigarettes, also known as e-cigarettes, are not currently advocated by the 
HSE as a means of quitting due to lack of long-term data on their safety. However, 
HSE smoking cessation services provide support to smokers who choose to use e-
cigarettes in their quit attempt in the form of the provision of information and 
behavioural interventions as appropriate to the individual smoker.  
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Epidemiology of smoking and smoking-related illness 
Over one in five (22.7%) people aged 15 years and over smoke in Ireland.(1) 
Smoking prevalence is higher in men (24.3%) than women (21.2%). In addition, 
19% of people are daily and 4% are occasional smokers. The prevalence of smoking 
in Ireland and the number of cigarettes smoked is in decline since 2008. It is difficult 
to determine the extent to which smoking decline will continue without changes 
being made to the quitting services provided to smokers. As smoking in Ireland 
declines, it is possible that the remaining group of smokers are those with high 
nicotine dependence and, or those who face barriers to accessing effective services.  
It is clear that there are inequalities in smoking cessation. Smoking prevalence is 
highest and successful quit attempts are lowest for smokers in the lowest socio-
economic groups. As the overall prevalence of smoking and the rate of new smokers 
declines, the demography of current smokers will change. This may require different 
approaches to how quitting services are delivered and which interventions are 
provided. 
Cigarette smoking has major negative implications for the health of current smokers, 
former smokers, and those exposed to second-hand smoke. Cigarette smoking 
results in significant morbidity and mortality, with further effects on quality of life 
and use of health service resources. Quitting smoking substantially reduces the risk 
of disease and can, over time, result in risks similar to that of people who have 
never smoked for a range of conditions.  
More than 5,400 deaths in Ireland each year are due to smoking. When deaths due 
to second-hand smoke are included, approximately one in five (20.5%) deaths each 
year are due to tobacco smoke. Using estimates of the proportion of disease that 
can be attributed to smoking, approximately 28,000 inpatient discharges and 11,000 
day cases are due to smoking each year in Ireland. 
Smoking during pregnancy is harmful. It is associated with an increased risk of 
congenital anomalies, preterm birth, intrauterine fetal growth restriction, placental 
abruption, stillbirth, sudden infant death syndrome, respiratory infection, adverse 
cognitive and behavioural outcomes in infancy, and the development of chronic 
disease in adulthood. 
Evidence shows that smokers with mental health disorders smoke more heavily, are 
more nicotine dependent, and have smoked for longer than smokers who do not 
have an underlying mental health disorder. The factors linking mental health 
conditions and cigarette smoking are varied and complex. Recent evidence suggests 
that quitting smoking may improve symptoms of mental illness. 
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Irish data on the prevalence of smoking in pregnancy and in people with mental 
health disorders are limited. Evidence from the Growing Up in Ireland (GUI) study 
reported that the prevalence of smoking in pregnant women in Ireland fell from 28% 
in 1998 to 18% in 2008. International data show that smoking prevalence is noted 
to be correlated with the severity of the mental illness, with prevalence rates of 33% 
to 70% reported for people with bipolar disorder and 45% to 88% for people with 
schizophrenia.  
Most smokers attempt to quit, and most do so more than once a year. Over time, 
smokers will typically make many attempts to quit before succeeding.It should be 
noted that smokers self-select what interventions they will use when attempting to 
quit. Data from the Healthy Ireland survey 2015 provide information on smoking 
behaviour and quit attempts in the Irish population. Half of those attempting to quit 
smoking in Ireland do so without help. A further 29% of smokers trying to quit use 
e-cigarettes as an aid. Approximately 16% of quit attempts are made using some 
form of pharmacotherapy (for example, NRT). However, reporting a quit attempt 
without support may not capture the interventions people have used on previous 
quit attempts. Those who make attempts without support may have used support 
previously and are therefore not necessarily without knowledge or understanding of 
what is involved. It is also possible that some smokers may consider receiving brief 
advice as ‘no support’, although there is no evidence to confirm or refute this. 
A number of legislative or policy interventions have been made in Ireland to reduce 
exposure to smoke and smoking. These include the bans on advertising, sales to 
minors, workplace smoking, and smoking in cars carrying minors. These policies are 
likely to have impacted on smoking either by encouraging quit attempts or by 
reducing the quantity of cigarettes smoked.  Population-level interventions support a 
move to a tobacco-free country. The interventions considered in this report support 
successful smoking cessation in individuals. As such, the individual-level factors that 
impact on successful quitting were considered, as well as how cessation services 
might be provided and organised in order to maximise successful cessation. 
Clinical effectiveness  
A review of clinical effectiveness considered studies evaluating smoking cessation 
interventions in three distinct population groups:  
1. general adult population’;  
2. people attending secondary mental health services;  
3. and pregnant women. 
 The primary outcome of interest was long term (six months or more) smoking 
cessation, and abstinence in late pregnancy in pregnant women. 
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General adult population 
An updated systematic review identified 313 studies that met the inclusion criteria 
for the general adult population, half of which were published after January 2000. 
Sixty two percent of the studies had follow up at 12 months or longer to estimate 
abstinence. A quarter of the studies were considered at low risk of bias. Sixty five 
percent of the studies used biochemical verification of quitting, and 58% measured 
continuous abstinence as distinct from point prevalence, that is to say abstinence at 
a point in time. 
Interventions could be broadly classified as pharmacotherapy or behavioural 
interventions. While the definitions of pharmacotherapy interventions were clear, 
definitions of behavioural interventions are not standardised. The absence of 
standard definitions for behavioural interventions, including the choice of treatment, 
provider and the duration, number and frequency of sessions added complexity to 
their classification. In addition, there may be overlap between behavioural 
interventions offered. Often, more than one support is provided at a time, and they 
may be provided with or without adjunct pharmacotherapy. In addition, many 
pharmacotherapy trials provided supportive care in the form of a behavioural 
intervention to both the control and intervention arm participants. 
A network meta-analysis of pharmacological and behavioural therapies was carried 
out. The effectiveness of each of the behavioural interventions was presented in 
relation to an active control, such as brief advice or written smoking cessation 
materials. 
All pharmacological interventions were found to be more effective than the control. 
Varenicline was the most effective single therapy, more than two and half times as 
effective as control. Varenicline with NRT was the most effective dual therapy, more 
than three and a half times as effective as control. Combination NRT was more 
effective than a single form of NRT alone. E-cigarettes were twice as effective as 
control however this estimate was based on only two trials including a relatively 
small number of participants. The evidence base for e-cigarettes will evolve as 
further trials are completed, and their effectiveness for smoking cessation should be 
re-evaluated as new evidence becomes available.  
All behavioural therapies were more effective than an alternative of ‘do nothing’. 
Group behaviour therapy was the most effective behavioural intervention, almost 
twice as effective as an active control, defined as brief advice or written materials. 
Individual counselling, intensive advice and telephone support were all found to be 
more effective than the active control. The substantial variation in how behavioural 
interventions were defined and delivered often resulted in differing treatment 
effects. Variability was seen in the frequency and intensity of interventions, with no 
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evidence of a dose-response relationship. The effectiveness of pharmacological 
interventions is improved by an average of 18% by providing adjunct behavioural 
therapy. 
Pregnant women 
In total 73 studies evaluating either pharmacological or behavioural interventions in 
pregnant women were included in this review. The studies broadly support the view 
that smoking cessation interventions are effective in pregnancy. Due to the fact that 
bupropion and varenicline are not recommended in pregnancy, NRT is the only 
pharmacotherapy licensed for use in pregnant smokers who wish to quit, and its 
efficacy appears to be lower in pregnant smokers than in non-pregnant smokers. 
Eight trials investigated NRT use as a smoking cessation aid in pregnancy, and they 
were deemed of high quality. Some evidence of a beneficial effect was found for 
NRT in this group with a 41% increase in cessation rates, but this did not reach 
statistical significance.  
The review identified 64 studies evaluating psychosocial interventions for smoking 
cessation in pregnancy; however, these were rated as being of low quality. There 
was evidence to suggest that counselling, health education and financial incentives 
increase cessation rates in pregnant smokers.  
Due to the limited effectiveness of interventions in pregnancy, smokers should be 
encouraged to quit prior to conception when more treatment options are available 
and therapy is more likely to succeed. As many smokers quit of their own accord in 
the early stages of pregnancy, it is possible that interventions in pregnancy 
(particularly in later pregnancy) are focused on more heavily dependent women and 
those with greater barriers to successful cessation. This may explain the lower 
efficacy compared with non-pregnant populations. The modest impact of NRT may 
be due to inadequate dosing in pregnancy. 
People attending secondary mental health services 
Ten studies examining smoking cessation interventions in people attending 
secondary mental health services were included in this review. In the mental health 
population group, efficacy data for cessation interventions were only retrieved for 
patients with schizophrenia, schizoaffective disorder and bipolar disorder. The only 
statistically significant evidence of a beneficial treatment effect was for bupropion 
when used as an adjunct to behavioural therapy plus NRT in a population with 
schizophrenia or schizoaffective disorder, where it was almost four times as effective 
as behavioural therapy plus NRT alone.  
The lack of evidence for effectiveness in the mental health population is due to the 
fact that few studies, in particular large-scale, high-quality studies, have been 
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conducted to date. Recruitment of patients to randomised controlled trials (RCTs) 
from mental health populations is reported to be problematic, and many trials 
focused on the adverse event profile rather than efficacy of the intervention. Studies 
excluded from this review include those that report shorter cessation outcomes and 
a smoking reduction rate. Researchers have speculated that reducing the risks of 
smoking, rather than cessation, may be a better initial focus for the mental health 
population due to the higher nicotine dependence and greater burden of disease 
compared with the general population. Absolute quit rates in the control arms 
tended to be low relative to those observed for the general population. Motivation to 
quit is important in this group; in two trials comparing bupropion to placebo, only 
one in three (33%) were motivated to quit smoking, lowering the likelihood of 
successful cessation.  
However, it is important to note that this review excluded the EAGLES 2016 trial; the 
largest trial conducted to date in patients with a current or previous mental heath 
condition comparing varenicline, bupropion, NRT and placebo. This trial did not meet 
the inclusion criteria of this clinical effectiveness review for participants to be 
attending secondary mental health services. However the safety data from the 
EAGLES trial was considered below. 
The studies included in this review were intended to be representative of the three 
populations of interest. In terms of age, gender, and level of dependency, the study 
populations would appear to be broadly applicable to the Irish setting. The mental 
health subgroup identified in this assessment relates to those attending secondary 
mental health services, and therefore may be considered to include those with more 
severe and enduring mental illnesses. The HSE Mental Health Division reports that 
over 90% of mental health needs can be successfully treated within the primary care 
setting. While the general adult population considered in this report would include 
those with mental health issues exclusively treated in primary care, the efficacy of 
smoking cessation interventions for this cohort was not specifically assessed. 
Safety 
A review of the safety profile of smoking cessation interventions found that 
pharmacological therapies are generally safe and well-tolerated in those for whom 
these treatments are medically indicated for use. Behavioural interventions were 
found to be safe. However, there are limited options available for certain patient 
groups, including pregnant women and certain mental health populations, due to 
contraindications* and relative contraindications to the use of selected 
pharmacological interventions.  
                                        
* A contraindication may be defined as a condition which makes a particular treatment 
potentially inadvisable. 
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Most adverse events associated with nicotine replacement therapy (NRT) are mild 
and temporary in nature. Commonly reported side effects include mild skin 
sensitivity (patch), hiccoughs and gastrointestinal disturbance (gum), local irritation 
of mouth, nose and throat (inhaler, spray and sublingual tablets). Chest pain and 
heart palpitations are the only potentially clinically significant serious adverse events 
to emerge from clinical trials. NRT does not appear to be associated with an increase 
in serious cardiovascular adverse events, in those with or without pre-existing 
cardiac disease. 
Nausea is the most commonly reported adverse event associated with using 
varenicline. Other common adverse events include insomnia, abnormal dreams and 
headache. There is conflicting evidence regarding cardiac adverse events associated 
with varenicline. A systematic review and meta-analysis from 2016 did not find 
evidence of an association in people with or without cardiovascular illness. Warnings 
about the use of varenicline in patients with pre-existing psychiatric conditions were 
lifted in May 2016 following the publication of safety and efficacy data from the 
EAGLES trial.  
The most common adverse events associated with the use of bupropion are 
insomnia, dry mouth and nausea. Allergic reactions requiring medical treatment are 
rare. Bupropion increases the risk for seizures; a seizure rate of one in 1000 is given 
in the product safety data. Bupropion is not recommended for use in patients with 
an increased risk of seizures, or in patients with a history of bipolar disorder as it 
may precipitate a manic episode.  
Nicotine crosses the placenta from mother to baby. The long-term fetal and neonatal 
effects of NRT are unclear; however, it is safer than continued smoking. No major 
congenital malformations associated with NRT use have been observed in 
randomised controlled trials and observational studies. NRT is recommended during 
pregnancy, particularly when behavioural therapy fails. However, the use of 
bupropion and varenicline is not recommended during pregnancy or breastfeeding. 
Safety data on e-cigarettes is limited to two small short-term clinical trials. Mild, 
temporary adverse drug reactions were found, such as throat and respiratory 
irritation and dry cough. Toxicological studies have demonstrated that while toxic 
chemicals may be present in e-cigarette vapour, they are at a lower concentration 
than in cigarette smoke. E-cigarettes have only been in use for a short time, and so 
data on long-term toxicity is not yet available. While the clinical effect of long-term 
e-cigarette use is unknown, the risk to bystanders from ‘passive vaping’ appears to 
be very low. The safety of e-cigarettes is an evolving area of research; while 
believed to be safer than smoking, evidence on long-term safety has yet to be 
established.  
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Economic evaluation 
A cost-effectiveness analysis found that all cessation interventions included in the 
analysis would be considered cost-effective when compared with unassisted quitting. 
E-cigarettes and using varenicline and NRT in combination were found to be the 
most cost-effective strategies when individual therapies are compared with each 
other. The cost-effectiveness of e-cigarettes is extremely sensitive to any new 
evidence that could change the estimated cost and effects of this intervention. This 
is of particular significance given the high degree of uncertainty that exists in 
relation to both its costs and effects.  
A comparison of alternatives to the current mix of smoking cessation interventions 
used in Ireland was carried out using international data as an indicator of plausible 
changes in the usage of the most cost-effective cessation interventions. This 
included a scenario where combination varenicline and NRT use was maximised, and 
a scenario where e-cigarette uptake reached levels recently reported in England. 
This analysis found that maximising the uptake of varenicline and NRT in 
combination is the most cost-effective strategy. 
However, it is unclear to what extent policy initiatives can influence overall smoking 
cessation preferences, particularly in light of the high use of e-cigarettes in Ireland in 
the absence of any explicit endorsement by quit services. Based on the currently 
available evidence, an increase in the uptake of e-cigarettes to rates of 45% 
currently reported in England is likely to improve the cost-effectiveness of the overall 
mix of cessation interventions in Ireland, by increasing the number of successful quit 
attempts, again at an acceptable cost.  
A budget impact analysis on the incremental cost associated with changes to the 
existing standard of care found that maximising the use of combination varenicline 
and NRT would be associated with an average increase of approximately €7.6 million 
in the annual cost of providing smoking cessation interventions in Ireland. A scenario 
analysis in which uptake rates of e-cigarettes is comparable to England (while still 
not being reimbursed through the Primary Care Reimbursement Scheme) was 
carried out. This analysis showed a resulting decrease in expenditure on smoking 
cessation interventions of approximately €2.6 million per year. Alternatively, if e-
cigarettes were funded to the same extent as NRT, the additional cost to the health 
service would be approximately €6 million per annum at current use rates, or €7.5 
million if this rose to rates currently reported in England. 
Wider implications 
From an ethical perspective, smoking is not generally considered to be morally 
wrong and therefore is a matter of individual choice for the consumer. Any smoking 
cessation intervention must be made available in a way that promotes individual 
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choice. This can be achieved by providing information concerning the risks and 
benefits associated with a particular intervention. In balancing ethical considerations 
of benefit versus harm, cessation aids have been shown to increase the chances of 
long-term quitting among those who are motivated to stop smoking. However, there 
are concerns about the social normalisation of some cessation aids, such as e-
cigarettes. If e-cigarette use becomes socially acceptable, it could lead to new use of 
nicotine by people who have never smoked before, later migration to tobacco 
cigarettes, long-term nicotine dependency, and other potential as yet unknown 
harms. When scientific data are contradictory or quantitatively scarce, it may be 
necessary to make temporary decisions that can be changed as new facts become 
known. In the absence of clear evidence in relation to potential long-term risks 
associated with some smoking cessation interventions, such as e-cigarettes, such an 
approach would involve continuing to advise smokers who wish to quit of all the 
cessation interventions while providing as much information as possible in relation to 
safety and efficacy.  
Marketing and advertising are important in public perception of smoking cessation 
interventions. The government has an ethical duty to ensure that the media 
portrayal of the product is appropriately aligned with its known degree of risk. This is 
the dealt with in the recent EU Tobacco Products Directive, which aims at 
harmonising the quality and safety requirements of tobacco products and e-
cigarettes for the benefit of consumers. Although negative health effects from the 
use of e-cigarettes are currently unknown, there is concern that potential legal 
liability may be possible if future research finds that negative effects do result from 
their use. Provided appropriate warnings and information leaflets containing accurate 
information are included with the sale of any such product, it is difficult to see how a 
legal action might successfully be taken if this were to occur. 
From an organisational perspective, efforts to increase the use of combination 
varenicline and NRT will place additional demands on general practitioner (GP) or 
nurse prescriber services. In the event that use of this intervention reaches plausible 
maximum levels, the number of prescriptions required could increase by over 50%. 
However, it is recognised that many smoking cessation interventions are 
opportunistic, with healthcare providers availing of opportunities to encourage 
cessation as part of consultations primarily directed at other areas of care.  
Alternatively, if e-cigarette use in Ireland (26%) rose to maximum levels currently 
reported in England (45%), and smokers choose this option without seeking medical 
advice, the number of prescriptions required could fall by nearly 40%. E-cigarettes 
are unusual as they are the only intervention in this analysis that is not advocated by 
HSE QUIT services or funded through the public health system. If the results 
reported so far are confirmed in subsequent trials and e-cigarette use continues to 
rise, there is a risk that an ever greater number of people will attempt to quit 
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smoking without involving any trained smoking cessation staff and the potential 
benefit of providing this treatment in conjunction with behavioural support 
interventions may be lost. Given the increasing use of e-cigarettes, it is of vital 
importance that their potential benefit and harms continue to be discussed with 
smokers to ensure informed decision-making in relation to their use. As new 
evidence emerges, there is likely to be ongoing resource implications for the health 
service to educate providers on this topic and to ensure that consistent advice is 
provided. In the long term, decreased smoking prevalence will result in a lower 
prevalence of smoking-related diseases and decreased demands on services 
providing treatment for these conditions. However, these changes are unlikely to be 
seen for many years. 
Best practice guidelines for smoking cessation have been developed to support 
mental health service providers. However, in the absence of reliable data, the extent 
to which smoking cessation interventions are consistently being offered to or availed 
of by smokers in secondary care mental health services in Ireland is unknown. There 
is limited evidence for smoking cessation interventions in the mental health 
population due to difficulties in recruiting and conducting randomised controlled 
trials (RCTs) in this population. As a result, it is difficult to make specific 
recommendations in terms of resource impact. Bupropion as an adjunct to 
behavioural therapy and NRT was found to have a beneficial effect in a population 
with schizophrenia or schizoaffective disorder. In the absence of evidence to say 
otherwise, it is assumed that interventions which are effective in the general 
population are also beneficial in mental health populations. International data 
suggest that smoking prevalence among the mental health population has changed 
little over the past 20 years. Specialist inpatient and community mental health 
services are particularly suited to the provision of tailored support by experienced 
mental health staff. However, the resource implications for providing interventions 
and staff training may be significant given the recognised staffing constraints that 
exist in mental health settings.  
Based on the available evidence, pregnant women who smoke should be offered a 
psychosocial intervention in the first instance. The psychosocial intervention with the 
largest body of evidence to support its effectiveness is counselling. Maternity 
services should ensure that all front-line staff are trained in some form of counselling 
intervention. The most significant resource implication for the implementation of 
counselling is time, both in antenatal clinics and training time. Evidence for the 
effectiveness of NRT for smoking cessation in pregnancy is unclear. Other smoking 
cessation interventions that are effective in pregnancy will have varying levels of 
resource implications. Health education interventions may require fewer resources, 
while incentives and feedback interventions may require more intensive resources in 
terms of time, training and finances. 
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Discussion 
This assessment shows that smoking cessation interventions are cost-effective when 
compared with unassisted quitting. E-cigarettes and use of varenicline and NRT in 
combination provide the best value for money based on currently available 
information. However, the effect estimate for e-cigarettes is based on pooling two 
trials. Neither trial found a statistically significant benefit, and both had absolute quit 
rates in the control and intervention arms that were low compared with average 
absolute quit rates among trials of other interventions with comparable relative 
effect sizes. Given the limited number of randomised controlled trials (RCTs) and the 
rapidly evolving range of e-cigarette products, there is a high level of uncertainty 
surrounding both the clinical and cost-effectiveness of this intervention. The results 
of the economic analysis of e-cigarettes are extremely sensitive to changes in both 
these parameters. There is also considerable uncertainty about the long-term health 
effects of e-cigarette use, along with concerns that their widespread promotion by 
health professionals could normalise nicotine consumption or act as a gateway to 
using tobacco for new generations of people who have never previously smoked.  
The assessment found that increasing the uptake of varenicline and NRT to the most 
likely maximum levels was the optimal strategy for improving quit rates. This would 
also be associated with significant additional drugs costs and increases in demand 
for GP and nurse prescribing services. There is considerable uncertainty about the 
extent to which health policy can influence uptake rates of different interventions 
among smokers, particularly given the existing low uptake rates of the most 
effective interventions observed in Ireland and elsewhere. While it is beyond the 
scope of this analysis to specify policy measures that could be used to reduce 
smoking rates, this HTA has identified policy objectives that smoking cessation 
services could work towards and considered the desirability or otherwise of expected 
changes that are likely to occur given current trends in the uptake of smoking 
cessation interventions.  
International data suggest that e-cigarette use will continue to grow in popularity as 
an aid to smoking cessation. Based on the available evidence, this would also be 
expected to improve quit outcomes compared with current practice, though less 
than that of maximising combination varenicline and NRT use. These results are 
again likely to change when further research becomes available. Increased e-
cigarette use would also likely result in lower expenditure by the public health 
system on other prescription drugs due to a decline in their uptake, assuming the 
current funding model remains unchanged. For those choosing to make a quit 
attempt without the aid of pharmacotherapy or e-cigarettes, there is good evidence 
to show that behavioural support increases quit rates compared with receiving no 
support. There is insufficient evidence to reliably differentiate between the 
effectiveness of different types of behavioural support when used in combination 
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with pharmacotherapy. However, based on existing studies the addition of any type 
of behavioural support is associated with a beneficial effect on quitting outcomes. 
Rather than considering other potential benefits of behavioural support and 
educational interventions (for example, harm reduction by reducing the number of 
cigarettes smoked per day, reducing the risk of relapse for those who successfully 
quit smoking), this analysis focuses solely on quit outcomes and may underestimate 
the clinical effectiveness and cost-effectiveness of some of the interventions 
evaluated. 
The evidence for smoking cessation treatments among specific subgroups of the 
population is more limited. Although there is a lack of data on the relative 
effectiveness of different smoking cessation interventions for people attending 
secondary mental health services, high-intensity programmes combining 
pharmacotherapy and behavioural support have been shown to improve quit 
outcomes in this group. Among pregnant women, behavioural support interventions 
such as counselling, health education and the use of financial incentives can 
significantly improve quit outcomes during pregnancy. 
Conclusion 
Smoking cessation services should seek to increase the uptake of the use of 
varenicline (alone or in combination with NRT or bupropion) among smokers wishing 
to use some type of pharmacological support in their attempt to quit. Although the 
available results for e-cigarettes are promising, there is insufficient evidence to 
demonstrate their effectiveness as an aid to smoking cessation at present. It would 
be appropriate to await the results of ongoing trials before deciding whether e-
cigarettes should be recommended for those for whom varenicline is 
contraindicated, not tolerated or non-preferred. The addition of any type of 
behavioural support is associated with a beneficial effect on quitting outcomes. 
High-intensity interventions combining pharmacotherapy and behavioural support 
have been shown to improve quit outcomes in people attending secondary mental 
health services. Among pregnant women, behavioural support interventions such as 
counselling, health education and the use of financial incentives can significantly 
improve quit outcomes during pregnancy. 
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1 Introduction 
1.1 Background to the request 
The Health Information and Quality Authority (HIQA) agreed to undertake a health 
technology assessment (HTA) of smoking cessation interventions in Ireland following 
receipt of a formal request for a HTA from the National Tobacco Control Advisor to 
the Department of Health. HIQA had previously been notified of a general motion 
carried at an annual general meeting of the Irish Medical Organisation calling on 
HIQA to carry out HTAs on both pharmaceutical and non-pharmaceutical smoking 
cessation products and services in order to properly inform smokers, health service 
managers, health professionals and politicians on the merits or otherwise of 
providing smoking cessation services to the smoking population. 
Reducing the numbers of smokers in Ireland is a long-established priority within the 
public health system. The mortality rate in smokers is two to three times higher than 
in those who have never smoked.(2) Twelve percent of mortality globally can be 
attributed to tobacco smoking, including second-hand smoke.(3) In 2015, 22.7% of 
persons aged 15 years and over in Ireland were smokers, and 18% of all deaths 
each year are attributable to tobacco smoke. When deaths due to second-hand 
smoke are included, approximately one in five (20.5%) deaths each year are due to 
tobacco smoke (see Chapter 3).  
The economic cost of smoking in Ireland is substantial. In 2013, the estimated cost 
to the healthcare system was over €460 million, the cost of lost productivity was 
over €1 billion, and the cost of loss of welfare was over €9 billion.(4)  
In October 2013, the Department of Health published its policy document ‘Tobacco 
Free Ireland’. This outlined the multi-faceted approach, targets and action plan for 
achieving a population smoking prevalence of less than 5% by 2025.(5) The policy 
and rationale of the report was based on the World Health Organization’s (WHO) 
MPOWER model.(6) This model was developed to enable countries to implement the 
Framework Convention on Tobacco Control measures. Six effective and evidence-
based tobacco control policies are identified by this framework:  
1. Monitoring of tobacco use and prevention policies 
2. Protecting people from second-hand smoke 
3. Offering to help people who want to quit 
4. Warning of the dangers of tobacco 
5. Enforcing bans on advertising, promotion and sponsorship  
6. Raising taxes on tobacco.  
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’Tobacco Free Ireland’ also includes themes such as protecting children, 
denormalisation of tobacco use, building and maintaining compliance with tobacco 
legislation and regulating the tobacco retail environment. Interventions provided to 
promote smoking cessation in current smokers who wish to quit may also impact on 
other policy areas, for example, the use of behavioural interventions to raise 
awareness of the dangers of tobacco and to motivate and encourage more smokers 
to make an attempt to quit. While the remit of this assessment is limited to smoking 
cessation, some of the interventions detailed may have an impact beyond what is 
considered in this report. 
A diverse range of smoking cessation interventions is currently funded by the public 
health system in Ireland. Pharmaceutical interventions that are currently reimbursed 
through the Primary Care Reimbursement Scheme (PCRS) include nicotine 
replacement therapy (NRT), varenicline and bupropion. The Health Service Executive 
(HSE) also provides and promotes a wide range of behavioural interventions, 
ranging from the internet-based intervention www.quit.ie , the telephone-based 
intervention QUITline, and a range of HSE QUIT clinics and courses, including 
individual and group behavioural support in some areas.(7) 
An evidence-based analysis of the clinical and cost-effectiveness of the existing mix 
of smoking cessation treatments was deemed necessary to consolidate activity by 
the HSE in this area and to ensure that the clinical benefits that can be obtained 
from the existing allocation of funding are maximised. This HTA will also provide the 
evidence to underpin development of a planned national clinical guideline on 
smoking cessation. National Clinical Guidelnes are quality assured by the National 
Clinical Effectiveness Committee (NCEC) and mandated by the Minister for Health to 
provide guidance and standards for improving the quality, safety and cost-
effectiveness of healthcare in Ireland. 
1.2 Terms of reference 
The Terms of Reference agreed between HIQA and the Department of Health were 
to: 
 Describe the range of smoking cessation therapies available. 
 Describe the epidemiology of smoking and smoking-related illness in Ireland. 
 Review the effectiveness and safety of the available smoking cessation 
interventions and their impact on long-term quit rates. 
 Compare the cost-effectiveness of interventions that are associated with 
improved rates of smoking cessation and to estimate the costs associated 
with these interventions within the public health system in Ireland. 
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 Examine any other relevant issues associated with a decision to change the 
provision of smoking cessation services by the HSE that may affect patients, 
staff or the organisation of existing services. 
 Based on this assessment, to advise on the optimal use of smoking cessation 
interventions in Ireland. 
The ‘Tobacco Free Ireland’ report outlines a range of initiatives, including 
population-based initiatives that aim to reduce the prevalence of smoking in Ireland 
to less than five percent by 2025.(5) The remit of this HTA is to assess the clinical 
and cost-effectiveness of pharmaceutical and non-pharmaceutical interventions that 
aid smoking cessation to inform policies aimed at helping individual smokers in their 
quit attempt. Harm reduction interventions designed to reduce the number of 
cigarettes smoked per day and interventions to reduce the risk of relapse for those 
who successfully quit smoking are outside the scope of this assessment. By 
excluding harm reduction outcomes, the HTA may underestimate the clinical 
effectiveness and cost-effectiveness of some of the interventions evaluated. The 
HTA examines other relevant issues in relation to the provision of smoking cessation 
services in order to advise on the optimal mix of treatment to help smokers quit. As 
noted, the HTA will also form the basis of a national clinical guideline on smoking 
cessation.  
1.3 Overall approach 
HIQA convened an Expert Advisory Group (EAG) comprising representation from 
relevant stakeholders. The role of the EAG is to inform and guide the process, 
provide expert advice and information and to provide access to data where 
appropriate. A full list of the membership of the EAG is available in the 
acknowledgements section of this report. The Terms of Reference of the EAG were 
to: 
 contribute to the provision of high quality and considered advice by the 
Authority to the HSE 
 contribute fully to the work, debate and decision-making processes of the 
group by providing expert guidance, as appropriate 
 be prepared to provide expert advice on relevant issues outside of group 
meetings, as requested 
 provide advice to the Authority regarding the scope of the analysis 
 support the Evaluation Team led by the Authority during the assessment 
process by providing access to pertinent data, as appropriate 
 review the project plan outline and advise on priorities, as required 
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 review the draft report from the Evaluation Team and recommend 
amendments, as appropriate 
 contribute to the Authority’s development of its approach to HTA by 
participating in an evaluation of the process on the conclusion of the 
assessment. 
HIQA appointed an Evaluation Team comprising internal staff from the Health 
Technology Assessment directorate to carry out the assessment.  
The Evaluation Team circulated a protocol to the EAG outlining the proposed 
approach to synthesising the available evidence in order to estimate the clinical 
effectiveness, cost-effectiveness and budget impact of smoking cessation 
interventions in Ireland. Consistent with the broader population-based initiatives that 
aim for a tobacco-free Ireland, the agreed primary outcome of interest was long-
term smoking cessation. Feedback was sought from the EAG on the specific 
subgroups of smokers that would be examined separately on the basis of important 
differences in either the clinical effectiveness or costs associated with their care. 
Given the additional time and resources needed to conduct separate assessments, it 
was noted that the number of subgroups must be limited to those of the highest 
priority in terms of policy making. Two distinct subgroups were identified and 
endorsed by the EAG: pregnant women, and people with serious mental illness. It 
was recommended that the latter subgroup should be defined on the basis of the 
setting and services within which care is provided rather than on the basis of their 
underlying illness with a view to maximising the usefulness of this analysis to inform 
future national guidelines and policy making. The mental health subgroup was 
therefore defined as those accessing secondary mental health services [inpatient, 
residential and long-term care for serious mental illness in hospitals, psychiatric and 
specialist units and secure hospitals] and patients who are within the care of 
specialist community-based multidisciplinary mental health teams. 
The Terms of Reference of the HTA were reviewed by the EAG at the initial meeting 
of the group. Interim findings from the assessment as well as other issues including 
the results for the cost-effectiveness model were discussed at a subsequent 
meeting. A draft report is being made available for public consultation prior to being 
finalised. Amendments will be made, as appropriate, and the draft will be reviewed 
again by the EAG before its submission for approval by the HIQA Board. The 
completed assessment will then be submitted as advice to the Minister for Health 
and the HSE and published on the HIQA website. 
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1.4 Public consultation 
The draft health technology assessment is being launched for a period of public 
consultation on 5 January 2017. The consultation process will run until 3 February 
2017. Key stakeholders will also be targeted via e-mail to alert them to the public 
consultation. A consultation feedback form has been developed to assist people in 
making a written submission. The draft assessment and feedback form for the public 
consultation are publically available in a downloadable format on HIQA’s website: 
www.hiqa.ie. As noted, following the consultation period, amendments will be made, 
as appropriate, before the assessment is finalised. A statement of outcomes report 
detailing the feedback received and the response to comments will also be 
published. 
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2 Description of the technology 
The interventions evaluated in this health technology assessment (HTA) are limited 
to those that can be provided to smokers at an individual level to help them increase 
their chances of quitting for good. This can include pharmacotherapy, behavioural 
support, or a combination of the two. Excluded from this analysis are interventions 
that are enacted at a societal level to reduce the number of people who start 
smoking in the first place, or that work as a disincentive to continued tobacco use. 
This includes measures such as packaging and advertising regulations, increased 
taxation, and limiting the locations where smoking is permitted.  
Furthermore, given the vast array of interventions that could potentially be provided 
to individual smokers, it is necessary to prioritise those that are most relevant to 
policy makers, patients and the Irish health system, as an exhaustive review of the 
clinical effectiveness and safety of all possible treatment options is not feasible. 
Identification of interventions for inclusion in this HTA was performed by combining 
recently published overviews of cessation interventions with data on the most 
commonly used treatments in Ireland, and advice from the Expert Advisory Group 
(EAG).  
It is also important to note that each of the included interventions is of interest only 
insofar as they help increase the chances of long-term smoking cessation. This HTA 
does not examine the impact of the interventions in terms of any potential harm 
reduction associated with their use, such as helping people to reduce the number of 
cigarettes smoked per day, reducing exposure to second-hand smoke, or relapse 
prevention measures. Neither does it extend to examining the relative effectiveness 
of different patient recruitment strategies that may be employed with various 
treatment modalities. Issues of access to, and uptake of, smoking cessation 
treatments in Ireland, and the likely implications of any potential future policy 
changes, are described in Chapter 7. 
2.1 Smoking cessation interventions 
Smoking cessation interventions that were evaluated in this HTA include both 
pharmacological and non-pharmacological interventions. The pharmacological 
interventions assessed were: nicotine replacement therapy (NRT), electronic 
cigarettes (e-cigarettes), antidepressants (specifically bupropion) and nicotine 
receptor partial agonists (NRPAs). The non-pharmacological interventions assessed 
were: acupuncture, and a range of behavioural interventions including motivational 
interviewing, brief advice, telephone-based interventions, internet-based 
interventions, mobile phone-based interventions, individual behavioural counselling, 
group behaviour therapy and the Allen Carr method. Financial incentives for 
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pregnant women to quit were also evaluated. The effectiveness and safety of these 
interventions is reviewed in detail in Chapters 4 and 5.  
2.1.1 Pharmacological interventions for smoking cessation 
There is a range of pharmacological interventions available for smoking cessation in 
Ireland. Figure 2.1 provides a timeline of important dates in relation to their 
availability, licensing status and reimbursement. The individual interventions are 
discussed in more detail in the sections below. 
Figure 2.1 Sales of pharmacological aides in Ireland – key dates 
 
2.1.1.1 Nicotine Replacement Therapy (NRT) 
Nicotine replacement therapy (NRT) aims to reduce the physiological and 
psychomotor withdrawal symptoms that smokers experience during a quit attempt, 
by replacing the nicotine from cigarettes by nicotine delivered without the use of 
tobacco.(8, 9) Due to the way in which nicotine is metabolised, oral tablets do not 
provide an efficient method of achieving adequate levels of the drug in the central 
nervous system. This has lead to the development of NRT products designed for 
absorption through the oral or nasal mucosa (chewing gum, lozenges, sublingual 
tablets, inhaler or inhalator, spray) or through the skin (transdermal patches).(8) NRT 
products may be used alone or taken in combination with other NRT products. It is 
generally recommended that NRT products are taken in conjunction with behavioural 
support and counselling. 
A range of NRT products have been licensed for use in Ireland since 1995. These 
products are regulated by the Health Products Regulatory Authority (HPRA) 
(available at www.hpra.ie). In 2014, the HPRA authorised Nicorette™ as the first 
NRT product to be sold in general retail and grocery outlets in Ireland, as opposed to 
being a pharmacy-only product. NRT products have been funded for Medical Card† 
holders through the Primary Care Reimbursement Scheme (PCRS) since 2001.(10) 
                                        
† Medical Cards allow people to access Family Doctor or GP services, community health services, dental services, 
prescription medicine costs, hospital care and a range of other benefits free of charge. Anyone above the age of 
16 and ordinarily resident in Ireland may apply for a Medical Card and eligibility is based on assessment of 
means. 
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While all NRT products available in Ireland are now available without a prescription, 
to be reimbursed through the PCRS they must be prescribed by a doctor or nurse 
prescriber who is registered with the PCRS. NRT prescriptions are not currently 
reimbursed by the PCRS for other categories (for example the Drug Payment 
Scheme‡) which may act as a disincentive for its use in these groups. The HSE also 
provides NRT at a discounted rate to hospital staff in certain locations to promote 
the health and wellbeing of staff, and as a support to the implementation of the HSE 
tobacco-free campus policy.(11) 
Beyond Ireland, only the UK fully funds NRT in Europe. France and Cyprus fund NRT 
with restrictions, Belgium funds NRT for pregnant women only, and Denmark funds 
NRT in certain counties.(12)  
While generally safe, the most serious adverse events reported with NRT 
administration are heart palpitations and chest pain, but there is no evidence of an 
increase in heart attacks or death.(4) More common, and less serious, adverse events 
include gastrointestinal complaints and insomnia.(4) Other adverse events are specific 
to the mode of administration, including skin irritation via transdermal patch, mouth 
soreness and ulceration via oral route, and throat irritation and coughing via inhaler 
or spray.(4) The safety of NRT is assessed in detail in Chapter 5. 
NRT is not indicated in children aged less than 12 years; however, it may be 
administered to adolescents aged 12 to 18 years under the recommendation of a 
health professional.(13)  
Different NRT products may be taken in combination. This approach is particularly 
useful in smokers whose nicotine dependence is resistant to NRT when taken as 
monotherapy.(14) In Ireland, Nicorette® has advised combining its transdermal patch 
(INVISIPATCH™) with Nicorette® gum when monotherapy fails or for those who are 
heavy smokers.(15) Certain forms of NRT are also licensed for periods of temporary 
abstinence from smoking, such as Nicorette® inhaler and gum.(16) Information on 
the range of NRT products available in Ireland is summarised in Table 2.1. 
 
                                        
‡ Under the Drugs Payment Scheme, an individual or family in Ireland pays a set amount each month (€144 in 
December 2016) for approved prescribed drugs, medicines and certain appliances for use by that person or his 
or her family in that month. 
http://www.hse.ie/eng/services/list/1/schemes/drugspaymentscheme/Your_Guide_to_Drugs_Payment_Scheme.html  
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Table 2.1 Nicotine replacement therapy (NRT) products and usual treatment regimens(13) 
Type of NRT Brand Name(s) Typical Regimen Behavioural support Contraindications 
Transdermal 
Patch 
Nicorette®  
Invisi Patch™, 
Nicotinell® TTS, 
NiQuitin® Patch 
Regimen for Nicorette® Invisi Patch™: 
Heavy smokers (>20 CPD): 
25mg for 8 weeks, then 15mg for 2 
weeks, then 10mg for 2 weeks 
Light smokers (<20 CPD): 
15mg for 8 weeks then 10mg for 4 
weeks 
 
Concurrent behavioural 
support is recommended 
Use in non-smokers 
Patients with hypersensitivity to 
nicotine or any of the components of 
the patch 
Patients with acute unstable coronary 
conditions, recent cerebrovascular 
accident 
Diseases of the skin at patch site 
Children under 12 (for those aged 12 
to 18 years, use is indicated only 
under the recommendation of 
healthcare professional) 
Gum Nicorette® Gum, 
Nicotinell® Gum 
Regimen for Nicorette® Gum: 
Heavy smokers (>20 CPD): 
4mg for 12 weeks (when there is an 
urge to smoke, max 15 per day) 
 
Light smokers (<20 CPD): 
2mg for 12 weeks (when there is an 
urge to smoke, max 15 per day) 
Patient counselling and 
support normally improve the 
success rate 
Use in non-smokers  
Patients with hypersensitivity to 
nicotine or any of the other 
ingredients in the gum 
Lozenge Nicorette® Lozenge, 
Nicotinell® Lozenge, 
NiQuitin® Lozenge 
Regimen for Nicorette® Lozenge: 
Heavy smokers (>20 CPD): 
4mg for 6 weeks, to a maximum of 9 
months, (when there is an urge to 
smoke, max 15 per day) 
Light smokers (<20 CPD): 
2mg for 6 weeks, to a maximum of 9 
months, (when there is an urge to 
smoke, max 15 per day, and 
discontinued when dose is reduced to 1-
2 per day)  
 
Should preferably be used in 
conjunction with a 
behavioural support 
programme 
Use in non-smokers or children under 
12 
Patients with hypersensitivity to 
nicotine or any of the ingredients of 
the lozenge. 
People with hypersensitivity to peanut 
or soya (NiQuitin® Lozenge) 
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Type of NRT Brand Name(s) Typical Regimen Behavioural support Contraindications 
Inhaler Nicorette® Inhaler Nicorette® Inhaler should be used 
whenever the urge to smoke is felt, up 
to a maximum usage of six 15mg 
cartridges per day, for a maximum of 3 
months 
Counselling and support from 
family, friends and health 
professionals can improve 
the chances of abstinence 
Use in non-smokers or children under 
12 
Patients with hypersensitivity to 
nicotine or any of the excipients of 
the inhaler  
 
Spray Nicorette® QuickMist 
Spray 
One spray delivers 1 mg nicotine in 0.07 
ml solution.  
Weeks 1-6: Use 1 or 2 sprays when 
cigarettes normally would have been 
smoked or if cravings emerge.  
Weeks 7-12: Start reducing the number 
of sprays per day. When subjects have 
reduced to 2-4 sprays per day, 
oromucosal spray use should be 
discontinued. 
 
Should preferably be used in 
conjunction with a 
behavioural support 
programme 
Use in non-smokers or children under 
12 
Patients with hypersensitivity to 
nicotine or any of the excipients of 
the spray 
 
Oro-dispersible 
Film 
NiQuitin® Strip Each orodispersible film contains 2.5 mg 
nicotine. 
Weeks 1 to 6: 1 nicotine film every 1 to 
2 hours 
Weeks 7 to 9: 1 nicotine film every 2 to 
4 hours 
Weeks 10 to 12: 1 nicotine film every 4 
to 8 hours 
 
Should preferably be used in 
conjunction with a 
behavioural support 
programme 
Use in non-smokers or children under 
12 
Patients with hypersensitivity to 
nicotine or any of the excipients of 
the film 
 
Key: NRT – nicotine replacement therapy; CPD – cigarettes per day; TTS – transdermal therapeutic system   
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2.1.1.2 Electronic cigarettes (e-cigarettes) 
E-cigarettes, also known as electronic nicotine delivery systems (ENDS), are 
electronic devices that heat a liquid to produce an aerosol (commonly referred to as 
vapour) which is then inhaled by the user. The liquid is contained in a reservoir 
within the device and generally consists of propylene glycol and glycerol, with or 
without nicotine and flavourings.(17) E-cigarettes do not contain tobacco, but provide 
sensations that are similar to cigarette smoking. This may help smokers achieve 
long-term abstinence by alleviating some of the sensory and behavioural challenges 
associated with smoking cessation, as well as helping to reduce nicotine withdrawal 
symptoms (in cases where the liquid also contains nicotine). 
Since their invention in 2003, there has been constant innovation and development 
of more efficient and appealing e-cigarette products. Currently, there are mainly 
three types of devices available.(18) First-generation devices generally mimic the size 
and look of regular cigarettes and consist of small lithium batteries and liquid-filled 
cartridges. Batteries may be disposable (to be used once only) or rechargeable. 
Second-generation devices consist mainly of higher-capacity lithium batteries and 
atomizers, with the ability to refill them with liquid (sold in separate bottles). Third-
generation devices consist of very large-capacity lithium batteries with integrated 
circuits that allow users to change the voltage or power (wattage) delivered to the 
atomizer. Studies to date have mostly analysed first-generation devices in terms of 
efficacy and safety.(18) 
Chemical and toxicological studies indicate that the use of e-cigarettes may be less 
harmful than smoking.(18) There is no tobacco and no combustion involved in e-
cigarettes use; therefore, regular users may avoid several harmful toxic chemicals 
that are typically present in the smoke of tobacco cigarettes. However, studies have 
demonstrated that trace amounts of potentially harmful chemicals may be released, 
such as formaldehyde and acetaldehyde,(19) and tobacco-specific nitrosamines 
(TSNAs).(20) It is worth noting, however, that levels of these compounds are 
substantially lower than that found in tobacco smoke, and in some cases (such as 
nitrosamines), are comparable to the amounts found in pharmaceutical nicotine 
products.(21)  
Passive inhalation of e-cigarette emissions has not yet been shown to be harmful; 
however, more studies are required in this area.(18, 22) For those who switch to using 
e-cigarettes containing nicotine, there is also concern around the health effects of 
sustained nicotine addiction. Direct confirmation from clinical studies that long-term 
e-cigarette use is safe and leads to reductions in smoking-related diseases is not 
available, and it will take a few decades before a beneficial effect relative to 
continued smoking can be established. Nonetheless, it is feasible to detect early 
changes in airway function and respiratory symptoms in smokers switching to e-
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cigarettes. Initial findings from long-term studies support a beneficial effect of e-
cigarette use in relation to respiratory outcomes when compared to continued 
smoking.(23) The safety of e-cigarettes is discussed in detail in Chapter 5. 
In Ireland, e-cigarettes are generally sold over the counter in retail premises; no 
product currently has a licensed indication for smoking cessation. In the UK, one e-
cigarette product has been licensed, however as of December 2016 it has not yet 
been marketed.(24) In May 2016, the regulations transposing the European Union 
(Manufacture, Presentation and Sale of Tobacco and Related Products) Directive into 
Irish law was signed. This provided for greater regulation in relation to the safety 
and quality requirements for e-cigarettes and refill containers, as well as stricter 
rules on advertising and sponsorship, and registration requirements for cross-border 
distance sales.(25) 
Since e-cigarettes first became available in 2006, there has been a significant 
increase in the prevalence of e-cigarette use. One large-scale study of e-cigarette 
use across the EU reported an increase in ever use (defined as current use or any 
past use or attempted use) from 7.2% in 2012 to 11.6% in 2014.(26) The majority of 
respondents to this survey were current or ex-smokers, with desire to quit reported 
as a major reason for their use. 
There is general agreement that compared with tobacco smoking, e-cigarette use 
reduces users’ exposure to toxic substances and, in the UK, support appears to be 
growing within the public health system for their use.(17, 27) However, many health 
organisations have been reluctant to support the use of e-cigarettes, citing a lack of 
long-term data on the effect of their use on users and those exposed to the exhaled 
vapour, concerns about the quality controls used in their manufacture, and fears 
that these devices will act as a gateway to tobacco use or to the renormalisation of 
smoking in society.(28) While the HSE smoking cessation services do not currently 
recommend their use as a means of quitting, they do provide support to individuals 
who choose to use e-cigarettes during a quit attempt.(29) 
2.1.1.3 Bupropion 
A number of different medications designed to treat depression have been studied 
as potential smoking cessation interventions. The exact mechanism by which these 
agents contribute to smoking cessation has not been definitively established.(30) The 
two drugs that have been studied most frequently in this context are bupropion and 
nortriptyline, and of these, only bupropion is currently licensed in Ireland for smoking 
cessation, under the brand name Zyban™. Due to the fact that it is not currently 
available in Ireland, nortriptyline is not included among the treatments examined in this 
HTA. 
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The most commonly reported adverse events associated with bupropion include 
insomnia, nausea or vomiting, and dizziness.(31) Bupropion is also associated with an 
increased risk of seizures (occurring at a rate of one in 1000 users, as per the 
product safety data).(32) Concurrent use of medications that lower seizure threshold 
must be avoided, such as antidepressants, antipsychotics, systemic corticosteroids, 
theophylline and tramadol. Patients who abuse alcohol or have sustained a head 
injury are also at risk of bupropion-induced seizure, as are patients who suffer from 
anorexia or bulimia nervosa.(33) Bupropion is contraindicated in patients with bipolar 
affective disorder, as this antidepressant can precipitate a manic, mixed, or 
hypomanic episode.(34) 
Concerns have been raised about the safety of bupropion (and varenicline, see 
section 2.1.1.4), particularly with regard to neuropsychiatric adverse events such as 
suicidality and aggression.(35) These concerns led to the EAGLES trial (Evaluating 
Adverse Events in a Global Smoking Cessation Study, published in April 2016), which 
sought to evaluate the neuropsychiatric safety of bupropion, varenicline and nicotine 
patch in smokers with and without psychiatric disorders. Relative to nicotine patch or 
placebo, the study did not show a significant increase in neuropsychiatric adverse 
events attributable to varenicline or bupropion in patients with or without pre-
existing psychiatric disorders.(36) It is important to note, however, the limitation of 
randomised controlled trials (such as the EAGLES trial) in capturing rare adverse 
events. The safety of included smoking cessation interventions is assessed in detail 
in Chapter 5.  
Use of bupropion is contraindicated in pregnant women in Ireland.(37) While studies 
are inconsistent, one epidemiological study of a registry of pregnancies found a 
higher frequency of cardiac malformations in pregnancies exposed to bupropion.(38) 
Conversely, another prospective safety study did not find a higher rate of major 
malformations; however, significantly more spontaneous abortions were 
observed.(39) The safety of bupropion is discussed in more detail in Chapter 5. 
Bupropion was licensed in Ireland in June 2000 as a prescription-only medication, 
and it is reimbursed on the Primary Care Reimbursement Scheme (PCRS).(16) Details 
on dosage, duration of treatment and contraindications for the use of bupropion are 
provided in Table 2.2.(13) 
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Table 2.2 Summary of usual treatment regimen and contraindications for 
 bupropion for smoking cessation(13) 
Parameter Details 
Brand name & dose Zyban™ 150 mg prolonged release tablets 
Behavioural support Indicated as an aid to smoking cessation in combination with 
motivational support in nicotine-dependent patients. 
Usual treatment 
regimen 
It is recommended that treatment is started while the patient is still 
smoking, and a target stop date is set within the first two weeks of 
treatment, preferably in the second week. 
The initial dose is 150 mg to be taken daily for six days, increasing 
on day seven to 150 mg twice daily. There should be an interval of 
at least eight hours between successive doses. The maximum single 
dose must not exceed 150 mg and the maximum total daily dose 
must not exceed 300 mg. Patients should be treated for seven to 
nine weeks. If at seven weeks no effect is seen, treatment should 
be discontinued. 
Contraindications Patients with hypersensitivity to bupropion or any of the 
medication’s excipients;  
those with a current seizure disorder or any history of seizures;  
those with a known central nervous system (CNS) tumour;  
those who are undergoing abrupt withdrawal from alcohol or any 
medicinal product known to be associated with risk of seizures on 
withdrawal;  
those with a current or previous diagnosis of bulimia or anorexia 
nervosa; those with severe hepatic cirrhosis;  
those taking monoamine oxidase inhibitors (MAOIs);  
those with a history of bipolar disorder;  
those being treated with any other medicinal product containing 
bupropion; 
pregnant women. 
2.1.1.4 Nicotine Receptor Partial Agonists 
Nicotine receptor partial agonists may help people to stop smoking by both reducing 
withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction 
(acting as an antagonist).(40) Three different agents in this class have been 
developed to date, however only one is currently licensed in Ireland. Varenicline 
(trade name Champix®) was licensed in Ireland in September 2006 as a 
prescription-only medication, and it is reimbursed on the Primary Care 
Reimbursement Scheme (PCRS).(30) 
Cytisine, sold under the trade name Tabex™, has been available in a number of 
eastern and central European countries since the 1960s, but is not licensed or 
distributed in Ireland or other western European countries.(41, 42) However, there has 
been renewed interest in this drug due to recent positive trial data and its relatively 
low cost.(43) 
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Varenicline is generally well-tolerated, with the most commonly reported adverse 
events consisting of nausea, abnormal dreams, insomnia, taste perversion, 
flatulence, dyspepsia, constipation, and headache.(44) Varenicline is not recommended 
during pregnancy, as the currently available studies of varenicline use in pregnancy are 
insufficient to provide evidence for safety.(45)  
Due to an initial concern of clinically significant neuropsychiatric events associated with 
varenicline administration, the European Medicines Agency issued a warning for its use 
in patients with pre-existing psychiatric conditions. However, this black triangle warning 
was subsequently removed in May 2016.(46) This emerged following publication of safety 
and efficacy data from the EAGLES (Evaluating Adverse Events in a Global Smoking 
Cessation Study) trial in April 2016 which found no increased incidence of adverse 
neuropsychiatric effects in patients with or without pre-existing psychiatric disorders.(36) 
Details on dosage, duration of treatment and contraindications for the use of varenicline 
are provided in Table 2.3.(13) 
Both varenicline and cytisine are assessed in this HTA. Although cytisine is not 
currently available in Ireland, there is a possibility that it may be licensed for use in 
the future, so an analysis of the clinical and cost-effectiveness of this treatment may 
be relevant in the medium to long term. However, all analyses are also carried out 
with cytisine excluded to reflect the current range of treatments currently available 
in Ireland.  
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Table 2.3 Summary of usual treatment regimen and contraindication for 
 varenicline for smoking cessation(13) 
Parameter Details 
Brand name & dose Champix® 0.5mg and 1mg film-coated tablets 
Behavioural support Smoking cessation therapies are more likely to succeed for patients 
who are motivated to stop smoking and who are provided with 
additional advice and support. 
Usual treatment 
regimen 
Dosing should usually start at one to two weeks before the target 
stop smoking date and treatment should continue for 12 weeks. For 
patients who have successfully stopped smoking at the end of 12 
weeks, an additional course of 12 weeks treatment at 1 mg twice 
daily may be considered for the maintenance of abstinence. 
The recommended dose is 1 mg twice daily following a one week 
titration as follows: 
Days 1-3 – 0.5mg once daily 
Days 4-7 – 0.5mg twice daily 
Days 8 – End of treatment – 1mg twice daily 
Contraindications Patients with hypersensitivity to varenicline or any of the 
medication’s excipients;  
pregnant women. 
2.1.2 Non-pharmacological interventions for smoking cessation 
2.1.2.1 Acupuncture 
Acupuncture is a form of complementary medicine that involves the insertion of fine 
needles into your skin at strategic points on your body, with the aim of reducing 
withdrawal symptoms associated with smoking cessation. There are mainly two 
acupuncture techniques used for this type of treatment, one involves needles being 
inserted for the duration of the treatment only (usually 15-20 minutes), while the 
other involves the use of indwelling needles that are left in place for a number of 
days, with patients being advised to press these needles when they experience 
withdrawal symptoms.(47) This HTA reviews the evidence supporting the use of 
acupuncture involving either of these techniques for long-term smoking cessation. 
While acupuncture is not currently reimbursed through the public health system, a 
number of private health insurance providers in Ireland do provide cover when the 
acupuncturists are registered with professional bodies, such as the Acupuncture 
Council of Ireland and the Acupuncture Foundation Professional Association. 
Adverse reactions to acupuncture are limited to mild, short-lasting effects such as 
pain at site of insertion, bleeding and worsening of pre-existing symptoms. Serious 
complications are exceedingly rare.(48) 
There are a range of related therapies that have previously been examined in the 
context of smoking cessation. These include acupressure (using pressure alone to 
stimulate various sites, rather than needles), laser therapy (stimulating areas of the 
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skin using a low level laser beam), or electrical stimulation using surface electrodes 
or through the application of an electrical current between pairs of acupuncture 
needles. However, due to insufficient evidence of efficacy, these have not been 
included in this HTA.  
2.1.2.2 Behavioural interventions 
There is a diverse range of behavioural support interventions designed to help 
smokers quit (see Chapter 4, Figure 4.6 for those considered in this HTA). These 
interventions can be used alone, or in conjunction with pharmacotherapy or other 
forms of behavioural support, and they may be delivered in a number of different 
settings. Behavioural interventions may also be designed to achieve additional 
outcomes, including raising awareness and warning about the dangers of tobacco, 
promoting a tobacco-free environment, and motivating individual smokers to make a 
quit attempt. These additional outcomes were not considered as part of this HTA 
which specifically examined the evidence supporting behavioural interventions in the 
context of smoking cessation. The following outlines the interventions that were 
considered. The population of interest was an unselected group of adult smokers in 
a community setting. Interventions targeting pregnant women and patients with a 
psychiatric comorbidity were assessed separately. 
2.1.2.2.1 Motivational interviewing 
Motivational interviewing is a behavioural support intervention designed to help 
smokers overcome any lack of motivation or resistance to change that may be 
hindering their attempt to quit. It was first described by Miller in 1983 in the context 
of alcohol abuse, where it was defined as ‘a directive, client-centred counselling style 
for eliciting behaviour change by helping clients to explore and resolve 
ambivalence’.(49) 
The four general principles underpinning the technique are:  
 expressing empathy 
 developing discrepancy 
 rolling with resistance 
 supporting self efficacy.(50) 
Motivational interviewing can range from single appointments to multiple sessions 
provided over an extended period of time. Sessions or appointments can be 
conducted face-to-face, by telephone or within groups.(51)  
Training in motivational interviewing is currently funded by the HSE, for example 
through dedicated training courses at nurse education centres and training courses 
aimed at other treatment providers (such as occupational therapists and speech and 
language therapists). Motivational interviewing is also provided free of charge in 
various antenatal clinics to support smoking cessation, again funded by the HSE.(52) 
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It is worth noting that training in motivational interviewing is often generic, however, 
and that this intervention may also be applied to a wide range of other risk factors 
targeting behavioural changes in relation to diet, exercise and alcohol consumption. 
2.1.2.2.2 Brief Advice  
Brief Advice interventions are designed to increase smoking cessation rates by 
encouraging healthcare professionals to enquire about the smoking status of 
patients and offer guidance and encouragement to smokers on quitting. These 
interventions may combine verbal advice with the provision of materials on smoking 
cessation, as well as one or more follow-up visits. The rationale for this type of 
intervention originated in trials carried out in the 1980s. These trials suggested that 
physician advice could help improve cessation rates.(7, 46, 52) 
The HSE currently funds training in brief advice in the form of ‘Brief Interventions for 
Smoking Cessation’. This training is aimed at a wide range of personnel in both the 
acute and community care settings. Its framework is based on the ‘5 As’: 
 Ask: systematically identify all smokers at every visit. Record smoking status, 
number of cigarettes smoked per day/week and year started smoking. 
 Advise: urge all smokers to quit. Advice should be clear and personalised. 
 Assess: determine willingness and confidence to make a quit attempt. 
 Assist: aid the smoker in quitting. Provide behavioural support. 
Recommend/prescribe pharmacological aids. If not ready to quit promote 
motivation for future attempt. 
 Arrange: follow-up appointment within one week or if appropriate refer to 
specialist cessation service for intensive support. Document the intervention.(40) 
A pharmacy-led smoking cessation service is also offered by the Irish Pharmacy 
Union, similarly following the ‘5 As’ of Brief Advice for Smoking Cessation.(53) 
2.1.2.2.3 Telephone interventions 
Telephone interventions designed to improve smoking cessation rates can involve 
telephone contact with minimal support (for example, the provision of printed self-
help material), or telephone calls in combination with pharmacotherapy or more 
intensive behavioural support interventions (for example, face-to-face 
counselling).(54) There are significant differences in the populations targeted by these 
types of interventions. Some of these interventions include smokers who have 
decided they want to make a quit attempt and initiate contact with a smoking 
cessation helpline (such as the HSE’s QUITline) in order to receive support and 
information about quitting. Other interventions have involved smokers who may, or 
may not, want to quit smoking and are contacted and provided with information, 
support and encouragement to increase their likelihood of making a quit attempt and 
succeeding.  
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This assessment will focus on the effect of additional telephone calls from 
counsellors for those who contact smoking cessation services, rather than the effect 
of offering counselling to smokers who had not contacted these services or 
expressed a desire to quit.  
In Ireland, the QUITline telephone service is funded by the HSE. Initially provided by 
the Irish Cancer Society, since 2014 its service has been outsourced (by open tender 
process) to provide an integrated service. In addition to a telephone support service, 
QUITline now incorporates SMS messaging, live chat, an online quit plan with 
targeted daily supportive emails, a quit app and a Facebook page. 
Following initial contact with the telephone service, a trained advisor explains the 
programme, and the client is asked to set a quit date and to sign up to a service of 
supportive phone calls over a 12 month period. The advisor calls the client on their 
target quit date, then once a week for the first four weeks, and again at three 
months and 12 months. In addition, advisors may be contacted at any time between 
phone calls (by text, email, live chat or phone).(50) 
2.1.2.2.4 Mobile phone-based interventions 
Text message-based interventions that use mobile phone technology to 
communicate with smokers in an effort to increase long-term abstinence rates have 
been used in Ireland and internationally.(55, 56) These can provide encouragement 
and support to smokers wishing to quit and are tailored to the stage of quitting the 
individual is at. Mobile phone-based interventions may be provided in conjunction 
with other types of behavioural or pharmacological interventions. The HSE-funded 
QUITline incorporates SMS messaging in its smoking cessation service.  
2.1.2.2.5 Internet-based interventions 
Given the increasing level of access, relatively low cost, and ability to deliver an 
interactive experience that is tailored to the needs of individual smokers, the internet 
would appear to be a potentially effective medium with which to provide behavioural 
change interventions. This assessment examines the evidence supporting the use of 
internet-based interventions for those wishing to quit, either as a stand-alone 
programme or as an addition to pharmacotherapy.(57) Different forms of internet-
based interventions are evaluated, including interventions of higher intensity 
(interactive sessions, tailored to the patient) and those of lower intensity (static 
websites, generic advice). The HSE provides the internet-based intervention QUIT 
(www.quit.ie), offering a range of services for smoking cessation. They include 
interactive e-mail and instant messaging by trained counsellors, along with online 
information on smoking cessation.(50)  
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2.1.2.2.6 Individual behavioural counselling 
One-to-one counselling for the purpose of helping smokers to quit is a behavioural 
support intervention that can be provided alone, or in conjunction with other 
behavioural supports or pharmacotherapy. A recent Cochrane review highlighted the 
difficulties extricating the effect of counselling for patients who present solely on the 
basis of a desire to quit smoking from counselling that is delivered to smokers who 
attend medical services during the course of their clinical care.(58) Given this issue, 
the approach adopted in this HTA was to examine studies where counselling was 
delivered on a one-to-one basis by counsellors trained in smoking cessation. 
Counselling delivered as part of routine clinical care in a given setting (and which 
may target multiple risk factors in addition to smoking) was considered under Brief 
Advice (Section 2.1.2.2.2). Individual behavioural counselling interventions that 
followed the principles of motivational interviewing were not included, as these were 
evaluated separately in the section on motivational interviewing (Section 2.1.2.2.1).   
2.1.2.2.7 Group behaviour therapy 
Group behaviour therapy has been reported to confer a number of benefits to 
smokers wishing to quit. These include generating emotional experiences, imparting 
information and teaching new skills.(59, 60) Group behaviour therapy can differ 
considerably in relation to the number and duration of meetings, and may be 
facilitated by health professionals or by former group members.(61) This HTA 
examines the effectiveness of group behaviour therapy involving multiple face-to-
face meetings where smokers receive behaviour support such as information, advice 
and encouragement to achieve long-term abstinence.  
2.1.2.2.8 Allen Carr method 
The Allen Carr method of smoking cessation is a self-help approach to smoking 
cessation, described in his 1985 book ‘Allen Carr’s Easy Way to Stop Smoking’. This 
book has since sold over 13 million copies worldwide.(29)  
The approach involves changing the way smokers think about their addiction, and 
the withdrawal symptoms associated with quitting, in a way that reduces their desire 
to smoke and makes it easier for them to achieve long-term abstinence. In addition 
to the book, the Allen Carr method is taught in seminars held in a host of countries, 
including Ireland.  
2.1.2.2.9 Financial incentives for pregnant women 
Smoking cessation programmes sometimes provide rewards in the form or money or 
vouchers to incentivise smokers to quit. These rewards can be given for attending 
the programme, or for having achieved milestones, such as having remained 
abstinent for a given period of time. This HTA examines the effectiveness of 
incentivised programmes to help pregnant women achieve abstinence, either for the 
duration of the pregnancy only, or for a longer period of time. It will not include 
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
45  
interventions aimed at other types of smokers, or interventions where the healthcare 
professionals providing the service receive financial incentives based on the 
performance of the programme. 
2.1.3 Excluded interventions 
As described earlier, the sheer number of potential smoking cessation therapies 
means that it is not feasible to include every type of intervention that can be 
provided to individuals attempting to give up smoking. As a result, it was necessary 
to prioritise therapies that are currently provided to or used by smokers in Ireland, 
and for which there was a prospect that sufficient evidence would be available to 
reliably estimate their clinical and cost-effectiveness.  
Some of the interventions that were not examined in this HTA include hypnotherapy, 
silver acetate, nicotine vaccines, cannabinoid type 1 receptor antagonists or 
anxiolytics. As noted previously, this HTA is confined to interventions that help 
smokers achieve long-term abstinence and so does not include studies aimed at 
preventing relapse or increasing the recruitment of smokers into cessation 
programmes. 
2.2 Discussion 
Almost half (48%) of all smokers who attempted to quit in 2014 in Ireland did not 
seek any help or use any quitting aid, choosing instead to rely on willpower alone.(47) 
The pharmacological and behavioural interventions described in this HTA, therefore, 
aim to increase the likelihood of cessation beyond what can be achieved by 
willpower alone. 
The interventions evaluated are not an exhaustive list of smoking cessation 
interventions. The prioritisation process took into consideration interventions that are 
most relevant to smokers and policy makers, and only interventions that are 
applicable to the Irish health system were included. It is worth noting, however, that 
these interventions are used in Ireland to differing degrees. Uptake is further 
examined in Chapter 3. 
The types of interventions evaluated are limited to those that can be provided to 
smokers at an individual level to encourage long-term cessation. This HTA does not 
examine the impact of treatments in terms of any potential harm reduction 
associated with their use, such as helping people to reduce the number of cigarettes 
smoked per day, nor does it examine interventions enacted at a societal level to 
reduce smoking initiation. 
A range of behavioural interventions were included in this HTA. Evaluation of these 
interventions is complicated however due to an absence of standard definitions for 
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these interventions, including the choice of treatment provider and the intensity of 
the intervention (influenced by duration, number and frequency of sessions). In 
addition, there may be substantial overlap between the interventions. Often, more 
than one intervention is provided simultaneously, and they may be provided with or 
without adjunct pharmacological aides, adding further complexity to their analysis. 
The target population in this assessment was unselected adult smokers in a 
community setting. Pharmacological interventions are contraindicated for certain 
patient groups. Both bupropion and varenicline administration are contraindicated in 
pregnancy. In addition, bupropion is contraindicated in a range of conditions, 
including that of bipolar affective disorder. Due to these contraindications, the 
additional risk to the fetus (in the case of pregnant women) and the higher 
prevalence of smoking in psychiatric patients (62), the safety and efficacy of the 
various smoking cessation interventions in these subgroups were analysed 
separately.  
Currently, prescribed pharmacological agents (nicotine replacement therapy (NRT), 
bupropion and varenicline) are reimbursed through the Primary Care Reimbursement 
Scheme (PCRS), although reimbursement of NRT is limited to Medical Card holders 
only. Behavioural interventions funded and provided by the HSE free-of-charge to all 
Irish residents include internet-based support (www.quit.ie), telephone-based 
support (QUITline), and HSE smoking cessation clinics (offering individual and group 
behavioural support in some locations). The cost-effectiveness and budget impact of 
the cessation interventions considered in this report are examined in Chapter 6. 
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2.3  Key points 
  
 Reducing the prevalence of smoking is a key priority within the public health 
system. 
 A diverse range of smoking cessation interventions is available in Ireland. 
 Pharmacological interventions include nicotine replacement therapy (NRT), 
electronic cigarettes, antidepressants (specifically bupropion) and nicotine 
receptor partial agonists (varenicline and cytisine). 
 Prescribed nicotine replacement therapy (NRT), varenicline and bupropion are 
currently reimbursed through the Primary Care Reimbursement Scheme, 
although reimbursement of nicotine replacement therapy is limited to Medical 
Card holders only.   
 Neither varenicline nor bupropion are indicated for use in pregnant women in 
Ireland.  
 Bupropion is contraindicated in certain patient groups, including those at 
increased risk of seizures and those with bipolar affective disorder.  
 Warnings cautioning the use of varenicline in patients with pre-existing psychiatric 
conditions were lifted in May 2016 following publication of safety and efficacy data 
from the EAGLES trial. The study did not show a significant increase in 
neuropsychiatric adverse events that could be attributed to varenicline or 
bupropion relative to nicotine patch or placebo in patients with or without pre-
existing psychiatric disorders. 
 Electronic cigarettes, also known as e-cigarettes, are not currently advocated by 
the HSE as a means of quitting due to lack of long-term data on their safety. 
However, support is provided by HSE smoking cessation services to smokers who 
choose to use e-cigarettes in their quit attempt. 
 Non-pharmacological interventions include acupuncture, motivational 
interviewing, brief advice, telephone-based interventions, internet-based 
interventions, mobile phone-based interventions, individual behavioural 
counselling, group behaviour therapy and the Allen Carr method. 
 The absence of standard definitions for behavioural interventions, including the 
choice of treatment provider and the intensity of the intervention (influenced by 
duration, number and frequency of sessions), adds complexity to their analysis. 
In addition, there may be substantial overlap between these interventions. Often 
more than one intervention is simultaneously provided, and they may be 
provided with or without adjunct pharmacological aides. 
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3 Epidemiology 
Since the 1950s, evidence has shown the link between tobacco smoking and 
morbidity. Initially, evidence focused on lung cancer in men, but subsequent 
research has shown causal links to a wide range of conditions. The purpose of this 
chapter is to provide an overview of current knowledge in relation to tobacco 
smoking and ill health. This chapter will also review data on the prevalence of 
smoking and smoking cessation in Ireland. 
3.1 Effects of smoking  
Since the early 1960s there has been a wealth of research on the effects of smoking, 
demonstrating causal links between smoking and a range of diseases. A 1962 
analysis combined data from the Framingham men with the Albany, New York, male 
cohort, and found cigarette smoking predicted myocardial infarction, coronary heart 
disease mortality, and all-cause mortality.(63) In 1964, the US Surgeon General 
published a report, ‘Smoking and Health’, which concluded that there was a causal 
link between cigarette smoking and lung cancer in men.(64) The report reviewed over 
2,000 documents and highlighted a dose-response relationship, stating that the risk 
of lung cancer is reduced by stopping smoking. It noted that from the year 1900, the 
prevalence of cigarette smoking in US adults increased steadily, reaching 42% of the 
adult population by 1964. The publication of the Surgeon General’s report that year 
marked the start of a decline in smoking prevalence; by 2012, 18% of US adults 
smoked.  
Almost all (98%) smokers in Ireland use manufactured or hand-rolled cigarettes.(65) 
This section therefore focuses primarily on the impact of cigarette smoking, as 
distinct from pipe, cigar or other forms of tobacco smoking. 
3.1.1 Physical impact of smoking 
Cigarette smoke contains more than 5,000 chemical compounds, including more 
than 70 established carcinogens.(66-68) These chemical components are held in a 
mixture of gas phase and particulate matter. There are a range of complex biological 
and behavioural mechanisms through which the inhalation of cigarette smoke leads 
to disease.(66) The quantity of toxic particles and gases inhaled from a cigarette 
depends on the nature of the tobacco, the volume and number of puffs of smoke 
drawn from the cigarette, the amount of air drawn in through ventilation holes as 
the smoke is inhaled, and the local characteristics of the smoker’s lungs.(66) Toxins in 
cigarette smoke are deposited and absorbed by the body as the inhaled smoke 
moves from the mouth, through the airways and into the alveoli in the lungs.  
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Cigarette smoke is classified as a Group 1 carcinogen (carcinogenic to humans) by 
the International Agency for Research in Cancer (IARC), causing a range of cancers, 
including cancers of the lung, oral cavity, oesophagus, stomach, and colorectum. It 
includes over 70 carcinogens evaluated by the IARC as having sufficient evidence for 
carcinogenicity, of which 16 are identified as Group 1 carcinogens. The IARC also 
now considers that there is sufficient evidence for the carcinogencitiy of parental 
smoking, specifically for hepablastoma in children with a positive association also for 
childhood leukaemia.(68)  
Clinical and experimental studies indicate that cigarette smoking contributes 
significantly to cardiovascular morbidity and mortality due to a combination of 
atherosclerosis, thrombosis and vascular dysfunction. Clinical atherosclerosis 
syndromes (such as, angina, acute coronary syndrome, and stroke,) start and 
progress due to the pro-inflammatory effect of cigarette smoke as well as its adverse 
effect on blood lipid profiles and its impairment of vasomotor function. Cigarette 
smoking is also associated with an increased incidence of myocardial infarction. This 
is thought to be due to its alteration of platelet function, fibrinolysis, and 
antithrombotic and prothrombotic factors leading to initiation and, or progression of 
thrombus (clot) formation and impaired clot dissolution. While nicotine contributes to 
smoking–related increases in cardiac output, heart rate and blood pressure, its 
impact on disease formation including atherosclerosis and thrombosis is more 
controversial. Instead, it is thought that these effects of cigarette smoking are due 
to free radical-mediated oxidative stress, including a loss of the protective effect of 
nitric oxide.(69) 
3.1.2 Attributable disease 
Exposure to tobacco smoke may cause disease through a variety of complex 
mechanisms. Genetic predisposition also impacts on how toxic components in 
tobacco smoke may cause disease. Furthermore, tobacco smoke may act in 
combination with environmental factors such as radon exposure. As such, the extent 
to which tobacco smoke will cause disease in a given individual depends on a wide 
range of factors. 
Numerous studies have sought to estimate the impact of smoking on morbidity, 
often through the use of health and lifestyle surveys that include disease status as 
well as smoking behaviour and other known risk factors, such as age and sex. 
Disease status is measured in relation to a set of diseases for which a causal 
relationship with smoking has been demonstrated.  
The risk of attributable disease is typically estimated separately for males and 
females, and also for current and former smokers. Smokers that quit continue to 
have an elevated risk for many diseases when compared with those who have never 
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smoked. The risk ratios are presented for all adults over a certain age, and are not 
provided by smoking history in terms of the quantity of cigarettes smoked. Given the 
difficulties in retrospectively determining smoking history, it is pragmatic to use a 
classification of current, former and never smokers. Current smokers can be further 
divided into regular and occasional smokers. Regular smokers are generally defined 
as those that smoke at least one cigarette per day, whereas occasional smokers do 
not smoke every day. 
Based on UK data, the risk ratios for 26 conditions show the differing impacts of 
smoking on current and former smokers (Table 3.1).(70) In all cases, the risk ratios 
are relative to the risk in the cohort of people who have never smoked. For most 
conditions, the risk ratio is substantially reduced for former smokers, with the 
notable exception of chronic obstructive lung disease and chronic airway obstruction. 
Risk ratios associated with cancers of the trachea, lung and bronchus, cancer of the 
larynx, and chronic airway obstruction are all in excess of four for both current and 
former smokers. 
3.1.3 Burden on healthcare utilisation 
Given the higher risk of disease in current and former smokers when compared with 
those who have never smoked, it is anticipated that smoking status may predict 
healthcare utilisation. A US study using survey data on 15,332 respondents showed 
that hospital utilisation was higher among current and former smokers than in 
people who had never smoked.(71) 
The number of inpatient and day case discharges in the Irish public healthcare 
system that can be attributed to smoking from 2012 to 2014 was estimated using 
the relative risks of disease related to smoking status (Table 3.2). The largest 
smoking-related contributor to inpatient discharges was chronic airway obstruction 
(31,554 discharges), followed by ischaemic heart disease (11,927 discharges). 
Regarding day cases, the largest contributors were cancer of the trachea, lung and 
bronchus (7,023 day cases), ischaemic heart disease (5,182 day cases) and chronic 
airway obstruction (3,742 day cases). In total, smoking-related illness is estimated to 
generate 27,540 inpatient discharges and 10,592 day cases each year. 
Hospital utilisation figures must be considered in the context of 1,854,908 inpatient 
discharges and 2,803,893 day cases in the same three-year period. Although the 
cases that can be attributed to smoking present only a small proportion of all 
hospital cases, these data does not take into account length of stay or the diagnosis 
related groups, which give an indication of the complexity of the cases. The figures 
are also a conservative estimate, as they do not include cases related to second-
hand smoke exposure.  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
51  
Table 3.1 Risk ratios for diseases in current and former smokers relative 
  to never smokers(70)  
Condition ICD10 code Age 
Females Males 
Current 
smokers 
Former 
smokers 
Current 
smokers 
Former 
smokers 
Cancers 
      Trachea, lung, bronchus C33-C34 35+ 12.69 4.53 23.26 8.70 
Upper respiratory sites C00-C14 35+ 5.08 2.29 10.89 3.40 
Oesophagus C15 35+ 7.75 2.79 6.76 4.46 
Larynx C32 35+ 13.02 5.16 14.60 6.34 
Cervical C53 35+ 1.59 1.14 N/A N/A 
Bladder C67 35+ 2.22 1.89 3.27 2.09 
Kidney and renal pelvis C64-C66, C68 35+ 1.40 1.10 2.50 1.70 
Stomach C16 35+ 1.36 1.32 1.96 1.47 
Pancreas C25 35+ 2.25 1.55 2.31 1.15 
Unspecified site C80 35+ 2.20 1.30 4.40 2.50 
Myeloid leukaemia C92 35+ 1.20 1.30 1.80 1.40 
Respiratory diseases       
Chronic obstructive lung disease J40-J43 35+ 12.04 11.77 17.10 15.64 
Chronic airway obstruction J44 35+ 13.08 6.78 10.58 6.80 
Pneumonia, influenza J10-J18 35-64 4.30 1.10 2.50 1.40 
 J10-J18 65+ 2.20 1.10 2.00 1.40 
Circulatory diseases       
Other heart disease I00-I09, I26-I51 35+ 1.49 1.14 1.78 1.22 
Ischaemic heart disease I20-I25 35-54 5.30 2.60 4.20 2.00 
 I20-I25 55-64 2.80 1.10 2.50 1.60 
 I20-I25 65-74 2.10 1.20 1.80 1.30 
 I20-I25 75+ 1.40 1.20 1.40 1.10 
Other arterial disease I72-I78 35+ 2.17 1.12 2.07 1.01 
Cerebrovascular disease I60-I69 35-54 5.40 1.30 4.40 1.10 
 I60-I69 55-64 3.70 1.30 3.10 1.10 
 I60-I69 65-74 2.60 1.30 2.20 1.10 
 I60-I69 75+ 1.30 1.00 1.60 1.10 
Aortic aneurysm I71 35+ 7.07 2.07 6.21 3.07 
Atherosclerosis I70 35+ 1.83 1.00 2.44 1.33 
Digestive system       
Stomach/duodenal ulcer K25-K27 35+ 5.50 1.40 5.40 1.80 
Crohns disease K50 35+ 2.10 1.00 2.10 1.00 
Periodontal disease/periodontitis K05 35+ 3.97 1.68 3.97 1.68 
Other diseases       
Age-related cataract H25 45+ 1.54 1.11 1.54 1.11 
Hip fracture S72.0-S72.2 55-64 1.17 1.02 1.17 1.02 
 S72.0-S72.2 65-74 1.41 1.08 1.41 1.08 
 S72.0-S72.2 75+ 1.85 1.22 1.76 1.14 
Spontaneous abortion O03 35+ 1.28 1.00 N/A N/A 
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Although cancers are almost exclusively treated in a secondary care setting, many of 
the other conditions which may be attributable to smoking will include management 
in a primary care setting. In the absence of detailed Irish primary care data, it is not 
possible to estimate the impact of smoking on the use of primary care services in 
Ireland. However, a US study estimated that smoking status was a statistically 
significant positive predictor of specialty care visits and hospitalisations, but not of 
primary care visits (adjusting for health status, age, sex, education, income, obesity 
and alcohol abuse).(72) Lower use of primary care by smokers has been found in 
other studies,(73, 74) suggesting that smokers use primary care services less 
frequently than former smokers and those who have never smoked. Jorm et al. 
concluded that smokers may have a lower propensity to seek healthcare, thereby 
missing out on access to preventive services.(74) 
3.1.4 Smoking in pregnancy 
Smoking during pregnancy can harm both mother and fetus. Maternal smoking is 
associated with an increased risk of a range of congenital anomalies, preterm birth, 
intrauterine fetal growth restriction, placental abruption and stillbirth.(75-78) Cigarette 
smoke contains chemicals which can contribute to poor infant outcomes.(79) Carbon 
monoxide displaces oxygen and impairs the release of oxygen from haemoglobin, 
reducing oxygen availability to the fetus. Nicotine reduces placental blood flow. Both 
carbon monoxide and nicotine adversely affect fetal growth. Intrauterine fetal growth 
restriction is the most common cause of antepartum stillbirth in normally formed 
fetuses.(80)  
A systematic review, which included 96 population-based studies conducted in five 
high-income countries (Australia, Canada, US, UK and the Netherlands), was 
published as part of the 2011 Lancet series on stillbirth prevention.(81) Maternal 
smoking was one of the seven most important risk factors for stillbirth in high-income 
countries, and one of two risk factors which can be altered. Raising awareness and 
the implementation of effective interventions for smoking in pregnancy is a priority. In 
high-income countries, a woman living under adverse socioeconomic circumstances 
has twice the risk of having a stillborn baby compared to a woman living without such 
disadvantage.(82) Improved access to appropriate antenatal care and programmes that 
increase the smoking cessation rate in pregnancy will help to reduce these health 
inequalities.   
  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
53  
Table 3.2 Hospital utilisation in Ireland attributable to smoking, 2012-
  2014 
Condition ICD10 codes Inpatient Daycase 
Cancers    
Trachea, lung, bronchus C33-C34 7,114 7,023 
Upper respiratory sites C00-C14 1,661 1,047 
Oesophagus C15 1,521 1,551 
Larynx C32 779 694 
Cervical C53 158 154 
Bladder C67 1,508 1,293 
Kidney and renal pelvis C64-C66, C68 599 789 
Stomach C16 557 632 
Pancreas C25 496 514 
Unspecified site C80 190 116 
Myeloid leukaemia C92 248 1,246 
    
Respiratory diseases    
Chronic obstructive lung disease J40-J43 715 669 
Chronic airway obstruction J44 31,554 3,742 
Pneumonia, influenza J10-J18 5,968 94 
    
Circulatory diseases    
Other heart disease I00-I09, I26-I51 7,662 1,928 
Ischaemic heart disease I20-I25 11,927 5,182 
Other arterial disease I72-I78 333 562 
Cerebrovascular disease I60-I69 4,548 124 
Aortic aneurysm I71 1,392 131 
Atherosclerosis I70 907 187 
    
Digestive system    
Stomach/duodenal ulcer K25-K27 1,147 1,159 
Crohns disease K50 328 1,532 
Periodontal disease/periodontitis K05 10 19 
    
Other diseases    
Age-related cataract H25 35 1,309 
Hip fracture S72.0-S72.2 984 0 
Spontaneous abortion O03 281 80 
    
Total  82,621 31,776 
Note: data uses discharge data from the Hospital Inpatient Enquiry system (HIPE) and smoking 
prevalence data from the Healthy Ireland survey combined with the relative risk data from Table 3.1.  
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Maternal smoking is also associated with an increased risk of sudden infant death 
syndrome and respiratory infections in infancy.(77) Adverse cognitive and behavioural 
outcomes associated with maternal smoking include conduct disorder, attention-deficit 
or hyperactivity disorder, poor academic achievement, and cognitive impairment.(83)  
The ‘Barker hypothesis’, also known as the ‘developmental origins of adult disease’, 
the ‘fetal origins hypothesis’ and the ‘developmental origins of health and disease’, 
proposes that many common chronic conditions are the result of poor intrauterine 
health and poor postnatal health.(84) Babies with low birth weight experience rapid 
catch up growth which can result in obesity and chronic disease such as coronary 
artery disease, diabetes and hypertension.(85) Smoking cessation during pregnancy 
would not only improve maternal and fetal health, but could also contribute to a 
reduction in the incidence of chronic disease in adults.(86) 
A proportion of women are highly motivated to stop smoking during pregnancy. An 
observational study(87) which explored the experience of pregnant women who quit 
smoking prior to initiating antenatal care reported that spontaneous quitters: 
 had been lighter smokers,  
 were less likely to have another smoker in their household,  
 indicated a stronger belief in the harmful effect of maternal smoking,  
 had a history of fewer miscarriages,  
 and entered antenatal care earlier than women who were smoking at the 
start of antenatal care.(87) 
3.1.5 Smoking and mental health 
Smokers with mental health disorders smoke more heavily, are more nicotine 
dependent, and have smoked for longer than the general population.(88) The 
relationship between mental health and smoking is complex, particularly given that 
nicotine dependence itself can be considered as a psychiatric disorder. ICD-10 
includes mental behavioural disorders due to both dependence on, and withdrawal 
from nicotine. Nicotine dependence is thus the most prevalent mental disorder, and 
once established, can persist for decades with rates of permanent remission of less 
than 3% per annum.(89) 
The reasons for widespread smoking behaviour in those with severe and enduring 
mental health conditions such as schizophrenia are not well understood. There is 
contradictory evidence that smoking may be a risk factor for schizophrenia 
(precipitating its onset in vulnerable individuals) or that it represents an independent 
protective factor against its development. Schizophrenia is associated with cognitive 
deficits, including impairments in learning, memory, executive function and cognitive 
processing speed, some of which may be transiently improved with nicotine.(89) 
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However, evidence also suggests that current cigarette smoking may be associated 
with worse cognitive and adaptive functioning in those with serious mental illness.(90) 
Tobacco smoking increases the metabolism of some antipsychotic medications, so 
patients may use tobacco to counteract their side-effects.(91)  
Evidence suggests that smoking increases the risk of mental health disorders, including 
depression and anxiety. Recent evidence suggests that these psychiatric symptoms may 
improve following chronic smoking cessation. (92) However, it is also noted that smoking 
cessation has been associated with a worsening of depressive symptoms in a minority 
of people with depression. Nicotine has also been suggested as a form of self-
medication, alleviating symptoms of depression due to nicotinic acetylcholine receptor 
desensitisation.(89, 93)  
3.1.6 Second-hand smoke 
Cigarette smoke can be inhaled as mainstream or sidestream smoke. Mainstream 
smoke is the smoke that is inhaled directly through a burning cigarette. Sidestream 
smoke is mainly produced by smouldering cigarettes, and is inhaled by the smoker 
and by those in the vicinity of the cigarette. Sidestream smoke is a major component 
of second-hand smoke. Although the chemical composition of mainstream and 
sidestream smoke differ, they are both carcinogenic. Second-hand smoke, also 
referred to as environmental tobacco smoke, is a mixture of sidestream smoke and 
mainstream smoke that has been exhaled by a smoker. Passive smoking is the 
inhalation of second-hand smoke. 
A major report by the US Surgeon General concluded that second-hand smoke 
causes premature mortality and morbidity in children and adults who do not 
smoke.(77) For children, exposure to second-hand smoke increases the risk of sudden 
infant death syndrome, acute respiratory infections, ear problems and more severe 
asthma. Furthermore, exposure to second-hand smoke slows lung growth. For 
adults, exposure to second-hand smoke has immediate adverse effects on the 
cardiovascular system, and causes lung cancer and coronary heart disease. 
Importantly, the report concluded that there is no risk-free level of exposure to 
second-hand smoke. 
Non-smokers can be exposed to second-hand smoke in a variety of settings. Since the 
introduction of the workplace smoking ban in Ireland, the primary source or exposure 
is within the home. Ireland was the first country to adopt a nationwide ban on 
smoking in workplaces, recognising the harmful health effects of second-hand 
smoke.(94) A report by the Environmental Protection Agency (EPA) in Ireland estimated 
that there were 846 cases of chronic bronchitis, 244 cardiopulmonary deaths, and 7.5 
cases of lung cancer occurring in non-smoking adults each year due to exposure to 
second-hand smoke in the home.(95) Similarly, in children, the EPA estimated there 
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were 3.9 deaths due to sudden infant death syndrome, 500 hospital discharges for 
lower respiratory illness, and 690 new cases of asthma each year due to exposure to 
second-hand smoke in the home. 
3.2 Health outcomes associated with smoking 
The increased morbidity associated with smoking has a consequent impact on both 
mortality and quality of life.  
3.2.1 Mortality 
Mortality in smokers is two to three times that of people who have never smoked.(96) 
Twelve percent of mortality globally can be attributed to tobacco smoking, including 
second-hand smoke.(3) 
A US study of 19,705 male physicians found significantly higher mortality rates 
among current smokers compared with former and never smokers.(97) The risk of 
death in former smokers was significantly reduced within 10 years of quitting 
smoking. Twenty years after quitting, the risk of death declined to that of people 
who had never smoked in smokers who quit before the age of 50 years. Studies 
have estimated the percentage of deaths attributable to smoking range from 21% 
for males and 17% for females in the US,(98) to 19% in England and Wales, 22% in 
Denmark, and 25% in the Netherlands.(99)  
The relative risk of mortality due to smoking has increased over time.(100) The 
increased mortality risk may reflect changes in cigarette design that affect the 
nature of the inhaled smoke and the absorption of toxic components into the body. 
The increased risk also reflects the expanding body of evidence that demonstrates a 
causal link between smoking and an increasing numbers of diseases. 
The impact of quitting on the risk of mortality is highly significant. The excess risk 
associated with smoking can be almost eliminated by quitting smoking before the 
age of 40 years.(100) Although the benefits of quitting are greatest if achieved before 
the age of 40 years, quitting at any age can confer reductions in risk.(101) There is 
also a dose-response relationship between the quantity of cigarettes smoked and the 
risk of mortality.(102) Estimates of attributable mortality are based on smoking status 
and not the quantity of smoking. As such, the applicability of relative risks across 
populations is dependent on smokers having similar histories in terms of the quantity 
of cigarettes smoked. 
Most of the increased mortality risk in smokers can be explained by the common 
diseases listed in Table 3.3. However, evidence suggests that there may be 
associations between smoking and a range of other causes of death. One US study 
estimated that 17% of excess mortality in smokers was not explained by cases 
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currently linked to smoking.(96) As such, estimates of smoking attributable mortality 
may represent substantial underestimates. 
Table 3.3 Risk ratios for adult mortality from smoking-related diseases 
 relative to never smokers, adults 35 years of age and older(103) 
Disease category Males Females 
Current 
smoker 
Former 
smoker 
Current 
smoker 
Former 
smoker 
Malignant neoplasms     
Lip, oral cavity, pharynx (C00–C14) 10.89 3.40 5.08 2.29 
Esophagus (C15) 6.76 4.46 7.75 2.79 
Stomach (C16) 1.96 1.47 1.36 1.32 
Colorectal (C18–C20) 2.14 1.47 2.14 1.47 
Liver (C22) 1.70 1.40 1.70 1.40 
Pancreas (C25) 2.31 1.15 2.25 1.55 
Larynx (C32) 14.60 6.34 13.02 5.16 
Trachea, lung, bronchus (C33–C34) 23.26 8.70 12.69 4.53 
Cervix uteri (C53)   1.59 1.14 
Kidney and renal pelvis (C64–C65) 2.72 1.73 1.29 1.05 
Urinary bladder (C67) 3.27 2.09 2.22 1.89 
Acute myeloid leukemia (C92.0) 1.86 1.33 1.13 1.38 
     
Cardiovascular diseases     
Coronary heart disease (I20–I25)     
Persons 35–64 years of age 2.80 1.64 3.08 1.32 
Persons ≥65 years of age 1.51 1.21 1.60 1.20 
Other heart disease (I00–I09, I26–
I28, I29–I51) 
1.78 1.22 1.49 1.14 
Cerebrovascular disease (I60–I69)     
Persons 35–64 years of age 3.27 1.04 4.00 1.30 
Persons ≥65 years of age 1.63 1.04 1.49 1.03 
Atherosclerosis (I70) 2.44 1.33 1.83 1.00 
Aortic aneurysm (I71) 6.21 3.07 7.07 2.07 
Other arterial disease (I72–I78) 2.07 1.01 2.17 1.12 
Diabetes Mellitus (E11) 1.37 1.14 1.37 1.14 
     
Respiratory diseases     
Tuberculosis (A15 – A19) 2.30 1.00 2.30 1.00 
Influenza, pneumonia (J10–J11, J12–
J18) 
1.75 1.36 2.17 1.10 
Bronchitis, emphysema (J40–J42, 
J43) 
17.10 15.64 12.04 11.77 
Chronic airways obstruction (J44) 10.58 6.80 13.08 6.78 
Note: the classification of ‘never smokers’ is based on those who answered ‘no’ to the questions: ‘Do 
you smoke tobacco products?’ and ‘Did you ever smoke tobacco products (in the past)?’.  
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According to Ireland’s Central Statistics Office (CSO), the total number of deaths 
registered between 2013 to 2015 was 88,560.(104) An estimated 16,372, or 18.5%, 
of those were attributable to smoking. The main contributors to smoking-attributable 
mortality were lung cancer, chronic obstructive pulmonary disease (COPD) and 
coronary heart disease. The smoking-attributable burden is equivalent to 
approximately 5,457 deaths each year. This is a conservative estimate, as it does not 
include the risks associated with second-hand smoke.  
In the Global Burden of Disease study, it was estimated that 90% of tobacco-related 
deaths could be attributed to smoking, and 10% to second-hand smoke.(3) If such a 
ratio was applicable to Ireland, then the burden of mortality due to smoking 
including second-hand smoke would be 20.5%. A report by ICF consultancy services 
on the economic cost of smoking in Ireland commissioned by the Department of 
Health estimated that there were 5,860 deaths in 2013 caused by smoking, and a 
further 92 deaths due to second-hand smoke.(105) The evidence on smoking-
attributable mortality is evolving as new data emerge demonstrating the magnitude 
of causal relationships between smoking and disease. This analysis focuses on the 
primary contributors to smoking-attributable disease rather than presenting an 
exhaustive list. It is evident that smoking-related mortality in Ireland is broadly 
similar to estimates from the US and Northern European countries. 
There are similar implications for people with mental health issues who smoke in 
terms of increased risk of morbidity and mortality. However, the higher prevalence 
of smoking in those with mental health issues has consequences for the size of the 
population at elevated risk.(106) Similarly, those with greater levels of psychological 
distress smoke greater quantities of cigarettes, on average, and extract more 
nicotine from each cigarette.(107) Due to the dose-response relationship between 
smoking and outcomes, it is probable that the relative risk of morbidity and mortality 
for the general population underestimates the risk for the population with mental 
health issues.  
Smoking-related morbidity is noted to be high in patients with severe and enduring 
mental illness, with half of all deaths attributed to smoking. US data from a cohort of 
individuals hospitalised on at least one occasion with a primary psychiatric diagnosis 
suggest that 53% of total deaths in schizophrenia, 48% in bipolar disorder and 50% 
in major depressive disorder are attributable to smoking. Excess mortality is 
particularly evident for smoking-related cardiovascular and respiratory disease,(108) 
with chronic lung disease and obstructive sleep apnoea noted to be highly prevalent 
in individuals with serious mental illness.(109, 110) Despite persistent high prevalence 
of other risk factors including obesity, diabetes and hypertension as well as 
significant post-cessation weight gain, sustained smoking cessation has been 
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documented to reduce 10-year cardiovascular risk in outpatients with a diagnosis of 
schizophrenia, schizoaffective disorder or bipolar disorder.(110) 
Table 3.4 Mortality in Ireland attributable to smoking, 2013-2015 
Disease category  Deaths (2013-2015) 
  Age range 
Total 
Attributable to 
smoking 
Malignant neoplasms  
  
Lung cancer 35+ 5,510 4,510 
Other cancers 35+ 10,269 2,241 
   
  
Cardiovascular diseases  
  
Coronary heart disease  35+ 13,388 3,294 
Other cardiovascular diseases 35-64 1,340 337 
Other heart disease 65+ 5,298 737 
Cerebrovascular disease 65+ 5,211 476 
Other vascular diseases 65+ 1,274 535 
Diabetes Mellitus 65+ 572 32 
   
  
Respiratory diseases  
  
Influenza, pneumonia, TB and COPD 35-64 456 312 
Influenza, pneumonia and TB 65+ 3,064 490 
COPD 65+ 4,224 3,408 
  
  
Total  
 
16,372 
Note: Data combines population and mortality data from the Central Statistics Office with smoking 
prevalence data derived from the Healthy Ireland survey. Relative risks derived from Table 3.3 with 
diseases grouped as per the methodology of the 2014 US Surgeon General’s report.(103) 
3.2.2 Quality of life 
Smoking is associated with a range of debilitating chronic diseases, and is therefore 
likely to be associated with reduced quality of life. A systematic review of quality of 
life and smoking found that: smoking reduces quality of life, the magnitude of the 
reduction is related to the quantity of cigarettes smoked, second-hand smoke 
reduces quality of life, and quitting smoking improves quality of life.(111) The 
magnitude of the difference between smokers and non-smokers varies across 
studies, and may be partly confounded by biological, clinical, lifestyle and 
socioeconomic factors.(112) Reported differences in quality of life scores between 
smokers and non-smokers are of the order of 0.03 to 0.05.(112-114) 
3.3 Smoking behaviour in Ireland 
Two main sources of data on smoking prevalence are used in this report: the 
monthly Smoking Prevalence Tracker 2002 to 2016, and the Healthy Ireland survey 
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
60  
2015. Smoking prevalence data are also collected as part of the CSO Irish Health 
Survey, and formerly through a variety of surveys including SLÁN and Living In 
Ireland. 
The Smoking Prevalence Tracker is carried out by a monthly telephone survey of 
1,000 adults and asks questions on smoking status, number of cigarettes smoked, 
and e-cigarette usage.(115) In this survey, a smoker is defined as someone who 
smokes at least one cigarette (packaged or ‘roll your own’) per week. 
The Healthy Ireland survey was an interviewer-administered survey of 7,539 adults 
conducted between November 2014 and August 2015.(65) The Healthy Ireland survey 
included questions on smoking status, types of product used, quit attempts and 
method used in quit attempt. The survey also asked about motivation to quit. A daily 
smoker was defined as someone who smoked at least once a day, while an 
occasional smoker smoked at least once a week. A current smoker is defined as 
those who either smoke daily or occasionally. Smokers include manufactured and 
‘roll your own’ cigarettes, pipes, cigars, and other products. 
For this section, a combination of both data sources will be used. The monthly 
Smoking Prevalence Tracker provides longitudinal data, while Healthy Ireland 
provides useful data on prevalence and cessation attempts. 
3.3.1 Prevalence 
The prevalence of current cigarette smoking in Ireland among persons aged 15 
years and over in 2015 was 22.7% (Table 3.5); 19% are daily and 4% are 
occasional smokers. This figure is equivalent to approximately 818,000 smokers 
aged 15 years and over. The prevalence is higher in males (24.3%) than females 
(21.2%), and is highest in those aged 25 to 44 years (29.3%). When considered in 
five-year age-bands, the prevalence is highest in those aged 25 to 29 years, with a 
third of this population smoking (33.4%). The prevalence of smoking follows a socio-
economic gradient, such that those of lower socio-economic status have a higher 
prevalence of smoking. Prevalence is higher in those with Medical Cards (28.3%) 
than those without (19.2%). 
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Table 3.5 Prevalence of smoking in Irish adults, 2015 (Healthy Ireland 
survey) 
Subgroup 
 
Prevalence Quantity* 
All respondents 
22.7% 11.6 
Sex 
  
 
Males 24.3% 12.5 
 
Females 21.2% 10.6 
Age group 
  
 
15-24 18.9% 7.7 
 
25-44 29.3% 11.0 
 
45-64 21.9% 14.1 
 
65+ 12.2% 12.6 
Medical Card status 
  
 
Medical Card holder 28.3% 13.4 
 
No Medical Card 19.2% 10.0 
Socio-economic group   
 
Higher managerial/professional 16.2% 8.9 
 
Intermediate 15.2% 10.6 
 
Routine/manual 28.7% 12.1 
 
Unspecified 33.7% 14.0 
* Quantity expressed as average number of cigarettes per day combining both regular and 
occasional smokers. 
Based on the Tracker data, the prevalence of smoking was largely static at 25% for 
males and females from 2002 until 2006 (Figure 3.1). The prevalence of smoking in 
women began to decline after 2007 to the current figure of 16.7%. The prevalence 
in men did not begin to decline until late 2009. The absolute number of smokers in 
Ireland between 2002 and 2016 peaked in 2008, with 932,000 smokers. The 
absolute number of smokers has been in decline since 2008, and is currently 
estimated at 682,000 smokers based on these data. As already noted, the Smoking 
Prevalence Tracker results show a lower estimate of prevalence than the Healthy 
Ireland survey, and therefore represents an underestimate of the total number of 
smokers at present and historically. A reducing prevalence of smoking has been 
observed globally in both developed and developing countries.(116) 
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Figure 3.1 Prevalence and quantity of smoking in Irish adults by month, 
2002 to 2016 
 
Note: HSE Smoking Prevalence Tracker data. Solid lines based on smoothing splines. The 
prevalence estimates from the HSE Smoking Prevalence Tracker are lower than those of the 
Healthy Ireland survey. 
The Healthy Ireland and Smoking Tracker surveys do not collect information in 
relation to pregnancy and diagnosed mental health conditions, and therefore do not 
provide data on those distinct subgroups of the population. 
There are a number of studies that provide data on the prevalence of smoking in 
pregnancy in an Irish population. The Growing Up in Ireland Longitudinal Study 
collected data on smoking in pregnancy from mothers of a nine month old infant 
cohort born between December 2007 and June 2008,(117) and from mothers of a 
nine year old child cohort born between November 1997 and October 1998. Women 
may under-report smoking in pregnancy due to the associated stigma, so reporting 
bias may have been an issue for both cohort studies. The child cohort study reported 
that 28% of mothers smoked at some stage during the pregnancy,(118) but this rate 
fell to 18% in the later infant cohort study. The infant cohort study reported that 
13% of mothers smoked during all three trimesters. Sixteen percent of women 
reported smoking in the first trimester of pregnancy, indicating that there was some 
degree of smoking cessation during the second and third trimesters.  
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A 2012 study of lifestyle changes in 718 women during pregnancy based at Cork 
University Maternity Hospital reported smoking prevalence of 23.9% before 
pregnancy and 20.9% during pregnancy.(119) The study found smoking prevalence to 
be highest in younger mothers, although this may have been confounded by 
educational status. A 2011 study of pregnant women attending the Coombe Women 
and Infants University Hospital in Dublin reported a prevalence of 12.2% at the first 
antenatal visit.(120) The study found that there was little change in smoking 
behaviour between the first antenatal visit and the third trimester of pregnancy.  
Secondary analysis of the Growing Up in Ireland child cohort data, conducted by the 
Institute of Public Health in Ireland and the Tobacco Free Research Institute Ireland, 
reported an association between smoking in pregnancy and low birth weight (less 
than 2.5kg at birth).(121) Based on these data, 43.8% of women who reported having 
a low birth weight baby reported smoking in pregnancy, while 27.2% of women who 
reported having a normal birth weight baby (greater than or equal to 2.5kg) 
reported smoking in pregnancy. The median (interquartile range) birthweight of 
babies born to smoking mothers was 3.3kg (2.99kg to 3.7kg) while it was 3.6kg 
(3.2kg to 3.9kg) for babies born to non-smoking mothers. However, the observed 
difference did not reach statistical significance levels. In a separate analysis of the 
child cohort data, a statistically significant association between maternal smoking in 
pregnancy and attention deficit hyperactivity disorder (ADHD) in the nine year old 
child was reported.(118) 
Data on smoking prevalence in those with mental health issues in Ireland are very 
limited. The 2015 Healthy Ireland survey recorded smoking status and whether the 
respondent had a probable mental health problem. The proportion classified as 
having a probable mental health problem was 6.3% for men and 14.4% for women. 
The prevalence of smoking was 35.2% in those with a probable mental health 
problem, in contrast to a prevalence of 21.5% in the rest of the population. The 
2007 SLÁN survey collected information on mental health and smoking status, 
reporting that smokers were more likely to report mental health problems than 
former or never smokers.(122) Smokers are almost twice as likely to report probable 
mental health problems, major depressive disorder, and generalised anxiety disorder 
compared with former and never smokers. The nature of the survey questions did 
not provide detailed psychiatric information, and hence it does not provide estimates 
of smoking prevalence in distinct groups such as those with schizophrenia or bipolar 
disorders. 
A joint report by the UK Royal College of Physicians and Royal College of 
Psychiatrists reviewed the evidence on smoking and mental health.(123) Prevalence 
varied by subgroups, although they reported a prevalence of 37% for those with a 
longstanding mental health condition. Using data from 1993 to 2010, they reported 
that, while smoking prevalence was in decline in patients with no longstanding 
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mental health condition, it had remained static in those with a longstanding mental 
health condition. Data from a 2007 Adult Psychiatric Morbidity Survey were 
highlighted, which indicated that 34.0% of adults reporting a common mental 
disorder were smokers. Further confirmation of a high prevalence of smoking in the 
mental population was suggested by 2009-2010 primary care data indicating a 
prevalence of 30.3% among adults with diagnosed mental disorders and those 
taking psychoactive medications. These figures were in the context of a smoking 
prevalence of 21% in the general population of England. 
A review of US surveys found a smoking prevalence of 24.9% among adults with 
mental illness (operationalised as those reporting severe psychological distress, 
probable depression, or receiving treatment for mental illness).(124) However, 
smoking prevalence may vary substantially by specific condition and is noted to be 
correlated with the severity of the mental illness. For example, based on 
international data smoking prevalence in people with schizophrenia is approximately 
three times that of the general population.(93) A national health interview survey 
from the US considered specific conditions and found smoking prevalence of 46.4% 
for bipolar disorder, 59.1% for schizophrenia, 37.2% for hyperactivity, 35.4% for 
dementia, and 38.1% for serious psychological distress.(106) This was relative to a 
prevalence of 18.3% in people with no specified lifetime mental illness. Elsewhere, 
prevalence rates of 45% to 88% have been reported among people with 
schizophrenia, 33% to 70% in those with bipolar disorder, while those with 
depressive or anxiety disorders are noted to be more than twice as likely to smoke 
as those without.(108) 
3.3.2 Types of tobacco products 
Based on the Healthy Ireland survey data, 78% of daily smokers use manufactured 
cigarettes, 24% use hand-rolled cigarettes, 1.3% use pipes and 0.7% use cigars. 
Among daily smokers, 3% reported using two or more tobacco products, 92% of 
whom used a combination of manufactured and hand-rolled cigarettes. 
Product usage was similar in occasional smokers, with 82% using manufactured 
cigarettes, 19% using hand-rolled cigarettes, 0.9% using pipes, and 3.3% using 
cigars. Four percent of occasional smokers use more than one product, 74% of 
whom used a combination of manufactured and hand-rolled cigarettes. 
3.3.3 Quantity of smoking 
As there is a demonstrated dose-response relationship between quantity of smoking 
and attributable risk, it is useful to consider the number of cigarettes smoked in 
Ireland and how that figure has changed over time. 
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In 2002, data from the HSE Smoking Prevalence Tracking survey suggest the 
average number of cigarettes smoked per day in Ireland was 14.1 for females and 
16.7 for males. Since then there has been a steady decline, with rates in the twelve 
months to March 2016 at approximately 10.3 cigarettes per day for females and 12.3 
per day for males (Figure 3.2). This corresponds with the estimates from the Healthy 
Ireland survey. 
Figure 3.2 Average number of cigarettes smoked per day by Irish adults, 
2002 to 2016 
 
Note: HSE Smoking Prevalence Tracker survey data. Solid lines based on smoothing splines. 
Despite the apparently low average number of cigarettes smoked per week, there is 
substantial variability in individual consumption. In both the HSE Smoking Prevalence 
Tracker survey and the Healthy Ireland Survey, some individuals report consumption 
in excess of 70 cigarettes per day. According to the Healthy Ireland survey data, one 
third (33%) of regular smokers of manufactured cigarettes consume 20 or more 
cigarettes per day. 
Cigarette consumption is lowest in 15 to 24 year olds (9.7 cigarettes per day) and in 
upper middle and lower middle class groups (10.2 cigarettes per day) (see Table 
3.5). 
Cigarette consumption is higher in those using manufactured compared with hand-
rolled cigarettes. In daily smokers, the average number of manufactured cigarettes 
consumed was 11 per day in contrast to 3.2 per day of hand-rolled cigarettes.  
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The Irish survey data do not give information on quantity of cigarettes consumed in 
pregnant women or those with mental health issues. Data from the Growing Up in 
Ireland study suggest that the number of cigarettes smoked per day during 
pregnancy ranged from seven, for those with the highest education, to 11, for those 
with the least education.(117) These data suggest that the quantity of cigarettes 
smoked during pregnancy is similar or slightly lower than that for unselected adult 
women. A US study showed that the number of cigarettes smoked increased with 
level of psychological distress, meaning those with mental health issues smoked 
more cigarettes on average than those with no mental health issues.(107)  
3.4 Smoking cessation 
The data on attributable risks and mortality indicate a clear benefit for former 
smokers relative to current smokers, and therefore a clear benefit from smoking 
cessation. In 2015, based on data from the Healthy Ireland survey, 32% of daily 
smokers and 30% of occasional smokers were either trying to quit or actively 
planning to quit when asked.(65) A further 34% of daily smokers and 22% of 
occasional smokers were thinking about quitting but not planning to. Quitting often 
occurs with little planning: a substantial proportion of quit attempts by smokers 
motivated to quit are spur of the moment.(125) 
An international study of over 21,000 smokers found that 40% of smokers report a 
quit attempt in a given year, and that there was an average of 2.1 quit attempts in 
this 40% in a year.(126) Another multi-country study including 2,431 smokers 
reported that 93% of participants had made previous quit attempts, and that the 
average number of previous quit attempts was 4.1.(127) However, the number of 
previous attempts is likely to be subject to recall bias, and could be substantially 
higher. A Canadian study estimated that the number of previous attempts was 6.3 
based on recall by successful quitters, but that the true figure could be as high as 
142 using alternative methods of estimation.(128) However, the latter figure was 
considered a probable over-estimate, and a more likely estimate was 29.6 quit 
attempts. 
At any given time, the majority of smokers are thinking about quitting, and most 
have made multiple prior unsuccessful attempts to quit. 
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3.4.1 Harm reduction 
While there is evidence of a dose-response relationship between cigarettes 
consumed and risk of disease, substantial risk reduction can be achieved through 
cessation. For this reason, interventions can be distinguished on the basis of 
whether they are intended to reduce harm (for example, through reduced 
consumption) or intended to lead to permanent smoking cessation. 
Thirty four percent of daily smokers and 48% of occasional smokers in Ireland were 
not considering quitting when asked in the 2015 Healthy Ireland survey. In the 
absence of a desire to quit, a policy of harm reduction through reduced consumption 
of cigarettes may be considered worthwhile from a public health perspective. 
However, there is little evidence to support the efficacy of this approach and it may 
not have any clinically relevant impact.(129) Despite fears that harm reduction may 
reduce willingness to attempt cessation, evidence suggests that it may improve the 
likelihood and success of quit attempts in the longer term.(127, 130) As noted however, 
this HTA is focused on interventions aimed at increasing the probability of successful 
cessation in individuals making a quit attempt. 
3.4.2 Methods used for cessation 
As described in Chapter 2, a wide range of interventions is available to support 
smokers attempting to quit. The interventions are intended to improve the likelihood 
of successful quitting over and above what can be achieved unassisted. A systematic 
review of studies of unassisted quit attempts found that the percentage of quit 
attempts that were unassisted ranged from 41% to 95%.(131) However, there was a 
clear temporal trend that the prevalence of quit attempts was declining over time, 
most likely due to the increasing availability of effective cessation aids. Those who 
choose to attempt quitting unassisted do so for many reasons, including autonomy 
and self-control, and it is likely that many smokers will continue to make quit 
attempts unassisted.(132) In fact, the majority of ex-smokers quit unassisted and the 
majority of current smokers will attempt to quit unassisted.(133) 
An international review of tobacco dependence treatment guidelines found that 75% 
of high-income countries had treatment guidelines in place.(134) The main 
interventions recommended in guidelines were brief advice (93%), intensive 
specialist support (93%), medications (96%), and telephone helplines (66%). 
Intensive specialist support was not clearly defined, but is assumed here to include 
counselling and behaviour support interventions. It is apparent that there is 
widespread support for most of the main therapies available. 
The World Health Organization (WHO) Framework Convention on Tobacco Control 
(FCTC) requires Parties to the Convention (including Ireland) to take effective 
measures to promote smoking cessation.(135) A 2011 survey of countries found that 
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only 56% of high-income countries promoted or encouraged brief advice in existing 
services.(136) Although 75% of high-income countries had a telephone quitline, only 
36% had nationwide specialised tobacco dependence treatment facilities. 
The extent to which different smoking cessation aids will be used in a population 
depends on numerous factors, including awareness, availability, acceptability, and 
cost. Quitlines, which are provided widely in high-income countries, may provide 
information of pharmacological cessation aids which may be available over-the-
counter or require a prescription. Some of the nicotine replacement therapies (NRT), 
for example, are available for sale in general grocery and retail outlets and therefore 
do not require consultation with a healthcare practitioner prior to purchase. The 
need for a prescription and interaction with a clinician should ensure provision of 
brief advice and may increase the likelihood of accessing other supportive 
interventions. However, the need to consult with a clinician may also represent a 
barrier for some, on cost grounds or otherwise. Consultation with a clinician is also 
premeditated, and may not be as widely adopted amongst smokers making 
spontaneous quit attempts. The relative popularity of different pharmacological 
cessation aids has changed over time, and individual products may appeal 
differentially to different population subgroups.(137) Data from the UK indicate that 
the total number of pharmacological treatment items prescribed peaked in the year 
2010 to 2011, and that the popularity of each of the three listed therapies (NRT, 
bupropion and varenicline) is declining.(138) 
A recent and substantial change to the smoking cessation landscape has been the 
development of electronic nicotine delivery systems (ENDS) and electronic non-
nicotine delivery systems (ENNDS), also known as e-cigarettes. As they are not a 
tobacco product, they are not subject to tobacco control legislation, and in many 
jurisdictions are therefore not expressly banned in indoor public spaces and can be 
advertised in mainstream media. Use of e-cigarettes is controversial for many 
reasons. There are concerns that they act as a gateway to cigarette smoking in 
adolescents, that the adverse effects and safety profile are not well known, and, as 
they are unregulated, the composition and effects of the inhaled vapour are not well 
known. Despite these concerns, e-cigarettes have become increasingly popular as an 
aid to smoking cessation. Data on use of e-cigarettes for smoking cessation was first 
recorded in England in 2009, and was associated with less than 3% of quit attempts. 
Popularity began to grow in 2011 and by early 2016, approximately 40% of quit 
attempts in England involve the use of e-cigarettes. The increasing popularity of e-
cigarettes coincides with a declining use of pharmacological aids, although the two 
patterns may be unrelated. 
Both varenicline and bupropion are contraindicated in pregnant women, and, as 
nicotine may be harmful in pregnancy, there may also be some reluctance to 
prescribe NRT to pregnant women.(139) NRT is considered safer than tobacco smoke 
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during pregnancy, but there may be a clinical preference for non-pharmacological 
smoking cessation interventions during pregnancy. A detailed assessment of the 
safety of smoking cessation interventions in pregnancy is presented in Chapter 5. 
The prevalence of smoking is higher and successful quit rates are lower in people 
with mental health issues than in those without.(140) A US survey found that those 
with mental health issues were more likely than those without to use NRT and to 
receive advice.(141) The number of past quit attempts was similar in both groups. 
Enacting the Tobacco-Free Campus Policy was a key action of the Tobacco Control 
Framework 2010. There are a number of issues that complicate smoking cessation 
management in patients with mental health issues. As noted in Section 2.1.1.3, 
bupropion (Zyban®) is contraindicated in bipolar affective disorder as this 
antidepressant can precipitate a manic, mixed, or hypomanic episode. Warnings in 
relation to clinically significant neuropsychiatric events associated with varenicline 
administration in those with pre-existing psychiatric conditions were reversed in May 
2016 by the European Medicines Agency. This followed the publication of safety and 
efficacy data from the EAGLES trial which found no increased incidence of adverse 
neuropsychiatric effects in patients with or without pre-existing psychiatric disorders. 
Cigarette smoking increases the metabolism of some antipsychotic drugs by inducing 
the cytochrome P450 enzyme system, resulting in lower therapeutic blood levels and 
decreased effectiveness.(93) Smoking cessation must be accompanied by a review of 
a patient’s medication to avoid the risk of adverse effects due to overdosing. The 
safety of smoking cessation interventions in the mental health population is assessed 
in detail in Chapter 5. 
3.4.3 Predictors of successful cessation 
There is a substantial body of literature regarding the clinical effectiveness of 
different smoking cessation interventions, and is reviewed in Chapter 4. Estimates of 
clinical effectiveness are preferably derived from randomised controlled trials (RCTs) 
and provide data on how well an intervention might work under ideal conditions of 
adherence and compliance to therapy. An alternative approach is to review 
observational data, such as surveys, to determine the factors that influence 
successful quit attempts. The major distinction is that in surveys, respondents have 
not been randomised to different smoking cessation interventions, but have self-
selected to participate. This means measures of effectiveness will be confounded by 
other factors and individual characteristics such as motivation to quit. For example, 
analysis of the data from the adult Special Eurobarometer for Tobacco survey 
demonstrated that the percentage of adults reporting having ever used an e-
cigarette increased from 7.2% in 2012 to 11.6% in 27 EU member states in 2014.(26) 
Certain groups were found to be more likely to have tried e-cigarettes (younger age, 
living in urban areas and higher educational level).(26) Further analysis from this 
survey, based on all 28 member states, found that 10.6% of those who had ever 
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attempted to quit smoking, and 27.4% of those who did so using a cessation aid, 
had experimented with e-cigarettes as a cessation aid.  
Unassisted quitting was common: 61.4% of current and ex-smokers who had ever 
attempted to quit reported not using any cessation aid. However, experimentation 
with e-cigarettes as a cessation aid was noted to have more than doubled in just two 
years, with 43.6% of current smokers reporting its use as an aid in 2014. Use for 
this purpose was more common among younger smokers (aged 15 to 24 years) 
compared with those aged 55 years and older (odds ratio (OR) 5.29) and those who 
reported financial difficulties (OR 1.33). While use of e-cigarettes as a potential 
cessation aid has increased, half (50.7%) of those who did so reported that they did 
not help them reduce smoking or that they smoked more after trying them. Those 
with a higher educational level were more likely to self-report being successful (OR 
2.23).(142)  
An analysis of survey data on quit attempts in the US, UK, Canada and Australia 
found that using medication to support a quit attempt was not predictive of 
abstinence at six months after adjusting for age, sex, socio-economic status and 
level of nicotine dependence.(125) The same study found that reducing smoking to 
quit was more predictive of abstinence than abrupt quitting. Those with moderate or 
high nicotine dependence were less likely to have successfully quitted than those 
with low dependence. 
An Australian study assessed the success rate of quitting smoking for a range of 
cessation interventions.(143) Based on data after the introduction of bupropion, the 
success rate was 40.2% for no help, 20.8% for bupropion, 39.0% for GP support, 
21.5% for nicotine patches, and 11.4% for nicotine gum. Individual characteristics 
such as age and socio-economic status were not accounted for in the analysis. 
A large observational study of over 46,000 supported quit attempts in the UK found 
that those using medication were more likely to successfully quit at four weeks than 
those using no medication.(144) Male clients and those paying for a prescription were 
more likely to succeed. However, when heaviness of smoking was taken into 
account, single NRT was no longer associated with a higher quit rate relative to no 
medication. It should be noted that as the standard treatment course for varenicline 
and bupropion is 12 weeks and seven to nine weeks, respectively, the quit rate at 
six or 12 months would be more meaningful that the quit rate at four weeks. 
A systematic review of 17 articles examining predictors of quit attempts and 
successful quitting provides information on the heterogeneity in study findings.(145) 
For example, some studies reported that older smokers were more likely to have 
made a quit attempt while other studies found the reverse. Some of the more 
consistent findings included a negative correlation between cigarette consumption 
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and quit attempts, and that past quit attempts predicted future quit attempts. There 
was some evidence to suggest that people of higher socio-economic status were 
more likely to succeed in quitting, as were people with lower levels of nicotine 
dependence. There is a potentially complex relationship between history of quit 
attempts and successful quitting, in that some studies found a negative association. 
It is possible that some smokers make many quit attempts without utilising 
appropriate supports or learning from previous failures. 
Observational studies tend to be impacted by a number of important confounders, 
and the results may not be applicable to other settings. The choice of smoking 
cessation therapy may be strongly linked to both individual characteristics and wider 
issues such as affordability and ease of access. As such, it is important to consider 
the available data for Ireland. 
3.4.4 Smoking cessation in Ireland 
There is a wide range of smoking cessation supports available through the health 
services in Ireland. These include brief interventions, pharmacological therapies, 
counselling, online and social media supports, quitline services, courses, and 
specialist quit clinics.(146) Tobacco cessation services are available nationwide from 
trained health professionals who provide behavioural support to those attempting to 
quit. The service is intended to provide structured support either through individual 
or group sessions, and the service can also be accessed through telephone or online 
support. A full description of the organisation of quit services in Ireland is provided 
in Chapter 7. 
Data supplied by 12 HSE smoking cessation service providers show that of almost 
3,000 people accessing those providers in 2015, 75% had a Medical Card. In the 
period 2013 to 2015, the providers experienced a 13% increase in the number of 
clients attending. Data were also provided on people that undertook a pre-quit 
consultation in the period January 2015 to early June 2016. In the 17 month period 
there were 1,943 interactions with the service. There was substantial regional 
variation in the uptake of this particular service. 
The 2015 Healthy Ireland survey collected data on quit attempts in the last 12 
months by current and former smokers. Of current smokers or those that had 
smoked within the previous 12 months, half (50.0%) had stopped smoking for a day 
or more in the previous 12 months as part of an attempt to quit smoking. Within the 
survey, respondents could report the cessation approach they took, choosing from 
the range of options outlined in Table 3.6. The option of ‘no help’ is interpreted here 
as using willpower alone. A total of 13.4% of respondents reported making a quit 
attempt in the 12 months leading up to the survey. The most common approach, 
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used by half (50%) of respondents, was to have no help, followed by e-cigarettes 
(29%) and NRT (12%) (Table 3.6). 
Table 3.6 Use of different smoking cessation supports in Ireland (Health 
  Ireland Survey 2015) 
Help used in quitting Percentage Population* 
No help used 50.3% 242,858 
E-cigarettes 28.7% 138,389 
NRT (Nicotine patches, gum, lozenges, spray) 12.0% 57,725 
Varenicline(Champix®) or buproprion (Zyban™) 3.5% 17,051 
Other aid, help, support 2.7% 12,805 
www.quit.ie 1.0% 4,642 
Acupuncture 0.6% 3,030 
Smokers telephone Quitline/Helpline 0.1% 663 
www.facebook.com/HSEquit 0.1% 542 
* Estimated number of people who used this intervention in a period of 12 months 
The Healthy Ireland results do not provide a further breakdown within product 
categories to give the relative popularity of products within a group. The number of 
eligible Medical Card holders redeeming prescriptions for a variety of smoking 
cessation products were used to estimate the relative popularity of NRT, varenicline 
and bupropion (Figure 3.3). Half (50.8%) of NRT prescriptions were for patches, 
17.4% for gum, 15.4% for sprays, and 14.2% for inhalers. The remaining 2.2% 
were for lozenges and tablets. In terms of prescriptions for the other 
pharmacological cessation aids, 89.2% were for varenicline and 10.8% for 
bupropion. In other words, there were just over eight people prescribed varenicline 
for every one patient prescribed bupropion. 
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Figure 3.3 Trends in redemption of prescriptions for NRT and other 
smoking cessation products by Medical Card holders, 2010 to 
2015 
 
Index: Six different formulations of nicotine replacement therapy (NRT) are included: gum, 
lozenge, patch, tablet, inhaler and spray.  
Between January 2010 to October 2015, the total expenditure by the HSE on 
prescribed smoking cessation products for Medical Card holders was €46.64 million. 
Annual expenditure for this cohort peaked in 2012 at €9.38 million, declining to 
€6.96 million in 2014. Intervention costs depend on the cost of the individual 
product and the duration of treatment.  
Primary Care Reimbursement Service (PCRS) data for Medical Card holders indicate 
that the average duration of bupropion prescriptions was 119 days (median 37 days) 
for the period 2010 to 2014, while for varenicline it was 65 days (median 28) and 51 
days (median 28) for NRT patches. As noted in Chapter 2.1.1.3, the recommended 
treatment course for bupropion is nine weeks while that of varenicline is 12 weeks. 
Prescriptions for Medical Card holders are dispensed in one month aliquots. Using 
gaps of at least 90 days to indicate a new treatment episode, PCRS data from 2010 
to 2014 suggest that 53% of bupropion treatment episodes and 62% of treatment 
episodes were for a period of six weeks or less. It is not known if the failure to 
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redeem additional prescriptions was because patients had successfully quit smoking 
and no longer needed support, or that treatment was discontinued due to lack of 
effect or intolerance. Again, assuming a gap of at least 90 days to indicate a switch 
to therapy, data from the period 2010 to 2015 indicates that 8% of patients 
switched therapies, with switches from varenicline to NRT patch (28%) and from 
NRT patches to varenicline (21%) being the most common switches made. 
The Healthy Ireland survey comprises data for a mix of current and former smokers, 
allowing the factors associated with successful quit attempts to be assessed. In 
analysing these data, it must be noted the sample size is relative small. Those self-
reporting as former smokers may only have quit recently, and are at substantial risk 
of relapse. Furthermore, there are no data on quantity of smoking for respondents 
classified as former smokers. Using a logistic regression model to analyse the data, 
the Evaluation Team estimated the probability of quitting as a function of age, 
gender, Medical Card status, area deprivation, and method of quitting. Women are 
more likely to succeed in a quit attempt, as are younger people, although age and 
gender were not statistically significant predictors. Those with no Medical Card and 
those from less deprived areas were more likely to have succeeded in quitting, and 
in both cases the coefficients were statistically significant. 
Medical Card status can act as a socio-economic indicator, but the fact that it 
remains a significant predictor after adjusting for deprivation is noteworthy. The 
majority of the cost of prescriptions for Medical Card holders is absorbed by the HSE. 
Patients pay a €2.50 charge per item, with a maximum charge of €25 per family per 
month. The cost of treatment should therefore not be a barrier to Medical Card 
holders, and yet Medical Card holders have a lower quit success rate. Due to the 
reported low uptake of some smoking cessation supports (for example, acupuncture 
and quit services), the coefficients associated with those supports are subject to 
substantial error. However, a hierarchy can be observed for the other supports. 
Relative to NRT, using no help or e-cigarettes are both statistically significantly 
associated with a greater likelihood of quitting. Pharmaceutical supports (varenicline 
and bupropion) are associated with a non-statistically significant increased likelihood 
of quitting, and other unspecified supports are associated with a statistically 
significant increased likelihood of quitting relative to NRT. Although the model had a 
classification accuracy of 78%, the area under the receiver-operator characteristic 
curve was 0.63, indicating relatively poor predictive power. It is also important to 
remember that smokers self-select what cessation supports they may avail of.  
The study of pregnant women at the Coombe Women and Infants University 
Hospital in Dublin recorded information on attempts to quit during pregnancy.(120) 
Change in smoking status was recorded at the booking interview compared with six 
months previously. Of those who attempted to quit, 81% used no help, and 12.5% 
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used NRT. Seventy two percent of those who used no help classified themselves as 
an ex-smoker, compared with 17% of those who used NRT. 
No data were retrieved in relation to use of smoking cessation interventions in those 
with serious mental health conditions in Ireland. International data suggest that the 
decline in prevalence of smoking in the general population has not been matched in 
those with serious and enduring mental illnesses. It is known that cognitive deficits 
coupled with disorganised thinking and poor task persistence and a higher 
prevalence of depression and substance misuse may contribute to a lower 
motivation to stop smoking for smokers with schizophrenia. However, according to 
international research, the sustained high prevalence of smoking in this cohort has 
partly been attributed to a failure of providers to offer smoking cessation 
interventions and advice to those with serious mental illness, despite emerging 
evidence that those with serious mental illness are motivated to quit and can achieve 
comparable abstinence rates to those without comorbid psychiatric disease in clinical 
trial settings.(90, 109, 147) 
3.4.5 E-cigarette use in Ireland 
Although e-cigarettes have been available since the mid-2000s, acknowledgement of 
their use in smoking cessation is more recent. The English smoking statistics have 
recorded data on e-cigarette use for cessation since 2009. Since August 2014, the 
HSE Smoking Prevalence Tracker survey has included a question on e-cigarette 
usage. Based on this data, the proportion of the population in Ireland using e-
cigarettes has been relatively stable from August 2014 to March 2016, with between 
two and three percent of the population aged over 15 years using them on a daily 
basis, and between one and three percent using them less than daily. Market 
penetration therefore appears to be relatively stable. 
From the Healthy Ireland survey data it is apparent that e-cigarettes have become a 
popular aid for smoking cessation, with almost 29% of quit attempts supported 
through e-cigarette usage. Unfortunately, these data on e-cigarette use in cessation 
are limited to a snapshot, and it is therefore not possible to analyse the trends in 
relation to cessation in Ireland. UK data suggest the use of e-cigarettes for cessation 
is increasing. Almost all (98%) of e-cigarette users are smokers and former smokers, 
with the prevalence of e-cigarette usage at approximately 6% in both groups. There 
is no evidence to suggest that the quantity of cigarettes smoked is less in smokers 
who also use e-cigarettes compared with smokers who do not use e-cigarettes. 
Seventy one percent of current smokers who also use e-cigarettes attempted 
quitting in the previous 12 months, compared with 43% of current smokers who do 
not use e-cigarettes. Similarly, 66% of current smokers who also use e-cigarettes 
are either trying to or actively planning to quit, compared with 30% of smokers who 
do not use e-cigarettes. It is not possible to state whether the higher intention to 
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quit and likelihood of a quit attempt in the previous 12 months is associated with e-
cigarette use or whether it reflects demographic or other factors of the cohort who 
are more likely to use e-cigarettes. 
E-cigarettes are not provided through the health services, so it is possible that they 
are not being used in conjunction with specialist advice on smoking cessation. Data 
from the UK show use of e-cigarettes as a smoking cessation support is increasing, 
but that use of pharmacological therapies and GP-triggered quit attempts are 
decreasing. It is not possible to determine the extent to which these trends are 
related or whether they reflect the changing demographics of the cohort of smokers. 
3.4.6 Inequalities in smoking cessation 
The HSE Smoking Prevalence Tracker and Healthy Ireland survey data include data 
on socio-economic status of individuals. Table 3.5 shows that there is a socio-
economic gradient in smoking, with a higher prevalence of smoking in lower socio-
economic groups. The higher rate of smoking persists after adjusting for age, sex, 
and Medical Card status. The average number of cigarettes smoked per day also 
increases with lower socio-economic status. The higher prevalence and intensity of 
smoking in people with lower socio-economic status creates challenges for smoking 
cessation services. 
Inequalities in smoking cessation, whereby people with lower socio-economic status 
are less successful at quitting, have been widely studied. An analysis of smoking 
cessation across Europe found that inequalities increased in the 2000s.(148) Of the 11 
countries analysed, the largest increase in inequalities between 2002 and 2012 was 
observed in Ireland. The findings of the study suggest that cessation rates in low 
socio-economic groups stabilised at the end of the 1990s whereas they have 
continued to increase in high socio-economic status groups. Data from the 
International Tobacco Control Four Country Survey, comprising survey data among 
smokers in Canada, the US, the UK, and Australia, indicates that those of moderate 
and high education and income levels are more likely to be planning to quit than 
those of low education and income level. Furthermore, those with a high education 
level are more likely to have attempted to quit than those of low education status. 
A UK study analysed the completion and success of over 550,000 quit attempts in 
relation to neighbourhood deprivation and individual characteristics.(149) After 
adjusting for age, sex, occupation, nicotine dependence and intervention 
characteristics, higher neighbourhood deprivation was associated with a lower 
likelihood of treatment completion and of successful quitting. Reduced success was 
not fully explained by reduced completion of treatment, indicating that other factors 
also affect successful quitting. The study highlighted the need for ensuring that 
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smokers in the most deprived areas receive the most effective interventions to 
maximise the likelihood of successful quitting. 
Some tobacco control policies, not limited to cessation interventions, may contribute 
to increasing cessation inequalities. For example, workplace smoking bans have 
been found to have a neutral or negative impact on cessation inequalities.(148) Socio-
economic inequalities in cessation may therefore be due to a range of factors 
including difficulties accessing services, barriers to completion of treatment, and 
lower probability of success due to higher nicotine dependency. Some of the 
inequalities may be addressed by ensuring equitable access to smoking cessation 
services. One proposed method to combat cessation inequalities is to incorporate an 
equity element into performance measurement in the quit services.(150) An increase 
in cessation inequalities does not imply that cessation has declined in those of lower 
socio-economic status. Cessation can increase in all groups, but a higher rate of 
cessation in those of higher socio-economic status is resulting in greater disparity. 
Increased inequalities may be due to higher motivation to quit in more affluent 
individuals combined with fewer barriers to accessing effective interventions. 
Achieving a reduction in cessation inequalities may require substantial positive 
inequalities in access to cessation services. On the basis of the data from the sample 
of Irish smoking cessation services, the disproportionate number of GMS clients 
suggests the presence of a positive inequality in access. It should be borne in mind 
that 79% of quit attempts do not involve State-supported interventions, as they 
involve either no support or the use of e-cigarettes. An effort to reduce cessation 
inequalities will require other approaches to be considered to reduce barriers to 
successful quitting, such as increasing motivation to quit, providing interventions not 
currently reimbursed, or providing them free at the point of care. 
3.5 Discussion 
This chapter has reviewed some of the key epidemiological issues in relation to 
smoking and smoking cessation, with particular attention to the prevalence of 
smoking in Ireland and the current approach to cessation. 
Cigarette smoking can have major implications for the health of both current 
smokers, former smokers, and those exposed to second-hand smoke. Cigarette 
smoking results in a significant burden on morbidity and mortality, with implications 
for quality of life and health service utilisation. Smoking cessation substantially 
reduces the risk of disease and can, over time, result in relative risks similar to that 
of people who have never smoked for a range of conditions. 
The prevalence of smoking in Ireland has been in long-term decline. The extent to 
which that decline will continue without changes to service provision is difficult to 
determine. As prevalence declines, it is possible that the remaining cohort of 
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smokers comprises those with high nicotine dependence and, or those who face 
barriers to accessing effective services. The inequalities in smoking cessation are 
such that smoking prevalence is highest and successful quit attempts are lowest for 
smokers in the lowest socio-economic groups. As the overall prevalence of smoking 
declines, and the rate of new smokers also declines, the demography of current 
smokers will shift. This may require different approaches to cessation services in 
terms of both how they are delivered, and which interventions are provided or 
favoured. 
Data from the Healthy Ireland survey provide information on smoking behaviour and 
quit attempts in the Irish population. Ninety one percent of quit attempts use either 
‘no help’ (50%), e-cigarettes (29%), or NRT (12%). A brief analysis suggested that 
those with no Medical Card and those from less deprived areas were more likely to 
have succeeded in quitting. These data also suggest that when compared with NRT, 
using no help, e-cigarettes, and other unspecified supports are associated with a 
greater likelihood of quitting. Pharmaceutical supports (varenicline and bupropion) 
are associated with a non-statistically significant increased likelihood of quitting. 
It must be noted that smokers self-select what supports they will use when 
attempting to quit, and those using particular supports may have a higher likelihood 
of success irrespective of the intervention used. However, evidence suggests that 
there may be issues of compliance and completion of therapy in certain subgroups, 
and this should be considered when evaluating the applicability of clinical 
effectiveness data. 
The Healthy Ireland data on cessation interventions used in Ireland does not provide 
information on what those interventions involve. For example, it is unclear what 
proportion of people using NRT are also provided with advice or counselling. 
Variability in how patients access therapies and what those therapies include may 
also contribute to reduced effectiveness relative to trial data. 
The fact that half of quit attempts are made without support is noteworthy and 
echoes what has been observed in other countries. The use of no support may not 
capture what interventions those people have used on previous quit attempts. Most 
smokers attempt to quit, and most do so more than once a year. Over time, smokers 
will typically make many attempts to quit before succeeding. Those who make 
attempts without support may have used support previously and are therefore not 
necessarily without knowledge or understanding of what is involved. It is also 
possible that some smokers may classify brief advice as no support, although there 
is no evidence to confirm or refute this. 
There have been numerous legislative or policy interventions in Ireland to reduce the 
exposure to smoke and smoking, such as the bans on advertising, sales to minors, 
workplace smoking, and smoking in cars carrying minors. These policies are likely to 
have impacted on smoking either by stimulating quit attempts or by reducing the 
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quantity of cigarettes smoked. These population-level interventions ultimately 
support a move to a tobacco-free country. The interventions considered in this 
report are those that support successful smoking cessation in individuals. As such, 
the individual-level factors that impact on successful quitting should be considered, 
as well as how cessation services might be provided and organised to maximise 
successful cessation. 
3.6 Key messages 
 There is a direct causal link between smoking and numerous diseases including a 
range of cancers, and respiratory and circulatory diseases. Smoking increases the 
risk of acquiring these diseases. While smoking cessation reduces the risk of 
these diseases, former smokers continue to have an elevated risk of disease 
compared to those who have never smoked. 
 Smoking causes disease through the inhalation of cigarette smoke, which 
contains over 70 carcinogens. Cigarette smoke can be inhaled directly through 
smoking or second-hand through environmental tobacco smoke, such as the 
smoke produced by a smouldering cigarette. 
 Using estimates of the proportion of disease attributable to smoking, each year in 
Ireland approximately 28,000 inpatient discharges and 11,000 day cases are due 
to smoking. 
 Smoking is associated with an increased risk of mortality. More than 5,400 deaths 
in Ireland each year are due to smoking. When deaths due to second-hand 
smoke are included, approximately 20.5% of deaths each year are due to 
tobacco smoke. 
 Smoking during pregnancy is harmful. It is associated with an increased risk of 
congenital anomalies, preterm birth, intrauterine fetal growth restriction, 
placental abruption, stillbirth, sudden infant death syndrome, respiratory 
infection, adverse cognitive and behavioural outcomes in infancy and the 
development of chronic disease in adulthood. 
 Smokers with mental health disorders smoke more heavily, are more nicotine 
dependent, and have smoked for longer than the general population. The factors 
linking mental health conditions and cigarette smoking are varied and complex. 
Recent evidence suggests that quitting smoking may improve mental health 
symptoms. 
 The prevalence of smoking in Ireland is 22.7% in people aged 15 years and over. 
The prevalence is higher in men (24.3%) than in women (21.2%), and in people 
aged 25 to 29 years (33.4%). Smoking prevalence follows a socio-economic 
gradient, whereby the prevalence is highest in those of the lowest socio-
economic group. 
 There are limited Irish data regarding the prevalence of smoking in pregnancy 
and in those with mental health disorders. Smoking prevalence is noted to be 
correlated with the severity of the mental illness, with prevalence rates of 33% to 
70% and 45% to 88% reported for those with bipolar disorder and 
schizophrenia, respectively.  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
80  
 The prevalence of smoking in Ireland and the quantity of cigarettes smoked has 
been in decline since 2008. 
 At any given time, the majority of smokers are thinking about quitting, and most 
have made multiple prior unsuccessful attempts to quit. In Ireland, half of those 
attempting to quit do so unaided. A further 29% of smokers trying to quit use e-
cigarettes as an aid. Approximately 16% of quit attempts are made using some 
form of pharmacotherapy (for example, nicotine replacement therapy). 
 
  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
81  
4 Clinical effectiveness 
This chapter summarises the available evidence on the clinical effectiveness of each 
of the smoking cessation interventions included in this health technology assessment 
(HTA). Effectiveness was considered using the outcome of long-term (greater than 
or equal to six months) smoking cessation. This assessment focused on the 
unselected adult smokers population, which is the group broadly targeted by 
national quit campaigns and which accounts for the majority of those utilising 
existing smoking cessations services. Other subgroups of interest that were 
examined separately include pregnant women and those accessing secondary care 
mental health services. Safety considerations are reviewed separately in Chapter 5. 
Much has been done to combine the substantial amount of scientific evidence on 
smoking cessation interventions that has been generated over the last number of 
decades, particularly through the efforts of the Cochrane Tobacco Addiction Group 
(TAG).(151) This HTA considered this work in order to estimate the relative 
effectiveness of the interventions of interest. High-quality reviews were used, where 
appropriate, to identify relevant studies to include in this HTA. 
4.1  Methods 
4.1.1  Criteria for considering studies for this review  
4.1.1.1 Types of studies  
Randomised controlled trials were considered in this review. 
4.1.1.2 Types of participants  
The primary population of interest in this analysis is unselected adult smokers. Two 
additional populations were considered: users of secondary care mental health 
services and pregnant women. 
The study populations are described as follows: 
1. Unselected adult smokers 
Adult smokers (aged 18 years or older) drawn from a general population, 
rather than being defined by a particular diagnosis (for example, 
schizophrenia, chronic obstructive pulmonary disease (COPD), and so on), or 
recruited from a population attending services for people with a particular 
disease or range of diseases (for example, cardiovascular wards, pre-
operative patients, and so on). 
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2. Users of secondary care mental health services 
Smokers aged 18 years or older who are users of secondary care mental 
health services. These typically include patients with psychotic disorders, 
schizophrenia or schizoaffective disorder, current depression or bipolar 
disorder. 
3. Pregnant women 
Women, not limited to those aged 18 and above, who smoke during 
pregnancy. Participants could be recruited in any trimester of pregnancy. 
4.1.1.3 Types of interventions  
As noted in Chapter 2, given the vast array of treatments that could potentially be 
provided to individual smokers, it was necessary to prioritise those that are most 
relevant to policy makers, patients and the Irish health system. To identify 
treatments for inclusion in this HTA, recently published overviews of the area were 
combined with data on the most commonly used treatments in Ireland and advice 
from the Expert Advisory Group. 
Studies were eligible for inclusion if they compared any of the following interventions 
with either no treatment (or placebo) or another eligible intervention: 
 nicotine replacement therapy (NRT) such as chewing gum, transdermal patches, 
nasal and oral spray, inhalers, tablets and lozenges, as monotherapy or 
combination (dual) therapy 
 electronic cigarettes, or e-cigarettes 
 nicotine receptor partial agonists (cytisine or varenicline only) 
 antidepressants (bupropion only) 
 motivational interviewing 
 brief physician advice 
 telephone-based interventions 
 mobile phone-based interventions 
 internet-based interventions 
 individual behaviour counselling 
 group behaviour therapy 
 acupuncture 
 Allen Carr method 
 financial incentives (for pregnant women only). 
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The interventions can be broadly grouped into pharmacological and behavioural 
interventions. An individual attempting to quit smoking may use multiple 
interventions in a single quit attempt, or combine pharmacological and behavioural 
interventions. Studies that assessed the provision of multiple interventions were 
included. 
4.1.1.4 Types of outcome measures  
For studies of unselected adults and users of secondary care mental health services, 
the primary outcome of interest was long-term smoking cessation rates, as indicated 
by quit rates at greater than or equal to six months (≥6 months). Biochemically 
verified results were preferred to self reports, and continuous or prolonged 
abstinence was preferred to abstinence at a particular point in time (point 
prevalence abstinence). Analyses were based on intention-to-treat (ITT) principles; 
this means that participants lost to follow up who could not definitively be classified 
as non-smokers were counted as smokers. Participants were retained in the groups 
to which they were randomised irrespective of adherence. 
For studies of pregnant women, the primary outcome of interest was abstinence 
from smoking during pregnancy, measured at the latest point prior to birth. 
Continuous abstinence measures timed from the date of randomisation, where 
available, were used in preference to point prevalence abstinence (7-day or 30-day 
abstinence) measures. Biochemically validated abstinence data, where available, 
were used in preference to self-reported data. 
Adverse outcomes are considered separately in Chapter 5 Safety. 
As noted in Chapter 2, this HTA does not examine the impact of treatments in terms 
of any potential harm reduction associated with their use, such as helping people to 
reduce the number of cigarettes smoked per day, or reducing exposure to second-
hand smoke, or as relapse prevention measures. Neither does it extend to examining 
the relative effectiveness of different patient recruitment strategies that may be 
employed with various treatment modalities. 
4.1.2 Search methods for identification of studies  
Searches were carried out for recent Cochrane systematic reviews of eligible 
smoking cessation interventions in populations which could be compared with 
Ireland. Where Cochrane systematic reviews were available for relevant 
interventions, these were used to identify studies matching the inclusion criteria 
outlined above. The Cochrane reviews were updated to identify any additional 
studies that had emerged since the original review was published. Systematic 
reviews published through the Cochrane Collaboration are recognised as being of 
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high quality. In the absence of a Cochrane systematic review for a given 
intervention, Medline and Embase were searched for relevant systematic reviews. 
Where no previous Cochrane or other high-quality systematic review was available 
for an intervention, electronic searches were conducted in Medline, Embase and the 
Cochrane Register of Controlled Trials to identify RCTs comparing that intervention 
with another eligible intervention or no treatment. Table 4.1 outlines the PICOS 
criteria (population, intervention, comparator, outcome, study design) for study 
eligibility for unselected adults. 
Table 4.1 PICOS criteria for study eligibility – unselected adults 
Population  Adult smokers (aged 18 years or older) drawn from a 
general population, rather than being defined by a 
particular diagnosis (for example schizophrenia, 
COPD), or recruited from a population attending 
services for people with a particular disease or range 
of diseases (for example, cardiovascular wards, pre-
operative patients, and so on). 
Intervention  
 nicotine replacement therapy (NRT), such as 
chewing gum, transdermal patches, nasal and 
oral spray, inhalers, tablets and lozenges, used as 
monotherapy or combination (dual) therapy 
 electronic cigarettes, e-cigarettes 
 nicotine receptor partial agonists (cytisine or 
varenicline only) 
 antidepressants (bupropion only) 
 motivational interviewing 
 brief physician advice 
 telephone-based interventions 
 mobile phone-based interventions 
 internet-based interventions 
 individual behaviour counselling 
 group behaviour therapy 
 acupuncture 
 Allen Carr method 
Comparator  No treatment (or placebo) or another eligible 
intervention. 
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Outcomes  Primary outcome of interest was long-term smoking 
cessation rates, as indicated by quit rates at greater 
than or equal to six months (≥6 months). 
Biochemically verified results were preferred to self 
reports, and continuous or prolonged abstinence was 
preferred to abstinence at a particular point in time. 
Study design  Randomised controlled trials 
 
4.1.3 Data collection and analysis  
4.1.3.1 Identification and selection of systematic reviews 
Given the volume of systematic reviews available, the initial search was restricted to 
the Cochrane library to identify reviews of interventions of interest. While potentially 
more up-to-date reviews of the same intervention may have been available, this HTA 
used the relevant Cochrane reviews as a basis for identifying studies that matched 
our inclusion criteria and updated these reviews where appropriate. This decision 
was based on the following criteria: 
 the approach to systematic reviewing used by the Cochrane group is 
identified in national guidelines(152) as representing best practice;  
 the reviews identified used inclusion and exclusion criteria (based on included 
study designs, populations, follow up, and outcomes) that encompassed 
those relevant to this assessment;  
 the risk of bias assessment using the Cochrane Risk of Bias tool was reported 
for each of the randomised controlled trials (RCTs) included;  
 and the quality of the reviews were rated as good (or more favourable than 
other reviews for the same population and, or intervention).  
De novo quality assessment of the Cochrane reviews was not undertaken, as a 
quality rating of each of the reviews identified was reported in a 2015 review of 
reviews of behavioural and pharmacotherapy interventions for tobacco cessation for 
the US Preventive Services Task Force.(153) These quality assessments, which used a 
modified version of the Assessing the Methodological Quality of Systematic Reviews 
(AMSTAR) tool to quality rate the reviews, were accepted for use in this report on 
the basis that they met best practice. 
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4.1.3.2 Selection of studies  
Where an existing high-quality systematic review existed for a given intervention, all 
included studies were re-assessed using this HTA’s inclusion criteria to identify 
relevant studies. 
For search updates or de novo searches to identify new studies not included in these 
reviews, all returned citations were first screened by one reviewer to eliminate 
clearly irrelevant studies. Two people then independently reviewed the remaining 
citations per the inclusion criteria, with any disagreements being resolved by 
discussion, or, if necessary, a third reviewer. 
4.1.3.3 Data extraction and management  
Data extraction from newly identified study reports was carried out independently by 
two people to reduce the likelihood of errors, with any disagreements being resolved 
by discussion or a third reviewer, if necessary.  
Where the HTA updated a previous systematic review, data were extracted from the 
systematic review rather than from the primary studies. In general, if the data 
extraction method used in the review was consistent with that which would have 
been used had an original search been conducted (that is, extracted independently 
by two people and cross checked, as above), re-extraction of the primary study data 
was not performed unless there was a specific reason to warrant it. For example, in 
some cases, two systematic reviews might report different numbers for the same 
study. Data for these studies were re-extracted independently by two reviewers, 
with any inconsistencies resolved through discussion or via a third party. 
For quality assurance purposes, a random sample of one in 10 studies was selected 
from the systematic reviews and data extraction from the primary studies was 
carried out. By comparing the data extraction from the primary studies to the data 
presented in the systematic reviews, it was possible to determine if there were any 
inconsistencies. 
4.1.3.4 Assessment of risk of bias in included studies  
Risk of bias was assessed using the Cochrane risk of bias tool for randomised 
controlled trials. This was performed on all reports of studies by two people 
independently, with any disagreement being resolved by discussion or a third party.  
Where the HTA updated a previous systematic review that used the Cochrane risk of 
bias tool, an assessment of the quality and rigour of that systematic review was 
carried out to decide if re-assessment was necessary. If the review used a different 
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method of assessing risk of bias, then the risk of bias analysis was carried out again 
using the Cochrane approach. 
For all interventions, small study bias was assessed using a funnel plot in 
combination with multiple tests for asymmetry (including the Harbord and Egger’s 
tests).(154) Due to the low power of such tests when there are few studies, this was 
only performed for comparisons involving 10 or more studies. Small study bias was 
interpreted as a potential indicator of publication bias. Where evidence of small 
study bias was detected, the trim and fill approach was used to determine the 
treatment effect adjusted for missing studies.(155) This approach was used to give an 
estimate of the impact of small study bias, but not used for final treatment effect 
estimates. 
4.1.3.5 Measures of treatment effect and data synthesis 
Effect sizes were expressed as the relative risk (RR) of a smoker having abstained 
from smoking for six months or longer in the intervention group compared with the 
comparison group(s). 
Preference was given to random effects meta-analysis, due to the variability in trial 
populations and how interventions were delivered. For example, study participants 
had different mean ages and levels of smoking dependency across studies. Both 
fixed and random effect estimates were computed in all cases, and the differences 
considered. In cases of fewer than five studies in a comparison, the fixed effect 
estimate is reported, as it was considered that there were insufficient data to 
support a reliable estimate of between-study variance. For head-to-head 
comparisons, the Mantel-Haenszel method was used to calculate the fixed effect 
estimate and the DerSimonian-Laird method was used to estimate the random 
effects estimate.  
Where there was sufficient indirect and direct evidence and the assumption of 
transitivity was justified, a network meta-analysis approach was considered. In the 
case of a network meta-analysis, the consistency model was used.(156) An unrelated 
mean effects (UME) model, also referred to as an inconsistency model, was also 
applied.(157) A random effects model was used. The node splitting approach was 
used to compare direct and indirect evidence, and an examination of deviance 
statistics was used to identify studies that were providing potentially inconsistent 
estimates.(158, 159) Node splitting generates separate models for direct and indirect 
evidence, and the network evidence is not a mathematical combination of the two. 
Some multi-arm trials may be excluded from the node splitting analysis if they 
provide both direct and indirect evidence for a given comparison. Node splitting has 
only been applied to comparisons for which there is both direct and indirect 
evidence. 
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Meta-regression approaches were also applied to determine if study-level covariates 
could explain some of the observed variance. Models were compared using the 
Deviance Information Criterion (DIC). Network meta-analysis models were run using 
package gemtc 0.8.1(160) in R 3.3.1. Models were run with a burn-in of 20,000 
iterations followed by 50,000 iterations on four chains. Model convergence in the 
adaption phase was checked using the Gelman and Rubin convergence diagnostic. 
Treatment effect estimates based on head-to-head evidence only were computed 
using Frequentist methods and are reported with associated confidence intervals. 
For network meta-analyses, which were based on Bayesian methods, treatment 
effects are reported with associated credible intervals. The two intervals have 
different interpretations reflecting the underlying methodology. A confidence interval 
is a statement of how frequent the true treatment effect lies in the confidence 
interval when the experiment is repeated a large number of times, each time with a 
different sample of data from the same underlying population. A credible interval is a 
statement of the range of values for which the treatment effect remains plausible 
given the particular sample of data that have actually been observed. The credible 
interval has a more intuitive interpretation for decision-making, as a statement can 
be made that ‘there is a 95% probability that the true treatment effect lies within 
the credible interval’. 
For both confidence and credible intervals, the reported range relates to the average 
treatment effect. Prediction intervals for some analyses are also reported. A 
prediction interval provides an estimate of the range of values that the treatment 
effect could take in a future study. Prediction intervals tend to be wider than 
confidence or credible intervals. When there are substantial differences, the 
prediction intervals may be very wide. For decision-making at a national level 
regarding smoking cessation, it may be more appropriate to focus on the confidence 
bounds or credible interval associated with the average treatment effect. The 
heterogeneity observed across studies reflects differences in study design, setting, 
participants, and implementation of the interventions. Such heterogeneity is likely to 
also be observed if cessation programmes are implemented across Ireland, but 
overall a treatment effect similar to the average observed across trials is anticipated. 
The difference between efficacy and effectiveness also needs to be considered. 
Efficacy refers to the performance of an intervention under ideal and controlled 
circumstances, whereas effectiveness refers to its performance under typical or ‘real-
world’ conditions. Effectiveness takes into account the fact that not all people will 
receive an intervention as intended. The systematic reviews undertaken for this 
chapter were restricted to data from randomised controlled trials (RCTs). Although 
evidence from RCTs may often be considered as measuring efficacy, many of the 
included trials could be more accurately described as measuring effectiveness. This 
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is because the interventions were evaluated under circumstances that more closely 
approach real-world practice, such as more heterogeneous patient populations, less-
standardised treatment protocols, and delivery in routine clinical settings. 
4.1.3.6 Assessment of heterogeneity  
An assessment of clinical heterogeneity was carried out based on the description of 
the interventions within each group. Statistical heterogeneity was examined using 
the I2 statistic. An I2 value of less than 50% was taken to indicate a low degree of 
heterogeneity and I2 values greater than 70% indicate substantial heterogeneity. 
Interpretation was based on both the point estimate of I2 and also the associated 
confidence bounds. If the point estimate for I2 suggested substantial heterogeneity 
but the lower bound for I2 was low, for example 10%, then it was considered 
evidence of moderate heterogeneity. Where substantial heterogeneity was observed, 
it was investigated using subgroups analysis or meta-regression, as appropriate. The 
coherence of the network of evidence was also considered by comparing the effect 
size estimates obtained from direct and indirect comparisons. 
Where there was evidence of heterogeneity, meta-regression with study-level 
covariates (such as year of publication, quality, length of follow up, measure of 
abstinence, and abstinence verification) was used to explore to whether 
heterogeneity could be explained. The risk of bias assessment was used as a proxy 
for study quality. It is appreciated that risk of bias was evaluated based on a limited 
set of study characteristics, and that a study at low risk of bias is not necessarily a 
high quality study. 
4.2 Clinical effectiveness in unselected adults 
The primary population of interest in this analysis is unselected adult smokers. This 
population group underpins the majority of published research on smoking 
cessation. 
4.2.1 Identified systematic reviews 
A total of 13 systematic reviews were identified that were relevant to the 
interventions considered in this HTA (Table 4.2). All of the identified reviews were 
Cochrane reviews. No review was identified for the Allen Carr method. These 
reviews are limited to those assessing the effectiveness of a pharmacological or 
behavioural intervention. Reviews of the effectiveness of combination therapy (that 
is, a pharmacological intervention with adjunctive behavioural therapy) are 
considered separately in Section 4.2.7. 
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Table 4.2 Identified systematic reviews 
Review (year) Intervention Primary studies 
White et al. (2014)(47) Acupuncture 38 
Hughes et al. (2014)(30) Antidepressants (bupropion) 65 
McRobbie et al. (2014)(17)* Electronic cigarettes 2 
Stead and Lancaster 
(2005)(61) 
Group behaviour therapy 53 
Lancaster and Stead 
(2005)(58) 
Individual behavioural counselling 30 
Civljak et al. (2013)(57) Internet-based interventions 28 
Whittaker et al. (2016)(56) Mobile phone-based 12 
Lindson-Hawley et al. 
(2015)(51) 
Motivational interviewing 28 
Cahill et al. (2016)(40) Nicotine receptor partial agonists 
(cytisine and varenicline) 
41 
Stead et al. (2012)(8) Nicotine replacement therapy (NRT) 150 
Rice et al. (2013)(161) Nursing interventions 49 
Stead et al. (2013)(7) Physician advice 42 
Stead et al. (2013)(7) Telephone counselling 77 
* An update of this review was published in September 2016 following search updates for this 
HTA.
(162)
 No additional studies were identified. 
While the majority of the identified reviews were no more than three years old, two 
of the reviews were published over 10 years ago. Not all of the primary studies 
included in the identified reviews were considered relevant to this HTA. Some 
studies appeared in multiple systematic reviews, as certain interventions could 
legitimately appear in multiple reviews (for example, motivational interviewing, a 
behavioural intervention provided by a physician, could appear in both the 
motivational interviewing and physician advice reviews) or individual arms of multi-
arm studies could be applicable to multiple reviews.  
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4.2.2 Identified trials 
The identified systematic reviews were updated (search dates 18 July 2016 to 13 
August 2016. A de novo search was carried out to identify trials evaluating the Allen 
Carr method on 20 May 2016. However, no studies evaluating the efficacy and 
safety of the Allen Carr method for smoking cessation that were eligible for inclusion 
in this HTA were identified (see Appendix 8, Figure 8.1). 
Trials that compared different intensities of the same intervention (for example, 
different doses of nicotine replacement therapy [NRT]) were excluded under the 
assumption that the choice of intensity was related to the level of dependence in the 
smokers receiving therapy. Based on subgroup analyses in the included Cochrane 
reviews, there was no evidence of a dose-response relationship for implementing 
more intense interventions. Trial arms that evaluated different intensities of the 
same intervention were collapsed into a single arm. If the trial did not include other 
interventions then it was excluded as it was effectively considered a single-arm trial. 
A total of 313 relevant studies were identified, published between 1971 and 2016 
(Table 4.3). Data were only extracted for study arms that were relevant to this HTA. 
The relevant number of trial participants ranged from 32 to 6,451 (mean 592, 
standard deviation 763). In terms of the number of included trial arms, we identified 
studies with two (n=283), three (n=25), four (n=4), and five (n=1) arms. Due to 
the large number of studies identified, they are listed in full in Appendix 8. 
The duration of follow up varied across trials, although most reported cessation rates 
at six months (n=113; 36%) and 12 months (n=170; 54%). Behavioural and 
pharmacological interventions had similar proportions of trials reporting six-month 
follow ups. Twenty-five studies reported greater than 12-months follow up, with two 
studies providing cessation rates at five years. The majority of studies with more 
than 12-months follow up were for behavioural interventions (n=20). 
Studies were also graded on quality, based on assessments using the Cochrane risk 
of bias tool. Studies at low risk of bias were considered high quality. Overall, just 
over one in four (26% or n=80) studies were considered high quality. More studies 
of pharmacological interventions were rated as high quality (31%) than studies of 
behavioural intervention (20%). 
Studies recorded smoking cessation through either self-reports or some form of 
biochemical verification, such as cotinine levels. Biochemical verification is the 
preferred measure of cessation as it is less prone to bias. Almost two out of three 
studies (65%) used biochemical verification, although the percentage varied 
between studies of pharmacological agents (86%) and behavioural interventions 
(38%). 
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Finally, abstinence from smoking was measured as either cessation from the quit 
date or abstaining at a particular point in time (also known as point prevalence). 
Measuring continued abstinence from the quit date gives a better indication of the 
true quit rate. Continuous abstinence was reported in 58% of studies, although this 
outcome was more typically used in pharmacological studies (69%) than in 
behavioural studies (41%).
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Table 4.3 Identified primary studies and main characteristics 
Intervention Studies 
(n) 
Participants 
(n)† 
Follow up*, n (%) High quality 
n (%) 
Biochemically 
verified 
n (%) 
Continuous 
abstinence 
n (%) 
Mean (SD) 
years since 
publication 
 
     6 months ≥12 months 
 Behavioural therapies 
Acupuncture 13 1,194 7 (54) 6 (46) 4 (31) 3 (23) 6 (46) 27.2 (8.2) 
Group behaviour therapy 28 5,497 10 (36) 18 (64) 3 (11) 13 (46) 7 (25) 22.4 (8.2) 
Individual counselling 17 3,646 11 (65) 6 (35) 7 (41) 12 (71) 6 (35) 17.3 (7.4) 
Intensive advice 39 11,210 19 (49) 19 (49) 9 (23) 20 (51) 13 (33) 15.3 (9.8) 
Internet-based 10 5,677 6 (60) 3 (30) 6 (60) 1 (10) 4 (40) 4.3 (3) 
Mobile phone-based 4 923 4 (100) 0 (0) 3 (75) 1 (25) 2 (50) 2.8 (1.7) 
Telephone support 45 26,426 10 (22) 33 (73) 7 (16) 13 (29) 24 (53) 13.0 (6.1) 
 Pharmacotherapies 
Bupropion 34 8,341 13 (38) 21 (62) 12 (35) 32 (94) 23 (68) 9.3 (4.2) 
Combination NRT^ 13 3,240 5 (38) 8 (62) 4 (31) 12 (92) 7 (54) 10.1 (7.6) 
Cytisine 4 1,732 2 (50) 2 (50) 2 (50) 2 (50) 3 (75) 15.0 (20.1) 
Electronic cigarettes 2 489 1 (50) 1 (50) 2 (100) 1 (50) 2 (100) 3.0 (0) 
NRT 141 33,556 48 (34) 92 (65) 32 (23) 114 (81) 89 (63) 18.2 (9.2) 
NRT + bupropion 7 1,509 4 (57) 3 (43) 0 (0) 6 (86) 4 (57) 8.3 (5) 
NRT + varenicline 2 392 2 (100) 0 (0) 2 (100) 2 (100) 2 (100) 2.0 (0) 
Varenicline 26 6,903 14 (54) 12 (46) 15 (58) 24 (92) 20 (77) 4.9 (3.7) 
Varenicline + bupropion 1 249 0 (0) 1 (100) 1 (100) 1 (100) 1 (100) 2.0 NA 
Notes: *a small number of studies ran for more than six months, but less than 12 months; ^Combination NRT refers to using more than one form of NRT 
(for example, transdermal patch plus gum). †‘Participants’ refers to number receiving the intervention and excludes control arm participants.
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4.2.3 Classification of interventions 
The definitions of interventions were very heterogeneous in the studies included in 
the systematic reviews. In particular, this is evident in behavioural interventions. 
Interventions could be provided at a variety of frequencies and intensities. If a dose-
response relationship exists, then treatment effects may vary by frequency and 
intensity. However, the identified Cochrane reviews included subgroup analyses that 
provided little evidence that treatment effect was related to the frequency and 
intensity of interventions. 
Some interventions could be interpreted in different ways. For example, a 
motivational interviewing intervention delivered by nurses could appear in both the 
motivational interviewing and nursing intervention reviews. Where possible, the 
Evaluation Team used a simplified categorisation. For interventions delivered by a 
healthcare professional, the Team did not distinguished between physicians or 
nurses. Based on the Cochrane review and exploratory analysis, it was assumed that 
the different forms of NRT (for example, transdermal patch, gum, and so on) are 
equally effective. 
It is possible to distinguish between different implementations or versions of 
cessation interventions based on intervention characteristics. For example, telephone 
support can be provided as reactive (in response to contact by the person seeking to 
quit smoking) or proactive (where the provider makes several calls to the person 
seeking to quit). Interventions that are different versions of a common concept have 
been grouped together when the supporting systematic review showed no evidence 
of differing treatment effect in subgroup analyses. For example, motivational 
interviewing, motivational support, and physician or nurse support bore many 
similarities in terms of duration and frequency of sessions. As such, they have been 
amalgamated in this analysis into a grouping called intensive advice.  
The interventions could be briefly defined as: 
 Nicotine replacement therapy (NRT): a range of replacement therapies (chewing 
gum, transdermal patches, nasal and oral spray, inhalers, tablets and lozenges; 
as monotherapy or combination therapy) that provide nicotine by means other 
than tobacco. 
 Electronic cigarettes (e-cigarettes): electronic devices with the ability to heat a 
liquid - usually comprising propylene glycol and glycerol, with or without nicotine 
and flavours, and stored in disposable or refillable cartridges or a reservoir - into 
an aerosol for inhalation. 
 Nicotine receptor partial agonists (cytisine or varenicline only) 
 Antidepressants (bupropion only) 
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 Brief physician advice: verbal instructions from the physician with a ’stop 
smoking’ message, irrespective of whether or not information was provided about 
the harmful effects of smoking. 
 Telephone-based interventions: provision of proactive or reactive telephone 
counselling to assist smoking cessation, to any population. 
 Mobile phone-based: any type of mobile phone-based intervention for smoking 
cessation based around delivery via mobile phone, and using any functions or 
applications that could be used or sent via a mobile phone. 
 Internet-based interventions: interactive, personalised and non-interactive 
interventions, focused on standard approaches to information delivery though the 
internet. 
 Intensive advice: combining interventions of motivational interviewing (a brief 
psychotherapeutic intervention intended to increase the likelihood that a person 
will make an attempt to change their harmful behaviour) and clinician support 
(more intensive than brief advice but less intensive than individual counselling in 
terms of frequency and duration of interaction). 
 Individual behaviour counselling: a face-to-face encounter between a smoking 
patient and a counsellor trained in assisting smoking cessation. 
 Group behaviour therapy: scheduled meetings of smokers including some form of 
behavioural intervention, such as information, advice and encouragement or 
cognitive behavioural therapy (CBT) delivered over at least two sessions. 
 Acupuncture: non-pharmacological stimulation interventions involving needle 
puncture, finger pressure or laser therapy in areas of the body described as 
acupuncture points. 
 Allen Carr method: a behavioural intervention as described by Allen Carr in a 
series of publications. 
4.2.4 Networks of evidence 
The identified interventions could be broadly grouped into behavioural interventions 
and pharmacotherapy interventions. For this analysis, e-cigarettes are considered as 
a pharmacotherapy as the intervention is similar to nicotine replacement therapy. 
Generally, drug trials include some form of behavioural therapy, however limited. 
But since this is provided to participants in all arms of the trial, the only difference 
between intervention and control groups is the use of the drug or drugs, thereby 
allowing its effect to be observed. The situation is reversed for trials of behavioural 
supports which involve a group that is provided with a given behavioural 
intervention (who are generally free to use some form of pharmacological cessation 
aid) compared to a group that receive another, usually less intense, behavioural 
support (who are also free to use some form of pharmacological intervention).  
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In addition to supportive care, most pharmacotherapy trials include use of placebo in 
the control arm. For example, in a trial of NRT gum, the control arm participants are 
typically provided with gum with no nicotine, or with a sufficiently small dose of 
nicotine to be considered placebo. For behavioural therapies there is, in most cases, 
no equivalent to placebo. Control arms are a mixture of ‘do nothing’ or minimal 
supportive care that is provided in all trial arms, such as brief advice or written 
materials. 
Although the patient populations were comparable in terms of age, sex and nicotine 
dependency, some of the populations in behavioural trials were not selected on the 
basis of an expressed desire to make a quit attempt, as the intervention may be 
designed to address the barriers smokers experience that prevent them making a 
quit attempt. On the other hand, all participants in drug trials must agree to receive 
the treatment (active or placebo), indicating a willingness to quit. As such, it is not 
clear that people who participated in all behavioural therapy trials can be compared 
to those in the pharmacotherapy trials. Only one randomised controlled trial directly 
compared a pharmacological intervention to a behavioural intervention. 
Two studies directly compared pharmacological interventions to behavioural 
interventions.(163, 164) Both studies included an NRT arm and a group behaviour 
therapy arm. NRT was provided with brief advice in both cases. One of the studies 
found a statistically significant treatment effect for NRT relative to group behaviour 
therapy.(164) The pooled estimate showed some evidence of effect in favour of NRT 
(RR=1.25, 95% CI: 0.98 – 1.59; p=0.071). The conflicting evidence of these two 
studies that provide the only link between pharmacological and behavioural 
interventions is not a good basis for considering a large combined network of 
evidence. 
For these reasons, trials evaluating behavioural interventions are considered 
separately from those evaluating pharmacological interventions. There were a wide 
range of comparisons available within those two groups, with direct evidence 
available between many of the interventions. As such, it was possible to consider 
evidence synthesis, including both direct and indirect evidence. 
4.2.5 Pharmacotherapy interventions 
There were 232 comparisons available across the 176 pharmacotherapy trials 
(Figure 4.1). Of those comparisons, 174 were between intervention and control. The 
largest quantity of evidence was for NRT, with 152 comparisons. There were 20 
head-to-head comparisons between interventions in total. For the purposes of the 
analysis, combinations of interventions are treated as distinct interventions. For 
example, NRT plus varenicline is a distinct combination therapy. 
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Most of the interventions appear in numerous different comparisons. Others, such as 
NRT plus varenicline and varenicline plus bupropion, each appear in a single 
comparison, although there may be multiple studies providing evidence for those 
comparisons. 
Figure 4.1  Network of evidence for pharmacotherapy interventions for 
  unselected adults 
 
 
4.2.5.1 Direct comparisons 
The direct head-to-head evidence between interventions was investigated. The 
pooled direct evidence is provided in Table 4.4. Where the pooled estimates have 
been combined using a random effects approach, the 95% confidence bounds are 
associated with the mean effect. In cases where there were five or more studies in 
the comparison, the 95% prediction intervals were also computed, and these give an 
indication of the range of effect sizes that might be observed in a future study. 
Relative to control, the seven interventions for which there was direct evidence all 
had a treatment effect that was statistically significant. That is, the intervention was 
better than control. It can be seen that the confidence bounds are relatively narrow 
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where there are many studies available. NRT and bupropion are similarly effective, 
with risk ratios close to 1.60. Varenicline is the most effective intervention, with a 
risk ratio of 2.66. 
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Table 4.4 Treatment effects based on direct evidence: pharmacological interventions 
Comparison 
Studies 
(n) 
 
Participants 
(n)  
Risk ratio (95% CI) p-value 
95% 
Prediction 
interval 
I2 (95% CI) 
NRT vs Control 116 53,066  1.59 (1.50 - 1.69) <0.001 (1.12 - 2.25) 0.34 (0.16 - 0.47) 
Bupropion vs Control 30 13,363 1.65 (1.51 - 1.79) <0.001 (1.47 - 1.84) 0.02 (0.00 - 0.42) 
NRT + bupropion vs Control* 3 1,240 1.73 (1.39 – 2.15) <0.001  0.31 (0.00 - 0.93) 
Combination NRT vs Control* 3 904 1.71 (1.30 – 2.25) <0.001  0.00 (0.00 - 0.64) 
E-cigarette vs Control* 2 662 2.29 (1.05 – 4.96) 0.037  0.00  
Cytisine vs Control* 3 2,151 1.87 (1.48- 2.38) <0.001  0.68 (0.00 - 0.91) 
Varenicline vs Control 17 9,275 2.66 (2.25 - 3.15) <0.001 (1.52 - 4.66) 0.58 (0.27 - 0.75) 
Bupropion vs NRT 8 5,485 1.03 (0.88 - 1.21) 0.696 (0.66 - 1.61) 0.56 (0.03 - 0.80) 
E-cigarette vs NRT* 1 584 1.26 (0.68 - 2.34) 0.463  NA  
Varenicline vs NRT 8 4,277 1.28 (1.12 - 1.47) <0.001 (0.96 - 1.70) 0.25 (0.00 - 0.66) 
NRT + bupropion vs NRT 6 3,277 1.29 (0.94 - 1.76) 0.109 (0.46 - 3.61) 0.81 (0.59 - 0.91) 
Combination NRT vs NRT 12 7,239 1.31 (1.16 - 1.47) <0.001 (1.05 - 1.62) 0.13 (0.00 - 0.53) 
Cytisine vs NRT* 1 1,310 1.43 (1.13 - 1.80) 0.002  NA  
NRT + bupropion vs Bupropion 5 2,644 1.15 (0.93 - 1.42) 0.210 (0.56 - 2.34) 0.64 (0.04 - 0.86) 
Combination NRT vs Bupropion* 3 1,216 1.27 (1.08 – 1.50) 0.003  0.64 (0.00 - 0.90) 
Varenicline vs Bupropion 6 3,994 1.42 (1.29 - 1.57) <0.001 (1.24 - 1.63) 0.00 (0.00 - 0.62) 
Combination NRT vs NRT + 
bupropion* 
2 1,076 1.06 (0.89 - 1.26) 0.512  0.63  
Varenicline vs Combination NRT* 3 1,511 1.04 (0.88 - 1.23) 0.628  0.68 (0.00 - 0.91) 
Varenicline + bupropion vs 
Varenicline* 
1 506 1.26 (0.95 - 1.68) 0.109  NA  
NRT + varenicline vs Varenicline* 2 787 1.42 (1.13 – 1.79) 0.003  0.60  
Notes: comparisons marked with * are based on fixed effect model. All other treatment effect estimates are based on random effects model. The fixed effect 
model was used when there were fewer than five studies.  
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Varenicline, cytisine and combination NRT show a statistically significant treatment 
benefit when compared with NRT monotherapy. Relative to bupropion, varenicline 
was shown to have a statistically significant treatment effect. On the basis of a fixed 
effect estimate, combination NRT was also shown to have a statistically significant 
treatment effect relative to bupropion. 
The direct evidence shows a hierarchy where the least effective pharmacotherapies 
are NRT monotherapy and bupropion, which are similarly effective. There is a small 
additional benefit to using NRT monotherapy and bupropion in combination. 
Varenicline is the most effective monotherapy, and has a small, but not statistically 
significant treatment benefit compared to combination NRT. 
The data on e-cigarettes is less clear, influenced by the small number of studies and 
comparisons available. Relative to control there was statistically significant treatment 
effect, although the confidence bounds were wide. Relative to NRT monotherapy 
there was a small, but not statistically significant treatment benefit. 
The evidence in many of the comparisons was subject to heterogeneity, although 
the bounds in many cases suggest that it was not substantial. The comparisons for 
which heterogeneity was a concern were varenicline versus control (n=17, I2=0.58), 
and NRT monotherapy plus bupropion versus NRT monotherapy (n=6, I2=0.81). 
Other comparisons also showed potentially substantial heterogeneity, but the 
bounds for the estimate of I2 included values of low heterogeneity. In the 
comparison of varenicline versus control, there were sufficient studies to investigate 
whether study-level covariates might explain some of the heterogeneity (Figure 4.2).  
Only continuous abstinence was associated with a statistically significant effect, 
whereby studies that used continuous abstinence observed a smaller treatment 
effect associated with the intervention. An assessment of influence statistics did not 
identify any single study that contributed to heterogeneity, and a leave-one-out 
analysis had only a small impact on the pooled treatment effect. 
Fixed effect and random effects models generated very similar point estimates of 
treatment effect for all but one comparison: cytisine versus control. The random 
effects estimate (RR=2.59, 95% CI: 1.19 to 5.65) was larger than the fixed effect 
estimate (RR=1.87, 95% CI: 1.48 to 2.38). With only three studies available, the 
estimate of between study variance is likely to be unreliable, and the random effects 
result may over-estimate the treatment effect. There are a further four comparisons 
for which the fixed effect estimate is associated with a statistically significant 
treatment effect, but the random effects estimate does not. 
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Figure 4.2 Forest plot of studies comparing varenicline versus control 
 
 
There were insufficient studies in the comparison of NRT monotherapy plus 
bupropion versus NRT monotherapy to consider a meta-regression. An inspection of 
the forest plot demonstrates the substantial heterogeneity (Figure 4.3). A review of 
the main study characteristics does not suggest a common feature to the studies 
that reported lower effect sizes.  
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Figure 4.3  Forest plot of studies comparing NRT plus bupropion versus 
NRT 
 
 
The potential for small study bias was also investigated using funnel plots for 
comparisons with 10 or more studies. There was some evidence of small study bias 
in the comparison of NRT versus control based on the Egger’s test (p=0.073), but 
not based on the Harbord test (p=0.508). A visual inspection of the funnel plot 
shows that there may be a tendency towards greater treatment effects being 
observed in smaller studies. However, the three studies with largest standard errors 
contradict this finding (Figure 4.4).  
Of note, when studies were split into two-arm and multi-arm trials, there was no 
evidence of small study bias in multi-arm trials that compared NRT monotherapy to 
control. Analysing only two-arm trials resulted in statistically significant evidence of 
funnel plot asymmetry based on the Egger’s test but not the Harbord test. The trim 
and fill method was applied to estimate what the treatment effect might be in the 
absence of such a small study effect. The treatment effect for NRT monotherapy 
reduced from 1.59 (95% CI: 1.50 - 1.69) to 1.52 (95% CI: 1.42 - 1.63). This 
suggests a potentially modest impact and would not change the interpretation that 
NRT monotherapy is superior to control. However, it should be noted that the 
application of trim and fill widened the prediction intervals to encompass no 
treatment effect. 
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Figure 4.4 Funnel plot of studies comparing NRT versus control 
 
4.2.5.2 Direct and indirect comparisons 
Given the available network of evidence and apparent consistency of evidence, the 
analysis of pharmacological interventions was extended to include both direct and 
indirect evidence. Direct evidence allows estimation of treatment effect between two 
interventions using head-to-head trials. Indirect evidence supports an estimate of 
treatment effect between two interventions using a common comparator. In the 
absence of any direct comparison between treatments A and B, it is possible to 
estimate the effect if there are trials comparing A to C and B to C. In a network 
meta-analysis, both direct and indirect evidence is combined to derive an estimate of 
treatment effects. Treatment effects were calculated on the log odds scale and then 
finally converted to risk ratios using the assumed control risk, which was calculated 
as the risk of smoking cessation pooled across the control arms. 
The first step was to estimate treatment effects using both consistency and 
inconsistency models to determine whether the assumption of consistency has a 
substantial impact on estimates of treatment effect. The consistency and 
inconsistency models produced very similar estimates of treatment effect, agreeing 
in terms of direction and magnitude of effect. All of the estimates from the 
consistency model were well within the confidence bounds for the corresponding 
inconsistency model estimates. The Deviance Information Criterion (DIC) was 
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marginally lower for the consistency model (639.2 versus 643.9), although the 
difference (<5) was not large enough to be considered important. The random 
effects standard deviation was 0.236 (95% CI: 0.173 to 0.303) for the consistency 
model, and 0.239 (95% CI: 0.215 to 0.238) for the inconsistency model. As such, 
the consistency model was considered appropriate. 
An analysis of heterogeneity estimated a global I2 of 29%. Based on an analysis of 
heterogeneity, potential issues were identified for two comparisons: varenicline 
versus control (p=0.077) and varenicline versus NRT monotherapy (p=0.054). A 
node-splitting analysis was used to investigate the contribution of direct and indirect 
evidence to treatment effect estimates (Table 4.5). There was no statistically 
significant difference in the direct and indirect evidence for any of the comparisons. 
For almost all comparisons, the direct and indirect treatment effects were in 
agreement in terms of direction and, for the most part, in terms of magnitude, 
although there were some differences. For example, the direct evidence showed 
combination NRT to be better than NRT monotherapy. The indirect evidence showed 
a non-significant treatment benefit associated with the monotherapy. The pooled 
estimate was driven by the direct evidence. 
For the estimate of varenicline versus control, the summary treatment effect was 
closer to that of the direct evidence. For the comparison of varenicline versus NRT 
monotherapy, the treatment effect estimate was more influenced by the indirect 
evidence. 
The 10 interventions in the network of pharmacological treatments were analysed in 
terms of their likely ranking (from best treatment to worst treatment) (Figure 4.5). 
There was a probability of 1 that control was the least effective treatment. Only two 
therapies had a probability of being most effective: combined varenicline and NRT 
monotherapy (probability = 0.64) and combined varenicline and bupropion 
(probability = 0.34). E-cigarettes and cytosine both had wide ranges of potential 
rankings, highlighting the uncertainty in relation to their effectiveness. 
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Table 4.5  Comparison of direct and indirect treatment effect estimates: pharmacological interventions 
Comparison Risk ratio p-value 
Direct estimate (95% 
CI) 
Indirect estimate 
(95% CI) 
Network estimate 
(95% CI) 
Bupropion vs Control 1.67 (1.49 to 2.18) 1.67 (1.27 to 2.53) 1.70 (1.54 to 2.16) 0.98 
Cytisine vs Control 2.10 (1.49 to 3.55) 2.28 (1.50 to 4.64) 2.20 (1.68 to 3.55) 0.66 
NRT vs Control 1.67 (1.56 to 2.05) 1.78 (1.47 to 2.51) 1.68 (1.58 to 2.05) 0.53 
NRT + bupropion vs Control 1.85 (1.34 to 2.97) 2.07 (1.60 to 3.25) 2.02 (1.70 to 2.97) 0.60 
Combination NRT vs Control 1.82 (1.19 to 3.25) 2.28 (1.96 to 3.25) 2.21 (1.93 to 2.97) 0.28 
Varenicline vs Control 2.83 (2.45 to 3.88) 2.23 (1.78 to 3.55) 2.64 (2.28 to 3.55) 0.10 
NRT vs Bupropion 0.97 (0.78 to 1.33) 1.00 (0.86 to 1.30) 0.99 (0.88 to 1.25) 0.80 
NRT + bupropion vs Bupropion 1.18 (0.92 to 1.67) 1.17 (0.66 to 2.28) 1.21 (0.99 to 1.67) 0.98 
Combination NRT vs Bupropion 1.36 (0.97 to 2.12) 1.38 (1.12 to 1.96) 1.34 (1.13 to 1.82) 0.90 
Varenicline vs Bupropion 1.58 (1.24 to 2.30) 1.60 (1.33 to 2.26) 1.60 (1.38 to 2.12) 0.91 
NRT vs Cytisine 0.67 (0.40 to 1.24) 0.78 (0.51 to 1.32) 0.74 (0.53 to 1.13) 0.65 
NRT vs E-cigarette 0.79 (0.36 to 1.87) 0.60 (0.17 to 1.87) 0.76 (0.41 to 1.53) 0.68 
NRT + bupropion vs NRT 1.33 (1.06 to 1.89) 1.02 (0.58 to 1.92) 1.22 (1.01 to 1.67) 0.35 
Combination NRT vs NRT 1.37 (1.16 to 1.86) 0.89 (0.47 to 1.84) 1.37 (1.17 to 1.79) 0.18 
Varenicline vs NRT 1.38 (1.09 to 1.94) 1.72 (1.49 to 2.36) 1.62 (1.43 to 2.10) 0.09 
Combination NRT vs NRT + bupropion 1.07 (0.74 to 1.75) 1.15 (0.84 to 1.76) 1.11 (0.88 to 1.58) 0.77 
Varenicline vs Combination NRT 1.16 (0.83 to 1.82) 1.20 (0.95 to 1.70) 1.19 (0.99 to 1.63) 0.88 
Notes: NRT refers to NRT monotherapy (only one pharmaceutical form used); Combination NRT refers to use of more than one formulation (e.g., 
transdermal patch plus gum or spray). CI, credible interval. The direct, indirect and network evidence are created from three different models, and the 
network estimate was not a weighted average of the indirect and direct studies. Results are presented for studies where there was both direct and indirect 
evidence not limited to data from a single multi-arm study). 
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Figure 4.5 Probability of rankings: pharmacological interventions 
 
Note: the graph shows the probability of a given intervention being ranked from 1 (most effective 
intervention) to 10 (least effective intervention. A high probability reflects greater certainty about the 
ranking of a particular intervention. For example, it is almost certain that ‘control’ is the least effective 
intervention with a probability of 0.997 of being ranked tenth. There is a probability of 0.64 that 
varenicline plus NRT dual therapy is the most effective intervention. 
The 95% credible intervals provided with the treatment effects indicate the bounds 
for the mean treatment effect. It is also possible to consider the prediction intervals 
which provide an indication of what might be observed in a future study (Table 4.6). 
When considered in terms of prediction intervals, all of the pharmacological 
interventions are associated with a statistically significant treatment effect relative to 
control. 
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Table 4.6  Treatment effect relative to control: pharmacological  
  interventions 
Intervention Risk ratio 95% CI 95% PI 
Control Reference   
NRT 1.68 (1.58 - 1.78) (1.14 - 2.41) 
Bupropion 1.70 (1.53 - 1.87) (1.13 - 2.44) 
NRT + bupropion 2.02 (1.70 - 2.40) (1.31 - 2.92) 
E-cigarettes 2.14 (1.26 - 3.35) (1.10 - 3.60) 
Cytisine 2.20 (1.68 - 2.83) (1.37 - 3.24) 
Combination NRT 2.22 (1.91 - 2.55) (1.48 - 3.18) 
Varenicline 2.57 (2.32 - 2.85) (1.74 - 3.60) 
Varenicline + bupropion 3.20 (2.05 - 4.60) (1.80 - 4.82) 
NRT + varenicline 3.54 (2.57 - 4.61) (2.28 - 5.03) 
Abbreviations: CI, credible interval; PI, prediction interval. 
From the rankings and the estimated effectiveness (Table 4.7), it is apparent that all 
active treatments are better than control. That is, the evaluated pharmacological 
interventions result in higher rates of long-term (six months or longer) smoking 
cessation than control. NRT monotherapy and bupropion are similarly effective. Used 
in combination they are more effective than when used as monotherapies, although 
the improved effect is only statistically significant compared to NRT monotherapy 
alone. Varenicline, either as monotherapy or combined with NRT monotherapy or 
bupropion is more effective than NRT monotherapy or bupropion as monotherapy. 
Cytisine and e-cigarettes are similarly effective. They are both supported by limited 
evidence and as such the confidence bounds around the average treatment effect 
are wide. 
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Table 4.7 Network meta-analysis treatment effect estimates: pharmacological interventions 
 
Risk ratio (95% credible interval) 
 
Control Bupropion Cytisine E-cigarette NRT 
NRT + 
bupropion 
NRT + 
varenicline 
Combination 
NRT Varenicline 
Bupropion 1.70 
(1.53 - 1.87) 
        
Cytisine 2.20 
(1.68 - 2.83) 
1.33 
(0.97 - 1.81) 
       
E-cigarette 2.14 
(1.26 - 3.35) 
1.29 
(0.72 - 2.20) 
0.97 
(0.49 - 1.80) 
      
NRT 1.68 
(1.58 - 1.78) 
0.99 
(0.88 - 1.11) 
0.73 
(0.53 - 1.00) 
0.76 
(0.41 - 1.34) 
     
NRT + 
bupropion 
2.02 
(1.70 - 2.40) 
1.21 
(0.99 - 1.48) 
0.91 
(0.62 - 1.30) 
0.94 
(0.50 - 1.68) 
1.23 
(1.01 - 1.48) 
    
NRT + 
varenicline 
3.54 
(2.57 - 4.61) 
2.33 
(1.58 - 3.27) 
1.80 
(1.08 - 2.81) 
1.86 
(0.93 - 3.30) 
2.35 
(1.61 - 3.28) 
1.96 
(1.27 - 2.89) 
   
Combination 
NRT 
2.22 
(1.91 - 2.55) 
1.35 
(1.12 - 1.60) 
1.01 
(0.70 - 1.41) 
1.04 
(0.57 - 1.84) 
1.36 
(1.16 - 1.58) 
1.11 
(0.88 - 1.40) 
0.53 
(0.33 - 0.86) 
  
Varenicline 2.57 
(2.32 - 2.85) 
1.60 
(1.39 - 1.84) 
1.21 
(0.87 - 1.65) 
1.25 
(0.69 - 2.13) 
1.61 
(1.43 - 1.83) 
1.33 
(1.06 - 1.65) 
0.65 
(0.42 - 0.99) 
1.20 
(0.99 - 1.44) 
 
Varenicline + 
bupropion 
3.20 
(2.05 - 4.60) 
2.07 
(1.22 - 3.25) 
1.58 
(0.85 - 2.75) 
1.64 
(0.75 - 3.20) 
2.08 
(1.24 - 3.27) 
1.73 
(0.98 - 2.86) 
0.87 
(0.43 - 1.69) 
1.57 
(0.90 - 2.61) 
1.32 
(0.77 - 2.18) 
Note: NRT, nicotine replacement therapy. Shaded cells indicate statistically significant treatment effect. 
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The impact of treatment combinations relative to an assumption of an additive effect 
is worth noting. For example, NRT monotherapy plus varenicline has a risk ratio of 
3.54. However, if assuming an additive effect on the log scale, the combined 
treatments should have a risk ratio of 4.32. Similarly for the other available 
combinations, two treatments together are less effective than if the two individual 
effects are combined. This apparent loss of effect is plausible. If the effects were 
additive on the log scale, it assumes that there is no overlap in effect. That is, none 
of the people benefitting from therapy A benefit from therapy B, and vice versa. To 
illustrate, consider a control arm quit rate of 10%. We would expect to observe, on 
average, quit rates of 16.8% with NRT and 25.7% with varenicline. Multiplying the 
relative risks generates an expected quit rate of 43.2% when using NRT in 
conjunction with varenicline. It is more plausible that combining the therapies means 
that some recipients would quit on either, and therefore do not gain additional 
benefit from dual therapy, while others benefit from one therapy, but not the other. 
In other words, the benefit of dual therapy is greater than for either therapy alone, 
but not equivalent to an additive effect. 
4.2.5.3 Sensitivity analysis 
The previous analyses have estimated treatment effect in terms of the risk ratios. It 
is useful to consider the absolute quit rates across the different study arms and how 
that relates to the length of follow up. Table 4.8 shows the pooled quit rates by 
study arm and by six-month and 12-month follow up. These estimates include only 
studies using exactly six or 12-month follow up. There was substantial and 
statistically significant evidence of heterogeneity for all estimates with three or more 
studies. In most cases the pooled quit rate is lower at 12 months than at six months. 
This is consistent with relapse occurring between six and 12 months. Notably for 
NRT, the quit rates at six and 12 months are almost unchanged. The quit rates in 
the two e-cigarette trials are much lower than any of the other active interventions. 
One e-cigarette trial involved no behavioural support, while the other included 
responsive telephone support. Given the widespread provision of supportive therapy 
in other pharmacological trials, the minimal support in the e-cigarette trials may 
partly explain the low absolute quit rates observed. 
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Table 4.8 Absolute quit rates across study arms: pharmacological 
interventions 
Intervention 6 months follow up 12 months follow up 
 studies quit 95% CI studies quit 95% CI 
Control 47 0.11 (0.09 - 
0.14) 
102 0.11 (0.10 - 0.12) 
NRT 44 0.19 (0.16 - 
0.23) 
84 0.18 (0.16 - 0.20) 
Bupropion 13 0.25 (0.21 - 
0.30) 
21 0.18 (0.16 - 0.21) 
NRT + bupropion 4 0.25 (0.18 - 
0.33) 
3 0.23 (0.13 - 0.37) 
E-cigarettes 1 0.07 (0.05 - 
0.11) 
1 0.11 (0.07 - 0.16) 
Cytisine 2 0.15 (0.06 - 
0.33) 
1 0.08 (0.06 - 0.12) 
Combination NRT 5 0.29 (0.17 - 
0.44) 
8 0.15 (0.10 - 0.21) 
Varenicline 14 0.35 (0.30 - 
0.41) 
12 0.23 (0.19 - 0.27) 
Varenicline + 
Bupropion 
0   1 0.31 (0.25 - 0.37) 
NRT + varenicline 2 0.32 (0.28 - 
0.37) 
0   
Notes: CI, credible interval. 
The average absolute quit rate across control arms is 11% at both six and 12 
months. It should be noted that almost all trials provided some form of supportive 
care to both the intervention and control arms. Typically, this was some form of 
behavioural therapy, such as individual counselling or group behaviour therapy. 
Studies were classified on the basis of the type of supportive care provided. A meta-
regression of quit rates was used across control arms to explore how supportive care 
may impact on quit rates. Data from the 174 control arms was used, including 
covariates of intervention, length of follow up, and type of supportive care. The type 
of intervention had no statistically significant impact on the quit rate in control arms. 
Length of follow up did not have a statistically significant impact (p=0.10) but was 
included in the model. 
Twelve-month quit rates in control arms were predicted for each type of supportive 
care (Table 4.9). The control arm quit rates were statistically significantly higher 
relative to placebo-controlled in studies that used individual counselling or group 
behaviour therapy as a supportive care. That is, control arm quit rates are higher in 
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pharmacological intervention studies that provide individual counselling or group 
behaviour therapy to all study arms.  
Trials that provide individual counselling or group behaviour therapy have a higher 
control arm quit rate. In turn, this may impact on the potential treatment effect of 
the intervention. With a control arm quit rate of 11%, an intervention that achieved 
a 100% quit rate would have a risk ratio of 9. Considering an extreme, if the control 
arm quit rate was, for example, 50%, then the maximum possible risk ratio would be 
2. Thus it is plausible that providing an effective supportive care to all trial arms may 
diminish the observed relative effectiveness of the active intervention. 
Table 4.9  Predicted 12-month quit rates in control arms by type of  
  supportive care 
Supportive care Quit rate (95% CI) 
Placebo 0.08 (0.06 - 0.10) 
Brief advice/written materials 0.07 (0.05 - 0.09) 
Intensive advice 0.10 (0.08 - 0.12) 
Individual counselling 0.11 (0.10 - 0.13) 
Group behaviour therapy 0.16 (0.14 - 0.19) 
Other 0.07 (0.05 - 0.10) 
Notes: CI, credible interval. 
The network meta-analysis was also run as a network meta-regression to determine 
if certain study-level characteristics might be acting as effect modifiers. Six different 
covariates were considered: two continuous variables (study year, length of follow 
up) and four dichotomous variables (high quality, biochemical verification of 
abstinence, continuous abstinence, and no provision of supplementary care). The 
meta-regression assumed a shared effect across treatments. Longer follow up was 
associated with a reduced effect size, while measuring continuous abstinence (rather 
than point prevalence) was associated with a larger effect size (Table 4.10). The 
other covariates were not associated with statistically significant effects. Inclusion of 
covariates did not impact on the Deviance Information Criterion (DIC). 
Table 4.10  Network meta-regression results 
Covariate Coefficient (95% CI) DIC Random effects 
SD 
No covariates - - 639.2 0.24 (0.17 to 
0.30) 
Study year 0.12 (-0.03 to 0.27) 640.7 0.22 (0.16 to 
0.29) 
Follow up -0.12 (-0.25 to 0.00) 639.8 0.22 (0.16 to 
0.29) 
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High quality 0.02 (-0.13 to 0.16) 640.4 0.24 (0.17 to 
0.30) 
Biochemically verified 0.11 (-0.08 to 0.31) 640.1 0.23 (0.17 to 
0.30) 
Continuous abstinence 0.17 (0.03 to 0.31) 638.3 0.22 (0.16 to 
0.29) 
No supplementary care 0.06 (-0.17 to 0.29) 640.2 0.24 (0.17 to 
0.30) 
Notes: CI, credible interval; DIC, Deviance Information Criterion; SD, standard deviation. 
The impact on treatment effects (relative to control) of including covariates in the 
model are shown in Table 4.11. Including length of follow up reduces the effect size 
for all interventions apart from cytisine. Including continuous abstinence increases 
the treatment effect for all interventions. The addition of covariates has a negligible 
impact on DIC and random effects standard deviation, indicating that inclusion of 
covariates has a small impact on reducing heterogeneity. 
Table 4.11  Impact on treatment effect (relative to control) of including 
  covariates in analysis 
Intervention No covariate Follow up = 12 
months 
Continuous 
abstinence 
 RR (95% CI) RR (95% CI) RR (95% CI) 
Bupropion 1.7
0 
(1.53 - 
1.87) 
1.65 (1.49 - 
1.82) 
1.7
6 
(1.59 - 
1.94) 
Cytisine 2.2
0 
(1.68 - 
2.83) 
2.31 (1.78 - 
2.95) 
2.3
4 
(1.80 - 
3.00) 
E-cigarette 2.1
4 
(1.26 - 
3.35) 
2.09 (1.25 - 
3.28) 
2.1
9 
(1.32 - 
3.42) 
NRT 1.6
8 
(1.58 - 
1.78) 
1.64 (1.54 - 
1.75) 
1.7
6 
(1.64 - 
1.88) 
NRT + bupropion 2.0
2 
(1.70 - 
2.40) 
1.97 (1.65 - 
2.33) 
2.1
2 
(1.78 - 
2.50) 
NRT + varenicline 3.5
4 
(2.57 - 
4.61) 
3.44 (2.51 - 
4.49) 
3.6
0 
(2.66 - 
4.65) 
Combination NRT 2.2
2 
(1.91 - 
2.55) 
2.16 (1.87 - 
2.49) 
2.3
0 
(2.00 - 
2.64) 
Varenicline 2.5
7 
(2.32 - 
2.85) 
2.49 (2.24 - 
2.78) 
2.6
3 
(2.37 - 
2.91) 
Varenicline + 
bupropion 
3.2
0 
(2.05 - 
4.60) 
3.11 (2.01 - 
4.46) 
3.2
6 
(2.13 - 
4.61) 
Notes: RR, risk ratio; CI, credible interval. 
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The impact of length of follow up suggests that if all trials followed up to 12 months, 
the treatment effects observed would be lower. This is plausible if the rate of failure 
(that is to say, recommencing smoking) is different in the control and intervention 
arms after six months. Given that the pharmacological treatments typically last for 
up to 12 weeks, it is possible that those in the intervention arm reach the point of no 
nicotine or active treatment three months after the participants in the control arm, 
and the failure curve may therefore be different. 
The influence of continuous abstinence implies that studies that record cessation on 
the basis of continuous abstinence observe a greater treatment effect than those 
using a point prevalence estimate. Continuous abstinence is considered a better 
measure of smoking cessation, as point prevalence does not account for those who 
have short-term relapses. People with short relapses may be less likely to succeed in 
long-term quitting. How the choice of abstinence measure might lead to a consistent 
bias is unclear. 
The meta-regression results should be interpreted with caution. The inclusion of 
covariates has a negligible impact on model fit, and the estimated impact may be 
influenced more by certain comparisons than others. For example, the use of 
continuous abstinence is least common in NRT trials, which also contribute the most 
evidence to the network. The potentially counter-intuitive findings, particularly with 
regard to continuous abstinence, may be an artefact or proxy for some other study 
feature. 
4.2.6 Behavioural interventions 
There were 166 comparisons available across 143 behavioural intervention trials 
(Figure 4.6). There were 112 comparisons of active intervention to control, and a 
further 22 comparisons of active control to ‘do nothing’. Fourteen trials provided 
data comparing control to ‘do nothing’. The control arms are based on participants 
receiving either brief advice or written materials, as this is presumed to constitute 
the standard of care for those seeking to quit smoking. The ‘do nothing’ arms are 
typically waiting list control or no further contact other than at follow up to 
determine smoking status. Both control and ‘do nothing’ arms have been included as 
separate arms in the following analyses, as they are distinct and provide contextual 
information when considering how effective behavioural interventions are. 
There were 47 comparisons involving telephone support, 42 involving intensive 
advice, and 34 involving group behaviour therapy. The majority of the studies were 
two-arm trials (n=127), but three-arm (n=12) and four-arm (n=4) trials were also 
included. There were only 19 head-to-head comparisons between the included 
interventions.  
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Combinations of therapies were excluded from this analysis. There were a variety of 
combinations reported, typically combining telephone or internet-based support with 
individual counselling. In some cases, the combination of therapies in both the 
control and intervention arms was unique, and therefore the trial could not link into 
the evidence network. For other combinations there was insufficient evidence 
regarding the use of those combinations in smoking cessation attempts in Ireland, 
and therefore the evidence would not contribute to the economic evaluation of this 
report. 
 
Figure 4.6  Network of evidence for behavioural interventions for  
 unselected adults 
 
4.2.6.1 Direct comparisons 
The pooled direct evidence for behavioural interventions is provided in Table 4.12. 
As for the comparison of pharmacotherapies, the pooled estimates have been 
combined using a random effects approach and the 95% confidence bounds are 
associated with the mean effect. In cases where there were five or more studies in 
the comparison, the 95% prediction intervals were also computed, and these give an 
indication of the range of effect sizes that might be observed in a future study. 
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Relative to ‘do nothing’, four of the five behavioural interventions evaluated had a 
statistically significant treatment benefit. Telephone support, based on a single trial, 
did not show a statistically significant treatment benefit. 
Control and ‘do nothing’ are clearly different, as is evidenced by the relative 
effectiveness observed across head-to-head comparisons (RR=1.67, 95%CI: 1.34 - 
2.07). A total of 14 trials included arms with no intervention and also arms that 
could be considered control on the basis of minimal intervention. As inclusion of 
some form of placebo is problematic for many of the behavioural interventions, the 
alternative is providing some form of minimal intervention to all study arms. Pooling 
control and ‘do nothing’ could create biased estimates, particularly if some 
interventions are more likely to be compared to minimal intervention than ‘do 
nothing’.
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Table 4.12 Treatment effects based on direct evidence: behavioural interventions 
Comparison Studies 
Participants 
(n) Risk ratio (95% CI) p-value 
95% 
Prediction 
interval 
I2 (95% CI) 
Individual counselling vs Nothing* 1 155 0.85 (0.27 – 2.63) 0.772 
 
NA 
 Telephone support vs Nothing* 1 1821 1.11 (0.74 - 1.67) 0.621 
 
NA 
 Internet-based vs Nothing* 3 3671 1.46 (1.18 – 1.81) 0.001 
 
0.61 (0.00 - 0.89) 
Control vs Nothing 14 9720 1.67 (1.34 - 2.07) <0.001 (0.97 - 2.85) 0.31 (0.00 - 0.64) 
Intensive advice vs Nothing 9 6707 1.74 (1.36 - 2.24) <0.001 (0.96 - 3.15) 0.36 (0.00 - 0.71) 
Acupuncture vs Nothing* 2 243 2.49 (1.23 – 5.02) 0.011 
 
0.00 
 Group behaviour therapy vs Nothing 6 846 3.16 (1.26 - 7.90) 0.014 (0.19 - 53.03) 0.69 (0.28 - 0.87) 
Acupuncture vs Control 12 2249 1.03 (0.83 - 1.29) 0.778 (0.76 - 1.40) 0.03 (0.00 - 0.60) 
Mobile phone-based vs Control* 3 1112 1.18 (0.88 - 1.60) 0.272 
 
0.51 (0.00 - 0.86) 
Intensive advice vs Control 25 16196 1.19 (1.05 - 1.35) 0.008 (0.84 - 1.67) 0.28 (0.00 - 0.56) 
Telephone support vs Control 41 44218 1.35 (1.21 - 1.51) <0.001 (0.78 - 2.35) 0.64 (0.49 - 0.74) 
Internet-based vs Control 5 5128 1.43 (1.02 - 2.00) 0.041 (0.45 - 4.51) 0.70 (0.23 - 0.88) 
Individual counselling vs Control 8 3696 1.48 (1.17 - 1.85) 0.001 (1.11 - 1.96) 0.00 (0.00 - 0.57) 
Group behaviour therapy vs Control 18 5072 1.80 (1.36 - 2.40) <0.001 (0.66 - 4.92) 0.66 (0.45 - 0.79) 
Individual counselling vs Telephone support* 2 1226 1.02 (0.74 - 1.42) 0.884 
 
0.22 
 Intensive advice vs Telephone support* 3 2869 1.11 (0.77 - 1.59) 0.572 
 
0.00 (0.00 - 0.88) 
Mobile phone-based vs Internet-based* 1 755 1.43 (0.88 - 2.31) 0.151 
 
NA 
 Group behaviour therapy vs Individual counselling* 4 2854 1.10 (0.87 - 1.40) 0.426 
 
0.42 (0.00 - 0.81) 
Intensive advice vs Individual counselling* 2 1028 1.40 (1.08 – 1.80) 0.010 
 
0.85 
 Intensive advice vs Group behaviour therapy* 3 351 1.05 (0.63 - 1.75) 0.853 
 
0.00 (0.00 - 0.33) 
Acupuncture vs Group behaviour therapy* 3 396 1.34 (0.80 – 2.24) 0.270 
 
0.64 (0.00 - 0.90) 
Notes: comparisons marked with * are based on fixed effect model, all other treatment effect estimates based on random effects model. 
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The direct evidence suggests a somewhat consistent picture whereby ‘do nothing’ is 
less effective than control or active intervention, apart from the single telephone 
support study. Acupuncture and mobile phone-based interventions appear to have 
similar effectiveness to control. The remaining five interventions (intensive advice, 
telephone support, internet-based, individual counselling, and group behaviour 
therapy) are superior to control and, based on limited evidence, there is no 
statistically significant evidence of any one offering a treatment benefit over another. 
Four of the included comparisons showed evidence of substantial heterogeneity. 
Two of the comparisons included sufficient studies to consider meta-regression. The 
comparison of telephone support versus control included 41 studies (I2=64%). When 
study-level characteristics were used as covariates, two were identified as 
statistically significant effect modifiers: length of follow up (p=0.0194), and 
continuous abstinence (p=0.0002). Increased follow up was associated with a 
reduced treatment effect. The mean follow up was 12 months, and the overall 
treatment effect (risk ratio = 1.35) reflects the effect at 12 months. At six months 
follow up the estimated treatment effect was 1.54. In terms of continuous 
abstinence, the estimated treatment effect was 1.60 with, and 1.11 without 
continuous abstinence. For the comparison of group behaviour therapy versus 
control (n=18, I2=66%), only biochemical verification was a significant effect 
modifier. In contrast to the overall effect of 1.80, the effect sizes were 2.46 with 
biochemical verification and 1.19 without. In other words, studies using self-reported 
abstinence had a lower effect size. 
Two further comparisons had substantial heterogeneity, but insufficient studies for 
meta-regression: group behaviour therapy versus ‘do nothing’ (n=6, I2=69%), and 
internet-based versus control (n=5, I2=70%). The forest plots for these two 
comparisons are provided in Figures 4.7 and 4.8. The heterogeneity in group 
behaviour therapy versus ‘do nothing’ is largely driven by two studies (from 1983 
and 1985) that found a modest treatment effect that was not statistically significant. 
In terms of internet-based interventions versus control, a 2011 study found a non-
statistically significant treatment benefit for the control arm. In fact, a statistically 
significant treatment benefit was only found in two studies from 2008. 
For the comparison of group behaviour therapy versus control, the fixed effect 
estimated (RR=1.45, 95%CI: 1.27 to 1.66) was lower than the random effects 
estimate (RR=1.80, 95% CI: 1.36 to 2.40). Given that the comparison was 
supported by 18 studies and there was evidence of substantial heterogeneity, the 
random effects analysis was considered more appropriate. 
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Figure 4.7  Forest plot of studies comparing group behaviour therapy  
  versus ‘do nothing’ 
 
 
Figure 4.8 Forest plot of studies comparing internet-based interventions 
  versus control 
 
The possible presence of small study bias was investigated using funnel plots for 
cases where there were 10 or more studies. In two comparisons there was 
statistically significant evidence of bias using both the Harbord and Egger’s tests: 
group behaviour therapy versus control (Harbord test: p=0.025; Egger’s test: 
p=0.008), and intensive advice versus control (Harbord test: p=0.023; Egger’s test: 
p=0.021). The evidence of bias in both cases is consistent with the concept of 
publication bias – smaller studies are associated with a larger effect size in favour of 
the intervention. 
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Figure 4.9  Funnel plot of studies comparing group behaviour therapy 
versus control 
 
The trim and fill technique was applied to both comparisons to determine the 
potential impact of small study bias on the estimated treatment effect. For the 
comparison of group behaviour therapy versus control, the risk ratio decreased from 
1.80 (95% CI: 1.36 to 2.40) to 1.36 (95% CI: 1.04 to 1.79). The reduction in 
treatment effect is quite marked, although the mean treatment effect is still superior 
to control. In the comparison of intensive advice versus control, the application of 
trim and fill reduced the treatment effect from 1.19 (95% CI: 1.05 to 1.35) to 1.14 
(95% CI: 0.99 to 1.31). The treatment effect size is only reduced by a modest 
amount, but the confidence bounds for the effect estimate include the possibility of 
no treatment effect. 
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Figure 4.10  Funnel plot of studies comparing intensive advice versus 
control 
 
4.2.6.2 Direct and indirect comparisons 
As with the analysis of pharmacological interventions, it was considered appropriate 
to extend the analysis of behavioural interventions to include both direct and indirect 
evidence. Treatment effects were again calculated on the log odds scale and then 
converted to risk ratios using the assumed control risk, which was calculated as the 
risk of smoking cessation pooled across the control arms. 
Treatment effects were first estimated using both consistency and inconsistency 
models to determine whether the estimates of treatment effect were sensitive to the 
assumption of consistency. The consistency and inconsistency models produced 
similar estimates of treatment effect in most cases. Four comparisons disagreed in 
the direction of effect. However, all of the estimates from the consistency model 
were well within the confidence bounds for the corresponding inconsistency model 
estimates. Comparing the models on the basis of DIC, the consistency model 
produced a DIC of 528.7 and the inconsistency model a DIC of 533.3. The credible 
intervals around treatment effect were larger in the inconsistency model than the 
corresponding comparisons in the consistency model. The random effects standard 
deviation was 0.36 (95% CI: 0.28 to 0.44) for the consistency model and 0.35 (95% 
CI: 0.26 to 0.44) for the inconsistency model.  
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An analysis of heterogeneity estimated a global I2 of 54%. Based on an analysis of 
heterogeneity, potential issues were identified for four comparisons:  
1. telephone support versus ‘do nothing’ (p=0.077),  
2. acupuncture versus control (p=0.005),  
3. internet-based versus control (p=0.077),  
4. and individual counselling versus intensive advice (p=0.082).  
Using a node-splitting analysis to investigate the contribution of direct and indirect 
evidence to treatment effect estimates, there was one comparison with a statistically 
significant difference in the direct and indirect evidence (Table 4.13). In the 
comparison of group behaviour therapy versus acupuncture, the direct evidence 
suggested a treatment benefit associated with acupuncture that was not statistically 
significant (based on three studies). The indirect evidence suggested a statistically 
significant treatment benefit for group behaviour therapy. Given that the direct 
evidence suggests that acupuncture has a similar effect to control, and that group 
behaviour therapy provides a statistically significant treatment benefit over control, 
the limited direct evidence between acupuncture and group behaviour therapy 
appears to contradict the general findings. 
Other comparisons associated with some evidence of inconsistency included: 
telephone support versus ‘do nothing’ (p=0.087), individual counselling versus 
control (p=0.083), and individual counselling versus intensive advice (p=0.098). In 
these cases the general interpretation was not changed by the addition of indirect 
evidence. 
For almost all other comparisons the direct and indirect treatment effects were in 
agreement in terms of direction and magnitude, although there were some 
differences. There were four instances of a difference in direction of effect, although 
the difference was not statistically significant due to the wide credible intervals. 
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Table 4.13 Comparison of direct and indirect treatment effect estimates: behavioural interventions 
Comparison Risk ratio p-value 
Direct estimate 
(95% CI) 
Indirect estimate 
(95% CI) 
Network 
estimate(95% CI) 
Control vs Nothing 1.69 (1.32 to 2.15) 1.37 (1.06 to 1.76) 1.49 (1.25 to 1.79) 0.242 
Acupuncture vs Nothing 2.56 (1.13 to 5.04) 1.59 (1.08 to 2.29) 1.75 (1.26 to 2.37) 0.302 
Internet-based vs Nothing 1.49 (0.98 to 2.24) 2.06 (1.43 to 2.98) 1.81 (1.37 to 2.37) 0.242 
Telephone support vs Nothing 1.10 (0.52 to 2.22) 2.08 (1.70 to 2.56) 1.98 (1.62 to 2.37) 0.087 
Intensive advice vs Nothing 1.88 (1.42 to 2.56) 2.10 (1.62 to 2.77) 2.00 (1.64 to 2.37) 0.600 
Individual counselling vs Nothing 0.85 (0.20 to 2.98) 2.13 (1.62 to 2.77) 2.06 (1.56 to 2.77) 0.166 
Group behaviour therapy vs Nothing 2.98 (1.90 to 4.48) 2.56 (2.03 to 3.45) 2.77 (2.13 to 3.45) 0.615 
Acupuncture vs Control 1.04 (0.74 to 1.42) 1.01 (0.24 to 3.21) 1.18 (0.87 to 1.59) 0.959 
Internet-based vs Control 1.44 (1.02 to 2.01) 0.93 (0.59 to 1.42) 1.21 (0.93 to 1.59) 0.113 
Mobile phone-based vs Control 1.17 (0.70 to 1.87) 1.78 (0.76 to 3.69) 1.31 (0.86 to 1.96) 0.389 
Telephone support vs Control 1.37 (1.21 to 1.55) 1.13 (0.70 to 1.82) 1.35 (1.19 to 1.52) 0.431 
Intensive advice vs Control 1.29 (1.08 to 1.55) 1.56 (1.15 to 2.10) 1.36 (1.17 to 1.59) 0.313 
Individual counselling vs Control 1.70 (1.20 to 2.37) 1.12 (0.79 to 1.55) 1.39 (1.09 to 1.78) 0.083 
Group behaviour therapy vs Control 1.82 (1.46 to 2.27) 2.15 (1.48 to 2.98) 1.85 (1.53 to 2.26) 0.472 
Group behaviour therapy vs Acupuncture 0.79 (0.39 to 1.59) 1.95 (1.32 to 2.77) 1.59 (1.14 to 2.20) 0.025 
Internet-based vs Mobile phone-based 0.70 (0.29 to 1.59) 1.08 (0.60 to 1.84) 0.93 (0.57 to 1.47) 0.397 
Telephone support vs Intensive advice 0.99 (0.56 to 1.76) 0.99 (0.79 to 1.22) 0.99 (0.81 to 1.20) 0.993 
Individual counselling vs Intensive advice 0.69 (0.39 to 1.20) 1.17 (0.86 to 1.57) 1.03 (0.78 to 1.36) 0.098 
Telephone support vs Individual counselling 0.96 (0.52 to 1.66) 0.97 (0.70 to 1.30) 0.96 (0.73 to 1.25) 0.996 
Intensive advice vs Group behaviour therapy 1.06 (0.50 to 2.18) 0.67 (0.51 to 0.88) 0.72 (0.55 to 0.92) 0.243 
Individual counselling vs Group behaviour therapy 0.83 (0.52 to 1.31) 0.68 (0.47 to 1.00) 0.74 (0.54 to 0.98) 0.527 
Notes: CI, credible interval. The direct, indirect and network evidence are created from three different models, and the network estimate was not a weighted 
average of the indirect and direct studies. Results are presented for studies for which there was both direct and indirect evidence not limited to data from a 
single multi-arm study). 
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The nine interventions in the network of behavioural treatments were analysed in 
terms of their likely ranking from best treatment to worst treatment (Figure 4.11). 
There was a probability of 1 that ‘do nothing’ was the least effective treatment. 
Group behaviour therapy had the highest probability of being most effective 
(probability = 0.91). Individual counselling and intensive advice were the next 
highest ranked treatments. Intensive advice, telephone support and mobile phone-
based interventions had wide ranges of probable rankings, indicating uncertainty in 
their effectiveness compared with the other interventions.  
Figure 4.11  Probability of rankings: behavioural interventions 
 
Note: the graph shows the probability of a given intervention being ranked from 1 (most effective 
intervention) to 10 (least effective intervention). A high probability reflects greater certainty about the 
ranking of a particular intervention. For example, it is almost certain that ‘control’ is the least effective 
intervention with a probability of 0.997 of being ranked tenth. There is a probability of 0.64 that 
varenicline plus NRT dual therapy is the most effective intervention. 
When considered in terms of prediction intervals, none of the behavioural 
interventions are associated with a statistically significant treatment effect relative to 
control (Table 4.14). In other words, the expectation is that futures studies for any 
of the behavioural interventions may show no treatment benefit relative to control. 
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Table 4.14  Treatment effect relative to control: behavioural   
  interventions 
Intervention Risk ratio 95% CI 95% PI 
Do nothing 0.66 (0.54 - 0.79) (0.32 - 1.26) 
Control Reference   
Acupuncture 1.17 (0.86 - 1.58) (0.59 - 2.52) 
Internet-based 1.22 (0.93 - 1.58) (0.60 - 2.23) 
Mobile phone-based 1.31 (0.84 - 1.97) (0.61 - 2.69) 
Telephone support 1.34 (1.19 - 1.51) (0.70 - 2.47) 
Intensive advice 1.35 (1.16 - 1.58) (0.72 - 2.35) 
Individual counselling 1.39 (1.10 - 1.76) (0.74 - 2.63) 
Group behaviour therapy 1.85 (1.53 - 2.23) (0.95 - 3.20) 
Notes: CI, credible interval; PI, prediction interval. 
The network meta-analysis provides estimates of the relative effectiveness of each 
intervention compared to each of the others in the network (Table 4.15). The 
general hierarchy observed in the direct evidence is apparent in the combined direct 
and indirect evidence, with the distinction being that group behaviour therapy has a 
statistically significant treatment benefit over all interventions other than mobile 
phone-based interventions. It should be noted that there were only four studies 
providing data on mobile phone-based interventions, and the effectiveness of the 
intervention has wide credible intervals.
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Table 4.15 Network meta-analysis treatment effect estimates: behavioural interventions 
 
Risk ratio (95% credible interval) 
Intervention Nothing Control 
Acupunctur
e 
Internet-
based 
Mobile phone-
based 
Telephone 
support 
Intensive 
advice 
Individual 
counselling 
Control 
1.50 
(1.26 - 1.79) 
       Acupuncture 
1.74 
(1.25 - 2.39) 
1.17 
(0.86 - 1.58) 
      Internet-based 
1.81 
(1.38 - 2.35) 
1.22 
(0.93 - 1.58) 
1.04 
(0.69 - 1.55) 
     Mobile phone-
based 
1.93 
(1.24 - 2.89) 
1.31 
(0.84 - 1.97) 
1.12 
(0.65 - 1.86) 
1.07 
(0.66 - 1.70) 
    Telephone 
support 
1.98 
(1.63 - 2.41) 
1.34 
(1.19 - 1.51) 
1.15 
(0.82 - 1.59) 
1.11 
(0.82 - 1.47) 
1.03 
(0.65 - 1.61) 
   Intensive advice 
2.00 
(1.66 - 2.41) 
1.35 
(1.16 - 1.58) 
1.16 
(0.82 - 1.62) 
1.12 
(0.82 - 1.51) 
1.04 
(0.65 - 1.64) 
1.01 
(0.83 - 1.23) 
  Individual 
counselling 
2.05 
(1.57 - 2.66) 
1.39 
(1.10 - 1.76) 
1.19 
(0.81 - 1.74) 
1.14 
(0.80 - 1.63) 
1.07 
(0.64 - 1.73) 
1.04 
(0.80 - 1.34) 
1.03 
(0.78 - 1.34) 
 Group behaviour 
therapy 
2.67 
(2.15 - 3.30) 
1.85 
(1.53 - 2.23) 
1.60 
(1.14 - 2.22) 
1.54 
(1.12 - 2.10) 
1.43 
(0.90 - 2.25) 
1.39 
(1.11 - 1.75) 
1.38 
(1.09 - 1.75) 
1.35 
(1.02 - 1.77) 
Note: shaded cells indicate a statistically significant treatment effect. 
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The majority of evidence in the network relates to comparisons between active 
interventions and control or ‘do nothing’. The number of head-to-head trials 
providing direct comparisons between behavioural therapies is very limited. Of the 
166 comparisons included, only 18 were head-to-head between behavioural 
interventions. Therefore, it is apparent that combined direct and indirect evidence is 
influenced primarily by the evidence relative to control and ‘do nothing’.  
The concept of ‘do nothing’ does not exist in the network of pharmacological 
treatments. In relation to behavioural interventions, ‘do nothing’ is clearly different 
to receiving brief advice or written materials. As control has been defined here to 
include brief advice or written materials, the finding of a treatment benefit relative to 
‘do nothing’ is consistent with the findings of the Cochrane review of brief advice. All 
of the behavioural interventions reviewed provide a treatment effect benefit over the 
alternative of ‘do nothing’.  
4.2.6.3 Sensitivity analysis 
Quit rates at six and 12 months were pooled across the different study arms (Table 
4.16). There are no studies with 12 months follow up for mobile phone-based 
interventions. All estimates with three or more studies, with the exception of 
acupuncture and group behaviour therapy at six months, show substantial and 
statistically significant evidence of heterogeneity. In almost all cases the pooled quit 
rate is lower at 12 months than at six months, which is consistent with there being 
relapse between six and 12 months. There is an apparent increase in quit rates for 
acupuncture between the six and 12-month follow-up data, and for individual 
counselling the rates are unchanged. 
Table 4.16  Absolute quit rates across study arms: behavioural 
interventions 
Intervention 6-months follow up 12-months follow up 
 studies quit 95% CI studies quit 95% CI 
Do nothing 11 0.07 (0.04 - 
0.11) 
15 0.04 (0.03 - 
0.06) 
Control 43 0.10 (0.08 - 
0.12) 
54 0.08 (0.06 - 
0.09) 
Acupuncture 7 0.09 (0.06 - 
0.13) 
3 0.24 (0.12 - 
0.43) 
Internet-based 6 0.13 (0.07 - 
0.24) 
2 0.08 (0.07 - 
0.10) 
Mobile phone-based 4 0.13 (0.08 - 
0.21) 
0   
Telephone support 10 0.16 (0.10 - 
0.24) 
22 0.10 (0.08 - 
0.13) 
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Intensive advice 18 0.15 (0.12 - 
0.18) 
15 0.08 (0.06 - 
0.11) 
Individual counselling 9 0.13 (0.07 - 
0.21) 
4 0.12 (0.06 - 
0.23) 
Group behaviour 
therapy 
10 0.26 (0.22 - 
0.31) 
16 0.17 (0.13 - 
0.23) 
Notes: CI, credible interval. 
Network meta-regressions were carried out using study-level covariates, as per the 
approach used for the analysis of studies including pharmacological interventions.  
Five different covariates were considered: two continuous variables (study year, 
length of follow up) and three dichotomous variables (high quality, biochemical 
verification of abstinence, and continuous abstinence). The meta-regression 
assumed a shared effect across treatments. As for the network meta-regression of 
pharmacological interventions, length of follow up was the only covariate associated 
with a reduced effect size (Table 4.17). Although none of the covariates were 
associated with statistically significant effects, some of the effect sizes were 
potentially large. Including covariates did not impact substantively on the Deviance 
Information Criterion (DIC), or the random effects standard deviation. 
Table 4.17  Network meta-regression results 
Covariate Coefficient (95% CI) DIC Random effects SD 
No covariates - - 528.7 0.36 (0.28 to 0.44) 
Study year 0.11 (-0.12 to 0.34) 529.1 0.36 (0.28 to 0.45) 
Follow up -0.15 (-0.45 to 0.14) 530.1 0.35 (0.27 to 0.44) 
High quality 0.07 (-0.17 to 0.32) 528.8 0.36 (0.28 to 0.45) 
Biochemically verified 0.19 (-0.02 to 0.39) 527.4 0.35 (0.28 to 0.44) 
Continuous abstinence 0.13 (-0.05 to 0.32) 529.8 0.35 (0.27 to 0.44) 
Notes: CI, credible interval; DIC, Deviance Information Criterion; SD, standard deviation. 
The impact on treatment effects (relative to control) of including covariates in the 
model are shown in Table 4.18. The inclusion of biochemical verification and 
continuous abstinence increases the treatment effect for all interventions. 
  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
128  
Table 4.18  Impact on treatment effect (relative to control) of including 
  covariates in analysis of behavioural interventions 
Intervention No covariate Biochemical 
verification 
Continuous 
abstinence 
Acupuncture 1.17 (0.86 - 1.58) 1.34 (0.96 - 1.86) 1.25 (0.91 - 1.69) 
Group behaviour 
therapy 
1.85 (1.53 - 2.23) 2.00 (1.62 - 2.47) 1.99 (1.61 - 2.46) 
Intensive advice 1.35 (1.16 - 1.58) 1.48 (1.23 - 1.77) 1.47 (1.22 - 1.77) 
Individual 
counselling 
1.39 (1.10 - 1.76) 1.51 (1.17 - 1.93) 1.51 (1.16 - 1.95) 
Mobile phone-
based 
1.31 (0.84 - 1.97) 1.48 (0.95 - 2.26) 1.36 (0.88 - 2.04) 
Telephone 
support 
1.34 (1.19 - 1.51) 1.51 (1.27 - 1.80) 1.42 (1.23 - 1.64) 
Internet-based 1.22 (0.93 - 1.58) 1.41 (1.03 - 1.90) 1.30 (0.98 - 1.71) 
The analysis shows that if all studies used biochemical verification, then larger 
treatment effects would be expected. Similarly, if all studies used continuous 
abstinence rather than self-reported abstinence, greater treatment effects would be 
expected. 
As with pharmacological interventions, the meta-regression results should be 
interpreted with caution. The inclusion of covariates has a negligible impact on 
model fit and the observed effects may be overly influenced by certain comparisons. 
4.2.7 Behavioural interventions as an adjunct to pharmacotherapy 
The systematic review of smoking cessation interventions in unselected adults found 
separate evidence regarding pharmacotherapy and behavioural interventions. With 
the exception of two studies, there was no evidence directly comparing 
pharmacological and behavioural interventions. However, it was clear that the 
majority of pharmacological interventions included some form of behavioural support 
intervention provided to both the control and intervention study arms. The 
behavioural interventions assessed offered a treatment benefit relative to ‘do 
nothing’ and, to a lesser extent, relative to control in the form of brief advice or 
written materials. It is therefore possible that combining pharmacotherapy with a 
behavioural intervention may lead to an increased treatment effect relative to 
pharmacotherapy or a behavioural intervention as a single intervention. 
4.2.7.1 Identification of studies 
Two systematic reviews investigated the clinical effectiveness of behavioural therapy 
with pharmacotherapy. The first review considered behavioural therapy as an 
adjunct to pharmacotherapy.(165) Studies were included if all patients were provided 
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with pharmacotherapy, and if the intervention arm participants received more 
intensive behavioural therapy than the control arm participants. The second review 
considered behavioural therapy in combination with pharmacotherapy.(166) Studies 
were included if all patients received behavioural therapy and all intervention arm 
participants were offered pharmacotherapy. Pharmacotherapy was offered as an 
adjunct to behavioural therapy in the second review. This HTA was restricted to the 
studies identified in those reviews, and the search was not updated given the recent 
publication date of the identified reviews. 
Of the 176 pharmacological intervention trials, only 12% did not include supportive 
care in all arms. Almost three out of four (73%) trials provided intensive advice, 
individual counselling or group behaviour therapy to all participants. However, only 
31 of 143 behavioural therapy studies clearly stated the provision of 
pharmacotherapy to participants. This HTA was primarily interested in behavioural 
therapy as an adjunct to pharmacotherapy as this is a common feature of these 
studies. Understanding the impact of behavioural support on the clinical 
effectiveness of pharmacotherapy is relevant as the provision of behavioural therapy 
may be incorporated into the product license requirements or guidelines. 
4.2.7.2 Available evidence 
The systematic review of behavioural therapy as adjunct to pharmacotherapy 
identified 47 trials, of which 36 were considered applicable to the review in this HTA. 
The remaining 11 did not meet the inclusion criteria for this review, mainly due to 
the study population not being applicable. The included studies were published 
between 1985 and 2014, and 42% (n=15) were considered at low risk of bias. The 
majority (n=26) used biochemical verification, but only 19% (n=7) recorded 
continuous abstinence. The pharmacological interventions used in the trials included 
NRT (n=24), bupropion (n=5), choice of pharmacotherapy (n=4), NRT plus 
bupropion (n=2), and varenicline (n=1). The review included studies that compared 
adjunct behavioural therapy either to no adjunct behavioural therapy (n=6), or to 
alternative configurations of low intensity (n=13) or high-intensity behavioural 
therapy (n=17). 
4.2.7.3 Results 
There was no statistically significant difference in treatment effect by type of 
pharmacological intervention or by the type of supportive care used in the control 
arms of the studies (Figure 4.12). There was moderate heterogeneity in the full 
analysis (I2=29.3%, p=0.053). The overall treatment effect of providing behavioural 
therapy as an adjunct to pharmacotherapy was modest, with a risk ratio of 1.18 
(95% CI: 1.09 to 1.28). A risk ratio of less than 1 was estimated in 10 of the 36 
studies, indicating the uncertainty of treatment effect. The prediction intervals for 
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the treatment effect were correspondingly wide (95% prediction interval: 0.91 to 
1.53). There was no evidence of funnel plot asymmetry using either Egger’s test 
(p=0.23) or the Harbord test (p=0.29). 
Meta-regression was used to determine if there was an association between study-
level covariates and treatment effect. Only study year was a statistically significant 
effect modifier, with more recent studies showing a greater treatment effect (p= 
0.0148). The predicted effect for a study published in 2014 was a risk ratio of 1.35 
(95% CI: 1.19 to 1.55). 
On average, the addition of behavioural therapy to pharmacotherapy results in an 
increased treatment effect over and above pharmacotherapy alone. In the main 
analysis, the treatment effect of NRT relative to control was an estimated risk ratio 
1.68, and the treatment effect of individual counselling was 1.39. If the treatment 
effects were additive on the log scale, then risk ratio for NRT plus individual 
counselling relative to NRT alone would be 1.39. The estimated risk ratio of 1.18 is 
somewhat less than that, suggesting a loss of effect. This could also be seen for 
combination pharmacotherapies where the risk ratio for NRT plus varenicline was 
less than the combination of effect sizes for NRT and varenicline individually. 
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Figure 4.12 Behavioural support as an adjunct to pharmacotherapy 
 
Although the use of pharmacotherapy as an adjunct to behavioural therapy is not 
being considered as a distinct intervention in this HTA, it is useful to briefly consider 
the findings of the published systematic review. The review included studies that 
compared behavioural support with the option of pharmacological interventions to 
usual care or some lower intensity of behavioural support. While 53 studies were 
identified, one was considered an outlier and removed from the analysis. The review 
reported a risk ratio of 1.83 (95% CI: 1.68 to 1.98), indicating that behavioural 
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support with optional pharmacological intervention was more effective than usual 
care or lower intensity behavioural support. Due to the criterion of lower intensity 
support and no systematic availability of pharmacological intervention in the control 
arms, it is unclear how the findings of this review may be interpreted. 
4.2.9 Summary 
Based on updating 13 systematic reviews, we identified 313 studies that met the 
inclusion criteria for an unselected adult population. Half of the studies had been 
published in the year 2000 or more recently. Sixty two percent of the studies had 12 
months or longer follow up for estimating abstinence. A quarter of the studies were 
considered at low risk of bias. Almost two out of three (65%) studies used 
biochemical verification of quitting, and 58% measured continuous abstinence as 
distinct from point prevalence. 
Interventions could be broadly classified as pharmacological and behavioural 
interventions. While the definitions of pharmacological interventions were clear, 
behavioural interventions tended to be quite heterogeneous. In addition, many 
pharmacotherapy trials provided supportive care in the form of a behavioural 
intervention to both the control and intervention arm participants. 
Both direct and indirect evidence were considered when evaluating the relative 
effectiveness of interventions. Due to differences in the trial participants and lack of 
direct evidence, pharmacotherapy and behavioural interventions were analysed 
separately. 
Direct evidence was available for many of the possible comparisons between 
pharmacological interventions. All of the interventions were found to be superior to 
the control group. The results of a network meta-analysis suggest that varenicline is 
the most effective monotherapy, and that dual therapy varenicline plus NRT is the 
most effective pharmacotherapy. NRT monotherapy and bupropion are similarly 
effective. The direct and indirect evidence were broadly in agreement. 
The relative effectiveness of e-cigarettes was estimated using data from two trials: a 
three-arm trial comparing e-cigarettes with NRT and with placebo e-cigarettes(167); 
and a two-arm trial comparing e-cigarettes with placebo e-cigarettes.(168) The three-
arm trial couriered e-cigarettes to participants, while those in the NRT arm were 
provided with vouchers that could be redeemed for NRT patches at a pharmacy. This 
approach may have introduced a barrier for those in the NRT arm, in which the quit 
rate at six months was 5.8%, well below the average six month quit rate of 19% 
seen in the NRT arms of studies (Table 4.8). The two-arm study did not provide any 
supportive care in conjunction with the intervention, and the control arm quit rate at 
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12 months was 4%. In both trials, the devices were first-generation devices 
providing low doses of nicotine.  
It is unclear to what extent the results of the trials apply to more recent generations 
of e-cigarettes. As the technology has developed, nicotine delivery has improved 
creating a closer approximation to smoking conventional cigarettes. This could 
plausibly reduce the effectiveness of e-cigarettes for cessation, as stopping may be 
associated with greater withdrawal symptoms, as would be experienced when 
quitting conventional cigarettes. However, it may also make it easier for smokers to 
transition to e-cigarettes before reducing nicotine intake as part of a quit attempt. 
Using the GRADE system, the Cochrane review of e-cigarettes for smoking cessation 
described the level of evidence as low. These caveats should be borne in mind when 
considering the clinical effectiveness of e-cigarettes for smoking cessation. There are 
a number of ongoing trials evaluating the effectiveness of e-cigarettes for smoking 
cessation, and on completion these may well change the estimates of effectiveness. 
Although e-cigarettes are a popular smoking cessation aid, this is not necessarily 
considered in their design. Given that the technology is developing and may become 
more or less effective for smoking cessation, this is particularly relevant. Given the 
paucity of evidence regarding e-cigarettes, the evolving evidence base for both 
effectiveness and safety should be monitored and re-evaluated to support decisions 
regarding their promotion for smoking cessation. 
In terms of behavioural interventions, the majority of evidence compared 
interventions to control or ‘do nothing’. For the purposes of this analysis, control was 
defined as minimal intervention, which usually comprised brief advice or written 
materials. All of the interventions and control were more effective than ‘do nothing’. 
Relative to control, only four of the interventions (group behaviour therapy, 
individual counselling, intensive advice, and telephone support) showed a statistically 
significant benefit in terms of average treatment effect. When considered on the 
basis of prediction intervals, the confidence bounds encompassed no treatment 
effect for all interventions. In other words, a future study of any of the interventions 
has a reasonable potential to find no effect relative to control. The significance of 
this is apparent if it is assumed that control (brief advice or written materials) 
represents the standard of care for those not accessing a behavioural intervention. 
Evidence of inconsistency was found when analysing the behavioural interventions. 
Some of this may be due to the small number of head-to-head comparisons 
available and relatively heterogeneity of interventions. In other words, when only 
one or a small number of studies are available in a given comparison, they may not 
be representative of the ‘average’ implementation of that intervention as seen in 
other comparisons. 
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There was some evidence that certain study-level covariates acted as effect 
modifiers. Most notably, studies using biochemical verification and continuous 
abstinence had a tendency to observe larger treatment effects in favour of the 
intervention. This finding may be considered counter-intuitive, as these 
characteristics might be expected to reduce the observed quit rates by removing 
bias due to deception and temporary relapses. There is no reason to expect that 
these differences would systematically bias against the control arms. Biochemical 
verification and continuous abstinence may act as measures of study quality that are 
not captured by the Cochrane risk of bias tool, but again that would not be expected 
to bias in favour of the treatment. 
There was evidence of small study bias for a limited number of comparisons. Small 
study bias indicates that smaller studies tend to report results that favour one of the 
study arms, in this case the intervention. It is often interpreted as evidence of 
publication bias in that smaller studies are more likely to get published if they report 
a statistically significant finding, usually in favour of the intervention. The effect of 
such a bias is to inflate the estimate of treatment effect. Using the trim and fill 
method to estimate the treatment effects in the absence of the small study bias, it 
could be seen that the treatment effects would be reduced, although generally by 
only a modest amount. In other words, the small study bias had a limited impact on 
the results. 
Based on the findings of a Cochrane review, the provision of behavioural support as 
an adjunct to pharmacotherapy increases the treatment benefit by 18%. This finding 
is consistent across types of supportive care and the type of pharmacological 
treatment. This can be interpreted as a modest additional benefit to pharmacological 
interventions derived from providing adjunctive behavioural therapy. 
The absolute quit rates varied by intervention arm. For both pharmacotherapy and 
behavioural intervention studies, the control arm quit rates were approximately 10% 
to 11% at six months. There was some divergence at 12 months, with control arm 
quit rates of 11% in pharmacotherapy studies and 8% in behavioural intervention 
studies. These quit rates are substantially lower than those observed in the Healthy 
Ireland survey data (see Chapter 3). Using the Health Ireland survey data based on 
those reporting smoking in the last year and those who made a quit attempt in that 
year, the estimated overall quit rate was 24.0%. This includes people who quit over 
a 12 month period and is a point prevalence estimate. Some of those may only have 
quit in the previous month, and hence the estimate is potentially subject to 
substantial bias. As the risk of relapse is highest in the first few months following a 
quit attempt, the figure of 24% is likely to be an overestimate of successful quit 
attempts.  
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However, the quit rates from the Healthy Ireland data are similar for a number of 
methods of quitting: unassisted quitting (27.1%), e-cigarettes (26.5%), and NRT in 
combination with a behavioural intervention (27.7%). The quit rate associated with 
NRT monotherapy was only 11.2%. The Healthy Ireland data do not record number 
of quit attempts, and the observed cessation rates may be influenced by smokers 
making numerous attempts, increasing the probability of successful quitting. The 
trial data presumes a single quit attempt, particularly for those using the measure of 
continuous abstinence. Healthcare professionals are trained in the provision of brief 
advice for smoking cessation, and the need to quit smoking is widely publicised. 
Smokers and former smokers who report a quit attempt as unassisted may not 
consider brief advice or written materials as an intervention, even though they have 
been exposed to it. To estimate the clinical effectiveness of behavioural 
interventions, we selected a control comprising minimal intervention as the reference 
for unassisted quitting, rather than ‘do nothing’. 
The differences between the trial and survey data raise questions about how the trial 
data generalise to the real-world setting, where smokers are free to choose a 
method of cessation that suits them, and where they may find a preferable method 
through experimentation and repeated failed attempts. Behavioural interventions are 
designed to provide smokers with mechanisms to manage quit attempts and reduce 
the likelihood of relapse. The skills obtained from a quit attempt using a behavioural 
intervention may increase the likelihood of successful quitting in future attempts. 
This may not apply to pharmacological interventions unless they are used with 
adjunctive behavioural support. Thus the relative effectiveness of behavioural 
interventions in a single quit attempt, as reported in clinical trial data, may 
understate their impact on further quit attempts and risk of relapse. 
4.3 Clinical effectiveness and safety in users of secondary care 
mental health services 
The primary population of interest in this analysis is users of secondary care mental 
health services. 
4.3.1 Identified systematic reviews  
The aim of this systematic review is to assess the effectiveness of smoking cessation 
interventions in users of secondary care mental health services.  
A scoping search identified a recent high-quality systematic review of the 
effectiveness of smoking cessation interventions in users of secondary care mental 
health services. The report was published by the UK Centre for Tobacco Control 
Studies in 2012 and was used a starting point for this review.(169) In addition, two 
high-quality Cochrane reviews were found. One of these assessed smoking cessation 
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interventions in individuals with schizophrenia and schizoaffective disorders, while 
the other looked at interventions in those with current and past depression. These 
reviews were cross-checked against the UK Centre for Tobacco Control Studies 
report to ensure all relevant studies were included.(170, 171) The PICOS criteria for 
study eligibility are included in Table 4.19.  
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Table 4.19 PICOS criteria for study eligibility – users of secondary 
mental health services 
Population  Adults aged 18 years or older who are users of 
secondary care mental health services. These 
typically include patients with psychotic disorders, 
schizophrenia or schizoaffective disorder, current 
depression or bipolar disorder. 
Intervention   Nicotine replacement therapy (NRT), such as 
chewing gum, transdermal patches, nasal and 
oral spray, inhalers, tablets and lozenges; as 
monotherapy or combination (dual) therapy 
 Electronic cigarettes (e-cigarettes) 
 Nicotine receptor partial agonists (cytisine or 
varenicline only) 
 Antidepressants (bupropion only) 
 Motivational interviewing 
 Brief physician advice 
 Telephone-based interventions 
 Mobile phone-based interventions 
 Internet-based interventions 
 Individual behaviour counselling 
 Group behaviour therapy 
 Acupuncture 
 Allen Carr method 
Comparator  No treatment (or placebo) or another eligible 
intervention. 
Outcomes  Primary outcome of interest was long-term smoking 
cessation rates, as indicated by quit rates at greater 
than or equal to six months (≥6 months). 
Biochemically verified results were preferred to self 
reports, and continuous or prolonged abstinence was 
preferred to point prevalence abstinence. 
Study design  Randomised controlled trials 
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4.3.2 Identified trials 
The UK Centre for Tobacco Control Studies review was updated by running further 
searches from 01 January 2012 to 18 August 2016 in Pubmed, EMBASE and the 
Cochrane Library, see Appendix 1 for details. The UK Centre for Tobacco Control 
Studies review searched a range of databases including Medline (Search date: 30 
Jan 2012), EMBASE (Search date: 09 Feb 2012, date limits: 1985-2012) and the 
Cochrane Library (Search date: 01 Jan 2012). The scope of the review was broader 
than that specified in this HTA and included a broader set of potential smoking 
cessation interventions such as clozapine, naltrexone and fluoxetine. These 
interventions were not included in this assessment as they are not representative of 
smoking cessation standard of care in Ireland nor are they licensed for this purpose. 
The UK Centre for Tobacco Control Studies report also included a broader range of 
study types such as non-randomised controlled trials, controlled before-and-after 
studies, interrupted time series and uncontrolled before-and-after studies not eligible 
for inclusion in this HTA. As such, of the fifty-one studies included in the UK Centre 
for Tobacco Control Studies report, only eight are eligible for inclusion in this 
review;(172-180) the reasons for excluding the remaining studies are reported in 
Appendix 1. Two additional studies were retrieved in the updated search.(181, 182)  
4.3.3 Summary of the evidence 
Of the 10 included studies, nine were based in the US,(173-179, 181, 182) one of which 
was US and Canada based,(181) and one was based in Australia.(172) Eight studies 
recruited from community volunteers,(172-177, 179, 181) one study from outpatient 
clinics(182) and the setting was unclear in one study.(178) Six studies included 
populations with a DSM-IV/DSIM-IV-TR (updated version) diagnosis of schizophrenia 
or schizoaffective disorder,(174, 176-179, 181) one of which was defined as the depressed 
type.(174) Two trials included people with a DSM-IV diagnosis of schizophrenia 
only,(173, 175) and one trial included patients with a ICD-10 diagnosis of psychotic 
disorder (over half of which had schizophrenia or schizoaffective disorder).(172) One 
trial included clinically stable adults who met the DSM-IV criteria of bipolar 
disorder.(182) These studies were published from 2000(178) to 2014(182) and were 
mainly small trials with participant numbers ranging from 19(175) to 298.(172) 
All 10 trials included behavioural interventions as an adjunct to pharmacological 
interventions, with some form of behavioural therapy provided to both the control 
and intervention study arms. See Table 4.20 and 4.21.  
The efficacy of bupropion as a cessation aid was investigated in five trials.(173-178) 
Two of these trials included adjunctive NRT (transdermal nicotine patch) in both the 
intervention and control arms.(173, 176) One trial also included nicotine gum, as 
required (that is, combination NRT as adjunctive therapy) in both arms.(173) The 
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efficacy of varenicline was assessed in two trials (n=1 schizophrenia or 
schizoaffective disorder; n=1 bipolar disorder).(181, 182) In each of these seven trials, 
the same behavioural intervention was delivered to both the intervention and control 
arm,(173-177, 181, 182) with the intensity ranging from nine to 12 once-weekly sessions. 
Three trials investigated the efficacy of different behavioural interventions. The first 
compared two types of group behavioural therapy − a generic programme and a 
programme tailored to those diagnosed with schizophrenia and schizoaffective 
disorder. NRT transdermal patches were used as adjunctive therapy in both 
arms.(178) One trial compared two types of individual counselling − both tailored to 
the mental health population, but varied by intensity. Again, both arms received 
adjunctive NRT (transdermal patch).(179) The remaining trial compared the use of an 
NRT transdermal patch plus individual behavioural therapy programme specifically 
tailored for a broader psychotic disorder population (comprising motivational 
interviewing and cognitive behavioural therapy) with routine care.(172)  
All data for the included studies were extracted. All 10 studies reported biochemically 
verified continuous abstinence, with five rated as having a high risk of bias, two low 
risk and three rated as unclear risk of bias. See Appendices 2 and 3 for full details of 
the included studies. Cessation interventions were classified as per Section 4.2.2.   
4.3.4 Results 
None of the studies identified included a mixed population attending secondary care 
mental health services. As such, the results are presented separately for those with 
a diagnosis of schizophrenia and schizoaffective disorder (Section 4.3.4.1), bipolar 
disorder (Section 4.3.4.2) and depression (Section 4.3.4.3).  
4.3.4.1 Schizophrenia and schizoaffective disorder 
Pharmacotherapy as an adjunct to behavioural interventions  
Five trials compared long-term smoking cessation (≥6 months) using bupropion as 
an adjunct to a behavioural intervention in the schizophrenia and schizoaffective 
disorder population. Participant numbers were small ranging from only 19(175) to 
59(176) patients, all community volunteers. The studies were based in the US and 
were undertaken between 2001(175) and 2008.(176) Of these, two trials also included 
adjunctive NRT (transdermal patch)(173, 176) or combination NRT(173) (transdermal 
patch plus nicotine gum up to 18mg per day as needed for cravings) in both the 
intervention and control arms. A transdermal patch with a dose of 21mg per day was 
used based on smoking rate of 21 cigarettes per day. One study inferred that the 
daily dose of NRT was tapered from 40mg per day down to 20mg per day over the 
course of the study.(173)  
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When used in conjunction with behavioural therapy and NRT (as mono- or dual 
NRT), bupropion was found to increase the likelihood of being abstinent at six 
months almost four-fold (RR=3.86, 95%CI: 1.01 to 14.80) in those with 
schizophrenia or schizoaffective disorder (Table 4.20). This was based on a small 
number of trials (n=2) with a small sample size (n=110), see Figure 4.13. Three 
earlier placebo-controlled trials showed no statistically significant effect for using 
bupropion as an adjunct to a behavioural intervention alone, again based on a small 
sample size (n=104), see Figure 4.14. Strong evidence does not exist for a 
difference in relative effect between bupropion as an adjunct to a behavioural 
intervention alone or in combination with NRT as the numbers of quitters was small 
across the groups. All studies included a lower initial dose (150mg per day), 
although one study (Evins et al. 2001) maintained this lower bupropion dose over 
the course of the study while the remaining studies increased to 300mg per day per 
licensed recommendations.(175) In addition, the one person who achieved smoking 
cessation in the study by Evins et al. (2001) was also on clozapine treatment. 
Although clozapine is not indicated for smoking cessation, there is evidence to 
suggest it may have an effect.(183) Removal of this study does not significantly affect 
the overall result.  
Due to the inherent differences between the studies (with or without NRT), the five 
trials have not been combined in a meta-analysis. However, they have been 
combined in previous high-quality systematic reviews which reported that the 
population was three times more likely to be abstinent at six months.(169, 170) As 
noted, the number of quitters was small in these studies. Absolute cessation rates 
were lower in the control group compared with the general population, with quit 
rates of approximately 7% across the control arms compared with 11% for the 
unselected adult population (see Section 4.2.5.3). This is despite the fact that the 
control arm in these trials typically included an intensive behavioural intervention 
involving weekly sessions for several weeks, with or without NRT. 
It is recommended that tests for funnel plot asymmetry are only used when there 
are at least 10 studies included in the meta-analysis, as the power of the tests is too 
low to distinguish chance from real asymmetry.(184) As such, an assessment of small 
study bias was not undertaken here.  
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Table 4.20 Summary of findings for schizophrenia or schizoaffective disorder 
Comparator Study (year) Included  
studies  
(n) 
Participants 
(n) † ‘ 
RR P 
value,  
overall  
effect 
Bupropion + behavioural intervention versus placebo + 
behavioural intervention 
Evins (2001) 
Evins (2005) 
George (2002) 
3 108 2.22 [0.52, 9.47] 0.28 
Bupropion + behavioural intervention + NRT versus placebo + 
behavioural intervention +NRT (¥both arms received transdermal 
patch, both received nicotine gum) 
Evins (2007)¥, 
George (2008) 
¥ 
2 110 3.86 [1.01, 14.80] 0.05 
Varenicline + behavioural intervention versus placebo + 
behavioural intervention 
Williams 
(2012) 
1 128 5.06 [0.67, 38.24] 0.12 
Group behavioural intervention (generic) + NRT (transdermal 
patch) versus group behavioural intervention (tailored to 
schizophrenia) + NRT (transdermal patch) 
George (2000) 1 45 0.88 [0.34, 2.23] 0.78 
High-intensity individual counselling + NRT (transdermal patch) 
versus lower intensity individual counselling + NRT (transdermal 
patch) (both arms tailored to mental health) 
Williams 
(2010) 
1 100 0.86 [0.30, 2.51] 0.79 
Individual counselling + NRT (transdermal patch) versus routine 
care (Counselling tailored to mental health) 
Baker (2006) 1 298 2.84 [0.74, 10.92] 0.13 
Note: Nicotine replacement therapy (NRT) was as an active comparator, that is to say, patients could not use NRT on its own. RR: Risk Ratio.  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
142  
Figure 4.13  Bupropion + behavioural intervention with NRT versus 
placebo + behavioural intervention with NRT in the 
schizophrenia and schizoaffective disorder population 
 
 
 
Figure 4.14  Bupropion + behavioural intervention versus placebo + 
behavioural intervention in the schizophrenia and schizoaffective 
disorder population 
    
 
 
One study (Williams 2012) sponsored by Pfizer assessed the efficacy of varenicline 
with adjunctive behavioural therapy on long-term smoking cessation (≥6 months) in 
patients with schizophrenia or schizoaffective disorder in a placebo-controlled 
trial.(181) Trial participant numbers were small (n=128), recruited from community 
volunteers in the US. Varenicline was administered per standard licensed 
recommendations. The behavioural intervention comprised weekly smoking 
cessation counselling (less than 30 minutes per session) for 12 weeks. Varenicline 
was not associated with a statistically significant treatment effect compared with the 
placebo arm (n=128, RR 5.06, 95% CI 0.67 to 38.24, p=0.12), see Table 4.20. The 
study authors noted that there were nine serious adverse events in the varenicline 
group, two of which were considered to be related to varenicline use. There was one 
serious adverse event in the control arm.  
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One study (George 2000) assessed the long-term (≥6 months) smoking cessation 
results of two different group behavioural therapy programmes; adjunctive therapy 
with NRT transdermal patches was provided to both the intervention and control 
arms.(178) A total of 45 people who met the DSM-IV criteria for schizophrenia or 
schizoaffective disorder and nicotine dependence were randomised to either a 
cessation programme specialised to those with schizophrenia or a generic smoking 
cessation intervention programme developed by the American Lung Association. The 
generic programme comprised a standard seven-week group behavioural therapy 
programme followed by supportive group counselling during the remaining three 
weekly group sessions. Each session lasted 60 minutes. The specialised 
schizophrenia smoking cessation programme included three weeks of motivational 
enhancement therapy and seven weeks of psychoeducation, social skills training, 
and relapse prevention strategies. A quit date was set during week three of both 
programmes. There was no evidence of a treatment effect associated with 
specialised smoking cessation group counselling sessions  at six months follow up 
(n=45, RR 0.56, 95% CI 0.10 to 3.16, p=0.51), see Table 4.20. 
One study (Williams 2010) reported long-term (≥6 months) smoking cessation 
results comparing two intensities of individual behavioural therapy. Adjunctive 
therapy with NRT transdermal patches was provided to both the intervention and 
control arms.(179) The study aimed to assess therapies which could be integrated into 
standard individual mental health treatment sessions. A total of 100 people who met 
the DSM-IV criteria for schizophrenia or schizoaffective disorder and nicotine 
dependence were included. The behavioural programmes included the Treatment of 
Addiction to Nicotine in Schizophrenia programme and the Medication Management 
programme. Treatment of Addiction to Nicotine in Schizophrenia is a high-intensity 
treatment of 24 sessions (45 minutes each) delivered over 26 weeks. It incorporates 
motivational interviewing, social skills training, use of NRT, and relapse prevention 
techniques. Behavioural intervention was delivered by mental health clinicians 
trained in smoking cessation interventions. The Medication Management programme 
is a moderate intensity treatment of nine sessions (20 minutes each) over 26 weeks. 
Brief advice on monitoring psychiatric symptoms and understanding medication 
interactions with tobacco is given to the patient in the Medication Management 
programme. A quit date was set during week five for both programmes. Both 
approaches used an active, educational approach and therapists were encouraged to 
develop a collaborative and focused working alliance with clients. Treatment 
manuals, training programmes, and training materials were developed to accompany 
the two approaches. At six-months follow up there was no statistically significant 
difference (n=76, 0.86 [0.30, 2.51] p=0.79), see Table 4.20. The authors noted that 
participants who had better attendance at individual sessions had better outcomes in 
terms of smoking cessation and reduction.  
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Baker et al. (2006) reported long-term smoking cessation results (≥6 months) 
comparing individual counselling plus NRT in the form of transdermal patches versus 
routine care.(172) A total of 298 people who met an ICD-10 diagnosis of psychotic 
disorders were included. Of these, 126 had a diagnosis of schizophrenia and 43 had 
a diagnosis of schizoaffective disorder (56.7%). Referrals were received from 
Australian community health agencies (82.2%), inpatient psychiatric units (8.3%), 
and the Neuroscience Institute of Schizophrenia and Allied Disorders schizophrenia 
register (7.0%). The behavioural programme comprised an eight-session, 
individually administered smoking cessation programme consisting of motivational 
interviewing and cognitive behaviour therapy. At six-months follow up those 
receiving this combined care were more likely to be abstinent compared with routine 
care, although this result was not statistically significant (n=298, RR 2.84, 95% CI 
0.74 to 10.92, p=0.13), see Table 4.20. Consistent with the findings of Williams et 
al., the authors noted a trend towards improved smoking cessation and reduction 
rates in those participants who had better attendance at individual sessions. 
As noted in Chapter 3, smoking cessation may have a negative effect on mental 
health symptoms. Limited data were reported in relation to mental health symptoms 
in the trials identified. George et al. (2002) reported that bupropion did not alter 
positive symptoms of schizophrenia, but significantly reduced negative 
symptoms.(177) In a later study by George et al. (2008), where NRT was provided to 
both study arms, they did not report a difference between positive or negative 
symptoms.(176)  
4.3.4.2 Bipolar disorder 
Behavioural interventions as an adjunct to pharmacotherapy 
The UK Centre for Tobacco Control Studies review retrieved one study which 
assessed bupropion in patients with bipolar disorder who were attending secondary 
care mental health services. This was limited to a pilot study of five people and did 
not meet our inclusion criteria.  
One study (Chengappa 2014) was retrieved in the updated search. Chengappa, 2014 
compared brief advice as an adjunct to varenicline in a placebo-controlled trial. A 
total of 60 clinically stable adults who met the DSM-IV criteria for bipolar disorder 
were recruited from the community in the US. The majority (82%) had bipolar I 
disorder. Brief advice consisted of 15 minutes of each visit dedicated to smoking 
cessation counselling. There was no statistically significant difference between the 
comparators at six-months follow up (n=60, 2.84, 95% CI 0.61 to 12.81, p=0.18), 
see Table 4.21. Absolute cessation rates were lower in the control group 
(approximately 7%) compared with that seen in the general unselected adult 
population (average 11% see Section 4.2.5.3).   
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Table 4.21.  Summary of findings 
Comparator Study  
(year) 
Studies  
(n) 
Participants 
(n) 
RR p value,  
overall  
effect 
Bipolar Disorder 
Varenicline + brief 
advice versus placebo 
+ brief advice 
Chengappa  
(2014) 
1 60 2.81 [0.61, 
12.81] 
0.18 
4.3.4.3  Depression 
The 2012 UK Centre for Tobacco Control Studies review assessed the effectiveness 
of smoking cessation interventions in users of secondary care mental health services, 
including studies for patients with a diagnosis of depression. Four of the 51 studies 
were for those with a diagnosis of depression. However, these have not been 
included on the basis of the interventions assessed (n=2), duration of follow up 
(n=1) and study design (n=1), see Appendices 4, 5 and 6 for full details of excluded 
studies.  
A Cochrane review by Van der Meer et al. (2013), including a total of 49 randomised 
controlled trials (RCTs), reviewed a range of smoking cessation interventions in 
individuals with either a current (n=33) or past diagnosis of depression (n=26).(171) 
Some of the interventions included (for example, fluoxetine, paroxetine, naloxone) 
are not applicable to this review. As noted, this assessment is limited to smoking 
cessation interventions in those attending secondary mental health services. Studies 
assessing interventions for those with a past history of depression were deemed not 
applicable as, unless stated otherwise, it was assumed that the majority would not 
be attending secondary care mental health services. From the studies reviewing 
smoking cessation interventions in those with a current diagnosis of depression, 10 
met the inclusion criteria. However, it was not clear if all included populations were 
attending secondary care mental health services. As such, these 10 studies were not 
included in this assessment. No additional studies were retrieved in the updated 
search.  
4.3.5 Discussion 
A systematic review of the effectiveness of smoking cessation interventions in users 
of secondary mental health services was undertaken. Limited evidence was retrieved 
from mainly small trials with small participant numbers (for example, participant 
numbers ranged from 19 to 298). Absolute cessation rates were lower in comparison 
with the general population. Average quit rates in the control arms were 
approximately 7% versus 11% for the unselected population (see Section 4.2.5.3), 
despite the fact that the control arm in these studies typically included an intensive 
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behavioural intervention with or without NRT. The combination of low control arm 
cessation rates and the small numbers of participants resulted in some large, but not 
statistically significant treatment effects. 
Relevant data were only identified for the schizophrenia and schizoaffective disorder 
and bipolar disorder populations. However, based on a recent Health Research 
Board study, these populations represent the main diagnoses associated with 
admissions in general hospital psychiatric units, psychiatric hospitals and 
independent or private charitable centres.(185) It estimates that depressive disorders 
amount to 29.7% of the total admissions, followed by schizophrenia, schizotypal and 
delusional disorders (13.1%), followed by neuroses amount (12.6%). Admission 
rates were higher in the private compared to the public setting for depression only. 
Patients with schizophrenia or schizoaffective disorder populations who used 
bupropion as an adjunct to a behavioural intervention plus NRT (monotherapy or 
combination NRT) were found to be almost four times more likely to be abstinent at 
six months in placebo-controlled trials. This was based on a small number of trials 
(n=2) with a small total sample size (n=110). Three earlier trials showed no 
statistically significant effect for bupropion when used as an adjunct to a behavioural 
intervention only, again based on a small sample size (n=104). This review agrees 
with previous high-quality systematic reviews.(169, 170) A meta-analysis of these five 
trials was not conducted based on their inherent differences, but have been 
combined in previous reviews reporting that a behavioural intervention with or 
without NRT as an adjunct to bupropion was three times more effective in this 
population.  
One placebo controlled trial was identified which indicated that varenicline used as 
an adjunct to a behavioural intervention increases abstinence rates at six months 
compared with behavioural therapy alone in patients with schizophrenia, although 
this was not statistically significant. This is in agreement with two recent systematic 
reviews which assessed varenicline in the schizophrenia population (2015)(186) and in 
a broader population of serious mental illness (2016)(187), neither of which found 
evidence of effect. These reviews reported a statistically significant beneficial effect 
for varenicline on smoking reduction, but the results were very heterogenous 
(I2=89%). Both reviews included additional studies which were not applicable to this 
review. For example, some reported short-term results or included patients with 
concurrent alcohol and nicotine dependence. One placebo-controlled study was 
identified which found no statistically significant effect for varenicline when used as 
an adjunct to brief advice, compared with brief advice alone in patients with bipolar 
disorder. 
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The Cochrane review by van der Meer et al. (2013) reviewed a range of 
interventions in both current and past depression. However, it was unclear if all 
included populations were attending secondary care mental health services, so none 
of the studies met the inclusion criteria of this assessment. The 11 trials reported a 
significant positive effect for a range of behavioural interventions which they termed 
psychosocial mood management in the current depression population (RR 1.47, 95% 
CI 1.13 to 1.92, n=1,844). The interventions generally compared a standard 
smoking cessation counselling intervention to that alongside cognitive behavioural 
intervention focused on depression.  
The 2012 UK Centre for Tobacco Control Studies review reported that the 
combination of bupropion with NRT may be effective for smoking cessation in 
populations with schizophrenia. However, it concluded that further high-quality 
research is urgently required the areas of smoking cessation, smoking reduction, and 
temporary abstinence in secondary care mental health service settings.(169) 
Clinical guidelines recommend that NRT can be used as a first line therapy for all 
smokers.(188) While no trials were identified that explicitly investigated the efficacy of 
NRT in those attending secondary mental health services, trials reporting use of NRT 
(as monotherapy or combination) as an adjunct to either behavioural therapy, 
bupropion, or a combination thereof were identified, with absolute quit rates of 
approximately 9% in the control arms incorporating NRT. One recent large scale and 
good quality RCT, requested by the FDA (Eagles trial), reported on the 
neuropsychiatric safety and efficacy of varenicline, bupropion, and NRT (in the form 
of a transdermal patch) in smokers with (n=4,116) and without psychiatric disorders 
(n=4,028).(36) The cohort of psychiatric disorders included people with a primary 
diagnosis per DSM-IV-TR for a range of Axis I and II disorders such as mood 
disorders, post-traumatic stress disorder and psychotic disorders. Only patients with 
psychiatric disorders who were stable and treated, or who had previous psychiatric 
conditions that were in remission were included. This trial did not meet the inclusion 
criteria of this study for participants to be attending secondary care mental health 
services.  
The trial found that the odds ratios for efficacy did not differ as a function of 
psychiatric status.(36) More specifically, at two to six-months follow up, participants 
who took varenicline or bupropion or transdermal patch had a significant rate of 
abstinence when compared with placebo. The odds ratios were varenicline 1.77 
(95% CI 1.33 to 2.36), bupropion 2.50 (95% CI 1.90 to 3.29) and transdermal patch 
1.65 (95% CI 1.24 to 2.20). In addition, participants who took varenicline had a 
higher rate of abstinence compared to transdermal patch and compared to 
bupropion (OR 1.51 95% CI 1.19 to 1.93; OR 1.41 95% CI 1.11 to 1.79). No 
significant difference was reported between bupropion and transdermal patch. No 
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significant increase in rates of neuropsychiatric adverse events were found with 
either varenicline or bupropion use relative to transdermal NRT patch or placebo. 
This study, and many of the studies reviewed, included a dose of 21mg per day with 
taper for the mental health population. However, given the fact that this population 
typically has higher nicotine dependence, it is possible that the dose of NRT provided 
was suboptimal.  
A US population survey carried out in 2012 (n=10,041) reported that individuals with 
a mental health condition (n=1,905) were more likely to have tried e-cigarettes 
(14.8%) and to be current users of e-cigarettes (3.1%) compared to the general 
population (6.6% and 1.1%, respectively; p<0.01).(189) However, limited studies 
were retrieved which assessed e-cigarette use in the mental health population. Of 
those retrieved, none were applicable as for example, the trials were not focused on 
cessation, the participants were not attending secondary care mental health services 
or there was no comparator group. One large scale trial carried out a secondary 
analysis of e-cigarettes compared with NRT in the mental health population 
(ASCEND trial, n=86).(190) The mental health population was defined as those 
reporting use of at least one medication associated with mental illness 
(antidepressants 72%, antipsychotics 28%, 14% hypotics or sedatives; 9% 
anxiolytics, 1% addictive disorder medications). Those with uncontrolled psychiatric 
or current chemical dependence were excluded. No statistically significant difference 
in cessation rates was found at six-months. 
Smoking cessation has the potential to deliver significant health benefits for smokers 
and their families, including those with mental health problems. For those using 
secondary care services, there are additional advantages, such as reduced length of 
stay in hospital, lower drug doses, fewer complications, higher survival rates, better 
wound healing, decreased infections and fewer re-admissions after surgery.(191) 
However, the mental health population smokes more than the general population.  
Why does the mental health population smoke more and are less likely to 
quit? 
A study in the US reported that the decline in smoking from 2004 to 2011 was 
significantly higher in the general population than in mental health populations.(124) 
They suggested that control policies and smoking cessation interventions for the 
general population were not as effective in mental health populations. Approximately 
one-third of people with mental health problems(192, 193) and two-thirds of people in 
psychiatric units smoke.(194) Smoking prevalence is particularly high in the 
schizophrenia population (70-80%)(172, 195) compared with other mental health 
diagnoses (50%).(196)  
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Theories to explain the high smoking prevalence and low cessation rate in serious 
mental illnesses They include the belief that ‘smoking improves mental health or 
relieves stress’.(197, 198) This relates to the ‘self-medication hypothesis’, where despite 
the health consequences of smoking this population may continue to smoke to 
alleviate symptoms associated with their disorder. Smoking is reported to increase 
the metabolism of some antipsychotic drugs,(91) with some smokers potentially using 
cigarettes to relieve the side effects of these drugs. It is also reported that it is more 
probable that smoking relieves psychological disturbances produced by smoking 
withdrawal itself.(199) In the US, tobacco industry internal documents were released 
showing that the industry made several indirect and direct efforts to slow down the 
reduction of smoking in people with schizophrenia.(200, 201)  
Eighty percent of people with schizophrenia or schizoaffective disorder are reported 
to have impairment in their cognitive function.(202) This is associated with difficulties 
in filtering out unnecessary information,(203) poor clinical and functional outcomes, 
and poor community integration.(204) These deficits may be associated with a 
vulnerability factor (termed the addiction vulnerability hypothesis) towards the 
initiation and maintenance of tobacco use.(204) In addition, pre-clinical evidence has 
shown positive effects of nicotine administration on neurocognition which appear to 
be more pronounced in smokers with schizophrenia.(204) This altered processing may 
require adaptations from traditional smoking cessation methods.  
Other factors reported to play a role in the increased prevalence of smoking and 
lower smoking cessation rate in mental health populations include: social factors 
such as unemployment, low educational attainment, peer influence and lack of 
smoking cessation treatment in mental health systems;(205) increased risk-taking 
behaviour and poor lifestyle choices;(206) shared environmental influences;(207) and 
difficulties forming a therapeutic alliance.(179) Barriers to cessation include: heavier 
nicotine dependence;(208) lower awareness of the harms of smoking; being unaware 
or having misconceptions about cessation services; perceived cost and time to 
access, for example, NRT; financial stress; lack of support for quitting among family 
and friends; lower levels of confidence in ability to stop smoking; regarding smoking 
as their ‘only pleasure’; and relieving boredom.(208) A heavier nicotine dependence 
relates not only to an increased number of cigarettes smoked, but also to the fact 
that they extract more nicotine from each cigarette which makes it more difficult to 
quit.(195, 209, 210)  
Why are there are limited studies in this cohort?  
Few studies, in particular few large-scale good-quality studies, have assessed 
smoking cessation interventions in the mental health population. Recruitment of 
patients to RCTs from mental health populations is reported as problematic and may 
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be due to concerns about their potential vulnerability and reduced decision-making 
capacity.(211) Patients may distrust the proposed research and the healthcare system 
in general.(212) In addition, responsibilities associated with participation, for example, 
more frequent and longer appointments, additional tests or assessments such as 
expired carbon monoxide testing, may further impact recruitment rates.(212) While 
mental health problems (including mild to moderate depression and anxiety 
disorder) are very prevalent, the prevalence of serious mental illness is lower. As 
such, there is a low pool of people to draw from for RCTs. For example, in the 
Healthy Ireland survey (2015) probable mental health problems are indicated by 9% 
of the Irish population aged 15 and over.(213) Welcome Trust data show that less 
than one in three trials of the general mental health population successfully achieved 
their recruitment targets within their predicted time frame.(214) This leads to 
extended recruitment periods and increases in study costs, and may help to explain 
why there are limited data in these populations for smoking cessation. In addition, 
the population of users of secondary care mental health services adds further limits.  
Most large scale, good trials of interventions in the mental health population focus 
on assessing adverse effects.(36) Large RCTs of ‘unselected’ populations do not 
typically exclude those with a mental health problem. As such, it may be thought 
that any evidence of effectiveness in this unselected population may be translated to 
a mental health population. Some systematic reviews report that, for example, the 
efficacy of NRT as a smoking cessation intervention in those with depression is 
comparable to that seen in the general population.(215) However, this may be 
dependent on whether the person is currently experiencing depression or has a past 
history of depression. Also, previous guidelines noted the paucity of studies in 
mental health populations and made recommendations based on evidence obtained 
in an unselected population.(188) Available systematic reviews of smoking cessation 
interventions in those with diagnosed mental health conditions demand further 
research in this population.(169-171)  
Why is there limited evidence of effectiveness? 
Our primary outcome of interest was smoking cessation at six months follow-up 
based on recommendations from the Society for Research on Nicotine and 
Tobacco.(216) Shorter term data are available, but were not included in our 
assessment. However, it is postulated that risk reduction, through reducing the 
number of cigarettes smoked per day, as opposed to cessation may be an 
appropriate outcome to consider in this population. Reduction has been reported as 
increasing the probability of cessation.(217) Since this population are more likely to be 
heavy smokers, researchers have speculated that focusing on an initial reduction 
may reduce nicotine levels which may help with future cessation.(170) Evidence that 
combination NRT (such as transdermal patch plus gum) is more effective than 
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monotherapy may also be relevant to the mental health population, particularly 
given the higher prevalence of heavy smokers in this group. 
Low motivation or desire to quit was reported in some studies (for example, one in 
three were motivated to quit in trials of bupropion as adjunctive therapy) and may 
be an important factor.(173, 174) It has previously been reported that patients with 
schizophrenia are often in the earlier stages of motivation to quit in comparison to 
the general population. 
4.4 Clinical effectiveness in women during pregnancy 
4.4.1 Search strategy 
This systematic review aims to assess the effectiveness of smoking cessation 
interventions in women during pregnancy.  
Searches were carried out for recent systematic reviews of eligible smoking 
cessation interventions in women during pregnancy. Where high-quality systematic 
reviews were available for relevant interventions, these were used to identify studies 
matching the inclusion criteria outlined above. The reviews identified were updated 
with any additional studies that have emerged since the original review was 
published. Electronic searches were conducted in Medline, Embase and the Cochrane 
Register of Clinical Trials to identify randomised controlled trials comparing any 
eligible smoking cessation intervention in women during pregnancy to another 
eligible intervention or to no treatment. The results of these searches were 
combined with each of the individual systematic reviews.  
Full details of the search are provided in Appendix 9 of this document. The PICOS 
(Population, Intervention, Comparator, Outcomes, Study design) analyses used to 
formulate the search are presented in Table 4.22. Unlike the reviews for unselected 
adults and those attending secondary care mental health services, no lower age limit 
was set for this review. 
Table 4.22 PICOS criteria for study eligibility 
Population  Women who smoke during pregnancy 
Intervention   Nicotine replacement therapy (NRT), such as 
gum, transdermal patches, nasal and oral spray, 
inhalers and tablets or lozenges 
 Electronic cigarettes 
 Nicotine receptor partial agonists (cytisine or 
varenicline only) 
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 Antidepressants (bupropion only) 
 Behavioural or psychosocial interventions; 
including counselling, health education, financial 
incentives, feedback and social support 
Comparator  No treatment (or placebo) or another eligible 
intervention. 
Outcomes  Self-reported abstinence from smoking during 
pregnancy, measured at the latest point prior to birth 
(point prevalence abstinence). Continuous abstinence 
measures timed from the date of randomisation, 
where available, are used in preference to point 
prevalence abstinence measures. Biochemically 
validated abstinence data, where available, are used 
in preference to self-reported data. 
Study design  Randomised controlled trials 
Two systematic reviews relevant to this HTA were identified; both were Cochrane 
reviews (Table 4.23).(218) (219) The first Cochrane review reviewed psychosocial 
interventions for supporting women to stop smoking in pregnancy and the second 
reviewed pharmacological interventions for promoting smoking cessation during 
pregnancy. Updated searches were conducted for additional studies that have 
emerged since both of these original reviews were published. The searches were 
restricted to studies published between January 2013 and October 2016 for 
psychosocial interventions and to studies published between January 2015 and 
October 2016 for pharmacological interventions. 
Table 4.23 Identified systematic reviews and results of updated search 
Review (year) Intervention Primary 
studies 
Updated 
search 
Chamberlain et al. (2013) Psychosocial 86 5 
Coleman et al. (2015) Pharmacological  9 0 
Note: search updated to October 2016  
The RCTs included in the systematic review by Coleman et al. met the inclusion 
criteria for this review.(219) The extension of the systematic review from January 
2015 to October 2016 did not identify any additional relevant RCTs. 
For psychosocial interventions in pregnancy, 59 of the 86 studies in Chamberlain et 
al. met the inclusion criteria for this review. An updated search (from January 2013 
to October 2016) identified five additional studies.(220-224) A flow diagram of this 
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search is provided in Appendix 9. Studies that did not meet the eligibility criteria 
were excluded for the following reasons: 
 participants were not adequately randomised,  
 population was not pregnant women or the intervention was not primarily aimed 
at cessation during pregnancy (for example, pre-pregnancy interventions, 
postpartum interventions, interventions aimed at the partners or families of 
pregnant women),  
 the trial did not study the effectiveness of a behavioural intervention (for 
example, a trial evaluating the effectiveness of a pharmacological agent whereby 
a similar behavioural intervention was provided in both arms), 
 primary cessation outcomes were not adequately reported, or not reported 
separately from spontaneous quitters, 
 and pregnant women belonged to a specific patient group, for example, studies 
where only drug or alcohol-dependent women were recruited. 
4.4.2 Identification of trials 
The primary outcome of interest for this analysis was smoking abstinence in late 
pregnancy (taking the latest measure prior to birth). Continuous abstinence, where 
available, was taken in preference to point prevalence. Biochemically validated 
outcomes were preferred over self-reported outcomes. Secondary outcomes include 
postnatal abstinence and obstetric and neonatal outcomes. For the purpose of this 
review, individual psychosocial interventions were categorised into five broad 
intervention groups: 
1. Counselling: interventions that provide support to increase problem solving 
and coping skills and increase motivation to quit. A broad range of 
interventions may fulfil these goals, including motivational interviewing, 
cognitive behaviour therapy, psychotherapy and so on. Interventions may be 
delivered face-to-face, by telephone or by interactive computer programmes. 
A range of healthcare providers may offer these interventions. 
2. Health education: interventions involving the provision of information about 
the risks of smoking and advice to quit. However, further advice or support is 
not delivered (unlike counselling interventions). 
3. Feedback: interventions involving the provision of information about the 
fetal health status or of by-products of tobacco smoking to the mother, such 
as ultrasound monitoring of the fetus or expiratory carbon monoxide 
measurement. Measurements in studies taken purely for the purposes of 
verification of smoking status are not included. 
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4. Incentive-based interventions: interventions involving a financial reward 
for abstinence, contingent on verification of the smoking cessation. Receipt of 
money or gift vouchers merely for participation in the trial is not included. 
5. Social support (peer or partner): these include where the intervention 
explicitly included provision of support from a peer or partner as a strategy to 
promote smoking cessation.  
A total of 73 relevant studies were identified, published between 1976 and 2016 
(Table 4.24). Data were only extracted for study arms relevant to this HTA. The 
relevant number of trial participants ranged from 17 to 1,885 (mean 364, standard 
deviation 346). These studies are listed in full in Appendix 10. Appendix 11 lists all 
the excluded studies. 
Studies were also graded on quality, based on assessments using the Cochrane risk 
of bias tool. Studies at low risk of bias were considered high quality. Overall, seven 
percent of studies (n=5) were considered high quality, all of which were studies of 
pharmacological interventions. 
Studies recorded abstinence either through self-reports or some form of biochemical 
verification, such as cotinine levels. Biochemical verification is preferred as it is less 
prone to bias. Across all studies, 81% used biochemical verification, although the 
percentage varied between studies of pharmacological agents (100%) and 
behavioural interventions (78.1%). For the purpose of this review, the latest 
measure of abstinence prior to delivery (late pregnancy) is used. Some trials report 
on post-partum abstinence, with the longest follow up of 12 months post-partum 
reported in two trials. 
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Table 4.24 Identified primary studies and main characteristics (pregnancy) 
Intervention Studies 
n 
Participants 
(n) 
High 
quality 
 n (%) 
Biochemically 
verified 
n (%) 
Continuous 
abstinence 
 n (%) 
Mean (SD) 
years since 
publicatio
n 
   
Acupuncture  0      
Bupropion 1 11 0 (0) 1 (100.0) 0 1 
Combination NRT 0 - - - - - 
Cytisine 0 - - - - - 
Electronic cigarettes 0 -     
NRT 8 2,199 5 (62.5) 8 (100.0)  2 (25) 8.4 (5.3) 
NRT + bupropion 0 - - - - - 
NRT + varenicline 0 - - - - - 
Varenicline 0 - - - - - 
Varenicline + bupropion 0 - - - - - 
Counselling 44 18,249 0 (0) 35 (79.6) 3 (6.8) 16.6 (8.2) 
Feedback 4  700 0 (0) 3 (75.0) 0 (0.0) 18.8 (11.3) 
Health education 6  1,425 0 (0) 3 (50.0) 1 (16.7) 18.2 (12.0) 
Financial incentives  3 743 0 (0) 3 (100.0) 1 (33.3) 2.0 (1.7) 
Social support 7  800 0 (0) 6 (85.7) 0 (0.0) 11.7 (4.4) 
Notes: NRT, nicotine replacement therapy; SD, standard deviation.
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Interventions were categorised according to the primary strategy employed. 
However, many interventions, particularly counselling interventions, incorporate 
several components. For this reason, further subgroups were created:  
 single intervention (whereby only one main strategy was used),  
 multiple intervention (whereby several strategies were used),  
 and tailored intervention (whereby additional strategies were available which 
were optional to women). 
The care received by the comparator group in these studies varied widely. A 
distinction was made in this analysis between ‘Usual Care’ – whereby the control 
group received the routine antenatal care provided to the population, and ‘Less 
Intensive Intervention’ – whereby the control group received some element of the 
intervention, albeit at a less intensive level. 
Levels of heterogeneity in all pooled analyses were examined using the I² statistic 
along with the Q-statistic. A substantial degree of heterogeneity was expected in the 
analysis of psychosocial interventions given the breadth and variability in the 
interventions. In an attempt to minimise heterogeneity, each psychosocial category 
is reported on separately (counselling, health education, feedback, incentive, and 
social support). Subgroups are also reported based on the comparator (‘usual care’ 
or ‘less intensive intervention’). Finally, studies were analysed based on intervention 
components (whether it was provided as a single, tailored or multiple component 
intervention). 
4.4.3 Pharmacological interventions for smoking cessation in 
pregnancy  
Nine trials, published between 2000 and 2014, were identified. Eight studied the use 
of NRT in pregnancy(225-232) and one studied the use of bupropion in pregnancy.(233) 
No trials investigating electronic nicotine delivery systems (e-cigarettes) or other 
smoking cessation pharmacotherapies such as varenicline, in pregnancy, were 
identified. Details of the study population, treatment regimens and outcomes for all 
included studies are provided in Appendix 10. 
4.4.3.1 NRT in pregnancy 
Five of the eight trials compared NRT and behavioural cessation support with 
placebo patch and behavioural cessation support.(225-229) Three trials compared NRT 
and behavioural cessation support with behavioural cessation support alone.(230-232) 
Intervention was in the form of transdermal patches in six trials, and in the form of 
2mg of NRT gum daily in one trial.(225) Another trial gave participants a choice of 
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transdermal patches, lozenges or 2mg of gum.(231) Over half (59%) of participants 
chose transdermal patches. The risk of bias was rated as high in three studies.(230-
232) Two studies reported continuous abstinence at birth.(219, 227) Self-reported 
abstinence was validated biochemically in all the studies. Six of the eight studies only 
recruited women in the second trimester of pregnancy. One study recruited women 
in the first trimester (median 17 weeks’ gestation, IQR 15 to 20),(227) and another 
study recruited women up to 30 weeks’ gestation.(232) 
A meta-analysis of the effect of NRT on smoking abstinence in late pregnancy 
showed a 41% increased likelihood for smoking cessation in late pregnancy (RR 
1.41; 95% CI: 0.99 to 2.00; p=0.054) (Figure 4.15). The 2015 Cochrane review 
reported a statistically significant relative risk of 1.41 for smoking cessation in late 
pregnancy (95% CI: 1.03 to 1.93).(219) Continuous abstinence data were reported in 
two trials, but the Cochrane review only included continuous abstinence data from 
one trial.(226)It included point prevalence abstinence data from the remaining seven 
trials. In keeping with the review protocol, continuous abstinence data were used in 
this review which explains the difference between the results of the Cochrane review 
and this review.  
Figure 4.15  Abstinence in late pregnancy: forest plot of studies comparing 
NRT versus control 
 
Low compliance rates substantially limited the assessment of safety.(226) Studies 
were underpowered to detect an effect of NRT on safety including obstetric and or 
neonatal outcomes. Analyses for obstetric and neonatal outcomes were conducted 
for singleton births only. Obstetric and neonatal outcomes were considered as 
secondary outcomes in all but one trial, which included a primary outcome measure 
for the newborn baby.(227) This trial was not sufficiently powered to detect an effect 
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of NRT on mean birth weight. The mean birth weight was 3065g (standard error 
44g) in the NRT group and 3015g (standard error 44g) in the placebo patch group. 
The clinical significance of a mean difference of 50g in birth weight between the two 
groups is uncertain. The safety of smoking cessation interventions in pregnancy is 
discussed in more detail in Chapter 5. 
NRT had no effect on the rate of preterm birth prior to 37 weeks’ gestation or on the 
rate of birth weight less than 2.5kg.(225-228, 232) (231) There was no effect on rates for 
late miscarriage, stillbirth, admission to the Neonatal Intensive Care Unit or neonatal 
death.(225-227) (231) NRT had no effect on the rate of Caesarean section or the rate of 
congenital abnormality.(226, 227) 
Three of the eight studies of NRT reported smoking cessation rates at three months 
postpartum.(225, 228, 231) Two of these reported biochemically validated seven day 
point prevalence smoking cessation rates.(225, 231) Participants in the third study were 
interviewed by telephone at three months and one year postpartum.(228) Self-
reported smoking cessation was not confirmed biochemically. Use of NRT during 
pregnancy had no effect on smoking cessation rates at three months or one year 
postpartum. 
Two studies recorded the rate of partner smoking, both reporting rates of 
approximately 74%.(226, 229) Antenatal support programmes for women and their 
partners need to focus on the health benefits of life-time abstinence for the woman, 
her partner and children.(230) 
4.4.3.2 Bupropion in pregnancy 
One pilot trial (n=11) compared bupropion and behavioural cessation support with 
placebo and behavioural cessation support.(233) The feasibility of the trial was 
challenging and the risk of bias was unclear. None of the five women randomised to 
bupropion reported abstinence after eight weeks of treatment (late pregnancy), 
while two of the six women randomised to placebo reported abstinence. Bupropion 
had no effect on biochemically validated or self-reported seven day point prevalence 
smoking abstinence rates in late pregnancy. Obstetric and neonatal outcomes 
mentioned in the study methods were not reported. 
4.4.4 Psychosocial interventions for smoking cessation in 
pregnancy 
Sixty-four trials, published between 1976 and 2016, were identified.  
Psychosocial interventions were classified into five broad categories (counselling, 
social support, health education, feedback and financial incentives). Counselling was 
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the most frequently studied psychosocial intervention (68.7%), followed by social 
support (10.9%), health education (9.4%), feedback (6.3%) and financial incentives 
(4.7%). Psychosocial interventions, apart from financial incentives (n=3), were 
categorised into single interventions (n=23), multiple interventions (n=30) or 
tailored interventions (n=8). Psychosocial interventions, apart from financial 
incentives (n=3), were compared with usual care (n=32) or less intensive 
intervention (n=29). Details of the study population, treatment regimens and 
outcomes for all of the included studies (n=69) are provided in Appendix 10.   
Gestation at recruitment to the trials of psychosocial interventions spanned all three 
trimesters. Six of the 44 counselling trials had a gestational cut-off of less than or 
equal to 32 weeks’ gestation,(234) (234-239) two had a cut-off of less than or equal to 
30 weeks’ gestation,(240, 241) and one had a cut-off of less than or equal to 36 weeks’ 
gestation.(242) 
Only one of the six health education trials recruited participants in the first 
trimester.(243) One trial recruited 72.5% (n=145) of participants in the first 
trimester.(224) Three trials recruited participants up to a gestational cut-off of less 
than 21 weeks’ gestation,(244) less than or equal to 24 weeks’ gestation(245) and less 
than 28 weeks’ gestation,(246) while one trial recruited women at any gestation.(247) 
Ideally, health education interventions should begin before pregnancy or in the first 
trimester.  
4.4.4.1 Health education 
Health education (n=6) was an effective intervention for smoking abstinence in late 
pregnancy, with a risk ratio of 1.43 (95% CI: 1.07 to 1.92).(224, 243-247) Subgroup 
analysis revealed that health education compared with ‘less intensive care’ (n=3) 
was effective with a risk ratio of 1.44 (95% CI: 1.04 to 1.99).(224, 243, 244) The 
effectiveness of health education compared to ‘usual care’ (n=3) however, was not 
found to be significant (RR 1.51; 95% CI 0.64 to 3.59).(245-247) No significant 
heterogeneity was observed.  
4.4.4.2 Counselling 
Counselling was also found to be an effective intervention for smoking abstinence in 
late pregnancy, with a risk ratio of 1.35 (95% CI: 1.17 to 1.57) (Figure 4.16). 
Subgroup analysis demonstrated that the effectiveness of counselling was similar 
between the ‘usual care’ comparator group (RR 1.33; 95% CI 1.12 to 1.58, n=26 
studies) and the ‘less intensive intervention’ group (RR 1.34; 95% CI 1.04 to 1.72, 
n=18 studies). Subgroup analysis did not demonstrate a large difference in 
effectiveness of counselling grouped by ‘single intervention’ (RR 1.27; 95% CI 1.02 
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to 1.58; n=16 studies), ‘tailored intervention’ (RR 1.39; 95% CI 0.99 to 1.95, n=6 
studies) or ‘multiple intervention’ (RR 1.39; 95% CI 1.1 to 1.75, n=22 studies).   
The evidence in many of the comparisons was subject to heterogeneity. The 
comparisons for which heterogeneity was a concern were counselling versus ‘less 
intensive’ (n=18, I2=0.73) and counselling (multiple intervention) versus control 
(n=22, I2=0.7). Figures 4.16, 4.17 and 4.18 demonstrate the forest plots of all 
studies comparing counselling versus control, subgroup analysis of counselling 
versus ‘less intensive’, and subgroup analysis of counselling (multiple intervention) 
versus control. 
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Figure 4.16  Forest plot of studies comparing counselling versus control 
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Figure 4.17  Forest plot of studies comparing counselling versus ‘less  
  intensive’ 
 
Figure 4.18  Forest plot of studies comparing counselling (multiple  
  component) versus control 
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The possible presence of small study bias was investigated using funnel plots for 
cases where there were 10 or more studies. Small study bias was detected in the 
counselling category (Figure 4.19).  
Figure 4.19  Funnel plot for studies comparing counselling with control 
 
The trim and fill technique was subsequently applied to determine the potential 
impact of small study bias on the estimated treatment effect. When comparing 
counselling with control, the risk ratio decreased from 1.35 (95% CI: 1.17 to 1.57) 
to 1.2 (95% CI: 1.03 to 1.39). While the reduced risk ratio is still superior to control, 
in two subgroups the treatment effect loses significance. With trim and fill technique, 
the risk ratio for counselling versus usual care reduces to 1.16 (95% CI: 0.95 to 
1.41), and counselling (single intervention) versus control reduces to 1.14 (95% CI: 
0.88 to 1.47). 
4.4.4.3 Feedback 
Feedback (n=4) was not an effective intervention for smoking abstinence in late 
pregnancy.(248-251) However, subgroup analysis by comparator found that feedback 
versus usual care was effective (RR 4.39, 95% CI: 1.89 to 10.21, n=2 studies). The 
remaining two studies evaluated feedback compared with less intensive feedback, 
for which a smaller treatment effect is plausible. 
4.4.4.3 Financial incentives 
A significant positive effect was found across the three studies investigating financial 
incentives (RR 2.28, 95% CI: 1.55 to 3.34).(222, 223, 252) Inconsistent results were 
found between trials; however, the study by Tappin (2015) found a significant 
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beneficial effect of using financial incentives on cessation rates (RR 2.63; 95% CI 
1.72 to 4.01), whereas both other studies failed to demonstrate any effect. See 
Figure 4.20.  
The Tappin (2015)(223) study differed from the other two studies with a substantially 
greater number of participants and higher intensity intervention. In this trial, the 
intervention group (n=302) received up to £400 worth of shopping vouchers for 
continued abstinence in late pregnancy in addition to the routine care received by 
the control group (n=302). The relative risk of not smoking at the end of pregnancy 
was 2.63 (95% CI 1.73 to 4.01). 
Figure 4.20 demonstrates the forest plot of studies which used financial incentives. A 
fixed effect model was used due to the small number of studies in this category. 
Figure 4.20  Forest plot of studies comparing financial incentives versus 
control(253-255) 
 
 
 
4.4.4.5 Social support 
Social support (n=7) was not found to be an effective intervention for cessation (RR 
1.25, 95% CI: 0.90 to 1.74).91-93, (256, 257) (258, 259) Subgroup analysis by comparator 
(usual care or ‘less intensive’) and by intervention type (single, tailored or multiple 
intervention) did not change the lack of effect. 
4.4.5 Discussion and conclusions 
The studies reviewed broadly support the view that smoking cessation interventions 
are effective in pregnancy.  
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There is some evidence of beneficial effect for NRT as an aid to smoking cessation 
(RR 1.41; 95% CI 0.99 to 2.0). However, as there was only one trial of bupropion 
and none investigating varenicline or e-cigarettes, the effectiveness of 
pharmacological interventions in pregnancy cannot be determined. Neither 
bupropion nor varenicline is licensed for use during pregnancy in Ireland. Due to the 
small number of trials and differences in reporting, obstetric and neonatal outcomes 
are difficult to evaluate. Coleman 2012 was the only trial which reported infant 
outcomes beyond the neonatal period.(219) Significantly better developmental 
outcomes were observed two years after birth in infants born to women who had 
been randomised to NRT.(260) This supports the use of NRT in pregnancy.(260)  
Historically, chemicals such as carbon monoxide were considered the most 
dangerous components of cigarette smoke. More recently, increasing recognition of 
direct nicotine toxicity to the fetus has generated concerns regarding the safety and 
efficacy of NRT.(233) While acknowledging that the evidence on the effectiveness of 
NRT in pregnancy is mixed, NRT is still advocated as safe in pregnancy by the 
National Institute for Health and Care Excellence (NICE) and the Royal College of 
Obstetricians and Gynaecologists in the UK.(261, 262) Current US guidelines 
recommend using NRT for pregnant smokers only if behavioural therapies fail, and 
only under close supervision of a healthcare provider. This recommendation is in 
light of the U.S. Preventive Services Task Force conclusion that NRT in pregnancy 
has ‘not been sufficiently evaluated to determine their efficacy or safety’.(263) Despite 
these recommendations, however, many obstetricians may still be reluctant to 
prescribe NRT due to safety concerns.(264) (265) 
Due to these concerns, smokers should be encouraged to quit prior to conception 
when more treatment options are available and therapy is more likely to 
succeed.(266) Additional recommendations voiced by researchers include use of 
intermittent dosage NRT preparations such as gum or nasal spray rather than 
continuous dose NRT via the transdermal patch, and the removal of the transdermal 
patch at night to reduce overall nicotine exposure. Pregnant women should also be 
cautioned against smoking while using the transdermal patch because this can 
increase nicotine levels in both the mother and the fetus.(267) NICE guidelines 
stipulate that a 2-week course should initially be prescribed, with discontinuation if 
smoking cessation is not achieved, in addition to removal of transdermal patch at 
night.(262) 
Evaluating the effect of psychosocial interventions in pregnancy was complicated by 
the fact that the definitions of the interventions were very heterogeneous. Clinical 
heterogeneity also arose from the differences in choice of treatment provider, 
frequency and intensity of intervention, and participants between studies. Of 
particular importance relating to the participants involved was the gestational age at 
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which the intervention was delivered and the age of the mother. Most studies 
recruited participants over the age of 18, although some specifically recruited 
adolescents. Albrecht et al. 2006, recruited participants aged between 14 and 19 
year of age in their study of peer support as a cessation aid, and Albrecht et al. 1998 
recruited participants as young as 12 years of age in their assessment of peer 
support as an adjunct to health education materials.(256, 257)   
Financial incentives were the most effective intervention for smoking cessation. 
Health education was the next most effective intervention; however, on subgroup 
analysis this effect was only seen when the comparator was ‘less intensive 
intervention’ and not ‘usual care’. Counselling was also effective, and the effect 
differed little by comparator (usual care and ‘less intensive’) or by intervention type 
(single, tailored or multiple interventions). Evidence of small study bias was obtained 
in these studies, however, indicating that the effect size is potentially overestimated 
by the available studies. Of note is the lack of a clear difference in effect seen by 
intervention intensity, challenging the assumption that an ever-increasing level of 
support increases cessation rates. A significant effect for social support or feedback 
was not obtained.  
No serious adverse events were reported in the trials included in this review. Five 
NRT trials reported non-serious adverse events.(227) (225, 226, 228, 230) The largest trial 
reported on 535 non-serious adverse events in the NRT group compared with 450 in 
the placebo group.(226) It is worth noting that adherence to NRT across trials was 
generally low, with limited adherence to the placebo patches also noted. Analysis is 
complicated by differences in the definition of adherence and persistence between 
studies. Adverse events in trials of psychosocial interventions were primarily focused 
on an increase in smoking behaviour among participants. Only one trial reported an 
increase in smoking among women who were unsuccessful in quitting.(268) 
Furthermore, the studies identified span more than 40 years, with the earliest trial 
published in 1976.(269) Since then, a wide range of professionals were involved in the 
implementation of the interventions, including midwives,(235) doctors,(251) (270) and 
routine clinic staff.(234) Difficulties in implementing these types of interventions are 
reported in trials and these are relevant to the implementation of any individual 
psychosocial intervention in the Irish healthcare setting. It is reported in the 
literature that heavy workloads lead to inadequate time to complete the 
intervention.(271-274) In addition, provider pessimism may also be a problem for 
implementing any smoking cessation intervention.(235) 
Overcoming the barriers of insufficient time in a busy clinic setting may include 
increasing the use of referral services. In recent years, use of telephone-based, 
quitline referral services (275) and technology-based interventions have gained 
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popularity.(276) (244) (252) In the UK, most services reported use of a quitline 
referral.(275)  
4.5 Discussion 
The review of clinical effectiveness considered studies evaluating smoking cessation 
interventions in three distinct population groups: unselected adults; people attending 
secondary mental health services; and pregnant women. The primary outcome of 
interest was long-term (six months or more) cessation, and abstinence in late 
pregnancy in pregnant women. Sixteen systematic reviews were identified for 
inclusion in this HTA. Searches were updated to capture any primary studies 
published since the original systematic reviews were undertaken. A large volume of 
data was retrieved regarding smoking cessation interventions among unselected 
adults. By comparison, there was a lack of data for mental health populations and a 
moderate number of studies evaluating smoking cessation interventions in 
pregnancy. 
Pharmacological and behavioural interventions have demonstrated effectiveness in 
unselected adult smokers and this is well documented in numerous systematic 
reviews on the topic. However, among pregnant women and patients with mental 
health disorders, the beneficial effect of smoking cessation interventions is less 
pronounced.  
A total of 313 trials investigating smoking cessation interventions among unselected 
adult smokers were identified for inclusion in this review. All pharmacological 
interventions were more effective than control. Varenicline was the most effective 
monotherapy (RR=2.57, 95% CI: 2.32 – 2.85). Varenicline with NRT was the most 
effective dual therapy (RR=3.54, 95% CI: 2.57 – 4.61). There was considerable 
heterogeneity in how behavioural interventions were defined. All evaluated 
behavioural therapies were more effective than an alternative of ‘do nothing’. When 
compared with control (defined as brief advice or written materials), group 
behaviour therapy was the most effective behavioural intervention (RR=1.85, 95% 
CI: 1.53 – 2.23). 
The studies reviewed broadly support the view that smoking cessation interventions 
are effective in pregnancy. Due to the fact that bupropion and varenicline are not 
indicated in pregnancy, NRT is the only pharmacotherapy licensed for use to 
pregnant smokers who wish to quit, and its efficacy appears to be lower than in non-
pregnant smokers. An analysis of eight studies showed a 41% increased likelihood 
for cessation associated with NRT use in pregnancy, but this did not reach statistical 
significance (RR 1.41; 95% CI: 0.99 to 2.00). A range of behavioural interventions in 
pregnancy were reviewed, and there is evidence of a small, but statistically 
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significant effect of counselling, health education and financial incentives on 
cessation rates. Due to the limited effectiveness of interventions in pregnancy, 
smokers should be encouraged to quit prior to conception when more treatment 
options are available and therapy is more likely to succeed. 
Due to the fact that many smokers spontaneously quit in the early stages of 
pregnancy, it is possible that interventions in pregnancy (particularly in later 
pregnancy) are focused on more heavily dependent women and those with greater 
barriers to successful cessation. This may partly explain the lower efficacy compared 
with non-pregnant populations. In addition, the modest impact of NRT may be due 
to inadequate dosing of NRT in pregnancy. It has been demonstrated that nicotine 
clearance is increased by 60% in pregnancy.129 In an attempt to limit the fetal 
exposure to nicotine, prescribers may also under-dose NRT, administering a lower 
concentration and less frequent dosing than is necessary to avert withdrawal 
symptoms. Finally, it is worth noting that compliance and persistence with NRT is 
low during pregnancy. Only 7.2% of participants in the active nicotine patch arm of 
the 2012 study by Coleman et al. persisted with treatment beyond one month. 
Very limited evidence was retrieved for smokers attending secondary care mental 
health services. The majority of evidence relates to small trials with small participant 
numbers. Absolute cessation rates were lower in this population compared with that 
in the unselected adult population, with average quit rates in the control arms of 
approximately 7% compared with 11% for the unselected population. The 
combination of low control arm cessation rates and small numbers of participants 
resulted in some large, but not statistically significant treatment effects. Relevant 
data were only identified for patients with the diagnoses of schizophrenia, 
schizoaffective disorder and bipolar disorder. For smokers with schizophrenia or 
schizoaffective disorder, the addition of bupropion to behavioural interventions plus 
NRT significantly increased cessation rates compared with behavioural interventions 
plus NRT alone. Based on one placebo-controlled study, there is evidence that 
varenicline increases abstinence rates at six months when used as an adjunct to 
behavioural therapy in the schizophrenia population, although this was not 
statistically significant. No trial was identified specifically investigating the efficacy of 
NRT in this population; however, both NRT monotherapy and dual therapy were 
used as an adjunct to behavioural therapy in trials investigating the efficacy of 
bupropion.  
The lack of evidence for effectiveness in the mental health population is due to the 
fact that few studies, in particular large-scale, high-quality studies, have been 
conducted to date. Recruitment of patients to RCTs from mental health populations 
is reported as problematic, and the focus of many trials related to the adverse event 
profile rather than efficacy of the intervention. Studies excluded from this review 
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included studies that report shorter cessation outcomes and smoking reduction rate. 
Researchers have speculated that risk reduction may be a better initial focus for this 
population due to the higher nicotine dependence and greater burden of disease 
compared to the general population. Motivation to quit is important in this 
population. Two trials comparing bupropion to placebo found only one in three 
participants were motivated to quit, lowering the likelihood of successful cessation.  
It is important to note, however, that this review excluded the EAGLES 2016 trial; 
the largest trial to date to have been conducted comparing varenicline, bupropion, 
NRT and placebo. Individuals were stratified by the presence (n=4,074) or absence 
(n = 3,984) of a history of psychiatric disorders.36 This trial was not included review 
it did not meet the inclusion criteria for participants to be attending secondary care 
mental health services. All of the first-line medications (varenicline, bupropion, and 
NRT) were more effective than placebo, with varenicline the most effective single 
agent. One limitation of the EAGLES trial, however, was that only smokers with 
psychiatric disorders who were stable and treated or who had previous psychiatric 
conditions that were in remission were included. Therefore, it may not be possible to 
generalise the findings to patients who are untreated or whose symptoms are 
unstable. 
The effect sizes for many interventions were clinically significant. For example, with 
a risk ratio of 3.54 associated with dual therapy with Varenicline and NRT, an adult 
smoker is over three-and-a-half times more likely to achieve successful cessation 
with this intervention. Effect sizes were smaller in pregnant populations, but not 
clinically insignificant. For example, a significant positive effect was found across the 
three studies investigating financial incentives, with a RR of 2.28 (95% CI: 1.55 to 
3.34). 
The studies included in this HTA were intended to be representative of the three 
populations of interest. In terms of age, gender, and level of dependency, the study 
populations would appear to be broadly applicable to the Irish setting. In the mental 
health population group, data were only retrieved on patients with schizophrenia, 
schizoaffective disorder and bipolar disorder. As these diagnoses constitute a large 
proportion of individuals attending secondary care mental health services in Ireland, 
the findings should be applicable to an Irish setting, if it is acknowledged that trial 
eligibility was often restricted to those with clinically stable disease. 
4.6 Key points 
Overview 
 The review of clinical effectiveness considered studies evaluating smoking 
cessation interventions in three distinct population groups: unselected adults; 
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people attending secondary care mental health services; and pregnant 
women. The primary outcome of interest was long-term (six months or more) 
cessation, and abstinence in late pregnancy in pregnant women. 
 Sixteen systematic reviews relevant to this HTA were updated to capture any 
primary studies published since the original systematic reviews were 
undertaken. 
Findings 
 For unselected adults: 
o 313 studies were identified, evaluating either pharmacological or 
behavioural interventions. 
o For pharmacological interventions, all were more effective than control. 
Varenicline was the most effective monotherapy (RR 2.57, 95% CI: 
2.32 – 2.85). Varenicline with NRT was the most effective dual therapy 
(RR 3.54, 95% CI: 2.57 – 4.61). 
o In terms of behavioural therapies, all evaluated therapies were more 
effective than an alternative of ‘do nothing’. When compared with 
control (defined as brief advice or written materials) group behaviour 
therapy was the most effective behavioural intervention (RR 1.85, 95% 
CI: 1.53 – 2.23). There was considerable heterogeneity in how 
behavioural interventions were defined. 
 For people attending secondary care mental health services: 
o We identified 10 studies relevant to the target population. The studies 
were generally small in terms of the number of participants. Absolute 
quit rates in the control arms tended to be low relative to those 
observed for unselected adults. 
o The only statistically significant evidence of a beneficial treatment was 
for bupropion when used as an adjunct to behavioural therapy and 
NRT in a population with schizophrenia or schizoaffective disorder (RR 
3.86, 95% CI: 1.01 – 14.80).  
 For pregnant women: 
o 73 studies were identified evaluating either pharmacological or 
behavioural interventions. 
o Eight trials were identified investigating NRT use as a smoking 
cessation aid in pregnancy, and they were deemed of high quality. 
Some evidence of a beneficial effect was found for NRT in this group 
with a 41% increase in cessation rates, but this did not reach statistical 
significance (RR 1.41; 95% CI: 0.99 to 2.00). 
o 64 studies were identified evaluating psychosocial interventions for 
smoking cessation in pregnancy. The studies were rated as being of a 
low quality.  
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o There was evidence to suggest counselling, health education and 
financial incentives increase cessation rates in pregnant smokers. 
 
Points to consider 
 There was substantial variation in how behavioural interventions were defined 
and delivered, often resulting in heterogeneity in observed treatment effects. 
Variability was seen in the frequency and intensity of interventions. 
 The studies included were intended to be representative of the three 
populations of interest. In terms of age, gender, and level of dependency, the 
study populations would appear to be broadly applicable to the Irish setting.   
 In the mental health population group, data were only retrieved on patients 
with schizophrenia, schizoaffective disorder and bipolar disorder. These 
diagnoses constitute a large proportion of individuals attending mental health 
services in Ireland and our findings should be applicable, albeit recognising 
that trial eligibility was typically restricted to those with clinically stable 
disease. 
 The evidence base for e-cigarettes is likely to evolve as further trials 
complete. The effectiveness of e-cigarettes for smoking cessation should be 
re-evaluated as new evidence becomes available. 
 The effectiveness of pharmacological interventions is improved by an average 
of 18% by the provision of adjunct behavioural therapy. 
 There are limited observational data against which to compare the trial data 
to determine applicability in the real world setting. 
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5 Safety  
5.1 Introduction 
This chapter will provide an overview of the current evidence in relation to the safety 
of pharmacological smoking cessation interventions and e-cigarettes. No substantive 
adverse effects were identified following review of the efficacy literature associated 
with behavioural interventions. For this reason, this chapter will focus on the safety 
of the pharmacological agents (nicotine replacement therapy (NRT), varenicline and 
bupropion) and e-cigarettes. The safety of these agents in pregnancy, people with 
mental health disorders and adolescents is also presented.  
A comprehensive review of the literature was performed. Firstly, a review of the 
adverse event profile from efficacy trials (identified in Chapter 4) was conducted. 
Following this, data from observational studies, surveillance reports and company 
submissions were reviewed in order to summarise the evidence on long-term safety 
(including rare events).  
5.2 Nicotine replacement therapy 
5.2.1 Health effects of nicotine 
Nicotine itself is not considered a carcinogen(277), but in vitro and animal studies 
have suggested that nicotine may play a role in tumour promotion.(278, 279) This risk 
has not been documented in humans, and nicotine supplementation is clearly safer 
than the continuation of smoking. Tobacco smoke contains thousands of 
compounds, including over 60 known carcinogens separate to nicotine. In addition, 
smoking produces a higher peak and average dose of nicotine than nicotine 
replacement therapy (NRT).(280) This suggests that smoking would lead to greater 
nicotine-related risk than using NRT.  
Nicotine produces haemodynamic effects (such as increased heart rate, increased 
systolic blood pressure and decreased digital blood flow) regardless of whether 
administered by cigarette smoking or NRT.(281) Studies suggest that nicotine may 
play a role in smoking-related cardiovascular disease through haemodynamic 
effects,(282-284) and possibly through the acceleration of atherosclerosis.(278, 
285) However, tobacco smoke contains many harmful chemical components other 
than nicotine that can harm the cardiovascular system, including combustion 
products such as carbon monoxide and nitrogen oxides.(286) It is not clear what 
fraction of cardiovascular morbidity can be attributed to nicotine intake. It is 
generally believed that the benefits of nicotine pharmacotherapy for smoking 
cessation far outweigh the risks among smokers with stable heart disease.(282, 287)  
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While nicotine is a highly addictive drug,(277) the addiction risk of nicotine in 
medications has proven to be very low compared to the risk posed by tobacco 
products. This is in part because of lower doses and slower absorption of nicotine 
obtained from NRT products compared with nicotine obtained from tobacco smoke 
inhalation.(288, 289) Studies have demonstrated that only a minority of long-term NRT 
use can be attributed to dependence; most long-term use represents the extension 
of the therapeutic efficacy.(290, 291)  
5.2.2 Common adverse events  
Most adverse events associated with NRT are mild and temporary in nature. A large 
meta-analysis of adverse events associated with nicotine patch use reports mild skin 
sensitivity as the most common adverse event, rarely leading to withdrawal of patch 
use, as well as sleep disturbance for some smokers using the 24-hour patch.(292) The 
major side effects usually reported with nicotine gum include hiccoughs, 
gastrointestinal disturbances, jaw pain and orodental problems. The major side 
effects reported with the nicotine inhaler and nasal spray relate to local irritation at 
the site of administration; the mouth and nose, respectively. Nicotine sublingual 
tablets have been reported to cause hiccoughs, burning sensation in the mouth, sore 
throat, coughing, dry lips and mouth ulcers.(293) 
5.2.3 Adverse events identified in systematic review 
Due to the varied way adverse events were reported across the studies included in 
their assessment, the Cochrane review of NRT did not conduct a quantitative 
analysis of each of the reported side effects of NRT use.(8) However, the review does 
provide a broad overview of the safety profile of this treatment, along with a meta-
analysis of the most clinically significant adverse event associated with its use – 
chest pain and heart palpitations. The most common adverse events for each type of 
NRT therapy are shown in Table 5.1. None of these adverse events were reported as 
severe. Studies identified following this Cochrane review did not differ in terms of 
the adverse event profile.  
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Table 5.1 Most common side effects associated with NRT use 
Type of NRT Most common side effects 
Gum Hiccoughs 
Gastrointestinal disturbance 
Jaw pain 
Orodental problems 
Patch Skin sensitivity and irritation 
Inhaler, intranasal and oral spray Nose, mouth or throat irritation 
Coughing 
Hiccoughs 
Tablets Mouth irritation 
Hiccoughs 
Sore throat 
Dry lips 
Mouth ulcers 
5.2.4 Chest pain and heart palpitations 
A recent systematic review and meta-analysis of adverse events associated with NRT 
has been carried out.(4) The review included 120 studies involving 177,390 
individuals and considered a possible excess of chest pains and heart palpitations 
among users of NRT compared with placebo groups.(4) The authors reported an odds 
ratio (OR) of 2.06 (95% CI 1.51 to 2.82) across 12 studies that documented these 
events.  
The Cochrane review replicated this data collection exercise and analysis where data 
were available across all 260 randomised controlled trials in their review. The event 
rate for chest pain and palpitations was 2.5% in the NRT groups compared with 
1.4% in the control groups in the 15 trials in which it was reported (OR 1.88; 95% 
CI 1.37 to 2.57).(8) The review reports that this is potentially the only clinically 
significant serious adverse event to emerge from the trials, and its occurrence is 
infrequent.  
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5.2.5 Cardiovascular adverse events 
The benefits of quitting smoking far outweigh any risks associated with correctly 
administered NRT. However, there is concern that some of the cardiotoxic effects of 
smoking may be attributable to nicotine. Nicotine, as a stimulant, increases 
sympathetic activity. This leads to an increase in heart rate, vasoconstriction, and a 
resulting increase in systolic blood pressure. It is also suggested that nicotine may 
contribute to endothelial dysfunction and to developing resistance to insulin.(294)  
Insulin resistance results in glucose intolerance, which may precipitate or aggravate 
diabetes, worsening cardiovascular risk.(294) 
Carbon monoxide exposure and hyperlipidaemia contribute to increased 
cardiovascular risk in smokers through increased thrombogenesis, oxidative damage, 
and reduced oxygen availability. These effects are not due to nicotine, and studies 
have demonstrated that smoking cessation using NRT has favourable effects on 
these factors.(295) Furthermore, nicotine levels achieved with replacement therapy 
are much lower than those found with smoking. Two coronary perfusion studies, one 
using quantitative thallium tests and the other using coronary angiography, suggest 
no increase in cardiac ischaemia in subjects using nicotine.(296, 297) 
When first licensed, concern was expressed about the cardiovascular effects 
associated with NRT use, leading to many clinical trials to investigate this effect.(298) 
However, a large meta-analysis that included 35 trials with over 9,000 participants 
did not find evidence of excess adverse cardiovascular events among those using a 
nicotine patch, and the total number of such events was low.(292) A more recent 
meta-analysis of 120 studies, for a total of 177,390 individuals, found no increased 
risk of myocardial infarction or death associated with the use of NRT.(4) However, 
patients with pre-existing cardiac disease were specifically excluded from the 
majority of these studies. 
Studies involving cardiac patients have also failed to find any evidence of an 
increased risk of cardiovascular effects or mortality associated with NRT use.(299, 300) 
One trial of nicotine patches, which recruited smokers aged over 45 with at least one 
diagnosis of cardiovascular disease, found no evidence that serious adverse events 
were more common in smokers in the nicotine patch group.(299) Events related to 
cardiovascular disease such as increase in angina severity occurred in approximately 
16% of patients, but did not differ according to whether or not patients were 
receiving NRT. The authors concluded that NRT should not be contraindicated in 
patients with cardiovascular or cerebrovascular disease. 
Similarly, a secondary analysis of subjects in the Lung Health Study (a randomised 
controlled trial for the prevention of chronic obstructive pulmonary disease), 
demonstrated that cardiovascular deaths were associated with continued smoking, 
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but not with those who used nicotine gum for up to five years. Increased 
cardiovascular morbidity or mortality was not observed regardless of the duration or 
dose of nicotine gum administered.(301)  
Regulatory authorities in Europe have taken action to support the use of NRT in 
patients with cardiovascular disease. In 2003, the AFSSAPS (French regulatory 
agency for medicines) recommended the changes to the Summary of Product 
Characteristics of NRT, removing all contraindications relating to cardiovascular and 
cerebrovascular disease.(302) In 2005, the UK’s Committee on Safety of Medicines of 
the Medicines and Healthcare Products Regulatory Agency (MHRA) brought in similar 
changes.(303) In Ireland, the Summary of Product Characteristics for licensed NRT 
products recommends a risk-benefit assessment be made in smokers with certain 
cardiovascular conditions, including recent myocardial infarction, unstable or 
worsening angina, severe cardiac arrhythmias and recent cerebrovascular 
accident.(304-306)  
 
5.2.6 Safety in adolescents 
There is little reason to believe that NRT poses a significantly greater risk to 
adolescent smokers compared to adult smokers. NRT is licensed in individuals over 
the age of 12 under the recommendation of a healthcare professional. See section 
5.7 for a detailed discussion on the safety of NRT in adolescents. 
5.2.7 Safety in pregnancy 
NRT may be safely administered in pregnancy under the supervision of a medical 
professional, particularly when behavioural therapies have failed.(307-309) See section 
5.5 for a detailed discussion on the safety of NRT in pregnancy. 
5.2.8 Neuropsychiatric safety of NRT 
NRT is not associated with an increased risk of neuropsychiatric adverse events in 
those with or without pre-existing psychiatric disease.(36) See section 5.6 for a 
detailed review of the safety of NRT and other smoking cessation medications in 
mental health populations. 
5.3 E-cigarettes 
5.3.1 General points 
Recently, studies on the safety of e-cigarettes have emerged. However, this research 
must be considered a ‘work in progress’ given that the safety of any product reflects 
an evolving body of knowledge and as the product itself is undergoing constant 
development. 
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Existing studies exploring the safety of e-cigarettes can be divided into chemical, or 
toxicological, and clinical studies. Clinical studies are the most informative, but also 
the most demanding. In particular, the safety profile of the product must be 
explored in cohorts of well-characterised users in the long-term in order to address 
the potential of future disease development. This would require following a large 
cohort for a substantial number of years before any firm conclusions on product 
safety can be made.  
5.3.2 Common adverse events 
The most commonly observed side effects of e-cigarette use in clinical trials and 
surveys are that of temporary throat and respiratory irritation and dry cough.(310-313) 
This is consistent with most in vitro studies demonstrating the non-specific irritant 
effect from e-cigarette vapour.(18) While symptoms of irritation occur most frequently 
in e-cigarette users, hypersensitivity to propylene glycol present in the e-cigarette 
vapour, and the possibility of unknown contaminants or byproducts contained in the 
vapour causing similar irritant effects cannot be discounted.(18) However, it remains 
unclear whether such an irritation could translate into clinically meaningful lung 
disease. 
5.3.3 Adverse events identified in systematic review 
Two randomised controlled trials (RCTs) were identified in the systematic review of 
the effectiveness of e-cigarettes for smoking cessation. Neither trial reported any 
serious adverse events linked to their use. There was no significant difference 
between the adverse event rates at six month follow-up in the trial comparing 
nicotine e-cigarettes to placebo e-cigarettes and NRT patches, or at three and 12 
month follow-up in the trial comparing nicotine e-cigarettes to placebo e-
cigarettes.(167, 168) The most frequently reported adverse events were cough (26%), 
dry mouth (22%), shortness of breath (20%), throat irritation (17%) and headache 
(17%).(168) With the exception of throat irritation, the frequency of all of these 
adverse events decreased over time. The Cochrane review also included cohort 
studies in their analysis of adverse events associated with e-cigarette use.(17) Similar 
to that of the included RCTs, the main adverse events consisted of mouth and throat 
irritation which dissipated over time. 
5.3.4 Nicotine poisoning 
Unintended fatal nicotine poisoning is extremely rare. Self-experiments in the 1890s 
suggested that ingestion of 30-60mg of nicotine is fatal, and while this figure is often 
quoted, the results are dubious.(314) Case reports of nicotine poisoning from 
accidental e-liquid ingestion by children indicate nausea, vomiting and ataxia to be 
common symptoms, usually resulting in spontaneous recovery.(315, 316) One fatality 
associated with nicotine exposure in children has been recorded.(317)  
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There has been an increase in calls to poison centres in recent years in Ireland 
following accidental nicotine ingestion. The National Poisons Information Centre lists 
nicotine as one of the most common agents involved in the enquiries they 
receive.(318) There has also been a spike in the number of e-cigarette fluid poisonings 
presenting to the Poisons Centre in Beaumont Hospital in recent years.(318) It would 
seem imperative that the e-liquid refill bottles should be in ‘childproof’ packaging to 
prevent small children, who may find the flavouring appealing, from drinking it.  
Nicotine has also been used in suicide attempts. One fatality has been documented 
where the subject drank three nicotine vials totalling over 10,000mg nicotine, and 
another whereby intravenous injection of nicotine occurred.(317, 319) 
5.3.5 Device explosion and fires 
Case reports of lithium battery explosions and thermal injuries have started to 
emerge. While rare events, such injuries may incur significant tissue damage 
requiring extensive treatment.(320)   
Concerns have also been voiced by researchers regarding the potential dangers of e-
cigarettes in the presence of home oxygen therapy. The heating element reaches a 
high temperature in order to aerosolise the e-liquid to be inhaled. Consequently, it is 
possible that it could ignite in the presence of oxygen.(321) 
5.3.6 Chemical and toxicological studies 
Chemical and toxicological studies indicate that the use of e-cigarettes may be less 
harmful than smoking.(322) There is no tobacco and no combustion involved in e-
cigarettes use; therefore, regular users may avoid several harmful toxic chemicals 
that are typically present in the smoke of tobacco cigarettes. However, studies have 
demonstrated that trace amounts of potentially harmful chemicals may be released, 
such as formaldehyde and acetaldehyde and tobacco-specific nitrosamines 
(TSNAs).(323) It is worth noting, however, that levels of these compounds are 
substantially lower than found in tobacco smoke, and in some cases (such as 
nitrosamines), are comparable to the amounts found in pharmaceutical nicotine 
products.(21)  
Goniewicz et al. (2014) performed toxicity testing to evaluate the nature of vapour 
generated from e-cigarettes, and to compare it to cigarette smoke and the reference 
product – the medicinal nicotine inhaler.(323) A comparison of six potentially toxic and 
carcinogenic compounds is given in Table 5.2. Toxic substances were found in e-
cigarettes; however, they were nine to 450 times lower than in cigarette smoke and 
were, in many cases, comparable with trace amounts found in the nicotine inhaler. 
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
179  
Potentially toxic carbonyls, such as formaldehyde, can form when e-liquids are 
heated to high temperatures. In early models of e-cigarettes, the temperature of the 
heating element was not sufficient to create these compounds. However, some 
newer ‘variable voltage’ models allow users to increase the temperature of the 
heating element to deliver more nicotine, also generating carbonyls.(324) One study 
demonstrated that high levels of aldehyde only form in ‘dry puff’ conditions however; 
this occurs when the liquid overheats causing a strong unpleasant taste, which users 
recognise and avoid.(325) Under normal conditions aldehyde emissions are very small, 
even in new-generation high-power e-cigarettes. 
Other investigators are interested in the flavourings and preservatives used in e-
liquids. A few studies have identified various nicotine-related degradation products 
and other impurities in e-liquids and vapours,(326, 327) although some researchers 
have concluded these impurities occur at levels unlikely to cause harm.(328)  
Table 5.2 Comparison of sample toxicants emitted by tobacco cigarettes 
and e-cigarettes. Adapted from Goniewicz et al. (2014) 
Toxic 
compound 
Tobacco 
cigarette (mcg in 
mainstream 
smoke) 
E-
cigarette (mcg 
per 15 puffs) 
Average 
ratio (conventional 
versus electronic 
cigarette) 
Formaldehyde 1.6–52 0.20–5.61 9 
Acetaldehyde 52–140 0.11–1.36 450 
Acrolein 2.4–62 0.07–4.19 15 
Toluene 8.3–70 0.02–0.63 120 
Tobacco-
specific 
nitrosamine 
(NNN) 
0.005–0.19 0.00008–0.00043 380 
Tobacco-
specific 
nitrosamine 
(NNK) 
0.012–0.11 0.00011–0.00283 40 
Two studies directly examined aldehyde levels in e-cigarette users. One cross-
sectional study reported that e-cigarette users had much lower levels of acrolein and 
crotonaldehyde in urine than smokers.(329) Another study, funded by the Medicines 
and Healthcare Products Regulatory Agency (MHRA), examined changes in acrolein 
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
180  
levels in smokers who switched to e-cigarette use.(330) Users who exclusively 
switched to e-cigarettes and those who became ‘dual users’ of cigarettes and e-
cigarettes significantly reduced their acrolein intake. 
5.3.7 Direct toxicity to the lung 
Animal studies raise questions regarding a direct toxic effect of e-cigarette vapour in 
the lungs. One study subjected mice to e-cigarette vapour over a two-week period, 
prior to infecting them with streptococcus pneumonia or influenza virus and killing 
them.(331) Relative to the control group, mice exposed to e-cigarette vapour 
demonstrated negative indicators such as an increase in pro-inflammatory cytokines, 
diminished lung glutathione and higher viral titre. 
A similar study exposed mice, human airway epithelial cells and human lung 
fibroblasts to e-cigarette vapour with flavourings.(332) Human airway epithelial and 
lung fibroblasts demonstrated an increase in secretion of inflammatory cytokines, 
and exposed mice demonstrated an increase in proinflammatory cytokines and 
reduction in lung glutathione levels. 
Another study investigated the effects of nicotine in e-cigarette fluid, by exposing 
mouse lungs and normal human airway epithelial cells to aerosolised nicotine-free 
and nicotine-containing e-cigarette fluid.(333) Exposure to inhaled nicotine-containing 
e-cigarette fluids triggered effects normally associated with the development of 
chronic obstructive pulmonary disease (COPD), including cytokine expression, airway 
hyper-reactivity and lung tissue destruction. These effects were nicotine-dependent, 
suggesting that inhaled nicotine contributes to lung disease in animal models. 
A meaningful interpretation of these studies is difficult, as in each case e-cigarette 
vapour was not compared to cigarette smoke. Human studies have not corroborated 
the findings of lung toxicity. A case study involving lipoid pneumonia, possibly 
caused by flavouring of e-cigarette vapour, was reported in 2012.(334) However, no 
further cases of this have since been reported. A study that monitored asthma 
patients who switched from smoking to vaping e-cigarettes found significant 
improvements in symptoms and in respiratory function.(23) 
5.3.8 Clinical studies 
There is no evidence from clinical studies that long-term e-cigarette use leads to 
reductions in smoking-related diseases, and it would take a few decades before a 
beneficial effect could be established. Nonetheless, it is feasible to detect early 
changes in airway function and respiratory symptoms in smokers switching to e-
cigarettes. Initial findings are supportive of an improvement in respiratory outcomes 
in those who switch.(23)  
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5.3.9 Acute pulmonary effects 
Vardavas et al. (2012) examined the short-term pulmonary effects of using an e-
cigarette, including the impact on respiratory flow resistance, impedance, and 
exhaled nitric oxide.(335) E-cigarettes were found to have immediate adverse 
physiological effects after short-term use that are similar to some of the effects seen 
with tobacco smoking. However, it must be noted that the reported 16% decrease in 
exhaled nitric oxide levels and 11% increase in peripheral flow resistance by impulse 
oscillometry from baseline after using an e-cigarette for five minutes were so small 
and well within test variability, that it is unlikely to have any clinical relevance.  
On the other hand, Flouris et al. (2013) did not elucidate a significant effect on 
pulmonary function (as measured by FEV1, FVC, FEV% and PEF) following acute 
active or passive e-cigarette use.(22) 
5.3.10 Long-term pulmonary effects 
Asthma and chronic obstructive pulmonary disease (COPD) are progressive diseases 
characterised by persistent inflammatory and remodelling responses of the airways 
causing progressive decline in lung function.(336) It has been well established that the 
inflammatory response to cigarette smoke plays a key role in COPD pathogenesis, 
and an increased morbidity and mortality have been reported in asthmatic 
individuals who smoke.  
A study of one group of smokers without COPD who switched to using e-cigarettes, 
and gave up tobacco smoking completely, found significant early positive changes 
from baseline at three months of a sensitive measure of obstruction in the more 
peripheral airways (that is to say, forced expiratory flow measured between 25% 
and 75% of FVC).(23) Steady progressive improvements were also observed at six 
and 12 months.(23) In a clinical study conducted to determine effect and safety of e-
cigarette use with asthma, substantial improvements in respiratory physiology and 
subjective asthma outcomes were reported.(337) Exposure to e-vapour in this 
vulnerable population did not trigger any asthma attacks.  
5.3.11 Cardiovascular effects 
The acute increase in heart rate and blood pressure that occurs after tobacco use is 
greater than that found following e-cigarette use.(322) In addition, the acute negative 
effects of smoking on coronary blood flow have not been elucidated by e-cigarette 
use.(322) 
5.3.12 Risks of passive e-cigarette vaping 
The risk to bystanders of e-cigarette users appears to be very low. One study 
showed that the nicotine content of exhaled e-cigarette vapours is eight times lower 
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than exhaled cigarette smoke.(338) Another study demonstrated that while nicotine 
from e-cigarette vapour is deposited on surfaces, the levels are very low.(339)  
In addition, in estimating environmental nicotine exposure, side-stream smoke (that 
is, the smoke from the lighted end of the cigarette, produced regardless of whether 
the smoker is puffing or not) accounts for 85% of passive smoking. There is no side-
stream vapour released from e-cigarettes.(340)  
5.3.13 E-cigarette use in youth and initiation of smoking 
The World Health Organization (WHO) commissioned a review of the data on the 
prevalence and trends of e-cigarette use among people aged 20 or less.(341, 342) 
Trend data was available of adolescent e-cigarette use from probability sample 
surveys from three countries (the USA, Poland and Italy). In Italy, current use of e-
cigarettes among smokers and non-smokers is very low and is not increasing. A 
similar situation is noted in England, although trend data is not based on probability 
samples. Conversely, USA and Poland both show a rapid increase in the current use 
of e-cigarettes. 
Considerable debate exists about whether e-cigarette use among non-smokers is a 
precursor or ‘gateway’ to smoking. Existing longitudinal studies indicate that e-
cigarette use by minors, who have never smoked, at least doubles their chance of 
future smoking initiation.(343-346) It is not clear if it is the experimentation with e-
cigarettes that leads to smoking, or if individual characteristics predict both e-
cigarette use and future smoking.  
5.3.14 Conclusions 
Based mostly on the levels and number of toxicants produced during the typical use 
of e-cigarettes, it is likely that e-cigarettes are less toxic than cigarette smoke.(347) 
However, e-cigarettes are unlikely to be harmless, and long-term use may increase 
the risk of chronic obstructive pulmonary disease, lung cancer, and possibly 
cardiovascular disease as well as some other diseases also associated with 
smoking.(348) The magnitude of these risks is likely to be smaller than from tobacco 
smoke, with Public Health England estimating e-cigarettes to be 95% safer than 
smoking.{,  #85;,  #88;,  #86} Nevertheless, some parties have called for the 
prohibition and or further regulation of e-cigarette products, as was discussed at the 
WHO Conference of the Parties to the WHO Framework Convention on Tobacco 
Control in November 2016.(342)  
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5.4 Varenicline 
5.4.1 Common adverse events 
Varenicline is a nicotine receptor partial agonist, with nausea consistently the most 
commonly reported adverse event associated with its use in clinical trials.(349-353) A 
meta-analysis that included 2,045 individuals cited nausea (29%), insomnia (14%) 
and headache (14%) as the most commonly reported adverse events.(354) In 
addition to insomnia, abnormal dreams are associated with varenicline use.(355, 356) 
Abnormal dreams are listed as ‘very common’ (≥ 1/10) adverse events in the 
product safety data for Champix®.(357) 
Nausea is most frequently mild to moderate and transient in nature, leading to a 
discontinuation rate of 3% due to symptoms. Symptoms of nausea may be reduced 
when varenicline is administered following food.(358) Patients should be advised to 
take varenicline with food or at least water to minimise symptoms of nausea.  
5.4.2 Adverse events identified in systematic review 
The Cochrane review of nicotine receptor partial agonists for smoking cessation 
includes an analysis of the incidence of adverse events associated with varenicline 
and cytisine.(40) They reported that the main side effect of varenicline was mild to 
moderate nausea (RR 3.27, 95%CI 3.00 to 3.55 compared with placebo), which 
decreased over time and did not result in high drop-out rates. With the exception of 
headache, these adverse events appear to be related to dosage, and in the case of 
nausea, can be reduced by dose-titration.(351)  
Meta-analyses of the other main adverse events demonstrated an increased rate of 
insomnia (RR 1.49, 95% CI 1.35 to 1.65), abnormal dreams (RR 2.12, 95% CI 1.88 to 
2.38) and headaches (RR 1.17, 95% CI 1.07 to 1.29) when compared with placebo.  
An analysis of the incidence of serious adverse events is also reported. The authors 
defined this as those that result in death, are life-threatening, require hospitalisation 
or prolong an existing hospital stay, lead to significant disability, or result in a 
congenital anomaly or birth defect.(40) There was a high degree of variability in the 
numbers of serious adverse events reported in the cytisine trials. One study 
comparing cytisine to placebo did not report any information; another reported no 
events; and the final study reported seven serious adverse events, none of which 
were deemed to be treatment related. In contrast, the study comparing cytisine to 
NRT reported 56 serious adverse events in 45 participants in the cytisine group, and 
45 events in 39 people taking NRT.  
In the varenicline trials, there were no treatment-related deaths in the varenicline 
group during treatment or follow up. Non-fatal serious adverse events occurred in 29 
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trials. A meta-analysis of all varenicline versus placebo studies in the Cochrane 
review, which included the recently completed EAGLES study, found that those 
receiving the treatment had an increased risk of experiencing a serious adverse 
event (RR 1.25, 95%CI 1.04 to 1.49). A subgroup analysis carried out for 
neuropsychiatric serious adverse events and cardiac serious adverse events found no 
statistically significant effect of varenicline treatment for either of these types of 
event compared with placebo (RR 0.82, 95%CI 0.57 to 1.19; and RR 1.36, 95%CI 
0.91 to 2.04, respectively). 
5.4.3 Cardiovascular adverse events 
The US Food and Drug Administration (FDA) approved varenicline in May 2006. The 
priority safety review published in 2006 found that varenicline-treated patients 
experienced serious cardiovascular adverse events more commonly than those treated 
with placebo.(359) In 2010, a post-marketing experience report published by the FDA 
highlighted the case reports of myocardial infarctions and cerebrovascular accidents 
that occurred in patients treated with varenicline; however, the role of smoking itself 
contributing to these events in smokers could not be ruled out.(40) In 2011 and 2013, 
further revisions to the marketing label highlighted results of individual studies and 
reviews that studied cardiovascular events in patients using varenicline.(360, 361)  
Three independent systematic reviews conducted around this time echoed these 
concerns; serious cardiovascular adverse events occurred more frequently in the 
varenicline treated group compared with placebo in each review.(362-364) Certain 
studies were included in more than one review; the trial by Rigotti and colleagues 
(365) that contributed most in terms of weight to the meta-analyses was included in 
all three reviews. 
Similarly, a large observational prospective cohort study of dispensed prescriptions 
for varenicline in New Zealand between April 2007 and November 2010, conducted 
by the Intensive Medicines Monitoring Programme, voiced concerns over the 
cardiovascular safety of varenicline.(366) In total, 172 cardiovascular adverse events 
were observed within the cohort. The investigators considered that two cases may 
have been triggered by the use of varenicline. 
On the other hand, a 2016 systematic review and meta-analysis of varenicline and 
cardiovascular serious adverse events, including 38 randomised controlled trials 
(RCTs) with 12,706 participants, found no evidence of an association in people with 
(RR 1.04, 95% CI 0.57 to 1.89) or without (RR 1.03, 95%CI 0.64 to 1.64) 
cardiovascular illness.(367) The study also analysed all-cause mortality, and found no 
difference between the varenicline and placebo groups (RR 0.88, 95% CI 0.50 to 
1.52). 
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Recent large observational studies from Denmark(368) and the UK(369) did not find a 
clear association with increased risk of cardiovascular events. The Danish study 
compared cohorts of people prescribed varenicline or bupropion (17,926 in each 
group) from 2007 to 2010 for rates of acute coronary syndrome, ischaemic stroke, 
and cardiovascular death six months from the start of treatment. The study found no 
excess of events in the varenicline group (6.9 cases per 1000 person-years) 
compared with the bupropion group (7.1 cases per 1000 person-years).(368) In the 
UK study, data from 753 National Health Service (NHS) general practices were 
reviewed to compare recipients of NRT (n=106,759; the reference group) with users 
of varenicline (n=51,450) and bupropion (n=6,557), for the incidence of 
neuropsychiatric and cardiovascular events.(369) Reduced risks of ischaemic heart 
disease (HR 0.80, 95% CI 0.72 to 0.87), cerebral infarction (HR 0.62, 95% CI 0.52 
to 0.73), heart failure (HR 0.61, 95% CI 0.45 to 0.83) and arrhythmia (HR 0.73, 
95% CI 0.60 to 0.88) was observed in varenicline compared with NRT users. 
It is clear from these studies that there is conflicting evidence regarding cardiac 
adverse events with varenicline. The CATS study, conducted among participants in 
the EAGLES 2016 study, was designed to monitor the incidence of major 
cardiovascular events for 28 weeks after the completion of the EAGLES (Evaluating 
Adverse Events in a Global Smoking Cessation Study) 2016 trial.(370) The results had 
not yet been published at the time of finalising this assessment.  
5.4.4 Abuse potential 
Varenicline appears to have little, if any, abuse potential.(371) 
5.4.5 Neuropsychiatric adverse events 
Due to an initial concern of clinically significant neuropsychiatric events associated 
with varenicline administration, both the European Medicines Agency (EMA) and the 
FDA issued a warning for its use in patients with pre-existing psychiatric conditions. 
However, the EMA removed the black triangle warning in May 2016. This occurred 
following publication of safety and efficacy data from the EAGLES trial in April 2016. 
The EAGLES trial found no increased incidence of adverse neuropsychiatric effects in 
patients with or without pre-existing psychiatric disorder.(36) See section 5.6 for a 
detailed discussion of the safety of varenicline in mental health populations. 
5.4.6 Varenicline in pregnancy 
See section 5.5.2 for a detailed discussion on the safety of varenicline in pregnancy. 
There are few studies demonstrating the safety and efficacy of varenicline in a 
pregnant population. Varenicline is currently not recommended during pregnancy or 
lactation in Ireland. NICE clinical guidelines in the UK (307) and the American College 
of Obstetricians and Gynecologists in the US (308) similarly caution against varenicline 
in pregnancy due to a lack of data. 
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5.5 Bupropion 
5.5.1 Common adverse events 
The most common adverse events associated with the use of bupropion are 
insomnia, occurring in 30% to 40% of patients, dry mouth (10%) and nausea.(372) 
Allergic reactions, including pruritus, hives, angioedema and dyspnoea have also 
been reported with the use of bupropion. Allergic and hypersensitivity reactions 
requiring medical treatment, however, are rare; occurring at a rate of 1:1000 to 
3:1000 in national surveillance schemes and clinical trials.(30, 373)  
5.5.2 Adverse events identified in systematic review 
The Cochrane review of antidepressants for smoking cessation carried out a detailed 
review of adverse events associated with bupropion.(30) Consistent with product safety 
data, the most common side effects were insomnia, dry mouth and nausea, with sleep 
disturbance occurring in up to half (30-50%) of patients. Allergic reactions were also 
reported.  
A meta-analysis of 33 trials comparing bupropion with placebo, carried out for the 
Cochrane review, showed that bupropion was associated with a marginal and 
statistically non-significant increase in the rate of serious adverse events (RR 1.30, 
95% CI 1.00 to 1.69).(30) Subgroup analysis of cardiovascular events also detected 
no difference between the two groups (RR 1.16, 95% CI 0.65 to 2.06, 25 trials). 
5.5.3 Seizures 
Bupropion was first used for the treatment of depression in the late 1980s and at 
this time was only available in an immediate release form.(374) In an open label trial 
of 3,341 patients using up to 450mg per day of this formulation, the risk of seizure 
during the first eight weeks of treatment was 0.36%.(375) In 1996 a sustained release 
formulation was introduced. Following this, a large, open, uncontrolled observational 
safety surveillance study was conducted by the manufacturers which examined 
3,100 adult patients using slow release bupropion for eight weeks for treatment of 
depression.(32) Three participants (0.1%) had a seizure considered to be related to 
the therapeutic use of bupropion. This gave rise to the figure of 1:1000 as the 
seizure rate given in the product safety data. 
The evidence for seizure risk from trials is consistent with findings from large 
observational studies of the use of bupropion SR (slow release formulation) for 
smoking cessation. A post-marketing observational cohort study reported on 11,753 
English patients who had been dispensed bupropion.(31) Eleven seizures were 
reported for a rate of one in 1000. However, four of these were associated with a 
past history of seizure. 
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Another observational study used a UK general practice database to estimate the 
relative incidence of seizure or sudden death in a large sample of 9,329 
individuals.(376) This is the largest safety study of first-time users of bupropion 
reported to date. An equivalent of one additional seizure per 6,219 first time 
bupropion users was found during the first 28 days of treatment, suggesting that 
bupropion has a better safety profile in relation to seizure than previously reported. 
They found no evidence of an increased risk of sudden death. 
Nonetheless, bupropion is contraindicated in patients with a current or past history 
of seizures, and the following predisposing conditions for seizures: 
 patients with a known central nervous system (CNS) tumour 
 patients undergoing abrupt withdrawal from alcohol or any medicinal 
product known to be associated with risk of seizures on withdrawal (in 
particular benzodiazepines and benzodiazepine-like agents) 
 patients with a current or previous diagnosis of bulimia or anorexia 
nervosa 
 patients also taking any other medicinal products known to lower the 
seizure threshold. 
5.5.4 Overdose 
Bupropion may cause adverse effects in overdose. Seizures occur in one in three 
cases of intentional overdose of the immediate release form.(377) There is a close 
relationship between seizures and dose. Those who take more than 30 tablets are 
more prone to seizures and almost every patient who takes more than 60 tablets has 
a seizure.(378)  
A review of bupropion-only, non-therapeutic exposures reported to the US Toxic 
Exposure Surveillance System for 1998-1999 identified 3,755 exposures to 
Wellbutrin® slow release, 2,184 to Wellbutrin®, and 1,409 to Zyban® (bupropion is 
marketed as both Wellbutrin® and Zyban®).(379) Non-therapeutic exposures included 
intentional overdose and unintentional ingestion, as well as reports of adverse 
reactions. Of those exposed to Zyban® who showed any symptoms, 13% developed 
a seizure. There were no deaths associated with Zyban®. To date, no patient is 
reported to have died while taking bupropion in trials for smoking cessation. 
5.5.5 Cardiac adverse events 
Bupropion has sympathomimetic effects, evidenced by the fact that in overdose, 
tachycardia, hypertension and seizures may occur. However, in clinical trials of 
bupropion in smokers with pre-existing cardiovascular disease, including 
hypertension, no significant adverse cardiovascular side effects were observed.(380-
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382) It is recommended that blood pressure is monitored in hypertensive patients if 
bupropion is co-administered with NRT. 
5.5.6 Abuse potential 
While bupropion is structurally similar to certain stimulants, clinical studies in healthy 
subjects and substance abusers suggest it has a low abuse potential.(383-386) 
Bupropion is not regulated as a controlled substance by the European Medicines 
Agency or by the US Drug Enforcement Administration under the International 
Conventions that regulate drugs with significant abuse potential. 
5.5.7 Precipitation of mania 
Bupropion is contraindicated in patients with a history of bipolar disorder as it may 
cause a manic episode during the depressed phase of their illness, according to 
product safety data. See section 5.6 for further discussion of administering 
bupropion in this group. 
The possibility of mood destabilisation has been observed only in a small number of 
individuals with bipolar disorder, however, and these patients were taking the 
medication as an antidepressant as opposed to smoking cessation.(387, 388) There is 
no strong evidence to suggest that bupropion induces mania in stably-treated bipolar 
disorder when used as a smoking cessation aid.(389) 
5.5.8 Neuropsychiatric adverse events 
Subgroup analysis of neuropsychiatric serious adverse events in the Cochrane review 
detected no difference between the bupropion and placebo groups, with a RR of 
0.60 (95% CI 0.28 to 1.28, 19 trials).(30) The event rates were 0.4% and 0.7%, 
respectively.  
As discussed previously, the 2016 EAGLES trial sought to evaluate the 
neuropsychiatric safety of bupropion, varenicline and nicotine patch in smokers with 
and without psychiatric disorders.(36) The study found a significant increase in 
neuropsychiatric adverse events could not be attributed to varenicline or bupropion 
when compared to nicotine patch or placebo in patients with or without pre-existing 
psychiatric disorders. 
Prior to this, recommendations were conflicting regarding the risk of adverse 
neuropsychiatric events. In 2009, the US Food and Drug Administration (FDA) added 
additional language to their existing boxed warning about the risk of serious mental 
health events, including depressed mood, hostility, and suicidal ideation associated 
with bupropion use for smoking cessations, based upon post-marketing surveillance 
data. This was in contradiction to the position taken by the European Agency for the 
Evaluation of Medicines, which had stated there was ‘no pharmacodynamic nor 
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clinical reason for suspecting bupropion to be causally associated with depression or 
suicide’.   
Observational data was similarly inconsistent before publication of the EAGLES trial. 
In an analysis of five years of data from general practices in the UK, no differences 
in rates of depression, suicide and non-fatal self-harm were detected between 
people prescribed varenicline, bupropion or NRT for smoking cessation.(390) Similarly, 
a registry-based cohort study in Denmark evaluated risk of psychiatric adverse 
events in people prescribed bupropion or varenicline over a three-year period.(391) 
They found no significant difference in psychiatric events between the bupropion 
and varenicline cohorts.(391) However, an analysis based on US data comparing 
suicidal behaviour and depression in people prescribed bupropion, varenicline or NRT 
for smoking cessation did detect significant group differences; both bupropion and 
varenicline demonstrated an increased risk of suicidality and depression compared to 
NRT.(392)  
See section 5.6 for a further discussion of the safety profile of bupropion in mental 
health populations. 
5.5.9 Bupropion in pregnancy 
There does not appear to be an increased risk of major congenital malformations 
associated with prenatal exposure to bupropion. There is insufficient evidence, 
however, regarding the risk of spontaneous abortion.(393) The use of bupropion is not 
currently recommended in pregnant women in Ireland. Similarly, NICE clinical 
guidelines in the UK(307) and the American College of Obstetricians and Gynecologists 
in the US(308) do not recommend the use of bupropion during pregnancy or 
breastfeeding for the purpose of smoking cessation. See section 5.5.3 for a detailed 
discussion on the safety of bupropion in pregnancy. 
5.6 Safety in pregnancy  
5.6.1 Nicotine replacement therapy 
The risks of smoking during pregnancy are well known. The use of tobacco products 
is associated with premature rupture of the membranes, preterm birth, intrauterine 
growth restriction, placenta praevia, abruption of the placenta and sudden infant 
death syndrome.(394) Nicotine easily crosses the placenta. In nicotine patch users, 
amniotic fluid nicotine levels are 88% higher than in maternal plasma, and nicotine 
levels in the fetal circulation are 15% above maternal levels. Nicotine affects fetal 
respiratory movements and circulation in a dose-dependent manner.(395) This raises 
the possibility of fetal toxicity.  
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The long-term fetal and neonatal effects of NRT in humans are unclear. However, 
epidemiological studies have linked prenatal tobacco exposure to the following 
neurobehavioural effects:(395)  
 Attention-deficit hyperactivity disorder 
 Learning disabilities 
 Behavioural problems  
 Increased risk of nicotine addiction 
Whether NRT, at the usually prescribed doses, has the same neurobehavioural 
effects is unknown. The clear benefit of NRT use during pregnancy is that NRT 
delivers nicotine without delivering the additional reproductive toxins present in 
tobacco smoke. Additionally, NRT exposes the mother to continuous low doses of 
nicotine, avoiding the peak levels associated with cigarette smoking. Women should 
receive as low a dose of NRT as possible to maintain smoking abstinence and to 
control cravings. See Chapter 3: Epidemiology for a further discussion on the burden 
of disease attributable to smoking in pregnancy. 
A retrospective study using the Danish National Birth Cohort (1996 to 2002) did not 
demonstrate a significant association between birth weight and duration of NRT use 
(difference in birth weight of 0.25g for each week of NRT use; 95% CI, 2.31 to 2.81) 
or type of NRT product (patch, gum, inhaler).(396) Another study using the Danish 
National Birth Cohort (1997 to 2003) reported no increased risk of major 
malformation the offspring (RR: 1.13; 95% CI, 0.62 to 2.07).(397) 
A meta-analysis of six trials of NRT use in pregnancy (n = 1,745) was inconclusive 
with regard to its safety and effectiveness in pregnancy.(398) There were no 
statistically significant differences between treated and untreated women in rates of 
miscarriage, premature birth, low birth weight, stillbirth, admission to the Neonatal 
Intensive Care Unit (NICU), or neonatal death. It was uncertain whether the lack of 
statistically significant differences was a true effect of NRT or if it was due to 
patients’ poor adherence. Reported compliance rates for either NRT or placebo in 
the studies included ranged from 7% to 29%. 
The Smoking, Nicotine and Pregnancy (SNAP) trial was a randomised controlled trial 
(RCT) involving 1,050 women with pregnancies of between 12 and 24 weeks’ 
gestation who smoked five or more cigarettes daily.(226) All participants received 
behavioural counselling and were randomised to receive either NRT (nicotine patch) 
or a transdermal placebo. There were no significant differences in mean birth weight 
(difference −0.05; 95% CI −0.17 to 0.08), rates of preterm birth (OR 0.90; 95% CI 
0.58 to 1.41), low birth weight (OR 1.38; 95% CI 0.90 to 2.09), or congenital 
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abnormalities (OR 0.70; 95% CI 0.30 to 1.66). However, as the rates of compliance 
were low, it is difficult to draw conclusions.  
A follow-up to this study analysing the long-term outcomes of NRT use found that 
more infants of mothers who were in the NRT group had no impairment compared 
with those in the placebo group (OR 1.40; 95% CI 1.05 to 1.86).(260) Although this 
was the first study to report outcomes beyond two years, the initial compliance rates 
were low and rates of abstinence were self-reported. 
In another RCT studying smoking abstinence rates and fetal effects of nicotine gum 
use for smoking cessation during pregnancy, 194 women were randomised to 
receive behavioural counselling and six weeks of treatment with either 2mg of 
nicotine gum or placebo.(225) Interestingly, birth weights were found to be 
significantly higher in the NRT group (3,287g ± 566 versus 2,950g ± 653, p< 
0.001). Gestational age at delivery was also greater with NRT use (38.9 ± 1.7 weeks 
vs. 38.0 ± 3.3 weeks, p = 0.014). Compliance was low but similar in each group, 
ranging from 90% at the first visit to 30% at the fifth visit. It is worth noting that 
the study population comprised women with comorbid substance-use disorder and 
mental health issues, which may have affected the external validity of the results. 
Two systematic reviews of NRT use during pregnancy concluded that behavioural 
support should be offered to pregnant women before NRT (including cognitive-
behavioural therapy and counselling).(399, 400) Both reviews recommended NRT 
administration under supervision where behavioural therapy fails or in the case of 
higher (more than 5 cigarettes per day) addiction, to decrease the risk for low birth 
weight and preterm delivery associated with continued smoking. 
The Cochrane review (Coleman, 2015) reported on safety outcomes from six trials 
assessing NRT use in pregnant women. Significant increases in serious adverse 
events were not found among the treatment groups.(226-228, 230, 231, 401)   
NRT is advocated as safe in pregnancy by NICE and the Royal College of 
Obstetricians & Gynaecologists in the UK.(307, 308) Current U.S. guidelines recommend 
considering NRT for pregnant smokers only if behavioural therapies fail, and only 
under close supervision of a treatment provider.(264) This recommendation is in light 
of the U.S. Preventive Services Task Force conclusion that NRT in pregnancy has ‘not 
been sufficiently evaluated to determine their efficacy or safety’.(402) The Society of 
Obstetricians and Gynaecologists of Canada’s Guidelines on Substance Use in 
Pregnancy and the CAN-ADAPTT guidelines similarly recommend behavioural 
therapy and or counselling before considering NRT.(403) Despite these 
recommendations, however, many obstetricians may still be reluctant to prescribe 
NRT due to safety concerns.(264, 404)  
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Additional recommendations voiced by researchers include intermittent dosage NRT 
preparations such as gum or nasal spray rather than continuous dose NRT via the 
nicotine patch, and the removal of the nicotine patch at night to reduce overall 
nicotine exposure. NRT should be discontinued if there has been no associated 
reduction in smoking. Pregnant women should also be cautioned against smoking 
while using the nicotine patch because this can increase nicotine levels in both the 
mother and the fetus.(267) 
5.6.2 Varenicline  
There are few studies demonstrating the safety and efficacy of varenicline in a 
pregnant population. Preclinical animal studies have demonstrated placental transfer 
of varenicline, however, they report conflicting evidence regarding adverse 
events.(405)  
A prospective cohort study using prescription event monitoring identified 6,882 
women of reproductive age over a four-year period who were prescribed 
varenicline.(406) For the 23 reports of pregnancy identified (0.84% of all cases), 
exposure to varenicline was from the time of conception for 19 cases. Duration of 
exposure during pregnancy ranged from one day to 16 weeks. Adverse outcomes 
were identified in five of 17 live births: one baby had birth asphyxia and recurrent 
chest infections, one had gastro-oesophageal reflux, one was diagnosed with 
ankyloglossia and two had feeding difficulties. This study suggests that 
approximately 1% of women of reproductive age prescribed varenicline may be 
exposed to this medicine during pregnancy, resulting in significant fetal exposure. 
Given the small study population, it is not possible to draw conclusions about the 
safety and efficacy of varenicline in pregnancy.  
An industry-sponsored, prospective, population-based cohort study analysing the 
effects of varenicline use during pregnancy on major congenital malformations and 
other abnormal pregnancy outcomes was completed by the manufacturer (the Pfizer 
Varenicline Pregnancy Cohort Study) in May 2016.(407) The results of this study are 
awaited.  
Varenicline is currently not recommended during pregnancy in Ireland. NICE clinical 
guidelines in the UK(307) and the American College of Obstetricians and Gynecologists 
in the US(309) similarly do not recommend varenicline use during pregnancy or 
breastfeeding.  
5.6.3 Bupropion  
Bupropion and its active metabolites cross the placenta to the fetal circulation.(408) 
Neither bupropion nor its metabolite appear to affect placental tissue viability or 
functional parameters.(409)  
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Initial reports from the GlaxoSmithKline Bupropion Pregnancy Registry suggested a 
possible increase in cardiovascular defects following exposure to bupropion during 
pregnancy.(410) Further analysis of data from the manufacturer’s pregnancy registry, 
which reported on prospectively enrolled pregnancies with 1,005 outcomes, 
however, observed no increased rate of major malformations compared with the 
general population.(411)  
Nonetheless, the effect on the fetus remains unclear, especially with first trimester 
exposure. Chun-Fai-Chan et al. (2005) found no increase in the rate of major 
congenital malformations compared with controls in 136 women exposed to 
bupropion in the first trimester.(39) In addition, there was no significant change 
observed in rates of live birth, stillbirth, therapeutic abortion, mean birth weight, or 
gestational age at birth. However, there were significantly more spontaneous 
abortions in the treatment group (14.7% vs. 4.5%, p = 0.009). The sample size in 
this study was small, and it is therefore difficult to draw conclusions about the safety 
of the drug.  
In a prospective observational matched control study of 44 pregnant women, the 
smoking cessation rate was 45% in women who received 150mg to 300mg of 
bupropion daily, compared with 13.6% in controls (p = 0.047), and there was no 
difference in pregnancy outcomes.(412)  
Another study of 1,213 women with first trimester exposure demonstrated no 
increase in malformations compared with those using bupropion after the first 
trimester, or using other antidepressants.(413) Some participants in this study were 
also on other antidepressants besides bupropion. A limitation of the study was that 
the authors were unable to confirm exposure to bupropion as information was 
obtained from dispensing data.  
In contrast, a retrospective case–control study of 6,853 infants with major heart 
defects and 5,869 control infants showed an association between bupropion 
exposure in early pregnancy and left outflow tract heart defects (OR 2.6;95% CI 1.2 
to 5.7, p = 0.01).(414) Bupropion exposure was defined as any reported use between 
one month pre-conception and three months post-conception. This finding, however, 
may have been confounded by a concurrent diagnosis of depression or recall bias 
regarding exposure to bupropion. 
Most studies have concluded that there does not appear to be an increased risk of 
major congenital malformations associated with prenatal exposure to bupropion. 
There is insufficient evidence, however, regarding the risk of spontaneous 
abortion.(393) The use of bupropion is currently not recommended in pregnant 
women in Ireland. NICE clinical guidelines in the UK(307) and the American College of 
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Obstetricians and Gynecologists in the US(309) similarly do not recommend the use of 
bupropion during pregnancy or breastfeeding for the purpose of smoking cessation. 
5.7 Safety in mental health populations 
5.7.1 Significance of smoking in psychiatric settings 
The burden of disease attributable to smoking in psychiatric populations is 
substantial. Patients diagnosed with severe mental illness are up to three times more 
likely to be smokers than the general population. Smoking prevalence reaches 
figures of up to 70% for certain sub groups, such as in-patients and patients with 
schizophrenia.(415, 416) Mental illness is associated with higher levels of nicotine 
dependence, intensity of smoking, and smoking severity.(195, 417) Smoking is believed 
to account for the majority of excess mortality among individuals with serious mental 
illness.(89) Life expectancy among people with severe mental illness is ten to 25 years 
less than that among the general population.(418, 419)  
The underlying reasons for the strong relationship between smoking and psychiatric 
disorders are complex and vary by diagnosis. Genetic, neurological and psychosocial 
factors are proposed to contribute to the increased smoking prevalence in this 
group.(420, 421) The interaction of nicotine with neurotransmitter systems in the brain 
mediates the release of neurotransmitters such as dopamine, serotonin and 
noradrenaline; affecting mood, attention, cognitive functioning and memory. Self-
medication of symptoms may serve as a potential explanation for the increased rates 
of smoking in individuals with mental illness.(422)  
Also of clinical relevance are the interactions caused by polycyclic aromatic 
hydrocarbons of tobacco smoke that induce liver enzymes and reduce the clearance 
of psychotropic medications. For example, when a patient stops smoking, clozapine 
and olanzapine dosages may need to be reduced by 30 to 40% to avoid toxicity.(423) 
Nicotine does not create this effect, and therefore NRT will not affect changes in 
medication levels following smoking cessation. 
5.7.2 Systemic Issues 
Between 2004 and 2011, the decline in smoking among individuals with mental 
illness was significantly less than among those without mental illness.(424) It appears 
that tobacco control policies for the general population were not as effective in 
mental health populations. It is widely believed that tobacco dependence has been a 
largely neglected issue in mental health settings.  
While a societal change towards reducing smoking and the exposure to tobacco 
smoke in public and work places has taken place in Ireland over recent years, 
smoking is still largely condoned across psychiatric settings. Many mental health 
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professionals inappropriately perceive it as an important coping mechanism for 
patients.(425) Smoking may also be perceived as constituting a means of reward or 
punishment in achieving compliance with treatment, and may play an important part 
in the context of social interaction between patients and staff.(401)  
5.7.3 Smoking cessation interventions 
In general, smoking cessation treatment in mental health populations follows similar 
principals to smoking cessation in other populations.(426) Contrary to common belief, 
smokers within mental health populations are frequently equally as willing to quit as 
those in the general population, and may do so without aggravating psychiatric 
symptoms if provided with appropriate support.(427) Unfortunately, success in 
quitting appears to be only half of that as in the general population, and relapse 
rates within mental health populations are higher.(428) 
Nicotine replacement therapy (NRT) is generally well-tolerated in psychiatric 
populations. In addition, behavioural interventions with proven effectiveness in the 
general population, including group support, have been successfully integrated into 
tailored behavioural programmes for patients with serious mental illness.(429) It has 
been noted that mental health populations may need a higher level of support to 
quit, especially one-to-one support.  
It has been demonstrated that NRT may be required at higher doses than in the 
general population, and a combination of patch and a faster-acting form (such as 
gum or inhaler) is preferable. It has also been demonstrated that a longer duration 
of NRT may be required for prolonged abstinence.(430, 431)  
5.7.4 Neuropsychiatric safety of varenicline, bupropion and NRT  
Concerns about the neuropsychiatric the safety of varenicline and bupropion arose 
from sporadic case reports (432) and post-marketing surveillance analyses (see 
below).  
Observational studies have demonstrated inconsistent results. RCTs (including the 
EAGLES trial) and meta-analyses of varenicline and bupropion in smokers with 
various psychiatric disorders identified no neuropsychiatric safety issues and no 
worsening of the underlying psychiatric condition.(30, 433-437) These results need to be 
viewed with caution, however, in view of the difficulties in disentangling treatment-
related events with other potential confounding factors (for example, psychiatric 
effects of nicotine withdrawal, and increased suicide rates among smokers).(170) 
5.7.5 Postmarketing surveillance  
In May 2007, the European Medicines Agency informed the FDA that they were 
investigating a signal of suicidality-related adverse events with varenicline. Later in 
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2007, a fatal case involving bizarre and aggressive behaviour by a varenicline-
treated patient became highly-publicised. The European Medicines Agency 
subsequently issued a black triangle warning for its use in patients with pre-existing 
psychiatric conditions.  
The FDA undertook evaluations of the post-marketing data regarding cases of 
suicide and cases of bizarre and aggressive behaviour associated with varenicline, 
bupropion and NRT.(438, 439) Varenicline had the largest proportion of reports (24%) 
in which it was explicitly stated that the suicidal events were a first-time significant 
behaviour change from the past, followed by bupropion (15%) and nicotine (none). 
Varenicline cases had the most reports that described worsening of pre-existing 
psychiatric disease (17%) compared to nicotine (12%) and bupropion (8%); 
depression was the most common pre-existing psychiatric condition that worsened 
for all three drugs. The study concluded there was a possible association between 
suicidal events and the use of varenicline and bupropion. A new product warning 
section was added to highlight the risk of serious neuropsychiatric adverse events 
associated with varenicline, especially in patients with pre-existing psychiatric 
disorders.  
For bupropion, there was a similar recommendation to add language to the already 
existing product warning about the risk of suicidality in those using bupropion for 
smoking cessation in 2009. This was in contradiction to the position taken by the 
European Agency for the Evaluation of Medicines, which had stated there was 
‘neither a pharmacodynamic nor clinical reason for suspecting bupropion to be 
causally associated with depression or suicide’.(438)  
The black triangle warning issued by the European Medicines Agency for varenicline 
was removed in May 2016 following publication of safety and efficacy data from the 
EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial.(440) 
The EAGLES trial, published April 2016, found no increased incidence of adverse 
neuropsychiatric effects in patients with or without pre-existing psychiatric disorders (this 
is further discussed below). Similarly, in September 2016, advisors to the FDA’s 
Psychopharmacologic Drugs Advisory Committee and Drug Safety Risk Management 
Advisory Committee voted to have the boxed warning removed following a review of 
data from the EAGLES trial. Pfizer announced in December 2016 that removal of the 
boxed warning for Chantix® has been approved.(441) 
Evaluating the risk of suicidal ideation and behaviour is complicated by the fact that 
people who smoke have a two-to-three-fold increased risk of suicide.(442, 443) The UK-
based Drug Safety Research Unit’s report of their cohort study of prescription event 
monitoring found no evidence of an excess of suicidal thoughts or behaviours with 
varenicline; both of the reported suicide attempts (out of 2,682 patients) occurred in 
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the context of precipitating factors for the event and with a previous history of 
psychiatric illness.(444) A similar study conducted in New Zealand by the Intensive 
Medicines Monitoring Programme identified one suicide in a cohort of 3,415 
recipients of dispensed varenicline prescriptions.(445)  
5.7.6 Observational studies 
A recent systematic review (June 17, 2016) was carried out by the FDA’s Division of 
Epidemiology to ascertain the neuropsychiatric risk of NRT, varenicline and 
bupropion based on all available observational studies.(438) Studies were selected for 
review if they reported the relative risk of neuropsychiatric events, used an adequate 
design to differentiate temporal relationship between drug exposure and outcomes, 
and attempted to account for baseline group differences because of the 
observational design. A literature review identified a total of six observational studies 
for in-depth review.(369, 390, 391, 446-448) All reviewed studies were retrospective, 
population-based studies. See Table 5.3 for a summary of the studies.  
Of the six studies reviewed, five included assessment of the risk of neuropsychiatric 
medical encounters associated with smoking cessation products (369, 391, 446-448) and 
three evaluated the association between smoking cessation products and the risk of 
suicide or non-fatal self-harm.(369, 390, 446)  
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Table 5.3 Observational studies evaluating neuropsychiatric safety of smoking cessation agents 
Study 
 
Setting Exposure Reference Stratified by 
Psych History 
Main Outcome Findings 
Molero et al. 
2015 
Sweden 
(Nationwide 
linked 
healthcare data) 
Varenicline 
during exposed 
period 
Unexposed 
period 
Yes New psychiatric 
diagnoses or 
suicidal behaviour 
No increased risk of suicidality during 
varenicline-exposed time 
Increased risk of neuropsychiatric 
outpatient visits during varenicline-exposed 
time 
Kotz et al. 
2015 
England 
(Database of 
NHS records 
from GP 
practices) 
Varenicline, 
bupropion, or 
NRT 
NRT No Six-month GP visits 
for depression or 
self-harm 
Significant reduction in neuropsychiatric risk 
among varenicline users vs NRT (34% 
reduction in outpatient depression visit and 
44% reduction in outpatient visit for suicide 
or non-fatal self-harm) 
Significant reduction in risk of depression 
visit in bupropion users compared to NRT 
Meyers et al. USA Varenicline or 
NRT 
NRT Yes 30-day 
neuropsychiatric 
hospitalisations 
No statistically significant difference in the 
risk of neuropsychiatric adverse events 
Cunningham 
et al. 2016 
USA Varenicline or 
NRT 
NRT Yes 30-day 
neuropsychiatric 
hospitalisations 
No statistically significant difference in the 
risk of neuropsychiatric adverse events 
Pasternak et 
al. 2013 
Denmark 
(Nationwide 
linked 
Varenicline or 
bupropion 
Bupropion Yes 30-day 
neuropsychiatric 
emergency 
department visits or 
No statistically significant difference in the 
risk of neuropsychiatric adverse events 
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healthcare data)  hospitalisations 
Thomas et al. 
2013 
UK  Varenicline, 
bupropion, or 
NRT 
NRT No 90-day suicide, 
nonfatal self-harm, 
depression, all-
cause mortality 
No statistically significant difference in the 
risk of neuropsychiatric adverse events 
Key: NRT – nicotine replacement therapy; NHS – National Health Service (UK); GP – general practitioners  
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The findings of the six reviewed epidemiological studies showed inconsistent results. 
Four of the studies did not observe a statistically significant difference in the risk of 
neuropsychiatric adverse events between varenicline versus NRT, varenicline versus 
bupropion, or bupropion versus NRT.(390, 391, 447, 448) The point estimates did not 
suggest a consistent trend of association.  
One study found a significant reduction in neuropsychiatric risk among varenicline 
users (34% reduction in risk of outpatient depression visit and 44% reduction in the 
risk of outpatient visit for suicide or non-fatal self-harm) and a 25% reduction in risk 
of depression visit in bupropion users, comparing to NRT users.(369) Yet, another 
study observed that while varenicline use was not associated with significant risk of 
suicide-related behaviours, the risk of neuropsychiatric in- or out-patient visits 
significantly increased by 18% during varenicline-exposed time compared to 
unexposed time in varenicline users.(446) 
Each of the reviewed studies had limited study designs. The most important 
limitations were:  
1) use of outcome measures with suboptimal sensitivity and specificity,  
2) residual confounding,  
3) use of bupropion (another smoking cessation drug with neuropsychiatric 
risk) as the reference group against which the neuropsychiatric risk of 
varenicline was examined,  
4) inability to assess the influence of pre-existing psychiatric illness on the 
association between smoking cessation treatments and neuropsychiatric 
outcomes.  
All studies relied on diagnostic codes to capture neuropsychiatric adverse outcomes, 
which likely underestimated the absolute risk of events. It is difficult to estimate how 
many outcome events were missed in each study or to know whether or not the 
proportion of outcome under-ascertainment varied among study drugs, which 
resulted in decreased precision of estimates and unpredictable direction of bias. 
Another major concern of the existing observational data is residual confounding and 
channelling bias, especially among the three studies that included data received 
after the publicity of the neuropsychiatric safety concern associated with varenicline 
and bupropion.(369, 390, 446) Adverse publicity may have resulted in patients with a 
history of neuropsychiatric illness being preferentially prescribed NRT, and healthier 
patients or patients at lower risk of neuropsychiatric events being preferentially 
prescribed the other two drugs (that is to say, channelling bias).  
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5.7.7 EAGLES 2016 trial 
EAGLES 2016, a double-blind triple-dummy randomised controlled trial (RCT), is the 
largest trial to date to have been conducted comparing varenicline, bupropion, NRT 
and placebo. Individuals were stratified by the presence (n=4,074) or absence 
(n=3,984) of a history of psychiatric disorders.(36) The primary safety endpoint was a 
composite measure of 16 neuropsychiatric adverse events. Rates of neuropsychiatric 
adverse events were similar across all four treatment groups, with more adverse 
events in the psychiatric cohort.  
Event rates in the psychiatric cohort during treatment and up to 30 days after were 
varenicline 6.5%, bupropion 6.7%, NRT 5.2% and placebo 4.9%. The corresponding 
rates in the non-psychiatric cohort were 1.3%, 2.2%, 2.5% and 2.4%, respectively. 
The risk difference between groups was significantly lower for the varenicline group 
compared with placebo in the non-psychiatric cohort (RD -1.28, 95% CI -2.40 to -
0.15); all other differences in the remaining comparisons (varenicline, bupropion, 
NRT, all versus placebo) in both cohorts were statistically non-significant. 
The authors interpreted this as indicating that none of the first-line smoking 
cessation treatments significantly increases the risk of neuropsychiatric adverse 
events when compared with placebo in smokers with or without psychiatric 
disorders. This large, multinational trial provides further evidence that varenicline 
and bupropion can be used safely by psychiatrically stable smokers.  
However, the EAGLES trial was not without its limitations. The trial only included 
smokers with psychiatric disorders who were stable and treated, or who had 
previous psychiatric conditions that were in remission. It may not be possible to 
generalise this to all patients accessing secondary mental health services, 
particularly those who are untreated or symptomatically unstable. In addition, they 
restricted the scope of the psychiatric cohort to smokers in four major disease 
categories (mood, anxiety, psychotic, and borderline personality disorders) and 
excluded participants with other current substance use disorders or who were at risk 
of suicide or self-harm. Finally, despite the fact that this was the largest trial of its 
kind, some sub-cohorts in the psychiatric cohort were smaller than others, and 
subsequently were not sufficiently powered to capture rare adverse events (such as 
completed suicide). 
Nevertheless, EAGLES provided additional evidence that varenicline and bupropion 
can be used safely by psychiatrically stable smokers, reflected in changes in safety 
warnings issued by the FDA and EMA. In addition, it provided valuable information 
on efficacy in this cohort. The first-line medications (varenicline, bupropion, and 
NRT) were more effective compared to placebo, with varenicline the most effective 
single agent. 
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5.7.8 Additional safety considerations with bupropion 
In addition to safety concerns regarding neuropsychiatric adverse events discussed 
previously, additional care must be taken when prescribing bupropion to specific 
patient groups. For these patients, NRT or varenicline should be considered. 
Bipolar affective disorder 
Bupropion is currently contraindicated in patients with bipolar affective disorder as it 
may precipitate manic symptoms during the depressed phase of the illness. This 
potential for mood destabilisation, however, has been observed only in a small 
proportion of individuals who were taking the medication as an antidepressant,(387, 
388) and there is no strong evidence to suggest that bupropion induces mania when 
used as a smoking cessation agent in stable bipolar affective disorder. Nevertheless, 
bipolar patients who are taking bupropion as a smoking cessation aid should be 
closely monitored for signs of accelerated mood cycling, and this medication should 
only be used in conjunction with a mood stabilising agent. Prescribers must also be 
aware of the potential for drug interactions with other mood stabilisers (for example, 
carbamazepine, which induces metabolism of bupropion and decreases plasma levels 
substantially).(449) 
Schizophrenia 
There is a theoretical concern about the safety of using bupropion in patients with 
schizophrenia, as bupropion may precipitate or exacerbate psychosis.(450) This is 
thought to be due, in part, to its dopaminergic action.(374) In addition, bupropion and 
its metabolite inhibit the cytochrome P450 CYP2D6 isoenzyme.(451) Therefore the use 
of bupropion alongside many of the drugs used in the treatment of schizophrenia 
that are metabolised by this isoenzyme (including antipsychotic medications such as 
risperidone and haloperidol) may cause significant drug interactions.(33)  
Conditions that lower seizure threshold 
Due to the risk of seizures, bupropion is contraindicated in certain conditions that 
lower the seizure threshold. Many patients with such conditions access secondary 
mental health services, including those with eating disorders (such as anorexia and 
bulimia nervosa),(452) withdrawal from benzodiazepines and alcohol(453) and certain 
antipsychotics.(389)  
Concurrent psychotropic medications 
Concomitant use of monoamine oxidase inhibitors (MAOIs) and bupropion is 
contraindicated.(454) MAOIs, used in the treatment of depression (including atypical 
depression), may result in hypertensive crises.(455) Bupropion inhibits the reuptake of 
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dopamine and norepinephrine and can increase the risk of hypertensive reactions 
when used together with drugs that also inhibit the reuptake of dopamine or 
norepinephrine, including MAOIs. The potential for drug interactions with mood 
stabilisers such as carbamazepine (449) and antipsychotics metabolised by 
cytochrome P450 CYP2D6 isoenzyme (456) must also be taken into consideration. 
Recommendations  
Key recommendations for the administration of bupropion in psychiatric populations 
include the following:(457)  
 cautious treatment initiation 
 close monitoring for mood and behaviour changes during therapy 
 patient and provider education  
 regular follow-up  
 regular plasma monitoring of therapeutic drugs. 
 
5.8 Safety in adolescents 
5.8.1 Nicotine replacement therapy  
There is little reason to believe that nicotine replacement therapy (NRT) poses a 
significantly greater risk to adolescent smokers compared to adult smokers. NRT is 
licensed in individuals over the age of 12 under the recommendation of a healthcare 
professional.(305)  
Several clinical trials of NRT in adolescents have been published.(458-461) In general, 
these studies tend to report low quit rates, with no significant difference between 
active and placebo treatments, and low adherence to therapy. However, the studies 
note no serious adverse events associated with NRT use in this group. 
5.8.2 Bupropion 
Bupropion has been widely used for psychiatric disorders in children and adolescents 
with few significant adverse events. Trials of smoking cessation with bupropion in 
adolescents with and without psychiatric disorders have proven safe, however 
efficacy is generally lower than the adult population.(462, 463)  
Zyban® is not currently recommended in Ireland for those under 18 years.(454)  
5.8.3 Varenicline 
The safety of varenicline has not been adequately evaluated in adolescents.(464) 
Champix® is not licensed for use in the adolescent population in Ireland.(357) 
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5.9 Discussion 
Pharmacological interventions for smoking cessation are generally safe and well-
tolerated. In the absence of contraindications, these agents are undoubtedly safer 
than the continuation of smoking.  
Unfortunately, there are limited options available for certain patient groups, 
including pregnant women and mental health populations, due to contraindications 
and relative contraindications to the use of selected pharmacological interventions. 
The safety of e-cigarettes is an evolving area of research. While believed to be safer 
than smoking, evidence on long-term safety of e-cigarettes has yet to be 
established. No substantive evidence of adverse events was identified associated 
with behavioural interventions for smoking cessation.  
5.10 Key points 
Nicotine replacement therapy (NRT) 
 Most adverse events associated with NRT are mild and temporary in nature. 
 Commonly reported side effects include mild skin sensitivity (patch), hiccoughs 
and gastrointestinal disturbance (gum), local irritation of mouth, nose and throat 
(inhaler, spray and sublingual tablets).   
 Chest pain and heart palpitations are potentially the only clinically significant 
serious adverse events to emerge from the trials. 
 NRT does not appear to be associated with an increase in serious cardiovascular 
adverse events, in those with and without pre-existing cardiac disease. 
E-cigarettes 
 Safety data on e-cigarettes is limited to two small short-term clinical trials. Mild, 
temporary adverse drug reactions were found, such as throat and respiratory 
irritation and dry cough. 
 Toxicological studies have demonstrated that while toxic chemicals may be 
present in e-cigarette vapour, they are observed at lower concentrations than in 
cigarette smoke. Data on long-term toxicity from e-cigarette use is not yet 
available. 
 While believed to be safer than smoking, direct confirmation from clinical studies 
that long-term e-cigarette use leads to reductions in smoking-related diseases is 
not available. Therefore, the clinical effect of long-term e-cigarette use is 
unknown.  
 The risk to bystanders from ‘passive vaping’ appears to be very low. 
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Varenicline 
 Nausea is the most commonly reported adverse event associated with varenicline 
use. Other common adverse events include insomnia, abnormal dreams and 
headache. 
 There is conflicting evidence regarding cardiac adverse events associated with 
varenicline. A systematic review and meta-analysis from 2016 did not find 
evidence of an association, in people with or without cardiovascular illness. 
Bupropion 
 The most common adverse events associated with the use of bupropion are 
insomnia, dry mouth and nausea. 
 Allergic reactions requiring medical treatment are rare. 
 Bupropion increases the risk for seizures; a seizure rate of one in 1000 is given in 
the product safety data. Bupropion is contraindicated in patients with an 
increased risk of seizures. 
 Bupropion is contraindicated in patients with a history of bipolar disorder as it 
may precipitate a manic episode. 
Pregnancy 
 Nicotine easily crosses the placenta. The long-term fetal and neonatal effects of 
NRT in humans are unclear; however, it is safer than continued smoking. 
 Major congenital malformations have not been observed in randomised controlled 
trials (RCT) and observational studies associated with NRT use. NRT is 
recommended during pregnancy, particularly when behavioural therapy fails. 
 The use of bupropion and varenicline is not recommended during pregnancy or 
breastfeeding in Ireland. 
Mental health populations 
 Observational and post-marketing surveillance data have shown inconsistent 
findings relating to neuropsychiatric adverse events for bupropion and 
varenicline.  
 The EAGLES 2016 (Evaluating Adverse Events in a Global Smoking Cessation 
Study) trial, however, did not show a significant increase in neuropsychiatric 
adverse events attributable to varenicline or bupropion relative to nicotine patch 
or placebo in patients with or without pre-existing psychiatric disorders. 
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6 Economic analysis 
This chapter reviews previously published cost-effectiveness analyses of smoking 
cessation interventions. It also outlines the methods used in the economic evaluation 
carried out as part of this HTA, including the results of a cost-effectiveness and 
budget impact analysis within the Irish health and social care setting. 
6.1 Review of cost-effectiveness studies 
A review of previous cost-effectiveness studies was carried out in order to 
summarise the cost-effectiveness estimates, and to examine the approaches taken 
to modelling the expected costs and benefits of smoking cessation interventions. 
6.1.1 Details of the search 
A search was conducted in Medline, Embase, the HTA database (via the Cochrane 
Library) and the NHS Economic Evaluation Database (NHS EED, also via the 
Cochrane Library) for cost-effectiveness modelling studies that estimated the long-
term costs and benefits of smoking cessation therapies. The inclusion criteria used 
for the review are shown in Table 6.1. 
Table 6.1 Inclusion criteria for review of cost-effectiveness studies 
Population Unselected adult smokers 
Intervention Interventions designed to optimise the mix of smoking 
cessation treatments provided by quit services at a 
population level that include some or all of the following: 
Pharmacotherapy interventions involving: 
 nicotine replacement therapy (NRT) 
 varenicline 
 bupropion 
 e-cigarettes 
 cytisine 
Behavioural interventions involving: 
 counselling 
 brief advice 
 telephone, text or internet support 
Comparator Current standard of care 
Outcome Incremental cost per additional quality-adjusted life year 
(QALY) or successful quitter 
Study Design Cost-effectiveness modelling study 
Details of the search and the number of studies identified are shown in Figure 6.1. 
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Figure 6.1  Flowchart of studies identified in the systematic review of  
  cost-effectiveness analyses (CEA) 
CEA Search Summary
Date: 22/07/2016
CEA Filter (Embase and Pubmed only): Royle & Waugh
NHS EED (via Cochrane Library): 178
HTA database (via Cochrane Library): 87
Medline (via Pubmed): 102
EMBASE: 137
Total Citations
504
Duplicates
26
Screened
478
Excluded
340
Reviewed
138
Pre 2012* – 94
Study design – 8
Publication type – 2
Outcomes – 1
Intervention – 4
Inaccessible – 2
Duplicate – 1
In progress – 2
Total excluded: 114
Smoking 
cessation CEA 
modelling studies
24
Studies evaluating 
optimal mix of 
interventions
0
Study design - 24
 
* Summary of relevant CEA studies to 2011 taken from systematic 
reviews by Bolin 2012(465) and Ruger 2012(466) 
 
The search identified two systematic reviews of cost-effectiveness analyses 
published in 2012.(465, 466) The results of these reviews were combined with an 
updated search to July 2016, which identified 24 additional studies of potential 
relevance (Figure 6.1).(11, 15, 24, 467-476) However, no prior studies that examined 
optimising the mix of interventions provided at a population level were identified.  
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6.1.2 Summary of cost-effectiveness results 
This HTA aims to identify the optimal mix of interventions that can be provided by 
the health service to reduce the overall prevalence of smoking in the population. The 
search found that no cost-effectiveness modelling studies have been published to 
date that examine this issue. Rather than comparing alternative mixtures of 
interventions with the current standard of care, most of the studies examined the 
cost-effectiveness of one type of intervention (pharmacotherapy, counselling, 
internet support, and so on) compared with placebo or with another type of 
intervention. The results of these studies are of limited relevance as they assume 
that all smokers in the modelled cohort will use their allocated intervention. This 
does not reflect that smokers can choose to use many different types of 
interventions in their quit attempt, and that the majority of smokers who want to 
quit will try to do so unassisted.(477)  
A narrative summary of the most important findings of the modelling studies that 
compare individual interventions to each other is provided in this section, to highlight 
some of the major methodological issues to be considered when estimating the cost-
effectiveness of smoking cessation interventions. As they do not address the 
research question under investigation in this assessment, the relevance and 
applicability of all of these studies is rated as low. 
A 2016 study of smoking cessation in Japan compared the current ‘market mix’ of 
interventions in that country (73% unassisted, 21% NRT, 5% varenicline, 2% 
behavioural therapy) to comparators in which all members of the cohort started their 
first quit attempt using a given treatment.(470) In this model, smokers were allowed 
to have multiple quit attempts and the choice of interventions was informed by 
survey data. The results indicated that varenicline dominated the existing standard 
of care, being more effective and less costly on average. At a willingness-to-pay 
threshold of zero, the probability that varenicline was more cost-effective than the 
existing standard of care was 38%. The degree of uncertainty in the incremental 
cost-effectiveness ratios (ICERs) was high, however, with ICER estimates obtained 
from Monte Carlo simulation being scattered across all four quadrants of the cost-
effectiveness plane.(470)  
Another study in the Netherlands estimated the overall cost-effectiveness of the 
health system reimbursing any smoking cessation intervention compared with not 
funding these types of interventions.(478) This study found that reimbursement of 
these interventions was cost-effective with an ICER of €3,939 per quality-adjusted 
life year (QALY). This was due to higher uptake rates of smoking cessation 
treatments and a greater number of quit attempts as a result of the free provision of 
these interventions.  
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Other relevant research in this area was the development of the NICE return-on-
investment tool, which is designed to allow commissioning groups and local 
healthcare providers in the UK’s National Health Service (NHS) to estimate the costs 
and benefits of changing the package of services offered.(479) The output of this 
project was an Excel-based programme that decision-makers can customise via a 
graphical user interface to estimate the effect of changing the overall package of 
interventions provided. While not a tool for cost-effectiveness analysis, it does 
estimate the difference in costs and QALYs for a given set of interventions over a 
specified time frame. Selection of the proportion of smokers receiving each type of 
intervention is at the discretion of the person using the programme, so it is unclear 
on what basis plausible estimates of the achievable increases in the uptake of 
various interventions are arrived at.  
A previous modelling study on the combined effect of all smoking cessation 
measures (including taxation and increased regulation) on smoking prevalence and 
mortality in Ireland estimated that changes in cessation treatment policy was 
associated with a 39% increase in cessation rates.(480) These changes mainly 
involved a greater level of reimbursement of pharmacotherapy interventions and 
behavioural treatments, as well as the establishment of a national QUITline service. 
Although almost all of the existing literature deals with the cost-effectiveness of 
individual interventions as opposed to the overall mix of therapies provided at a 
population level. The results of these analyses are still useful insofar as they provide 
information on the relative cost-effectiveness of different treatments when compared 
directly. Table 6.2 summarises the results of previous economic studies, modelling a 
cohort of smokers in a real life setting, that reported life years gained (LYG) or QALY 
outcomes for a range of pharmacological and behavioural interventions. All results 
are converted to 2016 Euro. The relevance and credibility of the results reported in 
these studies as they relate to the decision question being examined in this HTA was 
assessed using the ISPOR checklist.(481) All were rated as being of low relevance as 
none of the studies included all of the interventions of interest to this HTA, and no 
previous study used cost data that could reasonably be considered applicable to 
Ireland.
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Table 6.2 Summary of previous cost-effectiveness studies 
Study Comparison Perspective
(Country) 
Time 
horizon 
(Discount 
Rate) 
Results 
Fiscella 
1996(482)* 
Physician counselling plus NRT patch 
versus physician counselling alone 
Payer (USA) Lifetime 
(3%) 
Cost per QALY ranged from €5,942 to €14,812 in 
men, and from €6,707 to €9,452 in women 
Wasley 
1997(483)* 
NRT plus brief physician advice versus 
brief advice alone 
Payer (USA) Lifetime 
(5%) 
Cost per LYG ranged from €2,377 to €3,902 for men 
and €4,023 to €5,810 for women 
Song 
2002(484)* 
Counselling alone, counselling plus NRT 
or bupropion, counselling plus NRT and 
bupropion 
Payer (UK) Lifetime 
(0%) 
Cost per LYG vs counselling alone ranged from 
€1,701 to €4,079 for NRT, €1,086 to €2,538 for 
bupropion and from €1,513 to €3,348 for NRT plus 
bupropion  
Antonanzas 
2003(485)* 
Bupropion or NRT versus nothing Payer (Spain) 20 years 
(NA) 
Cost per LYG of €2,165 for bupropion and €5,524 for 
NRT 
Gilbert 
2004(486)* 
Physician counselling plus NRT or 
bupropion versus physician counselling 
Payer 
(Seychelles) 
Lifetime 
(3%) 
Cost per LYG ranged from €1,489 to €5,168 
Feenstra 
2005(487)* 
Minimal GP counselling with or without 
NRT versus intensive counselling with 
NRT or bupropion 
Societal 
(Netherlands) 
Up to 75 
years (4%) 
Cost per QALY ranged from €1,206 to €5,371 
Bolin 
2006(488)* 
Bupropion versus NRT Societal 
(Sweden) 
20 years 
(3%) 
Cost per QALY for bupropion of €740 for men, and 
€549 for women, versus NRT 
Cornuz 
2006(489)* 
Brief physician advice plus NRT or 
bupropion versus brief advice alone 
Payer (USA & 
Europe) 
Lifetime 
(3%) 
Cost per LYG ranged from €834 to €3,666 for men 
and from €3,078 to €9,165 in women 
Bolin 
2008(490)** 
Varenicline versus bupropion Societal 
(Sweden) 
Lifetime 
(3%) 
Varenicline dominated bupropion 
Hoogendoorn 
2008(491)* 
Varenicline versus unassisted quitting or 
NRT 
Payer 
(Netherlands) 
Lifetime 
(4% on 
costs, 1.5% 
on effects) 
Cost per QALY €281 versus unaided, €907 vs NRT 
Howard Varenicline versus bupropion, NRT and Payer (USA) Lifetime Varenicline dominated all comparators 
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Study Comparison Perspective
(Country) 
Time 
horizon 
(Discount 
Rate) 
Results 
2008(492)* unaided quitting (3%) 
Thavorn 
2008(493)* 
Pharmacy-based intervention versus 
routine care 
Payer 
(Thailand) 
Lifetime 
(3%) 
Intervention dominated usual care (cost saving and 
generated LYG) 
Annemans 
2009(494)* 
Varenicline versus brief counselling, 
unassisted quitting or bupropion 
Payer 
(Belgium) 
Lifetime 
(3% on 
costs, 1.5% 
on effects) 
Cost per QALY of €336 versus brief counselling, 
€2,315 versus unassisted quitting and cost saving 
versus bupropion 
Bae 
2009(495)** 
Varenicline versus bupropion and NRT Payer (South 
Korea) 
Lifetime 
(5%) 
ICER of €4,761 compared with bupropion and NRT 
Bolin 
2009(496)* 
Varenicline versus NRT in Belgium, UK, 
Sweden and France 
Payer 
(Europe) 
Lifetime 
(3.5%) 
Varenicline was cost saving in all countries except 
France, where the cost per QALY was €3,917 
Bolin 
2009(497)* 
Extended varenicline versus placebo Societal 
(Sweden) 
50 years 
(3%) 
Cost per QALY €7,345 for men and €7,389 for 
women 
Igarashi  
2009(498)* 
Physician counselling versus physician 
counselling plus varenicline 
Payer 
(Japan) 
Lifetime 
(3%) 
Addition of varenicline dominated in men, and had a 
cost per QALY of €2,980 in women 
Knight 
2010(499)* 
Extended varenicline versus varenicline, 
bupropion, NRT or unassisted quitting 
Payer (USA) Lifetime 
(3%) 
Extended varenicline dominated all comparators 
except for normal duration varenicline, where the 
cost per QALY was €971 
Linden 
2010(500)** 
Varenicline versus bupropion and 
unaided quitting 
Payer 
(Finland) 
20 years 
(5%) 
ICER of €9,466/QALY and €8,389/QALY compared 
with bupropion and unaided cessation, respectively   
Athanasakis 
2012(24) 
Varenicline versus bupropion, NRT and 
unaided cessation 
Payer 
(Greece) 
Lifetime 
(3%) 
Varenicline dominates all comparators 
Guerriero 
2013(15) 
Text message bases smoking cessation 
support versus usual care 
Payer (UK) Lifetime 
(3.5%) 
Text message support dominated 
Leaviss 
2014(471) 
Cytisine versus varenicline Payer (UK) Lifetime 
(3.5%) 
 
Cytisine dominated varenicline, being more effective 
and less costly 
VonWartburg Standard and extended-use varenicline Payer Lifetime Both varenicline regimens dominate comparators. 
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Study Comparison Perspective
(Country) 
Time 
horizon 
(Discount 
Rate) 
Results 
2014(475) versus bupropion, NRT and unassisted 
quitting 
(Canada) (3%) ICER for extended varenicline versus standard course 
was €3,602/QALY 
Cantor 
2015(467) 
Physician and or pharmacist training 
versus no training 
Payer (USA) Lifetime 
(3%) 
No training dominated either physician only, or 
pharmacist only, training. Training for both was 
associated with an ICER of €2,784/QALY compared 
with no training. 
* Identified in systematic review by Ruger; ** Identified in systematic review by Bolin; ICER – incremental cost-effectiveness ratio; LYG – life year gained; 
NRT – nicotine replacement therapy; QALY – quality-adjusted life year.
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
213  
The existing literature in this area has consistently found that practically all smoking 
cessation interventions are associated with very low ICERs, which would make them 
appear extremely cost-effective using conventional willingness-to-pay thresholds in 
Ireland and elsewhere. In many cases, varenicline was found to dominate 
bupropion, NRT and unassisted quitting, by both improving outcomes and reducing 
the overall costs to the health service. However, there are aspects of these analyses 
that limit their applicability to the policy question examined in this HTA, which is 
interested in the overall mix of treatments provided. These issues are described in 
the next section which examines relevant methodological aspects of the economic 
evaluation of smoking cessation services. 
6.1.3 Methodological issues in economic evaluations of smoking cessation 
Previously published studies differ from this HTA in how the comparators included in 
the economic models were defined. In the majority of these analyses, all smokers in 
the modelled cohort were assumed to receive the same treatment, and were 
compared with a cohort that all received either a different treatment or no 
intervention. While this is useful to directly compare two or more therapies, it does 
not provide information on the effect of policy decisions that aim to optimise the 
overall mix of interventions being funded in an effort to reduce the prevalence of 
smoking nationally. Taking this broader view has a number of implications. The first 
is that one needs to reliably estimate preferences in relation to cessation options for 
smokers attempting to quit. This can pose difficulties if national survey data on quit 
methods are unavailable, or fail to provide enough detail to estimate what 
proportion of quitters use each type of intervention (alone or in combination) or no 
support at all. Once the current standard of care has been sufficiently described, it is 
necessary to define alternative states of affairs based on plausible changes in the 
proportion of patients receiving each type of intervention. Estimating what can 
realistically be achieved in this context is challenging. For instance, evidence from 
Chapter 4 indicates that varenicline is associated with better long-term cessation 
outcomes than NRT, but 2015 Healthy Ireland survey data shows far fewer Irish 
smokers making a supported quit attempt use varenicline compared with NRT (<4% 
versus 24%). It is unclear what effect any prospective policy change designed to 
increase varenicline use would have on these figures.  
Similar uncertainty surrounds the use of e-cigarettes, which are now the second 
most popular option (after unassisted quitting) in Ireland for those attempting to 
quit (29%).(1) Given the uncertainty in relation to defining what effect a given policy 
will have on the overall proportion of people availing of each cessation intervention, 
the comparators in this analysis can more usefully be chosen with the aim of 
evaluating what changes are likely to efficiently reduce the overall smoking 
prevalence, and then trying to develop policies that help effect these changes. This 
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involves taking a more exploratory approach, similar to a scenario analysis, of the 
effect of altering the current mix of interventions, rather than evaluating the effect 
of a specific a priori policy decision. While this information is essential for designing 
policy that will bring about worthwhile changes in smoking cessation preferences 
among those attempting to quit, specification of particular policy measures that 
could be employed in the pursuit of a target mix of interventions is beyond the 
scope of this HTA. Instead, it focuses on the first step of identifying objectives that 
smoking cessation services could work towards, and considering the desirability or 
otherwise of expected changes that are likely to occur given current trends in the 
uptake of smoking cessation interventions.  
The way in which the clinical effectiveness of each of the smoking cessation 
interventions is estimated is obviously of crucial importance in the analysis. The 
findings of the review of published cost-effectiveness studies indicate that there is a 
high degree of heterogeneity in the estimates of absolute quit rates among groups 
using each type of cessation aid. These differences arise primarily due to two issues:  
1. the diversity of estimates of the quit rate for unassisted smoking cessation 
attempts, and 
2. the difficulty in estimating the combined effect of pharmacotherapy and 
behavioural support interventions for those whose quit attempt involves both.  
Unassisted quit rates used in recent economic analyses have ranged from 2% to 
9%.(15, 467) If the absolute quit rates for each of the intervention groups are 
calculated with reference to the unassisted quit rate (by applying the relative effect 
for each type of intervention), then any differences are propagated though the 
model. This potentially has significant implications for the overall results.  
Difficulties in estimating the combined effect of pharmacological and behavioural 
support interventions arise from the fact that the majority of the trials in this area 
have sought to isolate the relative effect of a single intervention (be it a drug or a 
form of counselling), rather than the combined effect of specified drug and 
behavioural support interventions when used together. While this makes sense when 
attempting to establish the efficacy of a particular treatment, it poses problems 
when modelling routine clinical practice that usually involves some form of input 
from a healthcare professional in addition to pharmacotherapy. The inconsistency in 
the evidence for the effect of behavioural therapies adds further complexity. Even 
among studies that can be broadly classified under one heading, there can be a high 
level of heterogeneity in the support provided, and in many cases there is also a lack 
of a consistent dose-response when comparing interventions that differ in intensity 
or duration of contact.  
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One option for estimating the combined effect of pharmacological and behavioural 
support interventions is to assume that the treatment effects can be considered 
either multiplicative or additive. This risks the combined effect being overestimated 
since it assumes that the full benefit of each treatment modality is achieved, when in 
fact the additional benefit of behavioural support as an adjunct to pharmacotherapy 
is less than when it is used as the sole intervention. An alternative is to examine the 
evidence from studies where behavioural therapy was used as an adjunct to 
pharmacotherapy.(166) A meta-analysis of these studies in an unselected adult 
population found that the addition of any type of behavioural support increased 
cessation rate by an average of 18% (RR 1.18, 95% CI 1.09 to 1.28, see chapter 4). 
However, there was no consistent evidence of a dose-response, as the effect 
estimate did not increase linearly with increasing levels of behavioural support. 
Previous economic analyses have also differed in the way the long-term clinical 
implications of smoking cessation were quantified. Smoking-related diseases typically 
included in the analyses were restricted to lung cancer, myocardial infarction (MI), 
stroke, coronary heart disease (CHD), chronic obstructive pulmonary disease (COPD) 
and asthma, although some studies omitted asthma due to a lack of evidence.(24, 465) 
A recent Japanese study that included stomach and hepatic cancers is also of 
note.(470) Increases in the prevalence of smoking-related illnesses are calculated 
using the population-attributable fraction for each disease. However, while this is 
likely to provide the correct population prevalence for each disease, it does not take 
into account the issue of comorbidity and any implications this might have for either 
costs or benefits. Adverse events beyond the incidence of smoking-related illness, 
such as those associated with the cessation interventions themselves, harm to 
others through passive smoking, or the risks associated with any increase in the risk 
of obesity as a result of smoking cessation, were not considered in any of the 
studies indentified in the review. The issue of obesity related to smoking cessation 
was examined in a recent modelling study to evaluate whether savings in health 
costs deriving from smoking prevention and its related diseases are greater than the 
costs associated with increased obesity. This estimated that body mass index (BMI) 
increased by 0.26kg/m2 for quitters compared with those who continued to smoke, 
but that the cost saving from quitting smoking far outweighed the additional costs 
associated with weight gain.(501) 
Most of the previously published cost-effectiveness analyses were based on a limited 
number of economic models that were repopulated with setting-specific clinical and 
cost data.(465) The most widely used of these was the BENESCO model, which was 
originally developed in 2008 to assess the cost-effectiveness of varenicline.(492) This 
is a Markov model with a cycle length of one year that follows a closed longitudinal 
cohort of smokers making a single quit attempt to death or until they reach 100 
years. Smokers who successfully quit can relapse, but smokers who fail on the first 
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quit attempt cannot ever make a second quit attempt. The model estimates clinical 
outcomes and costs for men and women separately, and distinguishes between 
three age groups (18-34, 35-64 and 65-100). Outcomes for males and females are 
modelled separately because of gender differences in smoking prevalence, as well as 
smoking-related mortality and morbidity. Disease states included in the model are 
lung cancer, COPD, ischemic heart disease (IHD), stroke and asthma exacerbation. 
No treatment-related adverse events are considered.  
Analyses using this model have tended to find that varenicline is the dominant 
comparator, being associated with greater health gain and reduced costs compared 
with other interventions. However, as pointed out by Leaviss et al., the assumption 
that smokers can only quit after receiving treatment during the first cycle is likely to 
favour interventions with greater efficacy, such as varenicline, since it perpetuates 
the differences in smoking cessation at one year, rather than allowing this to 
diminish over time as smokers quit unaided or after multiple quit attempts using 
cessation interventions of lower efficacy.(471)  
Among the other challenges that are presented by the economic evaluation of 
smoking cessation interventions is the issue of dealing adequately with the temporal 
effects of smoking on individuals and on smoking prevalence in society. There is a 
great deal of uncertainty about the impact of quitting history on what support 
smokers choose to use in any given quit attempt, and their chances of successful 
quitting, even though it is known that most smokers quit after a considerable 
number of failed attempts.(128, 502) In the absence of sufficient data to characterise 
this complex sequence of events, one option is to assume that each quit attempt is 
independent, and so has the same probability of success each time. This would 
appear to be an adequate approach when considering the populations involved in 
the smoking cessation trials upon which these estimates of effect are based, which 
included smokers drawn from an unselected adult population that would have had a 
diverse range of quitting histories prior to enrolment.  
Other potential temporal changes that may affect the cost-effectiveness of smoking 
cessation interventions delivered at the level of the individual include the continuing 
decrease in the prevalence of smoking as a result of population-level interventions 
such as mass media campaigns, price increases, plain packaging initiatives and 
changes in societal attitudes to smoking. Finally, there is the problem of modelling 
the long-term health consequences of smoking, which may take decades to 
manifest. The most common approach is to apply the relative risk of developing 
each of these diseases to people who are current or former smokers. While this 
provides a means of calculating the overall average burden of disease at a 
population level, it does not take into account differences in the duration or intensity 
of smoking history prior to quitting, or differences in the length of time that people 
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in this Markov state have abstained from smoking, which would affect their risk of 
developing a smoking-related illness within a particular age group. 
6.1.4 Summary of the review of cost-effectiveness studies 
No studies that examined the specific research question of interest in this HTA were 
identified in a review of previous economic evaluations of smoking cessation. While 
many have compared different smoking cessation interventions to each other, there 
is a lack of studies examining how to optimise the mix of smoking cessation 
interventions currently available compared with the existing standard of care. 
However, the existing literature does indicate that compared with other types of 
healthcare interventions, smoking cessation interventions are among the most cost-
effective use of resources, with ICERs far below conventional willingness-to-pay 
thresholds in Ireland and elsewhere. Challenges in relation to modelling the 
expected costs and consequences of changing the way smoking cessation services 
are provided in Ireland include: 
 adequately defining comparators,  
 estimating absolute quit rates for each intervention and for unassisted 
quitting,  
 and taking account of societal level interventions such as increased regulation 
and taxation on the long-term cost-effectiveness of smoking cessation 
services provided at the level of the individual. 
6.2 Economic analysis methods 
An analysis of the cost-effectiveness and budget impact of smoking cessation 
services in Ireland was carried out using an original decision analysis model 
developed for this HTA. This section reports the methods used in this analysis and 
the findings of the research. 
6.2.1 Type of economic evaluation 
A cost-effectiveness analysis was carried out to estimate the incremental cost per 
additional smoker achieving long-term cessation (six months or more) for a range of 
different comparators. These were defined in terms of the proportion of smokers 
using each type of cessation intervention, including unaided quitting, in their attempt 
to stop smoking.  
A cost-utility analysis was also carried out to estimate the incremental cost per 
quality-adjusted life year (QALY) gained for each comparator, taking into account 
the long-term costs and consequences associated with smoking-related illness. 
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Separate economic evaluations of smoking cessation interventions were not carried 
out for the two sub-groups identified in this assessment (pregnant women and 
people attending secondary mental health services). For pregnant women there was 
evidence of short-term benefits in terms of cessation during pregnancy, but not in 
terms of longer term cessation. The included studies were not designed to detect 
changes to obstetric and neonatal outcomes. Due to the lack of data on longer term 
outcomes a full economic evaluation was not justified. In relation to people 
attending secondary mental health services, evidence of effectiveness was only 
found for a limited number of interventions and thus there was insufficient evidence 
of long-term outcomes to justify an economic evaluation.  
6.2.2 Target population and setting 
The primary population of interest was unselected adult smokers aged 18 years or 
over making a quit attempt in Ireland. The population includes those with and those 
without a Medical Card. The model examined differences in the rates of the following 
four smoking-related illnesses in each of the modelled comparators: lung cancer, 
stroke, ischaemic heart disease (IHD) and chronic obstructive pulmonary disease 
(COPD). 
6.2.3 Base case and comparators 
The base case comparator was the current mix of interventions used (current 
practice) in Ireland, which was characterised by the proportion of current smokers 
using each type of smoking cessation method in their quit attempt. This was 
informed by data from the Healthy Ireland survey 2015, details of which are 
described in Figure 6.16. These data indicate that e-cigarettes are widely used as a 
cessation aid by Irish smokers seeking to quit, even though, unlike other smoking 
cessation therapies, e-cigarettes are not currently advocated by smoking cessation 
services or reimbursed through the Health Service Executive (HSE). Given their 
widespread use, and based on the availability of randomised controlled trial (RCT) 
data on their relative effectiveness as a smoking cessation option (Section 4.2.5), 
they are included in the analysis as part of the mix of interventions comprising 
current practice and in each of the comparator strategies. 
Interventions were initially compared directly to each other through a cost-
effectiveness analysis which assumed that 100% of smokers made one quit attempt 
per year, all using a given intervention, in order to estimate the relative cost-
effectiveness of each intervention on its own, compared to each other intervention 
on its own (for example, 100% of those attempting to quit using varenicline versus 
100% using NRT and so on). 
Comparator strategies were then chosen based on plausible changes in the 
proportion of smokers willing to use each individual type of cessation intervention as 
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a result of policies to promote evidence-based decision-making by smokers who wish 
to increase their chances of quitting. In formulating the strategies, consideration was 
give to the likely influence of patient preferences, economic incentives, and societal 
trends in smoking cessation. Strategies were also informed by international data on 
the proportion of quit attempts made using each type of intervention in other 
countries. 
For clarity, the difference between these two types of analysis is illustrated in Figure 
6.2. 
Figure 6.2 Illustration of the difference between the comparison of 
different intervention mixes and the comparison of individual therapies 
 
6.2.4 Perspective, time horizon and discount rate 
The analysis of the incremental cost per person quitting was carried out from a 
quasi-societal perspective, which took into account all direct costs of smoking 
cessation interventions, whether they fell on the individual or the publicly funded 
health and social care services. The analysis of the long-term QALY outcomes 
associated with smoking cessation (cost-utility analysis) included all costs included in 
the primary analysis, as well as the direct costs to the HSE for treatment of smoking-
related illness. The cost of cigarettes was excluded, so savings to individuals who 
successfully quit, or any associated decrease in tax revenue accruing to the State, 
were not factored into the cost-effectiveness analysis. 
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This analysis does not involve modelling the natural history of smoking at the level 
of the individual, as this would require detailed knowledge of the relationship 
between duration and intensity of smoking and the subsequent incidence of 
smoking-related morbidity and mortality decades later. Rather, the analysis models 
the effects of smoking at a population-level using data on the percentage of cases of 
a particular group of diseases that are attributable to smoking (the population 
attributable fraction [PAF]). Therefore, the important consideration when choosing 
the appropriate time horizon for the analysis is not the delay between exposure to 
tobacco smoke and the development of smoking-related illness, but rather the 
changes over time in the overall prevalence of smoking that could render individual-
level smoking cessation services more or less cost-effective over time. The 
uncertainty involved in estimating any future changes in smoking behaviour at a 
population-level means that the external validity of using an extended time horizon 
is questionable. For this reason, the time horizon used in this analysis was 20 years. 
A discount rate of 5% was applied to both costs and benefits, in line with national 
HTA guidelines.(152) 
6.2.5 Model structure 
An original state transition Markov model was developed to compare the costs and 
consequences of changing the proportion of smokers using each type of cessation 
intervention in their quit attempt. The model is an open cross-sectional population 
model that tracks the population of smokers at the outset of the simulation (2016) 
and allows new smokers to enter the model over the 20-year time horizon. The basic 
model structure is shown in Figure 6.3. 
6.2.6 Sensitivity Analysis 
Monte Carlo simulation was carried out, with each parameter being defined as a 
distribution based on the plausible range of values, which were then sampled over 
the course of 10,000 replications to take account of the uncertainty associated with 
the model outputs. Deterministic univariate sensitivity analysis was carried out to 
estimate the effect of uncertainty pertaining to individual parameter estimates. 
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Figure 6.3 Basic Markov model structure for each comparator 
Smokers
Former 
Smokers
Dead
New smokers entering the population
(Smokers who turn 18, 
those who take up smoking for the first time >18, 
people who are former smokers at the outset who relapse)
 
At the outset, the smoking state is populated with the total number of smokers in 
Ireland at present (2016). There is nobody in either the former smoker or dead state 
at the outset. New smokers enter each year, representing those who are smoking 
when they turn 18, those who take up smoking for the first time aged over 18, and 
those who were former smokers in 2016 who later relapse. The cycle length is one 
year and transitions between the states are as follows: 
 Smokers can either stay smoking, successfully quit to become former 
smokers, or die. 
 Former smokers can either remain abstinent, relapse to become current 
smokers, or die. 
The mortality rate and prevalence of smoking-related illness are age and sex-
dependent, and the age and sex structure of the entire cohort changes over the time 
horizon of the analysis in line with Irish demographic projections. The mortality 
differential (difference in life years gained [LYG]) between comparators is based on 
differences in the absolute numbers of people in the smoker and former smoker 
states, since the mortality rate for current smokers is greater than that of former-
smokers of the same age. 
Utility differences stem from the higher mortality rate and increased prevalence of 
the four smoking-related illnesses included in the analysis (lung cancer, stroke, IHD, 
COPD) in comparators with greater numbers of current versus former smokers, as 
these conditions are associated with reduced quality of life. Differences in costs 
between comparators are affected by any changes in the cost of providing cessation 
services, combined with differences in treatment costs associated with increased or 
decreased incidence of smoking-related illness between comparators. 
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All transition probabilities, utility weights and cost parameters used in the model are 
described in greater detail in the following sections. 
6.2.7 Clinical and epidemiological parameter estimates 
The overall mortality rate by five-year age group and gender for smokers and former 
smokers was calculated using data from the US Surgeon General’s report on the 
relative risk of all-cause mortality by age group. This was combined with three years 
of Irish population mortality data from the Central Statistics Office (CSO), and the 
results of the Healthy Ireland survey 2015 on smoking rates for men and women in 
each five-year age band.(1, 104, 503) Figure 6.4 shows the all-cause mortality rates for 
current and former smokers, by age group and gender. 
Figure 6.4 All-cause mortality rates by smoking status, age and gender
 
Irish data on overall lung cancer prevalence by age and gender were obtained from 
the National Cancer Registry Ireland (NCRI, ICD code C34) for the years 1994 to 
2014 (giving 21 years follow-up prevalence).(504) Prevalence rates for current, former 
and never smokers were calculated using the relative risk of lung cancer in each of 
these groups from the Health and Social Care Information Centre (HSCIC) report on 
smoking statistics in England 2015 (as reported in Chapter 3).(505) Prevalence rates 
within the population of smokers, former smokers and never smokers were 
calculated for all four diseases included in this analysis as shown in Figure 6.5.  
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Figure 6.5 Method for calculating disease prevalence rates in current, 
former and never smokers 
Total disease prevalence (PT) within the overall population is the weighted sum of 
the prevalence within the three subgroups (current smokers [PCS], former smokers 
[PFS] and never smokers [PNS], with the weights being the proportion of people in 
each group (current smokers [%CS], former smokers [%FS] or never smokers [%NS], 
Equation 1). 
                                                                
Disease prevalence within the group of current and former smokers can be 
expressed in terms of the prevalence among never smokers using the relative risk of 
the disease in current and former smokers (RRCS and RRFS, respectively). 
                                                                                           
                                                                                            
Substituting these into Equation 1 allows the disease prevalence among never 
smokers (PNS) to be expressed in terms of the total population prevalence (PT), the 
proportion of people who are current smokers (%CS), former smokers (%FS) or never 
smokers (%NS), and the relative risk associated with being a current or former 
smoker (RRCS, RRFS), all of which are known (Equation 8): 
                                                     
                                                             
  
   
                                                             
   
  
 
 
                       
                                    
    
  
                       
                                     
Solving for PNS then allows us to calculate PFS (prevalence rate in former smokers) 
and PCS (prevalence rate in current smokers) using Equations 2 and 3, above. 
Prevalence rates of lung cancer in never, former and current smokers, by age and 
gender, are shown in Figure 6.6.  
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Figure 6.6 Prevalence of lung cancer (ICD C34) by smoking status, age 
and gender 
 
In the absence of validated Irish data on the prevalence of stroke and 
cerebrovascular disease (ICD codes I60-I69), ischaemic heart disease ([IHD], ICD 
codes I20-I25) and COPD (ICD codes I41-I44) by age and gender, prevalence 
estimates were obtained from the international literature. For cerebrovascular 
disease and IHD, population prevalence estimates were based on US data from 
2015.(50) COPD population prevalence rates were taken from a 2011 study from the 
Netherlands.(506, 507) Prevalence among smokers and former smokers was calculated 
as described in Table 6.3 and applied to Irish population data for 2015 obtained 
from the CSO, using relative risks from the HSCIC report.(104, 505) The prevalence 
estimates for stroke, IHD and COPD used in the model are shown in Figures 6.7, 6.8 
and 6.9, respectively. The applicability of international data to Ireland is uncertain, 
given differences that may exist among populations in the distribution of risk factors 
for each disease. To capture this uncertainty surrounding the prevalence data, and 
to examine its potential impact on the results of the analysis, prevalence rates for 
each disease were varied ±20% in the model. 
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Figure 6.7 Prevalence rates for cerebrovascular disease (ICD I60-I69) by 
smoking status, age and gender 
 
Figure 6.8 Prevalence rates for ischaemic heart disease (IHD) (ICD I20-
I25) by smoking status, age and gender 
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Figure 6.9 Prevalence rates for chronic obstructive pulmonary disease 
(COPD) (ICD I41-I44) by smoking status, age and gender 
 
In order to apply these data to calculate all-cause mortality and disease prevalence 
rates within the economic model, it is necessary to estimate the age and gender 
structure of the current population of smokers in Ireland, and how this will change 
over the 20-year time horizon. In this analysis it was assumed that changing trends 
in the age structure of smokers follow those of the general population. This would 
mean that if, say, the percentage of the population that was aged between 18 to 25 
years was growing over time, then 18 to 25 years olds would tend to account for an 
increasing percentage of all smokers, as the absolute numbers within this age group 
would rise. Comparison of longitudinal data on the average age of the Irish smoking 
population from the Smoking Tracker Survey run by the Office of Tobacco Control 
(OTC) in the HSE and CSO data on the overall population structure over the same 
time period would appear to have comparable trends over time (Figure 6.10).(508)  
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Figure 6.10 Trends in the average age of smokers and the general 
population 2002 to 2015 
 
If, for the purpose of modelling, it is assumed that changes in the age structure of 
smokers tend to follow changes in the overall population over the given time 
horizon, it implies that quit rates within each age group remain fairly stable relative 
to each other. If this were not the case, and smokers in some age groups were 
quitting at a much faster rate than others, then one would expect to see smoking 
prevalence within that age group decrease more rapidly than in other age groups. 
To test this, age-specific prevalence rates over the last decade (2005 to 2014) from 
the UK HSCIC smoking statistics dataset were examined (see Figure 6.11). These 
show that although there is a degree of overlap for certain years, when a linear 
regression is performed, smoking prevalence trends over time within each group 
remain stable relative to each other. A possible exception to this trend is in those 
aged 60 and over, although smoking prevalence in this group is also declining. 
Similarly, when a linear regression is carried out on historical UK data on smoking 
rates in males and females, the rate of decline in both appears to be comparable 
(Figure 6.12). This suggests that for the modelling exercise it is reasonable to 
assume that an average quit rate can be applied to the population to estimate the 
change in the overall size of the smoking population over time. Changes in the age 
structure of the overall population can then be used to estimate the age structure of 
the population of smokers over the given time horizon. 
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Figure 6.11 Trends in smoking prevalence by age group (UK data)
Figure 6.12 Trends in smoking prevalence by gender (UK data) 
 
 
Based on this assumption, the expected changes in the percentage of male and 
female smokers in each five-year age group over the time horizon of the model 
(2016 to 2036) was calculated based on the age/gender structure of the current 
smoking population taken from the Healthy Ireland survey, and Irish population 
projections from the CSO (M1F1 population variant).(1, 104) 
As the analysis uses an open Markov cohort, new smokers enter the model each 
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when they turn 18 years, those who take up smoking for the first time after age 18, 
and those who were former smokers at the outset, but relapse over the course of 
the time horizon of interest. While it would be possible to use a closed model to 
compare the cost-effectiveness of different strategies, an open model that takes 
account of these additional smokers provides results that are more indicative of the 
actual scale of smoking cessation activity projected to occur over the time horizon, 
as well as allowing changes in overall smoking prevalence to be estimated into the 
future. However, there are a number of caveats associated with any estimate of 
smoking prevalence derived from this analysis. For example, it may overestimate 
future prevalence by not taking into account wider societal interventions (increased 
taxation, introduction of plain packaging, changing attitudes and behaviours, and so 
on) that may have a significant impact on smoking rates. It also assumes that the 
success rate for unassisted quitting observed in clinical trials applies to all smokers 
choosing this option in Ireland. However, this does not take into account that fact 
that those who are more likely to quit (for example lighter smokers) may be more 
likely to make an unassisted quit attempt. Neither does the analysis attempt to 
model the effect of net migration to or from Ireland, due to the uncertainty that 
exists in relation to the expected age/sex profile and smoking status of Irish 
immigrants and emigrants over the coming decades. Since this is not included in the 
model, national smoking prevalence rates are estimated using population projections 
from the CSO that do not include net migration, as including net migration in the 
denominator would tend to underestimate smoking prevalence in future years when 
net inward migration is anticipated.(104) 
The annual number of people who are smoking at 18 years was estimated using 
CSO projections on the number of people that will reach this age each year of the 
simulated time period, combined with 2015 Healthy Ireland data on the proportion 
of people already smoking at this age, assuming that the decreasing trend observed 
in the prevalence of smoking among 18 year olds between 2002 and 2015 from HSE 
Smoking Prevalence tracker data is maintained (annual percent change [APC] -2.1%, 
95% confidence interval -4% to -0.2%).(1, 104, 508)  
The annual number of people taking up smoking for the first time when aged over 
18 years was estimated using 2010 US data on the age at which people first started 
smoking. These data were taken from the US Surgeon General’s report on tobacco 
use among young adults (Figure 6.13).(509)  
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Figure 6.13 Estimated percentage of people starting smoking by age when 
first tried a cigarette (US data) 
 
These data were applied to the population of Irish non-smokers over 18 years to 
estimate the total number of Irish people over 18 years who will begin smoking for 
the first time each year between 2016 and 2036. Again, it is assumed that the rates 
of first time uptake over the age of 18 years will decrease at the same rate as that 
for 18 year olds (APC -2.1%).  
The final source of new entrants to the smoking population each year in the model is 
those who were former smokers at the outset, but relapse in subsequent years. To 
calculate this, relapse rates for people who have successfully quit smoking were 
estimated from the available literature. A meta-analysis of 10 studies reporting 
outcomes among smokers who had achieved 12-month abstinence reported an 
average relapse rate of 10% in the first year after quitting.(510) A separate 
longitudinal observational study that looked at relapse rates in 483 men who had 
successfully achieved continuous abstinence for two years reported annual relapse 
rates of between 2% and 4% between years two and six, with annual relapse rates 
of less than 1% for those who had remained abstinent for 10 years or more.(511) In 
the model, the relapse rate each year for those having achieving 12-month 
abstinence was based on a UK study on relapse rates from the British household 
panel survey published in 2010, which reported longitudinal data on the same 
population over 10 years.(512) The relapse curve obtained from this data is shown in 
Figure 6.14. Uncertainty about the rate of relapse was incorporated by varying the 
relapse rate by ±20%. 
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Figure 6.14 Annual smoking relapse rate by year since quitting 
 
At the outset of the model, the population of former smokers includes all those who 
quit prior to 2016, some of whom may have quit recently and others who may have 
quit many years ago. This analysis assumes that former smokers are distributed 
uniformly over time since quitting, so the relapse rate for the group of former 
smokers at the outset of the model is the average relapse rate over a time horizon 
of 20 years. In the first year of the model this is applied to the total population of 
former smokers in Ireland, which was estimated using data from the Healthy Ireland 
survey.(1) In the second cycle of the model (2017), the remaining population of 
former smokers from which new entrants to the model can emerge have all quit for 
at least two years, since anyone who was a smoker and quit in 2016 is accounted 
for in the former smokers state within the model (see Figure 6.3-Markov model). 
Similarly in cycle three (2018) new relapsers entering the model for the first time will 
be drawn from a population of former smokers who have quit for at least three 
years, and so on. This means that the relapse rate for those who were former 
smokers at the start of the simulation will decrease over time, to reflect the increase 
in the average duration of abstinence within this group, as will the population of 
former smokers to which this relapse rate is applied. Relapse rates in those who quit 
after 2016 are accounted for by the transition probability between the former 
smoker and smoker states in the model. This is calculated using the same relapse 
curve and is adjusted for the fact that in year two all people in the former smokers 
state have quit for one year (so the relapse rate is highest). As the model 
progresses, the former smokers state includes a mix of people who have quit in all 
of the prior years since the start of the model (so the average relapse rate decreases 
over the 20-year time horizon). 
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The three sources of new smokers are combined to estimate the total number of 
new smokers entering the population each year over the 20-year time horizon 
(Figure 6.15). 
Figure 6.15 New smokers entering the model over the 20-year time 
horizon 
 
The proportion of smokers using each type of intervention in their attempt to quit at 
present in Ireland was estimated using data from the Healthy Ireland survey 2015.(1) 
The survey included a list of pharmacological smoking cessation interventions 
(including e-cigarettes, NRT, varenicline or bupropion) and HSE quit service supports 
(Quit.ie, QUITline, Facebook) as well as a question about whether the person 
received any other form of behavioural support. Smokers who attempted to quit 
were asked to indicate all of the interventions they used in their effort to quit. This 
allows for the proportion of people who used different combinations of interventions 
to be estimated. The survey did not distinguish between single NRT and combination 
NRT use, so the split between these two interventions was estimated based on UK 
data indicating that the ratio of single NRT to combination NRT use is 8:5.(513) The 
survey also grouped varenicline and bupropion together, so the relative use of these 
two interventions was estimated using Irish data from the Primary Care 
Reimbursement Service (PCRS) which showed a ratio of 1:8 bupropion to varenicline 
prescriptions .(514) Current practice in regard to the use of different smoking 
cessation interventions in Ireland is shown in Figure 6.16. International data indicate 
that, on average, smokers attempting to quit make two attempts per year.(126) This 
was incorporated into the analysis comparing the current standard of care to 
alternatives, to avoid underestimating the costs associated with failed quit attempts. 
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Figure 6.16 Current standard of care for smoking cessation quit attempts in Ireland 2015 (Healthy Ireland data, 
excluding Refused/Don’t Know respondents) 
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The relative effect estimates for each of the smoking cessation interventions 
included in the analysis, and the baseline absolute quit rate associated with 
unassisted quitting were reported in the clinical effectiveness chapter (Chapter 4). 
These are summarised in Table 6.3. 
Table 6.3 Summary of effectiveness estimates used in the economic 
model 
Parameter Effect size 95% Confidence 
Interval 
Absolute quit rate for unassisted quitting   
Control arms with 12-month follow up 
(primary estimate) 
7.8% [6.5 to 9.5] 
Average over all control arms 8.6% [7.6 to 9.8] 
12-month follow up (continuous 
abstinence) 
5.1% [3.9 to 6.6] 
Range of unassisted quit rates used in 
univariate sensitivity analysis 
Lower bound: 3.9% 
Upper bound: 9.8% 
Nicotine Replacement Therapy (NRT) RR 1.68 [1.58 to 1.78] 
Bupropion RR 1.70 [1.53 to 1.87] 
NRT + bupropion RR 2.02 [1.70 to 2.40] 
Electronic cigarette RR 2.14 [1.26 to 3.35] 
Cytisine RR 2.20 [1.68 to 2.83] 
Combination NRT RR 2.22 [1.91 to 2.55] 
Varenicline RR 2.57 [2.32 to 2.85] 
Varenicline + bupropion RR 3.20 [2.05 to 4.60] 
NRT + varenicline RR 3.54 [2.57 to 4.61] 
Individual counselling* RR 1.39 [1.10 to 1.76] 
Intensive advice* RR 1.35 [1.16 to 1.58] 
Telephone support* RR 1.34 [1.19 to 1.51] 
Group behavioural therapy* RR 1.85 [1.53 to 2.23] 
Behavioural support as an adjunct to 
pharmacotherapy 
RR 1.18 [1.09 to 1.28] 
* Relative effect versus active control in the form of brief advice or written materials. 
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As outlined in this section, it is necessary to estimate the number of quit attempts 
made annually by the average smoker who is attempting to quit, for the analysis 
comparing the current standard of care to alternative mixes of therapies, in order to 
avoid underestimating the resource use associated with multiple failed quit attempts. 
An estimated average of two quit attempts per year for the half (50%) of smokers 
attempting to quit in any given year was used, based on a 2012 paper reporting 
data from the US, Canada, Australia and the UK.(126) 
6.2.8 Utility parameter estimates 
For the analysis comparing quality-adjusted life year (QALY) outcomes for each 
comparator, it is necessary to estimate both the baseline quality of life of the 
population of smokers and former smokers who do not have a smoking-related 
illness, as well as the utility weights associated with having a diagnosis of either lung 
cancer, stroke, IHD or COPD.  
In the absence of validated Irish data, baseline quality of life by age and gender for 
those with no current morbidity was taken from UK estimates for a general 
population based on data from the Health Survey for England (Figure 6.17).(515)  
Figure 6.17 Baseline utility for a general population with no current 
smoking-related morbidity, by age and gender 
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In the absence of Irish data, estimates of the average utility weight associated with 
lung cancer, stroke, IHD and COPD were taken from the literature. Estimates for 
lung cancer, IHD and COPD were taken from a 2014 HTA carried out by the National 
Institute of Health Research in the UK, and the utility weight associated with stroke 
was taken from a 2015 HIQA HTA.(471, 516) These are shown in Table 6.4, along with 
the individual studies from which they originated. There is a high degree of 
uncertainty surrounding these estimates due to limitations in the available data and 
the inherent difficulties in estimating an average utility weight for diseases that can 
differ considerably in terms of severity. In this analysis, each utility parameter was 
defined as distributions that were randomly sampled over the course of 10,000 
replications.  
Table 6.4 Utility estimates for disease states included in the analysis 
Health State Utility Weight (95% Confidence 
interval) 
Source 
Lung Cancer 0.50 (0.21 to 0.95) Trippoli 2001(517) 
Stroke 0.57 (0.46 to 0.68) Sorensen 2011(518), 
Tengs 2003(519) 
COPD 0.63 (0.15 to 0.85) Spencer 2005(520) 
IHD 0.63 (0.41 to 0.82) Hay 2005(521) 
QALY outcomes for the population of smokers and former smokers in each 
comparator were calculated using a multiplicative approach. For example, the QALY 
score for males aged 50-54 years with COPD was obtained by multiplying the 
baseline utility for that age by the utility weight for COPD. The difference in QALYs 
between the smoker and former smoker populations was then calculated using data 
on the differing prevalence of each of the four diseases within these two cohorts, 
taking account of the age/gender structure. Multimorbidity was not included in the 
model, so the full utility loss associated with the number of cases of each disease 
was calculated separately and summed for the overall population. 
6.2.9 Cost parameter estimates 
As outlined in the methods section, a limited societal perspective was adopted that 
included all of the cost of smoking cessation regardless of on whom they fall, as well 
as the direct costs of treatment for smoking-related illness. The cost of cigarettes for 
those continuing to smoke was not included in the primary analysis. 
The costs per course of treatment for each of the pharmacological interventions was 
calculated using the approach outlined in the National Centre for 
Pharmacoeconomics (NCPE) guidelines for estimating drug costs.(522) Costs for 
people who continue to use products beyond the stated period were not included. 
Ingredient costs for licensed medicines were obtained from the PCRS.(514) The costs 
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of e-cigarettes were obtained from the literature.(523) Based on data from the PCRS 
on the proportion of people who complete a full course of treatment in Ireland 
(assuming a minimum prescription of one month duration), an attrition rate of 40% 
was applied to all interventions to account for those who relapse in the early stages 
of their quit attempt and so do not incur the full costs of a complete course of 
treatment.(514) The cost of behavioural support interventions supplied through the 
HSE quit services was calculated based on the staff time required per quit attempt 
for the standard treatment programme provided by the HSE, and the costs of 
providing the telephone, text and online support services that forms part of this 
service. Uptake and adherence rates for the behavioural support services for the last 
three years was obtained from the HSE, showing the proportions of people who 
received each contact over the course of the standard treatment programme, which 
was taken into account when estimating the average cost of supporting a quit 
attempt using a behavioural intervention.(524, 525) 
While some smoking cessation interventions are available for general sale or are 
licensed for over-the counter use, current practice in Ireland is that they must be 
prescribed in order to be reimbursed through the HSE’s Primary Care 
Reimbursement Scheme (PCRS). For those with a Medical Card, up to three months 
supply of medication may be prescribed at a time (and dispensed in monthly 
aliquots). For interventions requiring a prescription and those items that require a 
prescription to be reimbursed through the PCRS, the cost of one GP consultation was 
therefore included (€55).(526) The average cost of a GP visit was estimated as 
follows. The number of annual GP visits for General Medical Scheme (GMS) and non-
GMS card holders were calculated using Living in Ireland Survey data. The average 
number of visits by age band was calculated to match the age bands for the PCRS 
data on eligible card holders. From this, the total number of GP visits (8,684,589 
visits) per annum for the GMS population (1,853,877 persons) was calculated, which 
accounted for almost 60% of all GP visits. From the 2012 PCRS annual report, the 
total fees and allowances paid to GPs was €483.14m. The average cost per visit was 
therefore €55.63 for the GMS population. This figure is very close to the anecdotal 
average out-of-pocket cost for non-GMS card holders as evident by the following 
comment in a 2009 report by the Competition Authority, which stated,  
‘discussion of the impact of GP fees on patient demand is constrained by the 
lack of comprehensive price data for the profession. Informal estimates 
suggest that the cost of GP visits is around €50 - €55 in urban areas, with 
slightly lower charges in rural areas. A range of €45-€60 in the price charged 
to private patients is typical.’(527)  
Table 6.5 shows the cost of each type of smoking cessation intervention. 
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Table 6.5 Costs of smoking cessation interventions 
Name Course of treatment 
Additional 
costs 
associated 
with 
treatment 
Total 
average 
cost per 
quit 
attempt* 
Varenicline 2mg/day for 12 weeks (1 weeks 
titration of 0.5mg once daily days 
1-3, and 0.5mg twice daily days 
4-7) 
GP visit €186.17 
Bupropion 300mg/day for 12 weeks 
(150mg/day for first six days) 
GP visit €152.27 
E-cigarettes 12 week supply (e-cigarette + 
3.55ml liquid per day) 
Replacement 
atomiser in 
months 2 and 3 
€93.80 
Single NRT 12 week course of NRT, 
calculated as the weighted 
average cost using PCRS data on 
the usage of each type of NRT 
product 
GP visit for 
those with 
Medical Card 
€118.58 
Combination 
NRT 
12 week course of NRT patch and 
gum 
GP visit for 
those with 
Medical Card 
€176.40 
Varenicline 
and NRT 
2mg/day for 12 weeks and 12 
week course of NRT (per single 
NRT cost calculation) 
GP visit €282.26 
Bupropion 
and NRT 
300mg/day bupropion for 12 
weeks and 12 week course of 
NRT (per single NRT cost 
calculation) 
GP visit €248.82 
Varenicline 
and 
Bupropion 
2mg varenicline and 300mg 
bupropion per day for 12 weeks 
(titrated as above). 
GP visit €287.48 
Behavioural 
support 
Cost of HSE Standard Treatment 
Programme consisting of four 
contacts over the first month and 
follow up contact at 3 months and 
12 months, plus the average cost 
per contact of the QUIT 
multimedia support service. 
None €46.37** 
* Factoring in adherence rates derived from PCRS data, as well as dispensing and prescription fees 
and wholesalers rebate, where applicable, per NCPE guidelines(514, 522), costs were varied ±20% to 
capture uncertainty **Cost of staff time limited to direct patient contact time only 
The cost of providing behavioural support through the HSE Quit service was 
estimated based on the staff cost of the time spent directly communicating with a 
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person attempting to quit. This was calculated using data supplied by the HSE on 
staff grades, average time spent in each session, attrition rate between first contact 
and 12-month follow up, and the average cost per person of providing telephone 
and web-based services in 2015 and 2016. Staff costs were calculated per the 
national HTA guidelines, which included adjustment for PRSI, pension and overhead 
costs.(528, 529) As the costs included in the model only relate to the direct contact time 
with smokers making a quit attempt, they do not reflect the full costs of providing 
this service. 
The average cost of treating a patient with each of the four smoking-related illnesses 
included in the analysis was calculated using Irish data on the total annual spending 
divided by the total number of people with a diagnosis of each disease.  
The total direct costs to the HSE of inpatient and day case treatment of lung cancer, 
COPD, IHD and stroke were estimated from the Hospital Inpatient Enquiry database 
(HIPE) for 2015, which are based on 2014 prices.(530) Total secondary care costs in 
each disease area, and cost per patient based on prevalence rates described 
previously, are shown in Table 6.6. 
Table 6.6 Cost per prevalent case of inpatient and daycase treatment 
Disease  
(ICD Code) 
Total Cases 
(2015)* 
(n) 
Total 
Inpatient 
Costs (€) 
Total 
Daycase 
Costs (€) 
Cost per prevalent 
case (€) [95%CI] 
Lung Cancer 
(C34) 
4,666 21,950,535 1,879,454 5,107 [3,915 to 6,499] 
COPD  
(J41-J44) 
73,901 63,756,866 375,081 868 [664 to 1,097] 
Stroke  
(I60-I69) 
88,790 79,415,753 74,941 895 [690 to 1,142] 
CHD  
(I20-I25) 
209,361 90,444,399 6,592,530 463 [352 to 588] 
* Total cases of each disease were calculated by applying the prevalence rates for each to the 2015 
Irish population 
Table 6.6 represents the average costs for all people with each of the relevant 
diagnoses, including those associated with low resource use due to having less 
severe disease, or having a prior history of a particular disease that is being 
appropriately managed, as well as those at the opposite end of the spectrum, who 
have more severe or acute disease. 
As well as the costs of secondary care, patients with smoking-related illness also 
incur significant primary care costs associated with ongoing management of chronic 
illness, including medication costs. However, Irish data on the overall annual costs of 
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treatment in primary care in each disease area are not routinely reported in a 
manner equivalent to that of secondary care by the HIPE database.  
In the absence of these data, it was necessary to rely on the currently available 
published literature and make simplifying assumptions. Annual primary care and 
medication costs for IHD and stroke were obtained from a report on European 
Cardiovascular Disease Statistics 2012, published by the European Society of 
Cardiology.(531) The annual cost of treating COPD was estimated using 2014 PCRS 
data on the total costs of adrenergics and other drugs for obstructive airway 
diseases.(532) As it is not possible to distinguish between different patient groups in 
the PCRS data, this medication cost includes the cost of providing these medicines 
for people with other respiratory diseases, such as asthma, but does not include the 
costs of GP consultations for the average person with a diagnosis of COPD. Neither 
does it include the costs of home oxygen therapy, which in 2006 was estimated to 
have cost the HSE approximately €4m.(533) In the absence of reliable Irish data on 
the average cost of primary care for lung cancer patients, only primary care costs for 
oral chemotherapy agents (afatinib, crizotinib, erlotinib, and gefitinib) that are 
funded by the PCRS via the High Tech Drugs Scheme were included.(534) While it is 
assumed that the majority of cancer treatment and follow up is provided in 
secondary care (inpatient or daycase), there are other costs associated with 
palliative care, primary care support services, and so on that are not included in the 
model. The costs included in the model are therefore likely to be an underestimate 
of the full cost of care.  
Total primary care costs in each disease area, and cost per patient based on 
prevalence rates, are shown in Table 6.7. 
Table 6.7 Cost per prevalent case of primary care treatment 
Disease (ICD 
Code) 
Total Cases* Primary Care 
Costs (€) 
Cost per prevalent 
case (€)[95% CI] 
IHD (I20-I25) 209,216 56,657,000 271 [207 to 342] 
Stroke (I60-I69) 88,729 20,262,000 228 [174 to 288] 
COPD (J41-J44) 73,657 48,760,000 662 [504 to 831]  
Lung Cancer (C34) 4,666 2,590,000 555 [423 to 698] 
* Total cases were calculated for the same year for which the costs were reported; 2009 for Stroke 
and IHD, 2014 for COPD and 2015 for lung cancer 
Given the lack of reliable Irish data with which to estimate these costs, they were 
varied ±25% in the model (rather than the 20% recommended in Irish 
guidelines(528)) to capture the increased level of uncertainty associated with them. 
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6.2 Cost effectiveness analysis results 
Monte Carlo simulation was performed over the course of 10,000 replications to 
derive estimates of the costs and consequences of each comparator in the economic 
model. Two types of cost-effectiveness analysis were carried out. In the first, all 
interventions were individually compared with each other to rank each type of 
intervention on its own. In this analysis it was assumed that all smokers made a 
single quit attempt every year, all with the aid of a given intervention. In the second 
analysis, the cost-effectiveness of the current mix of cessation interventions in 
Ireland was compared with alternative treatment mixes, based on international data 
on achievable uptake rates for each intervention. Both of these analyses were 
carried out for the numbers of people quitting (quit outcomes) and quality-adjusted 
life years (QALY outcomes). All analysis was carried out using TreeAge Pro 2016.(535) 
6.2.1 Cost-effectiveness analysis comparing individual interventions 
To estimate the cost-effectiveness of individual interventions compared with each 
other, 10,000 replications of the model were performed, with parameters sampled 
from their range of plausible values in each replication. Figure 6.18 shows that 
stable ICER estimates were achieved after about 3,000 replications. This indicates 
that 10,000 replications were sufficient to obtain stable results from the probabilistic 
analysis. 
Figure 6.18 Convergence of ICER estimates for the comparison of 
individual interventions (QALY outcomes) 
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Quitting outcomes 
The outcome in this analysis is the number of people making a successful quit 
attempt (greater than six months abstinence), and the costs are limited to the cost 
of providing these interventions. The cost-effectiveness plane for quit outcomes for 
the total Irish population of smokers over a 20-year time horizon is shown in Figure 
6.19. Table 6.8 shows the incremental costs and benefits of all non-dominated 
strategies. This shows that the most cost-effective option is e-cigarettes, which is 
associated with an average cost of €1,688 for each additional successful quitter, with 
the next most cost-effective choice being a combination of varenicline and NRT, 
which is associated with an incremental cost per additional quitter of €1,962 
compared with e-cigarettes.  
Figure 6.19 Cost-effectiveness plane for comparison of single smoking 
cessation interventions on quitting outcomes 
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Table 6.8 Incremental costs and benefits of non-dominated strategies 
for the comparison of individual smoking cessation 
interventions on quitting outcomes 
Strategy Cost  
(€ million) 
Incremental 
Cost  
(€ million) 
Effect 
(Quitters) 
Incremental 
Effect 
(Quitters) 
ICER 
(€/Quitter) 
Unaided 0 - 671,571 - - 
E-cigarettes 597.6 597.6 1,025,510 353,939 1,688 
Varenicline and NRT 1,185.2 587.6 1,325,025 299,515 1,962 
When interpreting these results it is important to note that they reflect the costs and 
number of expected quitters if all smokers were to make one quit attempt per year, 
all using a given intervention. Smokers who relapse in following years may quit 
again, so it is possible that they may be counted as having made a successful quit 
attempt multiple times. While the assumptions that every single smoker will make a 
quit attempt, and uptake rates of each interventions will be 100% within each 
comparator are clearly not realistic, they are necessary in order to compare the cost-
effectiveness of each intervention with each of the other interventions. In addition, 
while quit outcomes are helpful in determining the optimal treatment strategy within 
the field of smoking cessation, they do not provide a basis for comparing the cost-
effectiveness of smoking cessation interventions with other clinical areas that may 
be funded from the same budget. To do this, one needs to examine outcomes that 
are common across all disease areas, such as the quality-adjusted life year (QALY). 
These are reported in the following section.  
QALY outcomes 
QALY outcomes are based on the differences in average life expectancy among 
current and former smokers, combined with the difference in quality of life among 
former and current smokers due to differences in the risk of developing a smoking-
related illness. The cost-effectiveness plane for QALY outcomes in Figure 6.20 and 
Table 6.9 shows the incremental costs, effects, and ICERs for each non-dominated 
strategy compared with the next best option.  
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Figure 6.20 Cost-effectiveness plane for the comparison of single smoking 
cessation interventions on QALY outcomes 
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interventions on QALY outcomes 
Strategy Cost (€ 
million) 
Incremental 
Cost (€ million) 
Effect 
(QALY) 
Incremental 
Effect 
(QALY) 
ICER 
(€/QALY
) 
Unaided 1,723 
 
11,238,252 
  E-cigarettes 2,169 446.4 11,323,746 85,494 5,222 
Varenicline and NRT 2,634 465.3 11,399,086 75,340 6,176 
These results show that, as per the quitting outcomes, e-cigarettes are the most 
cost-effective strategy compared with doing nothing, with an incremental cost of 
€5,222 per additional QALY gained. The combination treatment of varenicline and 
NRT is the most cost-effective option compared with e-cigarettes, being more 
effective and more costly, with a slightly higher cost per additional QALY gained 
(€6,176). The cost-effectiveness acceptability curve (CEAC, Figure 6.21) shows that 
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at willingness-to-pay thresholds in excess of about €5,500/QALY, the optimal 
strategy is combination varenicline and NRT. To put this in context, the willingness-
to-pay threshold routinely used in Ireland to decide if a pharmaceutical intervention 
is cost-effective is €45,000/QALY(536). These results are consistent with those of 
previous cost-effectiveness studies, which found that smoking cessation 
interventions tend to be highly cost-effective (see section 6.1). 
Figure 6.21 Cost-effectiveness acceptability curve (CEAC) for comparison 
of individual smoking cessation interventions on QALY 
outcomes 
 
Univariate deterministic sensitivity analysis was carried out to identify how sensitive 
these results are to changes in the input parameters. In this type of analysis the 
model is run with each of the input parameters held at their upper and lower bound, 
while all the other parameters were assigned their mean value, to ascertain what 
effect it has on the ICER for a given comparison. Tornado plots for all interventions 
on the cost-effectiveness frontier (e-cigarettes versus unassisted quitting, and 
varenicline and NRT versus e-cigarettes) are shown in Figures 6.22 and 6.23, 
respectively. These show that the results are most sensitive to the relative 
effectiveness results for each of these interventions, with the wide bounds around 
the effectiveness of e-cigarettes in particular indicating that the cost-effectiveness 
results may change considerably when new evidence about the effectiveness of this 
intervention becomes available. It also shows that the results are relatively 
insensitive to changes in the prevalence of smoking-related diseases and utility 
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Based on these findings, the effect of changes in the estimated relative effectiveness 
of e-cigarettes on the overall cost-effectiveness of individual therapies was examined 
in a separate sensitivity analysis. This shows that e-cigarettes are dominated (less 
effective and more costly than alternatives) at the lower bound of effectiveness (RR 
1.26) and are the only treatment that would be considered cost-effective at its upper 
bound (RR 3.35, at which point the ICER for the next intervention on the frontier 
[varenicline and NRT] is €92,000/QALY, see Figure 6.24). 
Figure 6.22 Univariate sensitivity analysis for the comparison of e-
cigarettes with unassisted quitting  
 
Figure 6.23 Univariate sensitivity analysis for the comparison of 
varenicline plus NRT with e-cigarettes 
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Figure 6.24 Sensitivity analysis of varying the effect of e-cigarettes (RR 
2.14, 95%CI 1.26 to 3.35) on the cost-effectiveness of 
individual interventions  
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improved overall efficiency in the delivery of smoking cessation interventions at a 
national level. This analysis highlights the fact that even though varenicline with NRT 
and e-cigarettes are the only two interventions on the frontier, e-cigarettes are not 
the optimal choice for those who may not want to use varenicline with NRT. This is 
because once varenicline with NRT is removed from the analysis, the updated 
frontier now includes varenicline alone, or in combination with bupropion, and the 
most effective of these (varenicline and bupropion) would also be considered cost-
effective. Carrying out successive analyses of this type, where the most effective 
strategy from the previous analysis is excluded each time, provides an indication of 
whether the next most clinically effective option is cost-effective, and whether, 
therefore, increases in the use of this option at a population level would be 
considered beneficial, where such increases are driven by those smokers who cannot 
or will not choose a more effective option. This type of analysis is particularly useful 
in the area of smoking cessation, where individual preferences play such an 
important part in shaping current practice, and where the uptake rates of treatments 
that have long been shown to be superior to others continue to have very low 
uptake rates.  
The results of this analysis are shown in Table 6.10. This shows whether the ICER 
for each intervention is below a €20,000/QALY or €45,000/QALY threshold when all 
options that are more effective have been excluded. For clarity, the cost-
effectiveness plane for each ICER in Table 6.10 is shown in Appendix 12, illustrating 
which interventions are excluded each time and the effect this has on the frontier.  
Table 6.10 Cost-effectiveness of each strategy when all strategies that 
are more clinically effective are excluded (with e-cigarettes 
included as a treatment option) 
Effectiveness 
ranking 
Intervention ICER 
€/QALY 
1 Varenicline and NRT with behavioural support <20,000 
2 Varenicline and bupropion with behavioural support <20,000 
3 Varenicline with behavioural support <20,000 
4 Combination NRT with behavioural support >45,000 
5 E-cigarette with behavioural support <20,000 
6 Combination NRT >20,000 
7 Bupropion and NRT with behavioural support >45,000 
8 E-cigarettes <20,000 
9 Bupropion with behavioural support >45,000 
10 Single NRT with behavioural support <20,000 
11 Single NRT <20,000 
12 Behavioural support only <20,000 
__ ICER exceeds €45,000/QALY; __ ICER exceeds €20,000 
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This shows that in those for whom varenicline with NRT is not a viable option, 
varenicline with bupropion, or varenicline alone, are the next best choices, and both 
of these would be considered cost effective. It is only when any type of strategy 
involving varenicline is excluded as a treatment option that e-cigarettes (with 
behavioural support) emerge at the optimal strategy (Table 6.10). From the 
perspective of the health service this analysis shows that increases in the proportion 
of people using varenicline, alone or in combination with NRT or bupropion, are 
likely to be cost effective. Conversely, significant increases at a population level in 
the proportion of people using combination NRT, buproprion with NRT, or bupropion 
alone are unlikely to indicate increased efficiency, since even in cases where these 
are the most effective options, the additional benefit they provide compared to the 
next best option is achieved at a relatively high cost. 
Given the uncertainty surrounding the effectiveness of e-cigarettes, the same 
analysis was also carried out with this intervention excluded (Table 6.11).  
Table 6.11 Cost-effectiveness of each strategy when all strategies that 
are more clinically effective are excluded (with e-cigarettes 
excluded as a treatment option) 
Effectiveness 
ranking 
Intervention ICER 
€/QALY 
1 Varenicline and NRT with behavioural support <20,000 
2 Varenicline and bupropion with behavioural support <20,000 
3 Varenicline with behavioural support <20,000 
4 Combination NRT with behavioural support <20,000 
5 Combination NRT <20,000 
6 Bupropion and NRT with behavioural support >20,000 
7 Bupropion with behavioural support >45,000 
8 Single NRT with behavioural support <20,000 
9 Single NRT <20,000 
10 Behavioural support only <20,000 
__ ICER exceeds €45,000/QALY; __ ICER exceeds €20,000 
The results show that when e-cigarettes are excluded, the next best option once any 
type of strategy involving varenicline is excluded becomes combination NRT, and 
that this would also be considered cost-effective (Table 6.11). As with the first 
analysis (Figure 6.10), it shows that increases in the overall proportion of people 
using strategies involving bupropion are unlikely to indicate increased efficiency, 
since even in cases where these are the most effective options, the additional 
benefit they provide compared to the next best option is achieved at a relatively high 
cost.  
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6.2.2 Cost-effectiveness analysis comparing current practice with 
alternatives 
While the cost-effectiveness analysis of individual treatments allows for a 
comparison of how they perform in relation to each other, a more useful analysis for 
informing policy compares the current standard of care to plausible alternative mixes 
of interventions in order to identify improvements in smoking cessation services in 
Ireland. In this analysis the existing mix of interventions used by people making a 
quit attempt is compared to alternatives where more people are encouraged to 
choose more effective interventions. In each comparator the mix of interventions 
remains constant over the 20-year time horizon. The choice of comparators is 
informed by data on likely changes in the uptake of various interventions over time, 
and peak uptake rates for individual treatments that have been observed in other 
countries. The purpose of this analysis is to identify improvements in the mix of 
interventions used in Ireland that increase overall quit rates at an acceptable cost. 
International comparisons 
In England, the smoking toolkit study uses household survey data collected since 
2006.(537, 538) The 2016 figures from this study indicate that during a quit attempt in 
the previous 12 months, 43% of smokers and ex-smokers reported using no 
cessation aid, 36% reported using an e-cigarette, 11% reported using over-the-
counter NRT, 9% reported using a prescription medication (NRT, varenicline or 
bupropion), while only 3% reported using the NHS Stop Smoking Service (Figure 
6.25)(539). Use of e-cigarettes as a quitting aid has increased from negligible use in 
2010 to 36% in 2016, while other methods of cessation, including the use of other 
pharmacological interventions have declined. The authors of the Smoking Toolkit 
Study recently examined the association between e-cigarette use and changes in 
pharmacotherapy in a time series analysis.(537) They found that e-cigarette use was 
negatively associated with the use of prescription NRT, but had no effect on the use 
of over-the-counter NRT, varenicline or bupropion. They also reported that e-
cigarettes had a positive association with successful quit attempts. 
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Figure 6.25 Proportion of quit attempts made using smoking cessation 
interventions, England, Nov 2016 to Sept 2016 (6-month 
moving average) 
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of e-cigarette use (19% vs.36%) and a similar rate of smoking cessation medication 
use (18% vs. 20%) were reported compared with the Smoking Toolkit study.(539, 540) 
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aid is 10%, while the UK (19%), France (18%) and Ireland (19%) have the highest 
rates.(540) Overall, Ireland and the UK are very similar in terms of use of cessation 
aids (smoking cessation medication Ireland 17% vs. UK 18%; e-cigarettes Ireland 
19% vs. UK 19%; support from health professional or use of Stop Smoking Services 
Ireland 6% vs. UK 7%).(540) 
Sweden has the lowest prevalence of smokers in the EU28 (11%) and the highest 
proportion of ex-smokers (35%).(540) The Eurobarometer report indicates that in 
Sweden, 60% of smokers and recent ex-smokers try to quit smoking without 
assistance, while a high proportion use smoking cessation medications (20% 
compared with EU28 average of 12%). However, only 2% report using e-cigarettes 
and only 4% report using support from a health professional or special stop smoking 
service. Rutqvist reported on smoking cessation aids used by Swedish smokers in a 
cross-sectional survey conducted in 2009.(541) Although NRT and counselling were 
commonly reported as a smoking cessation aids in women in Sweden (35% nicotine 
gum, 22% nicotine patch and 36% counselling), snus (a type of smokeless tobacco) 
was the most commonly reported type of cessation aid reported by men (63% snus, 
15% nicotine gum, 8% nicotine patch and 20% counselling).(541) 
Data from the 2012 Eurobarometer survey were used to assess which factors 
determine the use of smoking cessation aids. They reported that respondents from 
countries with comprehensive tobacco cessation programmes who provide 
medication, QUITlines and other smoking cessation services free of charge are 
significantly more likely to use effective cessation aids.(542) 
A survey conducted in Canada by the Canadian Centre for Population Health Impact 
reported a smoking prevalence of 14.2% in 2015.(543) Among current and former 
smokers who had tried to quit smoking in the past two years, 44.2% used some sort 
of top smoking medication (data from 2012). Of these, the nicotine transdermal 
patch was the most popular (26%), nicotine gum was used by 20%, and products 
like bupropion were reported by 19% of current and former smokers. The use of e-
cigarettes as a smoking cessation aid was ascertained in an additional survey carried 
out by the centre in 2013 , with 22.9% of current and former smokers reporting its 
use as a cessation aid in the previous two years.(544) Canada currently does not allow 
for the sale of nicotine containing e-cigarette products, and therefore more than half 
of those using e-cigarettes report using nicotine-free liquids.(544) In Canada the 
phone number for the Smoker’s Helpline was added to labels for cigarette packages 
in 2012. The most recent survey, carried out in 2013, reported that 5.6% of current 
and former smokers who had tried to quit in the last two years had used the 
helpline, which was similar to estimates prior to 2012.(543)  
White and colleagues utilised a national Canadian survey to examine how 
subsidisation policies for smoking cessation medicines in some provinces, but not 
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others, affected medication use and quit success. They reported that a 
comprehensive subsidisation policy for smoking cessation medications was 
associated with a modest increase in NRT use and quit success, but it did not affect 
the use of prescription smoking cessation medications.(545) 
Smoking prevalence in Australia is lower than in Ireland and the UK, but similar to 
Canada (14.7%).(546) A survey carried out in Australia between 2002 and 2009 
shows that the use of any medication for smoking cessation (NRT, varenicline or 
bupropion) increased in Australia between 2002 and 2009 (32% to 52%). Use of 
NRT rose from 27.5% in 2002 to 39.1% in 2008, but decreased to 29.0% in 
2009.(547) This coincided with the introduction of varenicline to the Australian market 
in 2008, and a reported increase in its use from 4.6% in 2008 to 23.9% 2009.(547) 
Behavioural support such as the use of a helpline, internet or smoking cessation 
clinic also increased between 2002 and 2009, from 8.4% of respondents to 15% of 
respondents. Overall, the use of some sort of support, either pharmacotherapy and 
or behavioural support, increased from 37% in 2002 to 59% in 2009.(547) More 
recent data from the National Drug Strategy Household Survey in 2013 suggested 
that the use of NRT had remained stable (31%), while the use of other smoking 
cessation medications was reported as 16%. Data from this survey also indicated 
that 9% had contacted a helpline, 24% had asked their doctor for help, 16% 
reported using smoking cessation literature, 9% reported using the internet and 
13% reported using a mobile phone app. However, more than half of the 
respondents reported unassisted quitting (also known as going ‘cold turkey’).(548) 
The survey also asked about the dual use of e-cigarettes and tobacco smoking, and 
found that approximately 15% of smokers also reported using an e-cigarette in the 
previous 12 months.(549) A systematic review of unassisted quitting in Australia based 
on 19 Australian studies reported that 54% to 69% of ex-smokers quit unassisted 
and 41% to 58% of current smokers had attempted to quit unassisted. This 
indicates that unassisted quitting is the most popular method of quitting. The 
authors concluded that public health would benefit from a greater understanding of 
why so many smokers choose not to use smoking cessation aids.(133) 
In the United States (US), the prevalence of smoking is similar to Canada and 
Australia at 15.1%.(550) Based on the ‘Healthy People 2020’ report, the US aim to 
reduce adult cigarette smoking to 12% prevalence by 2020.(551) The tobacco use 
supplement to their Current Population Survey from 2010-2011 reported that 20.1% 
of smokers used NRT in a quit attempt in the previous year, while 10.4% used 
varenicline, 3.1% used bupropion and 5.0% used e-cigarettes. (552) More recent data 
from a nationally representative sample of 2,028 smokers who were surveyed in 
2012 and 2014 suggests a similar pattern to what has been seen in other countries, 
with the use of e-cigarettes for smoking cessation increasing to 24.8% and use of 
pharmacotherapy (NRT, varenicline and buproprion) decreasing to 17.8%.(553) 
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Almost 10% of respondents reported using both pharmacotherapy and e-cigarettes 
to try and quit.(553)  
Based on data from the International Tobacco Control Policy Evaluation Project (ITC 
-4) which included Canada, US, UK and Australia, 30% to 40% of respondents 
reported using more than one method of smoking cessation during the previous 12 
months, suggesting multiple methods are often chosen by smokers during quit 
attempts.(554) 
Summary of international data 
Overall, similar trends are seen throughout the EU and internationally. The use of e-
cigarettes as a smoking cessation aid is still low in many countries, but seems to be 
on the increase.(537, 540, 544, 555) Of the EU28, the UK, France and Ireland have the 
highest proportion of smokers and recent quitters who use e- cigarettes as a 
smoking cessation aid.(540) The use of NRT, varenicline and buproprion seems to 
have peaked in some countries, with its use decreasing in recent years in the UK, 
Australia, US and Ireland.(538-540, 547, 552, 553) It has been suggested that the increased 
use of e-cigarettes has negatively impacted on the use of prescribed NRT.(537) The 
unassisted quit rate is over half of all quit attempts in most countries, with the EU 
average for smokers and ex-smokers who tried to quit in the previous 12 months 
being 65%.(540) It has been suggested that more studies are necessary to discover 
why so many smokers choose to quit unassisted when effective cessation aids are 
available.(133) 
Comparators used in the analysis of alternative standards of care 
Current preferences for smoking cessation in Ireland were obtained from the Healthy 
Ireland survey (see Figure 6.16). This showed that half (51%) of all quit attempts 
currently made are undertaken without any behavioural or pharmacological support. 
The single most popular smoking cessation aids are e-cigarettes, which are the only 
support used by approximately a quarter of people trying to quit (24%), while a 
further 5% use e-cigarettes in combination with some other form of therapy. The 
next most common cessation aid is NRT, which is used either alone or in 
combination in 18% of quit attempts. Prescription medication (varenicline or 
bupropion) is used in only about 4% of attempts. 
It is of particular noted that e-cigarettes have achieved such high penetration since 
coming to market in 2011. This mirrors the experience in the UK, where the use of 
e-cigarettes as a cessation aid has risen consistently over the last six years, while 
the use of NRT and prescription medicines has declined (Figure 6.16).(556) As of 
September 2016, the proportion of all UK quit attempts made with the support of e-
cigarettes was approaching 40%, with no evidence that this increase is levelling off. 
A decreasing trend in the proportion of unassisted quit attempts was also observed 
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in the UK data, although this had been in evidence prior to the advent of e-
cigarettes. The rate of unassisted quitting has remained constant at around 41% 
between 2013 and 2016, despite e-cigarette use increasing substantially over this 
period.(556)  
As discussed earlier, data on unassisted quit rates for the EU28 countries in 2014 
were reported in a Eurobarometer report.(557) While there were some differences 
between the ‘Smoking in England’ and UK data for this year (Eurobarometer 
reported a 52% unassisted quit rate in the UK for 2014, compared with 42% in the 
‘Smoking in England’ dataset), the EU data show that the unassisted quitting rates in 
the UK and Ireland are among the lowest in the EU (52% and 54%, respectively), 
compared with an overall average of 65% (range 85% to 52%). They also show that 
the UK and Ireland are among the most enthusiastic adopters of e-cigarettes as a 
smoking cessation tool, with uptake rates of 19% reported for both in 2014, while 
the overall average among the EU28 was 10% (range 2% to 19%).(557) This 
indicates that the UK data represents the lower bound for internationally observed 
rates of unassisted quitting and the upper bound for the use of e-cigarettes for 
smoking cessation. 
Given the results of the cost-effectiveness analysis of individual therapies, the 
potential maximum uptake of NRT in combination with varenicline in Ireland is also 
of interest, as this was identified as the most effective smoking cessation 
intervention (Chapter 4), and the most cost-effective option at conventional 
willingness-to-pay thresholds. Accurate estimates of current usage rates of 
varenicline in Ireland and the UK are difficult to ascertain as it is generally grouped 
with other prescription medications rather than being reported separately. However, 
data from the Healthy Ireland survey indicate that it is used in less than 4% of quit 
attempts at present.(1) International survey data on varenicline use in four countries 
shortly after it was first marketed show peak usage rates of 22% in the US and 15% 
in both Canada and Australia, but usage rates in the UK at that time were 
considerably lower (4%).(558) If it is assumed that any initiative by the HSE to 
promote the use of NRT and varenicline would have most impact among those using 
some form of support in their quit attempt from HSE quit services or their GP, with 
far less influence among those choosing NRT or e-cigarettes without any contact 
with health professional (<10%), then the upper limit for the use of combination 
NRT and varenicline would be 8% to 12%. 
Based on these data, the alternative standards of care in Ireland that were 
compared to current practice in the cost-effectiveness analysis are shown in Table 
6.12. 
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Table 6.12 Comparators used in the analysis of the cost-effectiveness of 
alternatives to current practice for smoking cessation 
 Current 
practice in 
Ireland 
(95%CI) 
Current 
uptake rates 
in England 
(95%CI) 
Varenicline and 
NRT used  
in all receiving 
support (95%CI) 
Varenicline and NRT used 
in all receiving support 
and 10% not receiving 
support (95%CI) 
Unassisted 
quitting 
51.1% 
(41.3 to 60.9) 
40.0% 
(30.7 to 49.7) 
51.1% 
(41.4 to 60.9) 
51.1% 
(43.5 to 63.1) 
E-cigarettes 26.3% 
(18.2 to 35.1) 
45.0% 
(35.1 to 54.5) 
26.3% 
(18.2 to 35.5) 
23.7% 
(16.0 to 32.7) 
Single NRT 9.5% 
(3.8 to 15.2) 
5.9% 
(2.2 to 11) 
9.5% 
(4.6 to 15.9) 
8.6% 
(4.0 to 14.7) 
Combination NRT 4.7% 
(4.7 to 15.9) 
2.9% 
(0.6 to 6.9) 
4.7% 
(1.5 to 9.7) 
4.2% 
(1.2 to 8.9) 
Varenicline 2.9% 
(1.5 to 9.5) 
1.8% 
(0.2 to 5.4) 
0.0% 
(0 to 0) 
0.0% 
(0 to 0) 
Behavioural 
Support 
2.4% 
(0.6 to 6.8) 
2.4% 
(0.4 to 6.1) 
0.0% 
(0 to 0) 
0.0% 
(0 to 0) 
Single NRT with 
support 
0.8% 
(0.4 to 6.2) 
0.5% 
(0 to 2.5) 
0.0% 
(0 to 0) 
0.0% 
(0 to 0) 
E-cigarette with 
support 
0.7% 
(0 to 3.1) 
0.4% 
(0 to 2.3) 
0.0% 
(0 to 0) 
0.0% 
(0 to 0) 
NRT and 
Varenicline 
0.8% 
(0 to 3.2) 
0.5% 
(0 to 2.5) 
8.4% 
(3.8 to 14.4) 
12.5% 
(7.2 to 20.3) 
Combination NRT 
with support 
0.4% 
(0 to 2.3) 
0.2% 
(0 to 1.6) 
0.0% 
(0 to 0) 
0.0% 
(0 to 0) 
Bupropion 0.4% 
(0 to 2.2) 
0.2% 
(0 to 1.7) 
0.0% 
(0 to 0) 
0.0% 
(0 to 0) 
Model convergence 
To estimate the cost-effectiveness of alternative mixes of interventions, 10,000 
replications of the model were performed, with parameters sampled from their range 
of plausible values in each replication. Figure 6.26 shows that stable ICER estimates 
were achieved after about 4,000 replications. This indicates that 10,000 replications 
were sufficient to obtain stable results from the probabilistic analysis. 
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Figure 6.26 Convergence of ICER estimates for the comparison of 
individual interventions (QALY outcomes) 
 
Quitting outcomes 
The incremental costs and effects over a 20-year time horizon of changes to the 
existing standard of care are shown in Table 6.13 and Figure 6.27. These show that 
an increased number of successful quitters would be expected if uptake rates of 
smoking cessation therapies matched those of England, which are characterised by 
higher uptake rates of e-cigarettes and a lower proportion of unassisted quit 
attempts. Outcomes would be improved still further if the uptake rate of combination 
varenicline and NRT was increased, even if the proportion of people opting not to 
use any form of support did not change. 
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Table 6.13 Incremental costs and benefits of non-dominated strategies 
for comparison of current standard of care to alternative mixes of 
interventions (quitting outcomes) 
Strategy Cost (€ 
million) 
Incremental 
Cost (€ million) 
Effect 
(Quitters) 
Incremental 
Effect 
(Quitters) 
ICER 
€/Quitter 
Ireland current 
practice 575.1 
 
569,889 
  Intervention 
mix in England 623.7 48.6 600,264 30,375 1,600 
Maximum use 
of varenicline 
+ NRT 730.8 107.1 626,137 25,873 4,140 
 
Figure 6.27 Cost-effectiveness plane for comparison of current standard of 
care to alternative mixes of interventions (quitting outcomes) 
 
QALY outcomes 
The impact of changes to the existing standard of care on QALY outcomes are 
shown in Table 6.14 and Figure 6.28. Again, these show that if uptake rates of 
smoking cessation interventions in Ireland were to follow those currently observed in 
England, or if the use of varenicline in combination with NRT were to increase, 
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increases in both utility outcomes and costs could be achieved. The cost per 
additional QALY generated (ICER) for each of these alternatives is relatively low, so 
both would be considered highly cost-effective using conventional willingness-to-pay 
thresholds in Ireland (Figure 6.29). 
Table 6.14 Incremental costs and benefits of non-dominated strategies 
for comparison of current standard of care to alternative 
mixes of interventions (QALY outcomes) 
Strategy Cost 
(€ 
million) 
Incremental 
Cost 
(€ million) 
Effect 
(QALY) 
Incremental 
Effect 
(QALY) 
ICER 
€/QALY 
Ireland current 
practice 2,338.5 
 
11,219,778 
  Intervention 
mix in England 2,373.8 35.3 11,226,647 6,869 5,136 
Maximum use 
of varenicline 
+ NRT 2,474.1 100.4 11,232,287 5,640 17,793 
Figure 6.28 Cost-effectiveness plane for comparison of current standard of 
care to alternatives (QALY outcomes) 
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Figure 6.29 Cost-effectiveness acceptability curve for comparison of 
existing standard of care to alternative mixes of interventions 
(QALY outcomes) 
 
As expected, univariate sensitivity analysis of the comparison between the mix of 
interventions currently in use in Ireland, and one where e-cigarette use reaches 
levels currently observed in England, shows that uncertainty around the clinical 
effectiveness of e-cigarettes is a key driver. If the relative effect of e-cigarettes on 
quitting outcomes is at its lower bound, then the current standard of care in Ireland 
dominates, but is dominated at its upper bound (Figure 6.30). For the results 
comparing the current standard of care in Ireland with a scenario characterised by 
maximum uptake of varenicline in combination with NRT, the effectiveness of the 
combination therapy is again the most influential parameter: the ICER for a 
comparator in which use of combination varenicline and NRT is maximised remains 
below conventional willingness-to-pay thresholds when the effectiveness estimate is 
held at its lower bound (Figure 6.31). 
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Figure 6.30 Univariate sensitivity analysis for the comparison of the  
  current standard of care to uptake rates of smoking cessation 
  interventions in England (QALY outcomes) 
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Figure 6.31 Univariate sensitivity analysis for the comparison of the 
current standard of care to increased use of varenicline and 
NRT (varenicline and NRT used in all receiving support and 
10% not receiving support, QALY outcomes) 
 
 
6.3 Budget impact analysis 
A budget impact analysis (BIA) was carried out to estimate the total additional 
expenditure associated with changes to the mix of interventions used for smoking 
cessation in Ireland over the next five years. This analysis only includes direct costs 
of smoking cessation interventions for those with a Medical Card, for whom the 
provision of varenicline, bupropion and NRT is funded by the public health service, 
taking account of the fact that some people may not complete a full course of 
treatment. A scenario analysis estimates the total cost associated with a decision to 
fund a 12-week course of e-cigarettes in the same way. Costs used in the BIA 
include value-added tax (VAT) at 23%, where applicable.(559) The primary analysis 
assumes that 100% of smokers with a Medical Card who are attempting to quit 
using NRT will visit a GP in order to obtain a prescription, so that they can obtain a 
month’s supply for a prescription fee of €2.50. Unlike varenicline and bupropion, 
there are restrictions as to how NRT can be prescribed and dispensed on the 
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General Medical Scheme (GMS). The initial quantity of NRT prescribed for a patient 
is limited to a two-week supply in order to evaluate the effectiveness of the therapy, 
with further supplies dispensed in monthly aliquots.(560) Also, unlike varenicline and 
bupropion, NRT is freely available over-the-counter in any retail outlet, so it is 
unlikely that all Medical Card holders wishing to use NRT in their quit attempt will 
choose to obtain it though the GMS and instead pay for it out of pocket. Comparing 
the most recent data on the total cost of NRT medication funded through the PCRS 
with the full cost of NRT use among smokers with a Medical Card per Healthy 
Ireland survey data on usage rates, it would appear that approximately two thirds of 
the cost of NRT use is paid for through the GMS.(1, 534) 
Table 6.15 compares the expected budget impact in year one of the analysis with 
the actual expenditure reported by 2015 PCRS report.(534) The budget impact 
analysis does not include the costs of smoking cessation interventions funded 
through the Drugs Payment Scheme (DPS).(561) Under the DPS scheme, the total 
monthly combined cost to an individual or family for approved prescribed drugs is 
capped at €144 each month. While none of the smoking cessation interventions 
exceed this monthly cap, it is likely that the addition of these medications will raise 
some smokers’ monthly expenditure above €144, which will then impose additional 
costs on the health service. This does not apply in the case of NRT, as it is not 
covered under the DPS scheme.(560) Accurate estimates of the likely increase in DPS 
payments as a result of changes to routine practice for smoking cessation are 
difficult to predict, as they require knowledge of all other prescription medications 
being paid for by smokers without a Medical Card. Total DPS expenditure on 
varenicline (ingredient cost, excluding patient co-payments) has declined from €1.77 
million in 2009 to less than €270,000 in 2015. 
 
Table 6.15 Comparison of modelled and actual total GMS expenditure on 
smoking cessation therapies in 2015 
Treatment Modelled 
expenditure 
based on 
2015 data (€) 
Actual 
expenditure in 
2015 (€) 
% Difference  
(absolute difference as a 
percentage of actual 
expenditure in 2015) 
Varenicline 1,843,833 1,783,575 3.4% 
Bupropion 147,812 160,000 7.6% 
NRT with 65% GMS 
reimbursement 
5,141,612 4,951,645 3.8% 
The anticipated differences in total expenditure on each of the smoking cessation 
therapies currently funded through the GMS was calculated for each alternative 
standard of care assessed in the economic evaluation. This took account of the 
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relative reduction in the number of smokers (and therefore quit attempts) within 
populations in which a more effective mix of interventions is used. Figure 6.32 shows 
the five-year incremental budget impact for each of the alternative standards of care 
included in the economic analysis. 
Figure 6.32 Five-year incremental budget impact associated with the 
provision of GMS-funded smoking cessation therapies in each 
of the modelled comparators, compared with current practice 
in Ireland 
 
The results show that if the use of combination varenicline and NRT treatment is 
maximised (to 13%), it would increase the total annual cost of funding smoking 
cessation interventions in Ireland by approximately €7.6 million. A more moderate 
increase in the use of this treatment option (to 8%) would be associated with an 
incremental cost of €4.6million per annum. For both of these options, the 
incremental costs would decline over time as the increased effectiveness will be 
reflected in a lower smoking prevalence. If the relatively high usage rates for e-
cigarette observed in England were to be replicated in Ireland, without this 
treatment being funded through the public health system, there would be an annual 
decrease in expenditure on smoking cessation interventions of around €2.6million. 
Alternatively, if e-cigarettes were funded in the same way as NRT, resulting in an 
equivalent percentage of the total cost of e-cigarette use (as a short-term aid to 
quitting) falling on the public health service, this would be associated with an 
increase in the total cost of funding smoking cessation interventions of about €6 
million per annum (Figure 6.33). The additional demand this may place on GP or 
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nurse prescriber services is covered in Chapter 7. If e-cigarette use rose to levels 
currently observed in England (45% of all those attempting to quit), the additional 
cost over the next five years would be in the region of €7.5 million per annum over 
the next five years. 
Figure 6.33 Total five-year incremental budget impact of each comparator 
with reimbursement of e-cigarettes (compared to current 
practice with no e-cigarette reimbursement) 
 
6.4 Discussion 
Based on the results of the cost-effectiveness analysis, all smoking cessation 
interventions evaluated in the economic model are cost-effective compared with 
unassisted quitting. E-cigarettes are the single most cost-effective option, but this 
result is extremely sensitive to changes to the clinical effectiveness and cost 
estimates used, both of which are associated with a high degree of uncertainty. The 
most cost-effective strategy at willingness-to-pay thresholds routinely used in Ireland 
is combination varenicline and NRT treatment, which is associated with a cost per 
additional quality-adjusted life year (QALY) gained of €6,176 compared with 
unassisted quitting.  
Knowing the relative cost-effectiveness of individual smoking cessation therapies is 
only beneficial insofar as it informs efforts to change the current mix of interventions 
in order to maximise the uptake of those that represent the best value for money. 
To examine this, an analysis of prospective changes to the current standard of care 
in Ireland was carried out, using international data to estimate plausible maximum 
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uptake rates of the most cost-effective treatments. The results of this analysis found 
that at conventional willingness-to-pay thresholds in Ireland, the optimal strategy is 
to maximise the use of the most effective treatment (combination varenicline and 
NRT, ICER €17,793/QALY). If the use of e-cigarettes increased to the levels 
currently reported in England, an increase in the number of successful quit attempts 
would also be expected compared to current practice, at a lower cost per QALY 
gained (ICER €5,136/QALY). The base case analyses assumed that everyone making 
a quit attempt receives minimal behavioural support in the form of brief advice or 
written materials. 
There are a number of items to be considered when interpreting these results. The 
analysis only included four smoking-related illnesses (stroke, IHD, COPD, and lung 
cancer). Given the multitude of other diseases that are linked with smoking, the 
utility gain from smoking cessation used in the model is likely to be an 
underestimate. The inclusion of other smoking-related illnesses would tend to make 
cessation treatments even more cost-effective. Similarly, this analysis does not 
include the full costs of treatment for each of the four diseases due to a lack of 
available data. The inclusion of additional costs would again tend to make cessation 
interventions more cost-effective. The utility estimates used in the model are based 
on differences in disease prevalence among current and former smokers. These are 
applied at a population level to estimate the change in the absolute number of cases 
in each comparator, rather than modelling a smoker’s risk of developing these 
diseases based on smoking history, age, time since quitting, and other important 
factors that contribute to an individual’s risk profile. While this would reflect a truer 
picture of the consequences of smoking cessation, insufficient data are available to 
carry out this sort of detailed analysis with a reasonable degree of validity. The 
analysis also does not take account of multi-morbidity; for example, the costs and 
utility loss associated with a current or former smoker who has both COPD and 
ischaemic heart disease is calculated as the full cost and full utility loss associated 
with both diseases. While this approximation is adequate for the purposes of 
comparing across comparators in which the same assumption applies, the actual 
costs and utility loss from having multiple concurrent diseases is unlikely to be 
additive. Finally, unlike some previous analyses, there is no disutility associated with 
smoking for those without a smoking-related illness. Inclusion of any such disutility 
would again tend to result in lower ICER estimates; making smoking cessation 
interventions more cost-effective. 
The clinical effectiveness estimates for each of the individual therapies are based on 
a network meta-analysis of the available evidence, as outlined in Chapter 4. These 
are applied to the absolute quit rate for unassisted quitting to provide an estimate of 
the absolute quit rates for each intervention. The unassisted quit rate is therefore of 
key importance in the analysis. The central estimate was taken from a pooled 
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analysis of quit rates in the control arms of studies with no or minimal intervention 
that reported 12-month follow up. Different quit rates are obtained when pooling 
data from all control arms, or when limiting to studies reporting continuous 
abstinence (see Table 6.3). To ensure that the data used were consistent with the 
relative effect size estimates for each of the interventions, the central estimate was 
used, with the extreme upper and lower bounds observed across all three estimates 
of the quit rate in the control arms used to capture the uncertainty associated with 
this parameter. An additional difficulty in modelling the unassisted quit rate derives 
from the possibility that unassisted quit rates in a real life setting may be higher 
than those observed in clinical trials, due to self-selection. This would occur if 
smokers that are more likely to successfully quit, perhaps as a result of being less 
addicted, more motivated, and so on, are more likely to try unassisted quitting. Of 
note is a recent observational study of quit rates in the US, which found that in the 
majority of states (84%) unassisted quit rates were higher than assisted quit 
rates.(562) If a proportion of those who choose unassisted quitting do not stand to 
gain as much from switching to a pharmacological intervention as the model 
assumes, then any scenario that models a significant reduction in unassisted quit 
rates is of questionable validity. However, this analysis minimises this risk by 
ensuring that all comparators involving a reduction in unassisted quit rates are based 
on observed data in other countries, thus ensuring that quitting preferences are not 
set at unrealistic levels, as long as the reference population can be considered 
comparable to Ireland. 
This analysis aims to inform policy objectives in regard to the uptake rate of different 
therapies. However, the degree to which HSE smoking cessation services can 
influence overall population uptake rates is difficult to judge, particularly in light of 
the major changes in the uptake rate of e-cigarettes in the absence of any desire to 
promote their use by smoking cessation practitioners. As this analysis is based on 
2015 data, there is also the possibility that other shifts in the use of particular 
interventions may occur in the coming years that would diminish the relevance of 
the results. Of particular importance will be the results of ongoing studies on the 
effectiveness of e-cigarettes as a cessation intervention. These are likely to change 
the current estimates for this parameter and may significantly affect the results of 
this HTA. These issues will need to be considered by decision-makers when 
interpreting these results and how they can be used to inform prospective policy 
initiatives. However, the overall results of the analysis show that in the context of 
the wider health service, smoking cessation interventions are highly cost-effective, 
and that any attempt to increase the use of effective smoking cessation strategies 
among smokers wishing to quit is likely to represent good value for money. 
The results of the budget impact analysis on the likely changes in expenditure on 
smoking cessation therapies show that efforts to maximise the use of the most 
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effective treatment (combination varenicline and NRT) would be associated with 
increased costs of up to €7.6 million per year. However, this would correspond with 
an increase in the uptake rate of varenicline from 3.7% to 12.5%, and whether such 
a substantial increase can be brought about in practice is questionable. If the use of 
e-cigarettes in Ireland rose to levels currently observed in England (with 
corresponding decreases in the use of alternative smoking cessation interventions) 
then the cost of funding smoking cessation interventions would be expected to 
decrease by about €2.6 million annually, as a result of shifting the costs back onto 
the individual. Alternatively, if e-cigarettes were funded in the same way as NRT, 
where about 65% of the estimated total usage among Medical Card holders is 
reimbursed by the state, the costs of the provision of smoking cessation 
interventions through the General Medical Scheme would increase by €6 million 
annually at current usage rates, and by approximately €7.5 million at usage rates 
equivalent to those reported in the latest English data. 
6.5 Key Points 
 No previous cost-effectiveness analyses comparing alternative mixes of 
smoking cessation interventions with an existing standard of care were 
identified in a systematic review of the literature. 
 A number of published studies have evaluated the cost-effectiveness of 
individual smoking cessation therapies compared with unassisted quitting 
or another intervention. The results of these studies indicate that 
cessation interventions tend to be highly cost-effective, with varenicline 
generally emerging as the most cost-effective alternative. However, none 
of these studies included newer treatment options such as e-cigarettes, or 
combination therapy with varenicline and either NRT or bupropion. 
 A cost-effectiveness analysis comparing individual therapies in an Irish 
setting found that all would be considered cost-effective compared with 
unassisted quitting, with e-cigarettes and combination varenicline and NRT 
being the most cost-effective strategies when individual therapies are 
compared with each other. 
 The results for e-cigarettes are extremely sensitive to changes in the 
estimated cost and effects of this intervention. This is of particular 
significance given the high degree of uncertainty that exists in relation to 
both of these parameters in the model. Further research is very likely to 
have an important impact on the results of the cost-effectiveness of this 
intervention. 
 A comparison of alternatives to the current standard of care in Ireland was 
carried out, using international data as an indicator of plausible changes in 
the use of the most cost-effective cessation interventions. This included a 
scenario where combination varenicline and NRT use was maximised, as 
well as a scenario where e-cigarette uptake reached levels recently 
reported in England. 
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 This analysis found that maximising the uptake of combined varenicline 
and NRT therapy is the optimal strategy (ICER €17,800/QALY), but it is 
unclear to what extent policy initiatives can influence overall smoking 
cessation preferences, particularly in light of the high degree of 
penetration e-cigarettes have achieved in the absence of any explicit 
endorsement by quit services in Ireland. 
 Based on the available evidence, continuing increases in the uptake of e-
cigarettes are likely to improve the cost-effectiveness of the overall mix of 
cessation interventions in Ireland, by increasing the number of successful 
quit attempts at an acceptable cost (ICER €5,100/QALY at uptake rates of 
45% currently reported in England). 
 A budget impact analysis on the incremental cost associated with changes 
to the existing standard of care found that maximising the use of 
combination varenicline and NRT would be associated with an average 
increase of approximately €7.6 million in the annual cost of providing 
smoking cessation interventions in Ireland. 
 A scenario analysis in which uptake rates of e-cigarettes are comparable to 
England (while still not being reimbursed through the General Medical 
Scheme) found that this would result in a decrease in expenditure on 
smoking cessation interventions of approximately €2.6 million per annum. 
Alternatively, if e-cigarettes were to be funded to the same extent as NRT, 
the additional cost to the health service would be approximately €6 million 
per annum at current usage rates, or €7.5 million if this rose to usage 
rates currently reported in England. 
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7 Wider implications 
This chapter summarises the potential issues that might arise from implementing 
any changes to the mix of smoking cessation interventions provided in Ireland as a 
result of the clinical effectiveness, safety, cost-effectiveness and budget impact 
evidence in this HTA. These issues are grouped into two sections:  
 Section 7.1 describes the ethical, societal and legal considerations 
 Section 7.2 describes the organisational issues (the current configuration of 
services and potential issues for the implementation of services) for each of 
the three populations; unselected adults in a community setting, the 
maternity and mental health subgroups.  
7.1 Ethical, societal and legal considerations 
7.1.1 Introduction 
This section discusses the relevant ethical, societal and legal considerations arising 
within the broader public health context, as well as in relation to some of the specific 
interventions detailed in this report. 
7.1.2 Ethical principles 
Public health is concerned with promoting and protecting the health of the 
population. Collective interventions undertaken for the benefit of population health 
often involve or require government action, such as promoting a healthy diet to 
combat rising obesity levels or sun protection campaigns to inform citizens of skin 
cancer risks and so on. Collective action to promote and protect population health 
also occurs at the global level, such as the activities of the World Health 
Organization.  
Broadly speaking, ethics is the science or study of the morality of human acts 
through the medium of natural reason.(563) Medical ethics applies general ethical 
principles to solve the moral problems of the medical profession. It involves 
analysising the concepts, assumptions, beliefs, attitudes, emotions, reasons and 
arguments underlying medico-moral decisions.(564)33 Public health ethics primarily 
deals with the moral foundations and justifications for public health, the various 
ethical challenges raised by limited resources for promoting health, and the real or 
perceived tensions between collective benefits and individual liberty.(565) 
Many different approaches to medical ethics may be adopted. The most common 
approach used in practice is known as ‘principlism’, which has been adopted by 
many professional bodies and associations as a framework for ethical guidance. 
Principlism, also known as the Four Principles approach, focuses on respect for 
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autonomy, beneficence, non-maleficence, and justice.(566) However, some 
philosophers argue that the principles of dignity, precaution, and solidarity reflect 
the European ethos better than the liberal concepts of autonomy, harm, and justice. 
They argue that these principles elevate prudence over hedonism, communality over 
individualism, and moral sense over pragmatism.(567)  
The following sections look at what these different principles mean and how they 
might apply in the context of smoking cessation interventions. 
7.1.2.1 Respect for autonomy 
The word autonomy means self-rule, or making one’s own deliberate decisions. 
Respect for autonomy is of vital significance in the medical context. Patients must be 
consulted with and informed about their healthcare and thechoices available. 
Doctors are required to obtain informed consent from patients before any treatment 
or intervention is carried out (except in cases of incapacity or medical emergency). 
Respecting autonomy also requires maintaining patient confidentiality, practising 
appropriate behaviour and using good.  
Application to smoking cessation interventions: 
Existing tobacco controls encourage prevention and smoking cessation, while also 
respecting adult autonomy and protecting others from the associated harms and 
costs. Autonomy in decision-making is the norm, despite evidence of nicotine 
dependence. Warning labels inform consumers, smoking laws protect third parties 
from passive smoking, taxes internalise the social costs of smoking, and age limits 
and marketing restrictions exist to protect minors.(568) 
Smoking cessation intervention could take the form of either a harm-reduction 
strategy or a more absolutist approach. A harm-reduction strategy aims to eliminate 
the damaging effects of a particular behaviour, without eliminating the behaviour 
itself. A more absolutist approach would seek to eliminate the behaviour entirely. For 
example, drug addiction and prostitution are perceived to be inherently wrong, and 
in many countries are criminally prosecuted. However, alternative harm-reduction 
strategies also exist such as the provision of needle exchanges and safe injection kits 
to injection drug users, and the use of methadone to treat opiate addiction.(569)  
Although smoking is harmful to the smoker and to third parties who inhale tobacco 
smoke, it is not generally considered to be morally wrong and is therefore a matter 
of individual choice. Public health initiatives in recent years have attempted to 
ensure that this choice is more informed by advertising campaigns and plain 
packaging regulations. As such, any smoking cessation intervention must be made 
available in a way that continues to promote the autonomy of the individual. This 
can be done by providing information concerning the risks and benefits associated 
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with the particular intervention. However, this is challenging in the case of some 
interventions, such as e-cigarettes, as comprehensive safety evaluations cannot be 
made in the face of incomplete evidence, meaning the public cannot be given full 
information on which to base their decisions. The provision of inaccurate information 
on comparative risk is fundamentally unethical as it fails to allow consumers to make 
informed choices.(569) 
7.1.2.2 Beneficence and non-maleficence 
The ultimate aim in healthcare is to produce net benefit over harm, while 
recognising that it is inevitable for some risk of harm to exist when medical 
intervention takes place. Beneficence is the traditional Hippocratic duty to prioritise 
the patient’s best interests, while non-maleficence is the duty not to cause harm or 
risk of harm to patients. These duties mean that those who treat patients must be 
appropriately qualified, so as not to put patients at undue risk. Healthcare 
professions undertake to provide appropriate training and education to prospective 
and current practitioners to ensure patients are adequately protected.  
Application to smoking cessation interventions 
The benefit of smoking cessation interventions is that they increase the chances of 
long-term quitting in those who are motivated to stop smoking. In turn, this lowers 
the risk of developing lung cancer, heart disease and respiratory problems. The 
harms associated with the interventions are largely associated with pharmacological 
interventions and e-cigarettes.  
E-cigarettes 
While Public Health England reports that e-cigarettes are thought to be 95% less 
harmful than tobacco cigarettes, it is still unknown whether they will ultimately 
reduce harm.(27) (For example, reducing the number of lives lost, reducing numbers 
of new smokers, increasing numbers of those who successfully stop smoking and so 
on.) The international public health community is currently divided about whether to 
endorse a device whose safety and efficacy for smoking cessation is unclear. While 
e-cigarettes are safer compared with tobacco smoke, there is insufficient evidence 
thus far to state that they do not cause any harm.  
Although there is clear benefit to existing smokers from switching to e-cigarettes, 
there are concerns that if it becomes socially normalised, large numbers of people 
who have never smoked might take up smoking e-cigarettes, thus exposing 
themselves to health and financial risks that would otherwise be avoided. There is 
international evidence that people who have never smoked, particularly 
teenagers,(570, 571) are taking up e-cigarettes.  It is also possible that e-cigarettes will 
have a ‘gateway effect’ for non-smokers who take up e-cigarettes, and they may 
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later migrate to tobacco cigarettes or marijuana. Smokers who use e-cigarettes as a 
smoking cessation aid may in effect be swapping tobacco for another dependency, 
leading to long-term e-cigarette use and continued nicotine dependency. If those 
people used a different cessation aid such as NRT, they may be more likely to 
become nicotine-free. 
The tobacco control community are wary of accepting harm reducing products, such 
as e-cigarettes. Increased initiation and decreased quitting arising from public 
misperceptions of the products could have a negative population-wide health 
impact.(572) If e-cigarettes make smoking socially acceptable, this could be seen as a 
retrograde step after decades of anti-smoking efforts. However, from the 
perspective of harm reduction, it is unlikely that the population level harms resulting 
from e-cigarette uptake among non-smokers would overshadow the public health 
gains obtained from tobacco harm reduction among current smokers.  
7.1.2.3 Justice  
Justice generally means fairness, and may be described as the moral obligation to 
act on the basis of fair adjudication between competing claims. This can be 
subdivided into three categories of obligations:  
1. distributive justice which involves the fair distribution of resources;  
2. rights-based justice which involves respect for people’s rights;  
3. legal justice which involves respect for morally acceptable laws.  
Many moral conflicts can arise in this context, for example, how to decide between 
equally deserving patients when providing a scarce resource. There are also issues 
in regard to the wider use of resources, conscious that payment must be made for 
those resources either by the patient, an insurer or the state. A public health 
programme must consider equity of access and the rationale or justification for 
selecting particular population groups. 
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Application to smoking cessation interventions 
The harms that result from tobacco use are not experienced equally by all segments 
of the population. Health disparities exist in tobacco as in other health-related 
fields.(572) A harm-reducing strategy may fail if net harm is reduced, but in a way 
that is socially unjust; for example, some socially or economically vulnerable group 
becomes more at risk of harm or less able to benefit from the harm reduction 
strategies. Smoking rates are higher among people with a mental illness and those 
in lower socio-economic groups. These people are over represented in the 
population targeted by cessation interventions. If the HSE were to favour one or 
more smoking cessation intervention over others, the autonomy of the individual 
might be impacted if they cannot choose the intervention that most suits them. 
Although all interventions would continue to be available for purchase, this might 
negatively affect those in lower socio-economic groups who cannot afford to pay for 
alternative interventions out of pocket. 
7.1.2.4 Conclusion 
Saving lives and safeguarding health is accepted as important by policy makers. 
However, the action to increase good health at the expense of the state has 
exercised many governments, activists, academics and medical practitioners alike. 
The legal and moral responsibility of the state to save life and prevent disease, as 
well as promote good health for its citizens has been the subject of longstanding 
debate. Health policy, such as whether to introduce a disease screening programme, 
or to provide a vaccine, must take account of not only applying ethical principles to 
individuals but also the benefit, costs and risks to the public.   
It must be considered whether it is morally acceptable for the HSE or clinicians to 
promote a product whose long-term health effects are unknown. Cautionary policies 
based on the precautionary principle are significant in terms of public-health ethics. 
These policies state that when scientific data are contradictory or quantitatively 
scarce, it may be necessary to make temporary decisions that can be modified on 
the basis of new facts that eventually become known. A cautionary approach might 
be considered appropriate where there is a lack of evidence on potential long-term 
risks associated with some smoking cessation interventions, such as e-cigarettes. 
This approach must advise smokers who wish to quit of all the cessation 
interventions available, while providing as much information as possible in relation to 
safety and efficacy. Such a policy would have to be reviewed on a regular basis as 
new international research evidence becomes available.  
7.1.3 Regulation 
Ethical issues also arise in relation to the regulation of public health interventions. 
Measures adopted by states must try to meet the objective of improving population 
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health. This is possible by providing information to consumers that is as accurate as 
possible, in order to uphold autonomy. Broader public health interests must be 
protected by aiming to reduce smoking rates in the population generally and 
safeguarding vulnerable groups, such as young people.  
Questions for consideration here include whether e-cigarettes should be regulated as 
strictly as tobacco cigarettes due to the unknown health effects of vapours on 
bystanders, particularly pregnant women. However, regulating both in the same way 
might give the message that they are both similar, which in turn might result in 
increased inter-changeability between products.  
Marketing and advertising is also important in the public’s perception of smoking 
cessation interventions. The government also has an ethical duty to ensure that the 
media portrayal of the product is appropriately aligned with its known degree of risk. 
The EU Tobacco Products Directive which came into force in member states in May 
2016 sets rules governing the manufacture, presentation and sale of tobacco and 
related products, including electronic cigarettes, which aim at harmonising the 
quality and safety requirements of the products for the benefit of consumers.(25) In 
addition, rules on packaging and labelling ensure that consumers are better 
informed. 
7.1.3.1 Potential medico-legal liability 
There have been a small number of legal actions in the United States in relation to 
the safety of e-cigarettes that have exploded and caused injury to consumers. These 
actions have been taken against manufacturers and turn on product liability law, and 
are thus not a matter for the state or individual clinicians.  
New problems could arise if future research shows that negative health effects, 
which are currently unknown, arise from the use of e-cigarettes. As this product is 
not currently licensed as a medicinal product, it does not come within the remit of 
the Health Products Regulatory Authority to assess and monitor its safety and 
efficacy for licensing purposes. It is important to note that there are risks and side-
effects with almost all over-the-counter products that may be purchased, even 
pharmacological products such as aspirin or paracetamol. Where appropriate 
warnings and information leaflets containing accurate information are included with 
the sale of any such product, it is difficult to see how a legal action might 
successfully be taken with the benefit of hindsight in future years. It is important 
that the government continues to fulfil its moral and legal duty to the public with 
regular reviews of international research data and updates of consumer information. 
This can help encourage smoking cessation through various means and provide as 
accurate and up-to-date information as possible to consumers. 
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Similar considerations apply to individual clinicians who advise their patients to use a 
particular smoking cessation method. Current legal principles state a clinician will not 
be held liable for negligence if they act in accordance with the standards of the 
medical profession and dowhat any other reasonable doctor of the same specialty 
would do in the circumstances. However, there is a caveat that the clinician will not 
escape liability if there are obvious and inherent defects in the practice. In relation 
to potential liability for breach of the doctrine of informed consent, the Irish courts 
have taken a patient-centred approach to this issue. This means that doctors are 
under an obligation to inform patients of any material risk which the doctor knows or 
should reasonably be aware of in relation to the proposed treatment. These issues 
further underline the importance of accurate and up-to-date information being made 
available to enable patients and consumers to make an informed choice.  
7.2 Organisational implications 
This analysis of the clinical effecetiveness and cost-effectiveness of smoking 
cessation interventions is designed to identify potential improvements in the delivery 
of these services in Ireland. However, there may be significant organisational 
implications associated with efforts to change the mix of interventions offered to 
smokers, and this also needs to be considered by decision-makers. These issues 
range from the need for additional staff and resources to support increases in the 
delivery of existing interventions, to significant reorganisation of services required to 
deliver new interventions or existing interventions in a different way. This section 
discusses the potential organisational implications associated with the findings of the 
HTA. 
7.2.1 Unselected adults 
As noted in Chapter 1, the primary population of interest for this review was 
unselected adult smokers in a community setting. This is the group broadly targeted 
by national quit campaigns and accounts for the majority of those using existing 
smoking cessations services. 
7.2.1.1 Current configuration of services 
The HSE provides and promotes a wide range of smoking cessation services, ranging 
from HSE QUIT clinics and courses, primary care supports provided by GPs, 
pharmacists and dentists, online and social media supports on www.quit.ie and 
Facebook and a QUITline telephone support service. Tobacco cessation support 
services work to nationally agreed standards (National Standard For Tobacco 
Cessation Support Programme).(52) 
Current HSE policy is that every person who engages with front-line HSE staff should 
be asked about their smoking status and the response should be documented. Every 
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smoker should be advised to quit and offered support; this is known as Brief 
Intervention and should be provided at every opportunity. The HSE distinguishes this 
support from the intensive cessation support services that are provided by trained 
cessation specialists working in community or hospital settings, or with the national 
QUITline.  
Intensive cessation support is delivered by cessation specialists with dedicated time 
to deliver support. An intensive intervention is a consultation that lasts in excess of 
10 minutes. Intensive interventions usually involve a number of structured 
consultations provided over a defined period of time (that is, a Cessation Support 
Programme). 
A Cessation Support Programme is a structured programme which incorporates a 
series of contacts or consultations tailored to meet the client’s needs. Clients may be 
referred to this service from all services within the HSE or through self-referral. This 
programme involves ongoing support at intervals pre and post the client’s quit date, 
and for a period of one month following the quit date. The programme involves the 
monitoring of quit status at two further points (three months and 12 months). 
Tobacco cessation services vary from region to region due to differences in the 
availability of dedicated resources. All regional tobacco cessation specialists have 
undertaken nationally recognised training. Tobacco cessation specialists may also 
have other roles in tobacco control such as training, research, support for smoke-
free policy development and strategic planning for tobacco control.  
Depending on the region, the following interventions are available: 
1. Face-to-face support. An intervention offering one-to-one support, in person, 
between a Tobacco Cessation Specialist and a smoker. This behavioural 
intervention consists of advice, discussion and exercises. 
2. Telephone support. This support may be proactive, reactive or SMS-based. 
Tobacco Cessation Specialists can call the client following a referral from 
another service (a proactive service) or the client can call the service (a 
reactive service).  
3. Group support. This involves support through a closed group of smokers in a 
structured format. Groups are facilitated by Tobacco Cessation Specialists and 
are held weekly (usually for 6 weeks).  
4. Online support. Proactive or reactive support is available online (such as, 
email) by a Tobacco Cessation Specialist. 
Data from the 2015 HSE annual report indicate that 11,949 smokers received 
support from a cessation counsellor in that year.(573) A total of 1,279 healthcare 
professionals were trained through 131 training programmes, while 30 staff were 
trained to provide intensive tobacco cessation specialist support to smokers. An 
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ongoing commitment to training is evident in the 2017 HSE service plan, with a 
target to train an additional 1,350 front-line staff in 2017.(574) 
Between 2013 and 2015, on average, 8,513 smokers received intensive smoking 
cessation support from HSE smoking cessation services, with just over half (51%) 
entering a cessation support programme. Access to telephone support is provided 
through the QUITline which is available for 48 hours a week. This extends to 77 
hours a week in the month of January to cope with increased demand at that time. 
Demand for online support is evident through traffic on www.quit.ie. In September 
2016, there were over 1,400 visitors to the site; 1,258 of these created a QUITplan 
and 530 requested a call from an advisor. Nationally, there are 39 smoking cessation 
practitioners providing an average of 16 hours per week (range 0 to 39) in direct 
cessation activity.(575)  
A smoking cessation programme also provides assistance with choice of cessation 
medication and monitoring effective use of same. Varenicline and bupropion are 
prescription-only medications. While certain NRT products are now available over the 
counter. For reimbursement through the Primary Care Reimbursement Scheme 
(PCRS) they must first be prescribed by a practitioner registered with the PCRS. In 
addition to physicians, midwives and nurses may prescribe medicinal products if they 
are registered as Registered Nurse Prescribers with the Nursing and Midwifery Board 
of Ireland (NMBI). 
Varenicline and bupropion, classified as drugs used in nicotine dependence, are 
included in the Drugs Payments Scheme (DPS) and can be reimbursed through the 
PCRS for Medical Card holders. 
NRT is not included in the DPS. For reimbursement through the PCRS, the following 
criteria apply:(576)  
1. The quantity to be prescribed and dispensed on the initial prescription must 
be limited to a two weeks’ supply in order to evaluate the success of the 
therapy. 
2. NRT may not be prescribed on General Medical Scheme repeat prescription 
forms. 
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More than one formulation (for example, NRT patch with NRT gum) may be 
prescribed. This is known as combination NRT, and patients are not limited to a 
maximum duration of therapy. However, while consistent with the criteria for 
reimbursement of any medications for Medical Card holders, some of the criteria 
may act as a barrier to access and discourage certain patients from availing of these 
interventions. If a medication is prescribed (or recommended in the case of over-
the-counter (OTC ] NRT) by a provider other than the patient’s GP, the patient must 
arrange for it to be transcribed onto a dedicated General Medical Scheme 
prescription to be reimbursed through the PCRS. In the case of NRT, limiting the 
initial prescription to a two weeks’ supply and disallowing the use of repeat 
prescriptions may lead to additional GP visits and act as a barrier to access. 
Excluding NRT from the Drugs Payment Scheme may also act as a barrier to access 
for some patients.  
In addition to HSE services, there are also likely to be some additional supports 
provided through private health insurers or occupational health schemes. However, 
the impact of these services on overall smoking cessation is difficult to determine 
due to a lack of centralised data on the quantity and type of services offered, and 
the number of smokers accessing them. 
7.2.1.2 Evidence and implications for practice 
The analysis of the clinical and cost-effectiveness of smoking cessation interventions 
found that all interventions evaluated were cost-effective compared with unassisted 
quitting. Combination varenicline and nicotine replacement therapy (NRT) was found 
to be the optimal smoking cessation strategy when all interventions were compared 
with each other. Increased use of NRT and varenicline will have implications for 
licensed prescribers, due to an increase in the number of smokers requiring 
prescriptions. However, if smokers increasingly choose to use e-cigarettes in their 
quit attempt without seeking the advice of medical practitioners, demand on these 
services would decrease. The additional number of GP or nurse prescriber 
consultations associated with each of the comparators included in the HTA is shown 
in Table 7.1. These estimates are based on the following assumptions: 
 all those with a Medical Card who use NRT will obtain a prescription,  
 no GP consultation will be sought for unassisted quit attempts or those 
involving e-cigarettes alone,  
 and, everyone taking varenicline or bupropion will require a single 
consultation. 
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Table 7.1 Differences in the average annual number of GP or nurse 
prescriber consultations required for each comparator over a 
5-year time horizon* 
 Current 
Practice 
(Ireland) 
E-
cigarette 
uptake 
rates in 
England 
Moderate 
Varenicline & 
NRT uptake 
Maximum 
Varenicline & 
NRT uptake 
Average annual number 
of prescriptions needed 
87,475 54,485 114,938 139,109 
% change Reference point -38% 31% 59% 
*Assuming current mechanisms for reimbursement of cessation aids remain unchanged and that e-
cigarettes are not reimbursed by the publicly-funded healthcare system. 
Table 7.1 shows that significant increases in the use of e-cigarettes as the sole 
quitting aid would lead to a substantial drop in the number of consultations needed 
annually. A 40% decrease in consultations is anticipated if e-cigarette use reaches 
the levels observed in England (that is an increase from 26% to 45% of annual quit 
attempts). Alternatively, if e-cigarette use remained stable and the use of varenicline 
and NRT was increased, additional demands would be placed on health services. 
It is difficult to measure the impact of this increased demand for service planning. 
Many smoking cessation interventions are opportunistic, with healthcare 
professionals availing of opportunities to encourage cessation as part of 
consultations primarily directed at other areas of care. Therefore, the numbers of 
consultations required for each comparator strategy may overestimate the scale of 
the incremental activity required. Furthermore, the projected figures do not account 
for reductions in the number of consultations required due to a reduction in 
smoking-related illnesses associated with a lower smoking prevalence for each of 
these comparators. Any decision to reimburse e-cigarettes through the PCRS in a 
similar way to NRT would place additional demands on prescribing services. 
However, unlike NRT, no e-cigarette is currently licensed as a medicinal product in 
Ireland, so it is unclear exactly how any such a funding scheme would operate.     
As discussed in Chapter 4, the evidence is unable to differentiate between the 
effectiveness of different types of behavioural support when provided in addition to 
pharmacotherapy. While the optimal type of behavioural support to provide is 
unclear, the addition of any type of behavioural support to a pharmacological 
intervention increases the chances of successful quitting. The limited evidence is 
especially problematic given the significant amount of time and resources needed to 
train health professionals in the delivery of behavioural support interventions, and 
the fact that changing the type of support provided (for example, from brief advice 
to individual counselling or group behaviour therapy) may be logistically more 
challenging than substituting one pharmacotherapy intervention for another. It is 
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also worth noting that the reported cessation outcomes associated with behavioural 
interventions do not capture the full benefit of these services, which are also 
designed to raise awareness of the harms of smoking in order to discourage people 
from starting and to motivate more smokers to make a quit attempt. As described in 
section 3.4.4, a wide range of smoking cessation supports is currently available 
through health services in Ireland. This includes brief interventions, pharmacological 
therapies, counselling, online and social media supports, QUITline telephone 
support, courses, and specialist quit clinics. Additional staff training may also be 
required to ensure all staff enagaged in smoking cessation are aware of the most 
up-to-date evidence on the potential benefits and harms of different smoking 
cessation interventions, particularly e-cigarettes, if these are to be included among 
the treatments options discussed with smokers.  
As well as having implications for providing smoking cessation interventions, 
changes in current practice may also affect resource use in the services that provide 
care for smoking-related diseases, such as lung cancer and ischaemic heart disease. 
A number of simplifying assumptions were made in the model to estimate cost-
effectiveness in order to estimate the long-term changes in disease prevalence as a 
result of lower smoking prevalence. It was assumed that prevalence rates of 
smoking-related illness in former smokers would apply to the population of former 
smokers in the model each year. In the time horizon for the budget impact (five 
years), all of these former smokers have quit for between one and five years, 
whereas disease prevalence rates applied to this group are drawn from cross-
sectional studies that included smokers who had given up decades previously, as 
well as those who had only managed to quit recently. While the comparison of 
different strategies in this assumption is still valid, it likely overestimates the 
reduction in smoking-related disease prevalence in any given comparator in the 
short term.  
However, as the time horizon is extended, the model should converge on an 
approximation that is more indicative of the absolute prevalence in each group. This 
occurs as, by year 20, the former smokers group includes people who have quit over 
the course of two decades, and is therefore more consistent with the population that 
was used to calculate the relative risk of each disease in former smokers. Reliably 
estimating the changes in disease prevalence in the short term would require 
detailed information on risk profile by year since quitting, along with information on 
smoking history (pack years), age at starting and age at quitting, which is not readily 
available. Differences in the estimated number of prevalent cases of each disease 
per year by the end of the 20 year time horizon (2,036) among the cohort who were 
smokers on or after 2016, are shown in Table 7.2.  
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Table 7.2 Decrease in the annual number of deaths and prevalent cases 
of smoking-related illnesses in each comparator compared 
with routine care by 2036 in those who were smokers on or 
after 2016 
 Deaths 
averted  
Lung cancer 
cases averted 
COPD cases 
averted  
IHD cases 
averted 
Stroke cases 
averted 
E-cigarette 
uptake rates 
in England 
71 54 27 790 515 
Moderate 
varenicline & 
NRT uptake 
86 65 32 966 630 
Maximum 
varenicline & 
NRT uptake 
134 102 50 1,501 979 
This analysis shows the uncertainty that exists in relation to e-cigarette use and the 
impact this will have over the coming years. The available RCT evidence on the 
effectiveness of e-cigarettes consists of two trials, neither of which demonstrated a 
statistically significant effect on their own, but when pooled showed benefit 
compared with non-nicotine e-cigarette controls. While the results of ongoing studies 
are awaited, the potential implications of strong evidence for advocating e-cigarette 
use should be considered. As shown above and in the economic analysis, increased 
use of e-cigarettes may be associated with decreased demand on prescribing 
services and reductions in public spending on smoking cessation therapies under 
current funding arrangements, by shifting costs back onto smokers. However, these 
additional costs to smokers are offset by the savings they will achieve during a 
period of abstinence from cigarettes. As such, the absence of General Medical 
Scheme funding of e-cigarettes is unlikely to be a barrier to most smokers. However, 
if smokers increasingly choose to use e-cigarettes in their quit attempt without 
seeking support from healthcare professionals, it may result in an ever increasing 
proportion of smoking cessation activity being undertaken without the involvement 
of organised smoking cessation services. This could lead to the loss of beneficial 
effect of adjunct behavioural support, resulting in suboptimal quitting rates.  
As noted in Chapter 3, there are a number of national surveys that capture data on 
smoking prevalence and uptake of smoking cessation interventions in Ireland. The 
monthly HSE Smoking Prevalence Tracker provides longitudinal data on prevalence 
of smoking and e-cigarette use while the Healthy Ireland survey provides useful data 
on prevalence and cessation attempts. Data are also available from the Slán survey, 
Eurobarometer surveys on tobacco use and the Health Behaviour in School-aged 
Children (HBSC) survey. Tobacco Free Ireland, the national tobacco control policy 
document published in October 2013, also recommended that a national database 
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for the collection and collation of data from all smoking cessation services should be 
established.(577) This would provide useful information on how frequently cessation 
interventions are offered to smokers, their uptake and the outcomes achieved. 
7.2.2 Mental health services 
In contrast to the decline in smoking prevalence in the general population, smoking 
among those with mental illness has changed little over the past 20 years according 
to international data.(193) People with mental health problems smoke significantly 
more and are more dependent on nicotine than the population as a whole, with 
levels about three times higher than those observed in the general population. 
Chapter 3 describes the effect of smoking on health and the prevalence of smoking 
and smoking cessation in mental health populations in Ireland. 
As noted in Chapter 1, the mental health population in this HTA is defined by the 
setting and services through which care is provided for patients with mental illness 
(rather than defining them by their underlying illness). This definition aims to 
maximise the usefulness of this analysis in informing future national guidelines and 
policy making. The organisational issues described in this section are specific to 
those accessing secondary care mental health services, including patients accessing 
inpatient, residential and long-term care for serious mental illness in hospitals, 
psychiatric and specialist units and secure hospitals, and patients who are within the 
care of specialist community-based multidisciplinary mental health teams. 
7.2.2.1 Current configuration of mental health services 
The Mental Health Division was established by the HSE in 2013 and is accountable 
for specialist secondary care mental health services in Ireland.(578) An overview of 
the services provided is detailed in their 2016 report, Delivering Specialist Mental 
Health Services 2014-2015.(578) This highlights that primary care is typically the first 
point of contact for people with mental health issues, however, some attend the 
emergency department (ED) in an emergency situation where a psychiatric 
assessment is available 24/7.(578) Following assessment at primary care or ED level, 
the next step is to access secondary mental health services via the community 
health organisation as described in Figure 7.1. Community mental health teams are 
a key component of service delivery and are the first-line of acute secondary mental 
healthcare provision.(578) The Mental Health Division reports that over 90% of mental 
health needs can be successfully treated within the primary care setting, with less 
than 10% referred to specialist community-based mental health teams for 
assessment or treatment.(578) Of this 10%, they report that approximately one in ten 
experience acute phases of their illness necessitating acute inpatient care.(578)  
A Report of the Expert Group on Mental Health Policy - A Vision for Change (2006) 
noted a general perception among providers of mental healthcare that the mental 
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health service is grossly under-resourced, both in financial terms and in the range of 
staffing and physical resource required to provide a quality service.(579) This report 
set out a plan for improving the delivery of mental health services.(579) Progress 
against this plan, in particular in relation to staffing, was documented in a 2016 
report ‘Delivering Specialist Mental Health Services 2014-2015’. The 2016 report 
stated that in December 2015 there was a total of 1,758 staff in the General Adult 
Community Mental Health Service (1,548 clinical), which represents 80% of the 
staffing levels recommended in the Vision for Change report.(579) Mental health 
services also include clinician and peer-led information programmes, some of which 
were developed by the HSE in response to the Vision for Change Report. These 
include the EOLAS programme for people with a diagnosis of schizophrenia and 
bipolar disorder, their family members and significant others.(580) These provide 
education and training for participants about managing mental health, their 
diagnosis, medication use and behavioural interventions. 
Figure 7.1 Accessing mental health services in Ireland 
 
 
 
 
 
 
 
 
 
Note: ED – emergency department 
7.2.2.2 Mental Health population 
The Healthy Ireland survey (2015) reports that probable mental health problems are 
indicated in 9% of the Irish population aged 15 and over.(213) Based on Central 
Statistic Office (CSO) population estimates for 2015, this equates to approximately 
400,000 people.(581) A probable mental health problem was calculated using the 
MHI-5 score (Mental Health Inventory) which provides an estimate comparable to 
other measures of psychological distress, associated with service use and decreased 
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level of functioning, with scores of 56 or less indicating a probable mental health 
problem.(582)  
The mental health subgroup specifically considered in this report comprises those 
patients attending secondary care mental health services. As noted, it is estimated 
that the majority of mental health needs can be successfully treated in primary care, 
with less than 10% being referred to secondary mental health services. Delivery of 
community mental healthcare is categorised by service type, that is child and 
adolescent, general mental health, and psychiatry of old age services. In 2015, a 
total of 37,091 new cases were offered an appointment by community general 
mental health teams with 9,836 new cases offered an appointment by the psychiatry 
of old age services.(457) A proportion of new cases seen will have previously attended 
the service and been discharged. Re-referral rates of 31.1% for community general 
mental health teams and 32.6% for psychiatry of old age services. 
A report on the activities of Irish Psychiatric Units and Hospitals from the National 
Psychiatric In-patient Reporting System (NPIRS) provides details of national and 
regional admissions, discharges and deaths.(185) The report, published by the Health 
Research Board, details a total of 17,860 admissions to Irish psychiatric units and 
hospitals in 2015, a rate of 389.3 per 100,000 total population. The majority of these 
admissions related to depressive disorders (26.9%), schizophrenia, schizotypal and 
delusional disorders (19.9%), and mania (10.7%). Readmissions were common, 
accounting for 11,746 admissions in 2015 (rate of 256.0 per 100,000). The report 
also shows 17,662 discharges, with an average length of stay of 36.1 days, and 94% 
of all discharges occurring within three months of admission in 2015.  
7.2.2.3 Smoking and mental health – current legislation and guidelines 
A ban on smoking in enclosed workplaces was introduced under Section 47 of the 
Public Health (Tobacco) Acts 2002 and 2004 to prohibit the smoking of tobacco 
products in all indoor workplaces with limited exemptions. Under the legislation, 
certain premises are exempt, one of those listed premises being a standalone 
psychiatric hospital. The basis for this exemption was the practical difficulties 
anticipated in not permitting smoking by residents. Smoking is an accepted 
component of the culture of many mental health settings, making cessation more 
difficult. A recent report from the Royal College of Physicians and Royal College of 
Psychiatrists in the UK stated that smoke-free policies are a vital means of changing 
this culture.(193)  
However, a secure hospital in the UK which went smoke-free was challenged in the 
High Court by service users who argued their human rights were breached under 
Article 8 of the Human Rights Act.(193) The High Court found that the service users 
had no ‘legal right to smoke’ and noted that it had a duty to take ‘all reasonable 
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precautions’ to protect staff from second-hand smoke.(193) In addition, 
implementation of the legislative requirements in Ireland does not negate the duty 
of care that the HSE and senior management have to protect the health and safety 
of its staff from second-hand smoke.  
The HSE Tobacco Free Campus Policy aims to make all of its workplaces and 
campuses smoke free, and is being implemented in a phased way across all HSE 
services.(583) Data from the HSE’s 2015 annual report indicate that successful 
implementation was achieved in 39% of mental health units and 24% of mental 
health residential services.(573) This contrasts with a 99% successful implementation 
rate in primary care. 
The national tobacco control policy document (Tobacco Free Ireland) makes a series 
of recommendations to reduce smoking prevalence in the overall population.(577) It 
makes reference to Best practice guidelines for tobacco management in the mental 
health setting which were introduced by the HSE and Health Promoting Hospitals 
Network (2008).(584) They state that smoking is treated as a care issue for all clients 
in mental health settings, and that smoking cessation support should be made 
available to staff and clients in an effort to reduce consumption. See Table 7.3. 
Table 7.3 Best practice guidelines for tobacco management in mental 
health (2008) 
Smoking is treated as a care issue for all clients in mental health settings  
 
A. 
 
 
 
B. 
 
 
C. 
 
 
D. 
Establish a system to identify and record the smoking status of all clients on 
admission and incorporate into overall client care plans, including specific smoking 
cessation techniques. 
 
All nicotine dependant clients should have appropriate pharmacological therapies 
including NRT made available to them.  
 
All medications should be carefully monitored during the quitting process and while 
the client is being treated for nicotine dependence.  
 
Awareness raising campaigns highlighting smoking-related problems specific to 
clients of mental health services should be used to inform clients, staff and visitors 
to bring about cultural change.  
Smoking cessation support should be made available to staff and clients in an 
effort to reduce consumption  
 
A. 
 
 
 
 
B. 
All organisations / services should have a smoking cessation service or access to a 
smoking cessation service with a designated smoking cessation facilitator trained in 
mental health for the purpose of helping smokers, staff and clients to quit.  
 
Continuously assess smoker’s readiness to change and devise a comprehensive 
smoking cessation support programme for staff and clients to include 
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Targeting smoking prevalence in the mental health population has also been a 
specific focus in other countries. The UK aims to reduce smoking prevalence in the 
mental health population to less than 5% by 2035, and has produced several reports 
and guidelines for smoking cessation in mental health, which set standards and 
provide implementation guidelines for the delivery of smoking cessation 
interventions. (169, 193, 585-588) 
A smoking cessation and mental health brief for front-line staff was published by the 
HSE in 2016 which aims to support and guide staff in their day-to-day interactions 
with clients and service users.(589) This was based on the 2014 National Centre for 
Smoking Cessation and Training briefing document in the UK. The HSE guidelines 
recommend 30 seconds of brief advice incorporating an ‘act’ step which recommends 
NRT (patch, gum/lozenge, inhaler, mouth spray), varenicline and bupropion as 
cessation aids. The guidelines note that NRT should be offered to all smokers to 
reduce nicotine withdrawal symptoms throughout the duration of an inpatient stay, 
even if they have no intention of quitting or show no desire to stop smoking. These 
recommendations are primarily based on evidence of effectiveness in the unselected 
adult population. 
7.2.2.4 Evidence and implications for practice 
Treatment for smokers typically comprises pharmacological intervention with NRT, 
varenicline or bupropion, combined with regular behavioural support. The efficacy, 
safety and cost-effectiveness of these interventions in the general unselected adult 
population have been established in Chapters 4, 5 and 6 of this report. In the 
absence of evidence to the contrary, it is generally assumed that smoking cessation 
interventions that are effective in the general unselected adult population of smokers 
are likely also to be effective in those with common mental disorders. Observational 
and post-marketing surveillance data have shown inconsistent findings relating to 
neuropsychiatric adverse events for bupropion and varenicline. However, the 2016 
EAGLES trial found no evidence of a significant increase in neuropsychiatric adverse 
events attributable to varenicline or bupropion relative to nicotine patch or placebo 
in patients with or without pre-existing psychiatric disorders. 
Ten studies relevant to the population accessing secondary care mental health 
services were identified in a systematic review of the literature. Nine RCTs related to 
 
 
 
 
C. 
 
 
 
D. 
pharmacological therapies and knowledge on all researched alternative methods for 
smoking cessation support.  
 
Specific resources should be allocated for the cessation service, to ensure that 
systematic referral and audit systems are in place and that clients are followed up 
after quitting.  
 
Information on smoking and smoking cessation methods should be widely available 
to all staff, clients and the community. 
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those with schizophrenia or schizoaffective disorder, while one RCT related to those 
with bipolar disorder. Trials tended not to involve long follow-up periods, thus 
limiting the available evidence for this review. These were generally small studies 
and typically comprised mono- or combination pharmacotherapy (NRT including 
combination NRT and, or bupropion) with adjunctive individual or group behavioural 
programmes specifically designed for those with serious mental illness. Only one trial 
investigating the effect of varenicline was identified for inclusion. Evidence of a 
beneficial treatment was only found for bupropion when used as an adjunct to 
behavioural therapy and NRT in a population with schizophrenia or schizoaffective 
disorder. Despite the intensity of the interventions offered, absolute quit rates in the 
control arms tended to be low compared to those in the general population. 
A number of issues contribute to the limited availability of evidence in this 
population, such as: 
 the common practice of excluding people with mental disorders from RCTs of 
drug therapy,  
 the difficulty of recruiting and retaining those with serious mental illness in 
clinical trials, and 
 the shorter duration of follow up in many of the available trials.  
As noted in Chapter 5, while the EAGLES trial provided evidence of the safety and 
efficacy of varenicline, bupropion, and NRT in individuals with a history of psychiatric 
disorder, this was limited to those who were stable and treated or who had previous 
psychiatric conditions that were in remission. It also excluded those who were at risk 
of suicide or self-harm. Therefore, the findings may not be generalisable to those 
attending secondary care mental health services, particularly those who are 
untreated or symptomatically unstable.  
As other systematic reviews published in this area have stated, better evidence is 
required to determine the optimal smoking cessation interventions in smokers with 
mental health issues. Researchers have speculated that harm reduction, through 
reducing the number of cigarettes smoked per day, may help with future cessation 
(see Chapter 4). Since this population are more likely to be heavy smokers, focusing 
on an initial reduction would reduce nicotine levels and may help with future 
cessation. A review of the evidence on preventing long-term relapse would also be 
helpful. While there has been significant growth in the use of e-cigarettes among 
smokers internationally, there are limited data in relation to their use in the mental 
health population. Further research as to their safety and efficacy, and their 
potential role as a cessation aid or as part of a harm reduction strategy, is needed in 
this cohort. 
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While legislation prohibiting smoking in public buildings and best practice guidelines 
to support service providers are in place, the extent to which smoking cessation 
interventions are consistently being offered to or availed of by smokers in the 
secondary mental health services in Ireland is unknown. The national tobacco 
control policy document, published in 2013, also recommended that a national 
database for the collection and collation of data from all smoking cessation services 
should be established.(577) Availability of this data would provide useful information 
on the type and extent of cessation interventions being offered to smokers attending 
secondary care mental health services, their uptake, and the outcomes achieved.  
International data as well as limited national data from the 2007 Slán survey suggest 
that current messages are not reaching these populations, given the minimal decline 
in smoking prevalence. Specialist inpatient and community mental health services 
are particularly suited to the provision of tailored support by experienced mental 
health staff. However, this is likely to have resource implications both for providing 
interventions and ensuring that all staff have been trained in their delivery given the 
existing staffing constraints. Aside from the mental health staff trained in provision 
of brief advice, data from the 2015 HSE annual report indicate that of 30 staff 
trained to provide intensive tobacco cessation support to smokers, 14 were from 
mental health services.(573) Given the high admission rate and length of stay, in 
particular for those with schizophrenia, admission may provide an opportunity to 
intervene to reduce smoking. This would allow for supervision and monitoring for 
exacerbation of psychiatric symptoms during a cessation attempt, particularly given 
the requirements of smoke-free environments in this setting. 
A number of issues specific to those with serious mental illness should be included 
as part of provider and patient education in relation to smoking cessation. It is noted 
that smokers with serious mental illness tend to have a heavier nicotine dependency 
with increased intensity in terms of the number of cigarettes smoked and the 
amount of nicotine extracted per cigarette. As in the unselected adult population, 
combination NRT (for example, use of a transdermal patch plus a faster-acting 
product such as a spray or gum) may be more effective than monotherapy to 
minimise nicotine withdrawal and enhance quit rates. As noted in Section 3.4.2, 
metabolism of several psychotropic drugs and antidepressants is increased in 
cigarette smokers, reducing their blood level of antipsychotic drugs by as much as 
50%. In the event of increased uptake of smoking cessation interventions, education 
is necessary to ensure that patients and providers are aware that stopping smoking 
could reduce the dose of antipsychotic required. As these interactions are not caused 
by nicotine, this is also relevant to those who use NRT or e-cigarettes in their 
cessation attempt.  
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7.2.3 Maternity services 
7.2.3.1 Current configuration of services  
In 2014 a total of 66,338 women gave birth to babies weighing greater than or 
equal to 500g in Ireland. Almost all (99.8%) of these babies are born in the 
country’s 15 maternity units and four maternity hospitals. Maternity units provide 
care to women and their babies in units situated in a general hospital, while 
maternity hospitals are stand-alone hospitals. The four stand-alone maternity 
hospitals in Dublin and Limerick will, in due course, re-locate to new state-of-the-art 
hospitals on the campuses of adult teaching hospitals. Planned home births comprise 
0.2% of births in Ireland. The HSE provides planned home birth services to families 
choosing this model of maternity care predominantly in association with Self 
Employed Community Midwives (SECMs), along with services based in two maternity 
units (Cork University Maternity Hospital, Waterford Regional Hospital) and one 
maternity hospital (the National Maternity Hospital, Dublin).  
Currently, the Maternity and Infant Care Scheme provides an agreed programme of 
maternity care, free of charge, to all expectant mothers who are ordinarily resident 
in Ireland. This service is provided by a GP of a woman’s choice and a consultant 
obstetrician in a maternity unit or a maternity hospital. The National Maternity 
Strategy encourages women to avail of this scheme and states that women should 
continue to have the option to receive their antenatal care as part of a shared model 
of care with their GP. 
Midwives routinely document the smoking status of women in the medical record at 
the first antenatal visit to a maternity unit or a maternity hospital. Of the four 
maternity hospitals, on-site smoking cessation services are only available in two 
hospitals. There are no on-site services at the National Maternity Hospital, Dublin or 
the Coombe Women and Infant’s University Hospital, Dublin. These two maternity 
hospitals, however, have nearby community smoking cessation services available to 
them. Three of the 15 maternity units do not have on-site smoking cessation 
services: St Luke’s Hospital, Kilkenny; Mayo General Hospital and Portiuncula 
Hospital. There is very limited onsite service in the South Tipperary Unit. While there 
are nearby community services available to St Luke’s Hospital, Kilkenny, there are 
none available to Mayo General Hospital or Portiuncula Hospital. These units must 
refer patients to QUITline.(590) Two maternity units use the carbon monoxide breath 
test to validate self-reported smoking status. While multiple readings may be 
obtained during the course of a pregnancy, repeated use of biochemical verification 
is not consistent.  
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Based on the current configuration of maternity services and the need to make every 
contact count, healthcare professionals in a position to provide smoking cessation 
interventions in pregnancy include: 
 GPs,  
 midwives working within maternity units, maternity hospitals and community 
services provided by these units or hospitals,  
 self-employed community midwifes (SECMs)  
 consultant obstetricians,  
 non-consultant hospital doctors (NCHDs), and  
 fertility specialists.  
GPs in particular have several opportunities at visits both prior to and during 
pregnancy to educate and support women to stop smoking. GPs are also usually the 
first healthcare professional that a woman encounters in pregnancy. 
While the analysis of the clinical effectiveness of smoking cessation interventions in 
pregnancy did not include specific interventions in the postnatal period, GPs, 
midwives, public health nurses and paediatricians are in a position to offer ongoing 
support during this period, including relapse prevention and referral to services 
available to the general population. 
7.2.3.2 Smoking cessation interventions in pregnancy  
Chapter 4 provides a detailed discussion on the clinical effectiveness of smoking 
cessation interventions during pregnancy. Due to the fact that bupropion and 
varenicline are not indicated in pregnancy, NRT is the only licensed 
pharmacotherapy available to pregnant smokers who wish to quit, and its efficacy 
appears to be lower in this cohort than in non-pregnant smokers. A range of 
behavioural interventions in pregnancy were reviewed, and there is evidence that 
counselling, health education and financial incentives improve cessation rates. It is 
worth noting that the largest body of evidence related to counselling interventions 
(44 studies, with a total of 17,796 participants). The quantity of evidence was lower 
for the other interventions evaluated, consisting of financial incentives (three 
studies; n=681), health education (six studies; n=1,425), feedback (five studies; 
n=950), and NRT (eight studies, n=2,199).  
A wide range of types and intensity of counselling interventions were evaluated, 
including; brief advice, telephone counselling, face to face counselling based on the 
5As, counselling based on cognitive behavioural therapy, counselling based on 
motivational interviewing and psychotherapy sessions with a mental health therapist. 
Some interventions were delivered as a once off, while others involved multiple 
interactions with the healthcare professional. It is unclear if any form of counselling 
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was more effective than others. Counselling interventions were provided by a range 
of healthcare professionals including GPs,(268) midwives,(235, 272, 591-594) smoking 
cessation counsellors,(595) health educators,(221, 237, 596-598) mental health 
therapists,(240) veteran staff members of a quitline or telephone helpline,(220) medical 
students,(269) general resident doctors,(242) an anaesthetist(599) and physicians.(270, 600) 
It is unclear if the effectiveness of counselling varies according to the discipline of 
the healthcare professional, the choice of which would affect the resources 
necessary. 
The type of health education interventions also varied and occurred in forms 
including; a pamphlet,(247) a booklet,(246) a self-help manual,(243, 245) automated 
tailored text messages(244) or a fully automated smoking cessation website which 
was structured, tailored and personalised. The implementation or augmentation of 
health education interventions may have fewer resource implications than other 
interventions. However, there will be a requirement for all staff interacting with 
pregnant women to be aware of the range of interventions available, and their 
potential benefits and harms, to ensure that consistent advice is provided.  
Financial incentives were found to be the most effective intervention for smoking 
cessation in late pregnancy. This finding is based on only three studies, however; 
further research in this area is warranted. If financial incentives were implemented, 
carbon monoxide breath testing would be necessary in all maternity units and 
maternity hospitals so that self-reported smoking status could be validated 
biochemically. This would require staff training and investment in handheld carbon 
monoxide monitors and mouthpieces. If urinary cotinine were utilised as a marker 
for smoking cessation, nicotine products (NRT and e-cigarettes) would also result in 
a positive reading. 
Similarly, feedback interventions may incur significant resource implications. 
Participants studied were given feedback about urinary cotinine levels(249) or 
information about the negative effects of smoking at the time of an 18-week 
ultrasound scan and an additional 32-week ultrasound scan,(251) or had an 
ultrasound feedback session lasting approximately 30 minutes at the time of the 18-
week ultrasound scan.(250) If feedback were implemented, urinary cotinine 
measurement or carbon monoxide breath testing would be necessary. In the case of 
ultrasound feedback interventions, additional ultrasound scans would be necessary. 
All three interventions require higher resources in terms of time, training and 
finances.  
The efficacy and safety of e-cigarettes in pregnancy is unknown. Currently the Royal 
College of Obstetricians & Gynaecologists in the UK do not recommend e-cigarettes 
as a cessation aide.(308) See Chapter 5. Due to the rising prevalence of e-cigarette 
use, it is possible that they are also being used by pregnant women to aid cessation. 
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While this area requires further research, the potential harms and benefits of e-
cigarettes should be discussed with pregnant women when providing health 
education or cessation interventions to ensure informed decision-making.     
7.2.3.3 Implications for practice 
Smoking during pregnancy is a significant problem in Ireland. The Growing Up in 
Ireland study (2007) estimates that 13% of mothers smoked during all three 
trimesters, and 18% smoked at least at some stage during pregnancy.(117)  
Based on the evidence, pregnant women who smoke should be offered a 
psychosocial intervention in the first instance. Counselling is the type of psychosocial 
intervention with the largest body of evidence to support its effectiveness. It is 
unclear if any type of counselling is more effective than another and it is also unclear 
if the effectiveness of counselling varies according to the discipline of the healthcare 
professional. The most significant resource implication for the implementation of 
counselling is time, both in antenatal clinics and training time. Re-visiting smoking 
status at antenatal clinic visits at appropriate intervals will require additional clinic 
time. This will have implications for the organisation of antenatal clinics both in 
terms of the duration of an appointment and the number of appointment slots 
available.  
NRT should only be offered to women when psychosocial interventions have been 
unsuccessful. Licensed prescribers must use their professional judgment when 
offering women a prescription for NRT, and it should only be provided following 
discussion about the potential risks and benefits. This advice is in keeping with that 
recommended in international guidelines. For example, the National Institute for 
Health and Care Excellence (NICE) recommends that healthcare professionals only 
prescribe NRT once pregnant women have stopped smoking, or have set a quit date 
and that only two weeks of NRT are prescribed from the day women have agreed to 
stop.(300) Women should only be given subsequent prescriptions once they have 
demonstrated at the time of re-assessment that they are still not smoking.  
For reimbursement through the Primary Care Reimbursement Scheme (PCRS), NRT 
must be prescribed on a dedicated General Medical Scheme prescription by a 
prescriber who is registered with the PCRS. As noted in Section 8.1.1, 
reimbursement is limited to Medical Card holders. If providers increase prescribing 
NRT in hospital and community-based antenatal clinics, there would be implications 
for primary care providers as Medical Card holders will need to first bring their 
prescription to their GP for it to be transcribed onto the relevant prescription form. 
In addition to physicians, midwives and nurses may prescribe medicinal products if 
registered as Registered Nurse Prescribers (RNPs) with the Nursing and Midwifery 
Board of Ireland (NMBI). The total number of nurses and midwives registered as 
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RNPs with the NMBI is 141, however only one is dedicated to smoking cessation 
services.(326, 459)  
Tobacco Free Ireland, Ireland’s national tobacco control policy document published 
in 2013, recommends providing targeted approaches for pregnant women and 
women in the postnatal period and training all front-line healthcare workers in 
smoking cessation interventions, as part of their routine work.(577) In addition, it 
recommends establishing a national database for the collection and collation of data 
from all smoking cessation services.(577) This would provide useful information on the 
type and extent to which cessation interventions are offered to pregnant women, 
their uptake, and the outcomes achieved.   
Maternity services must therefore ensure that front-line healthcare professionals are 
trained in some form of counselling intervention. The HSE currently delivers 
evidence-based brief intervention in smoking cessation training courses, targeting 
front-line health professionals as per the HSE National Service Plan and Tobacco 
Control Programme Action Plan. For smoking cessation, brief interventions involve 
opportunistic advice, discussion, negotiation and encouragement. This typically takes 
between three and 10 minutes. Interventions may involve referral to a more 
intensive treatment. Interventions should be recorded and followed up as 
appropriate. Additional forms of counselling, available free of charge to all smokers, 
include the telephone-based counselling service QUITline and the internet-based 
service www.quit.ie, both funded by the HSE.  
This follows the World Health Organization (WHO) recommendations, published in 
2013, on the management of tobacco use and second-hand smoke exposure in 
pregnancy.(17) The WHO recommends that psychosocial interventions should be 
offered to pregnant women who are current or former tobacco users as early in 
pregnancy as possible. These psychosocial interventions involve behavioural support 
that may include one or more of the following: counselling, health education, 
incentives and peer or social support. No evidence of effectiveness for peer or social 
support was found in this evaluation. The WHO also recommends that healthcare 
providers should ask all pregnant women about their tobacco use (past and present) 
as early as possible in pregnancy and at every antenatal care visit. Pregnant women 
with prior history of tobacco use should be asked about their current tobacco use at 
every antenatal care visit because of their risk of relapse.  
Ireland’s first National Maternity Strategy was published in January 2016.{, 2016 
#631} This acknowledges that pregnancy and birth is a time when women have a 
unique opportunity to focus on their health and wellbeing and that of their baby. 
Healthcare professionals, by providing appropriate information and supports, can 
make ‘every contact count’ to support positive behavioural change in women, in 
particular around reducing lifestyle behaviours with harmful effects such as smoking. 
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However, healthcare professionals must be mindful of the social factors that can 
affect a woman’s ability to make positive choices. Maternity units and maternity 
hospitals should be tobacco-free campuses and have an on-site smoking cessation 
service available for pregnant women.{, 2016 #631} The Strategy also recommends 
that midwives and other front-line healthcare professionals have formalised and 
documented training in smoking cessation.  
Furthermore, the National Standards for Safer Better Maternity Services, launched 
on 21st December 2016, include a number of specific features on smoking cessation 
in pregnancy and the training needs and competencies of staff. 
7.3 Key Points 
 Smoking is not generally considered to be morally wrong and as such is a 
matter of individual choice for the consumer. Therefore, any smoking 
cessation intervention must be made available in a way that promotes the 
autonomy of the individual by providing information on the risks and benefits 
associated with the particular intervention. 
 There are concerns about the social normalisation of some cessation aids, 
such as e-cigarettes, leading to new use by people who have never smoked, 
later migration to tobacco cigarettes, long-term nicotine dependency, and 
other potential as yet unknown harms. 
 In relation to potential long-term risks associated with some smoking 
cessation interventions such as e-cigarettes, smokers who wish to quit are 
advised of all the cessation interventions and provided with as much 
information as possible in relation to safety and efficacy. Such a policy would 
have to be reviewed on a regular basis as new international research data 
becomes available. 
 Marketing and advertising contribute to the public’s perception of smoking 
cessation interventions, so the government has an ethical duty to ensure that 
the media portrayal of any cessation product is appropriately aligned with its 
known degree of risk. The recent EU Tobacco Products Directive addresses 
this by aiming to harmonise the quality and safety requirements of tobacco 
products and e-cigarettes for the benefit of consumers. 
 Concern has been expressed about potential future legal liability if future 
research shows that there are (currently unknown) negative health effects 
arising from the use of e-cigarettes. Provided appropriate warnings and 
information leaflets containing accurate information are included with the sale 
of any such product, it is difficult to see how a legal action might successfully 
be taken in future years. 
 From an organisational perspective, efforts to increase the use of varenicline 
and NRT among unselected adults will place additional demands on GP or 
nurse prescriber services. If use of this intervention reaches plausible 
maximum levels, the number of prescriptions required could increase by over 
50%. Alternatively, if e-cigarette use in Ireland (26%) rose to levels currently 
reported in England (45%), the number of prescriptions required could fall by 
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nearly 40%, assuming the current funding model remains unchanged.   
 In the long term, decreased smoking prevalence will result in a lower 
prevalence of smoking-related diseases and decreased demands on services 
providing treatment for these conditions. However, these changes are unlikely 
to become apparent for some years. 
 There is limited evidence on the effectiveness of smoking cessation 
interventions in the mental health population because of difficulties in 
recruiting and conducting randomised controlled trials (RCTs) in this 
population. Beneficial results were found for bupropion as an adjunct to 
behavioural therapy and NRT in a population with schizophrenia or 
schizoaffective disorder. In the absence of evidence to the contrary, it is 
generally assumed that interventions that are effective in the general 
population will also be beneficial in mental health populations.  
 International data suggest that smoking prevalence among the mental health 
population has changed little over the past 20 years. Given the high 
prevalence, particularly in inpatients, there may be resource implications both 
for providing interventions and staff training, particularly given the staffing 
constraints that exist in mental health settings.  
 The available evidence indicates that pregnant women who smoke should be 
offered a psychosocial intervention in the first instance. As counselling is the 
type of psychosocial intervention with the largest body of evidence to support 
its effectiveness, maternity services should ensure that all front-line staff are 
trained in some form of counselling intervention. Evidence for the 
effectiveness of NRT for smoking cessation in pregnancy is equivocal. 
 The most significant resource implication for the implementation of 
counselling is time, both in training time in the antenatal clinics. 
 Other smoking cessation interventions that are effective in pregnancy will 
have varying levels of resource implications. Health education interventions 
may require fewer resources, while incentives and feedback interventions may 
require more intensive resources in terms of time, training and finances. 
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8 Summary and conclusions 
8.1 Summary of findings 
The purpose of this HTA is to inform policy designed to maximise the number of 
smokers who successfully quit, given the resources allocated for the provision of 
these services in Ireland. In doing so, it brings together the best available evidence 
on the safety, effectiveness and costs of different smoking cessation interventions, 
their current usage rates and plausible changes in usage based on international 
experience, as well as Irish data on smoking prevalence and demographic 
projections over the next 20 years. 
More than 5,400 deaths occur each year in Ireland due to smoking. Approximately 
19% of Irish people aged 15 years and over smoke daily, with a further 4% smoking 
occasionally. The prevalence is higher in men (24.3%) than women (21.2%), and 
highest in people aged 25 to 29 years (33.4%). Smoking prevalence follows a socio-
economic gradient, whereby the prevalence is highest in those in the lowest socio-
economic group. There are limited Irish data on the prevalence of smoking in 
pregnancy and in those with mental health disorders. Smoking prevalence is noted 
to be correlated with the severity of the mental illness, with prevalence rates of 33% 
to 70% reported for those with bipolar disorder and 45% to 88% for those with 
schizophrenia. At any given time, the majority of smokers are thinking about 
quitting, and most have made multiple prior unsuccessful attempts to quit. In 
Ireland, half of those attempting to quit do so unaided. A further 29% of smokers 
trying to quit use e-cigarettes as an aid. Approximately 16% of quit attempts are 
made using some form of pharmacotherapy (for example, nicotine replacement 
therapy [NRT]). 
A review of the clinical effectiveness and safety of pharmacological and behavioural 
smoking cessation interventions in helping smokers achieve long-term cessation was 
carried out for three separate populations; unselected adults, users of secondary 
care mental health services and pregnant women. The mental health subgroup 
identified in this assessment relates to those attending secondary care mental health 
services and therefore may be considered applicable to those with more severe and 
enduring mental illnesses. The Mental Health Division reports that over 90% of 
mental health needs can be successfully treated within the primary care setting. 
While the general adult population considered in this report will comprise those with 
mild to moderate mental health conditions, the efficacy of smoking cessation 
interventions for this cohort was not specifically considered in this report. 
In a general population of adult smokers, all pharmacological interventions were 
more effective than no treatment. Varenicline was the most effective monotherapy 
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(RR 2.57, 95% CI: 2.32 – 2.85), and varenicline with NRT was the most effective 
dual therapy (RR 3.54, 95% CI: 2.57 – 4.61). The analysis of the effectiveness of 
behavioural therapies was complicated by considerable heterogeneity in how these 
interventions were defined. All evaluated therapies were more effective than an 
alternative of ‘do nothing’. When compared with control, defined as brief advice or 
written materials, group behaviour therapy was the most effective behavioural 
intervention (RR 1.85, 95% CI: 1.53 – 2.23). The only statistically significant 
evidence of a beneficial treatment for people attending secondary care mental health 
services was bupropion when used as in addition to behavioural therapy and NRT in 
a population with schizophrenia or schizoaffective disorder (RR 3.86, 95% CI: 1.01 – 
14.80). Among pregnant women there was some evidence of a beneficial effect with 
NRT, but this did not reach statistical significance (RR 1.41; 95% CI: 0.99 to 
2.00).There was also evidence to suggest counselling, health education and financial 
incentives increase cessation rates in pregnant smokers. 
A review of the safety profile of these interventions found that pharmacological 
therapies for smoking cessation are generally safe and well-tolerated in those for 
whom these treatments are not contraindicated. No substantive evidence of adverse 
events associated with behavioural interventions for smoking cessation was 
identified. However, there are limited options available for certain patient groups, 
including pregnant women and mental health populations, due to contraindications 
to the use of selected pharmacological interventions. The safety of e-cigarettes is an 
evolving area of research. While believed to be considerably safer than smoking, 
evidence on long-term safety has yet to be established. 
A cost-effectiveness analysis comparing individual interventions in an Irish setting 
found that all interventions would be considered cost-effective compared with 
unassisted quitting, with e-cigarettes and combination varenicline and NRT the most 
cost-effective strategies when individual therapies are compared to each other. The 
results for e-cigarettes are extremely sensitive to changes in the estimated cost and 
effects of this intervention. This is of particular significance given the high degree of 
uncertainty that exists in relation to both of these parameters in the model. Further 
research is very likely to have an important impact on the results of the cost-
effectiveness of e-cigarettes.  
A comparison of alternatives to the current standard of care in Ireland was carried 
out, using international data as an indicator of plausible changes in the usage of the 
most cost-effective cessation interventions. This included a scenario where use of 
combination varenicline and NRT was maximised, as well as a scenario where e-
cigarette uptake reached levels recently reported in England. This analysis found 
that maximising the uptake of varenicline and NRT is the optimal strategy, with an 
incremental cost-effectiveness ratio (ICER) of €17,800 per quality-adjusted life 
year(QALY). However, it is unclear to what extent policy initiatives can influence 
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overall smoking cessation preferences, particularly in light of the high degree of 
penetration that e-cigarettes have achieved in the absence of any explicit 
endorsement by smoking cessation services in Ireland. Continuing increases in the 
uptake of e-cigarettes are likely to improve the cost-effectiveness of the overall mix 
of cessation interventions in Ireland, by increasing the number of successful quit 
attempts at an acceptable cost (ICER €5,100/QALY). The base case analyses 
assumed that everyone making a quit attempt receives minimal behavioural support 
in the form of brief advice or written materials. 
A budget impact analysis on the incremental cost associated with changes to the 
existing standard of care was carried out. This analysis found that maximising the 
use of varenicline and NRT would be associated with an average increase of 
approximately €7.6 million in the annual cost of providing smoking cessation 
interventions in Ireland. A scenario analysis in which uptake rates of e-cigarettes are 
comparable to England (while still not being reimbursed through the Primary Care 
Reimbursement Scheme [PCRS]) found that this would result in savings of 
approximately €2.6 million per annum due to a decline in the uptake of other 
prescribed pharmacotherapies. Alternatively, in a hypothetical situation where e-
cigarettes were funded to the same extent as NRT, the additional cost to the health 
service would be approximately €6 million per annum at current usage rates, or €7.5 
million per annum if this rose to usage rates currently reported in England. However, 
it is unclear how any such funding programme would operate given the propensity 
for long-term e-cigarette use and the fact that no e-cigarette product is currently 
licensed as a medicinal product in Ireland. 
The HTA also examined any wider implications that changes to the provision of 
these services may have for patients, the health service, and society in general. 
From an ethical perspective, smoking is not generally considered to be morally 
wrong and therefore is a matter of individual choice for the consumer. Any smoking 
cessation intervention must be made available in a way that promotes the autonomy 
of the individual by providing information on the risks and benefits associated with 
the particular intervention. In balancing ethical considerations of benefit versus 
harm, cessation aids have been shown to increase the chances of long-term quitting 
among those who are motivated to stop smoking, but there are concerns about the 
social normalisation of some aids, such as e-cigarettes, leading to new use by never 
smokers, later migration to tobacco cigarettes, long-term nicotine dependency, and 
other potential as yet unknown harms. In the absence of clear evidence in relation 
to potential long-term risks associated with some smoking cessation interventions, 
such as e-cigarettes, empowered smokers to make informed decisions would involve 
continuing to inform them of all the cessation interventions while providing as much 
information as possible in relation to safety and efficacy as well as known risks and 
side-effects.  
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From an organisational perspective, efforts to increase the use of varenicline and 
NRT will place additional demands on GP or nurse prescriber services. If use of this 
intervention reaches plausible maximum levels, the number of prescriptions required 
could increase by over 50%. Alternatively, if e-cigarette use in Ireland (26%) rose to 
the levels currently reported in England (45%), the number of prescriptions required 
could fall by nearly 40%, assuming that smokers choose this option without seeking 
medical advice. E-cigarettes are unusual insofar as they are the only intervention in 
this analysis that is not advocated by HSE quit services or funded through the public 
health system. If the results reported so far are confirmed in subsequent trials and 
e-cigarette usage continues to rise, there is a risk that an ever greater proportion of 
smoking cessation activity will be undertaken without any involvement of trained 
smoking cessation staff. This means the potential benefit of providing e-cigarettes in 
conjunction with behavioural support interventions may be lost. Given the growing 
use of e-cigarettes, it is imperative that their potential benefit and harms continue to 
be discussed with smokers to ensure informed decision-making in relation to their 
use. As new evidence emerges, there are likely to be ongoing resource implications 
for the health service to educate providers on this topic and to ensure that 
consistent advice is provided. In the long term, decreased smoking prevalence will 
result in a lower prevalence of smoking-related diseases and decreased demands on 
services providing treatment for these conditions. However, these changes are 
unlikely to become apparent for many years. 
8.2 Discussion 
Quitting smoking is a complex, iterative process in which the choice of cessation 
intervention is only one of many factors that influence outcomes. However, there is 
good evidence that cessation rates can be improved if smokers choosing to make an 
assisted quit attempt are encouraged to use more effective interventions. A cost-
effectiveness analysis of individual therapies found that while all included treatments 
were cost-effective compared with unassisted quitting, e-cigarettes and combination 
varenicline and NRT provide the best value for money, on average. However, the 
pooled effect estimate for e-cigaretttes is based on two trials, neither of which 
showed a statistically significant benefit within the trial itself. Both trials had absolute 
quit rates in the control and intervention arms that were low compared with average 
absolute quit rates among trials of other interventions with comparable relative 
effect sizes. Given the lack of available studies and the wide range of rapidly 
evolving products, there is a high level of uncertainty surrounding both the clinical 
effectiveness and costs of this intervention. Furthermore, the results of the cost-
effectiveness analysis of e-cigarettes are extremely sensitive to changes in both 
these parameters. There is also considerable uncertainty about the long-term health 
effects of e-cigarette use, and concerns that their widespread promotion by health 
professionals could ultimately prove counterproductive by renormalising nicotine 
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consumption or acting as a gateway to tobacco use among new generations of 
people who have never previously smoked. The results for varenicline and NRT in 
combination are also based on a pooled analysis of two studies comparing it to 
varenicline alone, one of which failed to show a statistically significant effect. 
However, there are a multitude of studies demonstrating the effectiveness of both 
varenicline alone and NRT alone versus placebo.  
Translating the results of the cost-effectiveness analysis into meaningful 
improvements in smoking outcomes is impacted by the ability of the health service 
to influence uptake rates of interventions, particularly given the existing low uptake 
rates of the most effective interventions in Ireland and elsewhere. A cost-
effectiveness analysis was carried out to compare the current uptake of cessation 
therapies among smokers trying to quit in Ireland with alternative mixes of 
interventions. This was also informed by international data on smoking cessation 
preferences. The analysis found that increasing the uptake of combination 
varenicline and NRT to plausible maximum levels was the optimal strategy for 
improving quit rates. This would also be associated with significant additional drugs 
costs and increases in demand for GP and nurse prescribing services. A more likely 
scenario, however, is that e-cigarette use will continue to grow in popularity as an 
aid to smoking cessation. Increased e-cigarette use would also likely result in lower 
expenditure by the public health system on other prescription drugs due to a decline 
in their uptake, assuming the current funding model remains unchanged. Based on 
the available evidence, this would also be expected to improve quit outcomes 
compared with current practice, though less than that of maximising use of 
varenicline and NRT in combination. These results are again subject to the caveats 
outline above and are likely to change once further research becomes available.  
For those choosing to make a quit attempt without the aid of pharmacotherapy or e-
cigarettes, there is good evidence to show that behavioural support increases quit 
rates when compared with no support. There is insufficient evidence to reliably 
compare the effectiveness of different types of behavioural support in combination 
with pharmacotherapy, but existing studies show the addition of any type of 
behavioural support is associated with a beneficial effect on quitting outcomes. This 
analysis focused solely on quit outcomes and as such, it does not consider other 
potential benefits of behavioural support and educational interventions in lowering 
smoking prevalence; for example, motivating more people to want to quit or 
decreasing the proportion of people who start smoking.  
The evidence for smoking cessation treatments among specific subgroups of the 
population is more limited. Although there is a lack of data on the relative 
effectiveness of different smoking cessation interventions for people attending 
secondary care mental health services, high-intensity programmes combining 
pharmacotherapy and behavioural support have been shown to improve quit 
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outcomes in this group. Among pregnant women, behavioural support interventions 
such as counselling, health education and the use of financial incentives were shown 
to significantly improve quit outcomes during pregnancy. 
8.3 Conclusion 
Smoking cessation services should seek to maximise the uptake of varenicline (alone 
or in combination with NRT or bupropion) among smokers wishing to use some type 
of pharmacological support in their quit attempt. While the available results for e-
cigarettes are promising, given the current paucity of evidence to demonstrate their 
effectiveness as an aid to smoking cessation, it is reasonable to await the results of 
ongoing trials before deciding whether to recommend e-cigarettes in preference to 
combination NRT for populations where varenicline is contraindicated, not tolerated 
or non-preferred.  
High-intensity interventions combining pharmacotherapy and behavioural support 
have been shown to improve quit outcomes in people attending secondary mental 
health services. Among pregnant women, behavioural support interventions such as 
counselling, health education and the use of financial incentives were shown to 
significantly improve quit outcomes during pregnancy. 
 
 
  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
303  
9 References 
 
  
DRAFT HTA of smoking cessation interventions for public consultation 
Health Information and Quality Authority 
 
304  
10 Appendices  
All appendices to the report are available to download as a separate document on 
the HIQA website. Please see www.hiqa.ie/healthcare/health-technology-assessment 
for more information.  
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